1. The option that expired

For the past few years, anyone working on getting drugs into the human brain has held a free option. The option was to wait.

Not wait on Arrowhead specifically. Wait on the question. Could a drug injected under the skin cross into the brain and shut off a gene, or was that going to stay a monkey result forever? While the answer was unknown, every company with a brain program could proceed at its own pace, because a result that might have changed the whole field might equally have led nowhere.

On October 14 that option expired, because the question got answered. I wrote most of what follows in the days after, and it has had two weeks to be tested against what the rest of the field did next.

Who was holding that option, what it cost them when it expired, and the part almost nobody said out loud at the time. Some of this is now a matter of record rather than prediction, and I have marked where.

The question was open, so waiting was free. On October 14 the question closed.

2. What Arrowhead actually won

Arrowhead is the first company to show that a drug given as an injection under the skin can sharply reduce the protein output of a gene in the human central nervous system. Healthy volunteers given 12.8 milligrams per kilogram on Day 1 and Day 15 had a mean 73 percent reduction in spinal-fluid tau at Day 105, which is ninety days after the last injection. The measurement is tau protein in spinal fluid, which is the standard readout in this field and an indirect one. The cohorts are eight people each, six on drug and two on placebo, so that 73 percent is the average of six. The interim safety profile was encouraging: most reported events were mild, with no serious treatment-emergent adverse events, no discontinuations attributed to those events, and no persistent anemia or neurobehavioral adverse events.

It matters which part is first. Carrying a drug into the human brain by binding a receptor on the barrier was done before, and done well enough to win an approval. The receptor route had taken an enzyme and antibodies across. What it had never taken was a gene-silencing drug given under the skin, with knockdown to show for it. That is a real first and it is worth exactly what it says.

Worth being blunt about what the result does not show. Spinal fluid tau is an indirect readout, not a measurement of what happened inside brain tissue. The cohorts carried six people on drug. Regional distribution in a human brain, which cell types the receptor actually reaches, and whether the pathological forms of tau fall along with the total are all untested in people. Durability to Day 105 supports the idea of quarterly dosing and does not establish a maintenance regimen, nor what happens after years of repeated injections.

The human data strongly support gene silencing in the central nervous system. They do not yet show clinical benefit. Closing that gap takes more than a biomarker and more than one trial.

3. Everyone else arrives by appointment

The receptor Arrowhead uses to get into the brain is the transferrin receptor, which normally ferries iron across the barrier. Hijacking it is not a new idea, and Arrowhead is not the only company doing it.

Figure 1. Compiled from prescribing information, company disclosures and trial registrations through October 2026. The comparison concerns delivery route and treatment burden, not relative efficacy or direct competition across indications.

Denali has an approved medicine that uses that receptor to carry a replacement enzyme into the brains of children with Hunter syndrome. The FDA granted it accelerated approval in March on the strength of a reduction in a spinal-fluid disease marker, which means confirmation of clinical benefit is still outstanding. It is meaningful human evidence that this receptor can deliver a payload into the brain at a dose that matters, and it arrived before today.

Denali also has a tau oligonucleotide using the same receptor. DNL628 dosed its first patient in March, is given intravenously, and expects human biomarker data in the first half of 2027. Roche has an antibody shuttle on the same receptor in Phase 3 for Alzheimer’s.

Everyone else reaches the brain by the older road, and there are a great many of them. Seventeen programs are in the clinic by lumbar puncture, against three subcutaneous ones that all run on Arrowhead chemistry. Biogen’s tau drug goes into the spinal canal, and so does Novartis’s, which has been recruiting a Phase 3 in progressive supranuclear palsy since June. One of Arrowhead’s own partnered programs goes that way too, SRP-1004 against ataxin-2, because the route is a choice made target by target rather than a doctrine. Alnylam goes there five times. Every clinical program in its central nervous system pipeline arrives by lumbar puncture: a tau siRNA called ALN-5288 dosing Alzheimer’s patients since late 2025, brezosiran in Huntington’s disease with a pivotal study planned for 2027, mivelsiran against the amyloid precursor protein in Phase 2 in two indications, ALN-SOD in ALS dosed twice a year, and ALN-SNCA in early Parkinson’s disease.

That last one is worth pausing on. It is the cleanest comparison in the field.

Alnylam’s ALN-SNCA and Arrowhead’s ARO-SNCA silence the same gene, alpha-synuclein, for the same disease. Same modality, same target, same biology. Alnylam delivers it through a needle in the spine and is dosing Parkinson’s patients now. Arrowhead designed its competing program for delivery under the skin and licensed it to Novartis in late summer 2025 for two hundred million dollars up front, more than a year before its platform had human validation. ARO-SNCA is still preclinical.

Two companies, one gene, two roads. One of those programs has already helped anchor a two-hundred-million-dollar upfront deal. Which road produces the better medicine is still unknown.

That comparison tells you nothing about which drug will work. Alnylam is in patients and Arrowhead is not, and ARO-MAPT is human evidence for the platform rather than for ARO-SNCA. It tells you this instead: the route was a choice, both companies made it deliberately, and only one of them now has human evidence about what that kind of choice is worth.

Denali’s approved drug is an intravenous infusion, once a week, running about four hours each time. That is a morning in a chair with a line in your arm, fifty-two times a year. Its tau program is infused. Roche’s antibody is infused. The two tau programs in the spinal canal need a lumbar puncture each time.

Arrowhead’s is a shot, and the durability data suggests it may be given four times a year. That is a difference in kind rather than in count, and the case against reading it as decisive comes later in this note.

None of that diminishes what Arrowhead reported, and the route is why. The sentence I would defend is that Arrowhead was first to show gene silencing in the human brain from a subcutaneous dose, not that Arrowhead is the only company that can reach the brain. Others got there first. They got there by appointment.

The receptor was proven before October 14. What was not proven is that you can use it with a syringe instead of an infusion chair.

4. The installed base

Treating the human brain by acting on RNA is not new. Three drugs already do it, all approved, and all delivered through a needle between the vertebrae.

What they share is the route, and the route is not a choice. These molecules are large and carry a strong negative charge, and they do not cross from the blood into the brain. Going in through the spine is not the preferred way. It is the only way that worked.

The Spinraza label spells out what that costs the patient. Five milliliters of spinal fluid are withdrawn. The drug is injected into the space around the spinal cord over one to three minutes. Loading doses first, then maintenance every four months, for life. The patients are often children.

The scale is real. Spinraza was approved at the end of 2016, more than fourteen thousand patients have been dosed with it worldwide since, and it brought in 374 million dollars in the first quarter of this year alone.

Fourteen thousand people have taken a drug that works, and the price of taking it is a needle in the spine every four months, for as long as they need it.

Now the part an investor should care about. Spinraza was the established treatment when a daily pill and a one-time gene therapy gave patients other choices, and its sales have come down from their peak since. Not every dollar of that decline belongs to the lumbar puncture, and the argument does not need it to.

The drug did not stop working. The market acquired a choice.

That is what every intrathecal program has to think about now. The question is no longer whether patients will tolerate a needle in the spine. They demonstrably will. The question is what happens when they might not have to.

5. An open line is open for both sides

The chess idea that organizes all of this is simple.

When a file or a diagonal opens in a chess game, it does not open for one player. The pawns come off and the line is simply there, available to whoever has a piece ready to occupy it. Players spend whole middlegames maneuvering to be the one with a rook pointed down the file at the moment it opens, because the opening of the line is not the achievement. Being positioned on it is.

Arrowhead opened a line on October 14. It proved, in people, that the systemic route into the brain carries a gene-silencing payload deep enough and long enough to matter. That proof cost years of work and an enormous amount of money to produce.

Every company holding a receptor-based delivery platform and a nucleic acid payload woke up on October 15 with better information than it had the day before, and none of them paid for it. One important scientific uncertainty, the one that kept boards cautious about those programs, just diminished for all of them at once.

The experiment de-risked a route, not every molecule that might someday travel it.

The proof was expensive to produce. It is free to read. That asymmetry is what to think about.

6. Why Arrowhead is still better placed than that sounds

The open-line problem is real and it is not fatal, because being positioned on a line is different from knowing the line exists.

Several advantages separate it from a company that merely knows the route works. It has the only human data showing gene silencing in the brain from this route, and data is what moves regulators and partners. It manufactures its own material, which matters in a field where chemistry, process control and reproducibility decide whether a promising construct ever becomes a scalable medicine. A shot instead of an infusion is a difference patients feel and payers eventually price. It also has two rare tauopathies already in regulatory conversations, which gives it a development path beyond Alzheimer’s, though Novartis is further along clinically in one of them.

A large partner had also committed to this platform in the brain before anyone could be sure it worked. Novartis signed a deal in late August of last year carrying a two hundred million dollar upfront payment for the alpha-synuclein program and further collaboration rights, more than a year before the human validation arrived.

The deeper advantage is less visible. A delivery platform is not one invention. It is a receptor binder, a linker, a payload chemistry, a dosing schedule, and a manufacturing process that can make it at scale without ruining it.

The binder choice alone helps decide what the product can become. Arrowhead built its construct around a receptor-binding antibody fragment rather than a whole antibody or a fusion protein. That architecture may help with a subcutaneous route, though size alone does not explain it: payload, formulation, dose and tolerability all bear on how a drug can be given. The point is narrower and more useful. Arrowhead did not find a different way to administer an existing drug. It engineered a construct meant to make systemic dosing practical.

Knowing the route works tells a competitor little of that. It tells them the destination exists.

The result is free to read and the patents are free to read too. Arrowhead has an issued patent covering specified receptor-binding antibodies and their conjugates, including the linker chemistry, plus pending applications reaching for the fragment format and the cap that stabilizes the construct.

Reading them gives nobody the right to practice them. That is what a claim is for. It is also not a wall: issued claims protect particular constructs, pending ones protect little until they issue, and a competitor can build outside them. What the estate does not do is close the route. Denali, Roche and others have their own binders and have had them for years. The protection sits around Arrowhead’s construct, not around the idea of going in this way.

Arrowhead now has clinical proof of delivery into a fifth organ system, after the liver, the lung, skeletal muscle and fat, and says it expects to reach a new cell type every eighteen to twenty-four months. On the call Chris Anzalone described the brain platform as feeling like a company’s worth of potential value on its own. That is management’s assessment rather than an independent valuation, and it captures the scale of what a buyer would be evaluating.

The lead Arrowhead holds today is technological. Whether it becomes clinical, regulatory and commercial is the work ahead.

7. Arrowhead was holding the option too

Here is what the coverage missed.

Arrowhead said publicly that if early ARO-MAPT data were encouraging, it would substantially expand its central nervous system pipeline beginning at the end of this year. That was sensible to say when the data might not arrive. That morning it became a plan with numbers on it: two clinical trial applications by year end or early next, at least three new wholly owned brain candidates into the clinic within twelve months, and another partnered candidate behind them in 2027.

Expanding a CNS pipeline means naming targets, running toxicology, building supply, and spending money, in the same window the company is commercializing Redemplo for familial chylomicronemia syndrome and preparing a supplemental application to take the same drug into severe hypertriglyceridemia.

The scientists answered their question. The finance department gets the next one.

That cuts the other way too. Every program Arrowhead adds costs money. Every potential buyer inherits a decision about whether that program deserves more.

Arrowhead is not starting from an empty treasury. At the end of June it reported roughly 1.6 billion dollars across cash, restricted cash and available-for-sale securities. The question is not how to finance the first few brain programs. It is which ones deserve the capital, how aggressively to advance them, and which ones Arrowhead should fund itself rather than partner.

That is what success looks like in this business, and I am not complaining about it. I mention it because a reader who treats the readout as pure upside will be surprised by the next earnings call. The clock that started on October 14 started for everyone, and Arrowhead is standing on the same board.

The good news and the obligation arrived in the same press release.

8. What waiting costs now

Large pharmaceutical companies can still wait. No part of a healthy-volunteer readout forces a purchase, and it puts no clock on a corporate development team.

What changed is not whether they can wait. It is what waiting costs.

Take the central nervous system expansion Arrowhead has said it intends to pursue on encouraging data. Its patent filings describe a world of possible brain targets extending well past tau, across diseases where a protein needs lowering and nobody has been able to reach it. Those disclosures are not a funded development plan. They show how broadly the company is thinking, and the decisions ahead are about which of them deserve real money.

Figure 2. Compiled from Arrowhead’s October 14 presentation and webinar remarks, and from Denali’s 2026 disclosures.

Three new wholly owned brain programs are meant to enter the clinic inside a year. Two applications go in by year end or early next. Regulators are already in conversation about frontotemporal dementia and progressive supranuclear palsy, with a further one to two quarters of back and forth on trial design and studies aiming to begin in 2027. Patient data arrives that year too.

A buyer looking at Arrowhead a year from now is looking at a different company. More programs in the clinic. More capital committed. Some risk retired, some newly exposed. Whether that company is worth more or less turns on what gets proved along the way. Every favorable result retires another piece of scientific risk, and a buyer who waits for that evidence may find itself negotiating over a more valuable asset. The next result could also disappoint. That is the bargain: certainty has a value, and so does the chance to buy before certainty arrives.

The best disclosed reference point is the Novartis agreement. In the late summer of last year it committed two hundred million dollars up front for exclusive rights to Arrowhead’s alpha-synuclein program and the right to select further targets, against as much as two billion in milestones. That is not a clean price for one drug, and it should not be read as one. What it tells you is that a large pharmaceutical company was willing to commit serious capital before the central question had an answer.

That question has now been answered. Whether the next agreement commands better economics is unknown. What is not unknown is that Arrowhead walks into those conversations holding evidence it did not have when Novartis signed.

Waiting buys certainty and may cost opportunity. Moving early buys opportunity and carries the risk patient data will eventually expose. Nobody gets both the early price and the late evidence.

It is worth saying plainly when waiting stays the right call. Patient data is still ahead and could disappoint. Competing architectures are advancing on their own timelines, and a buyer that waits may find a second supplier rather than one. Arrowhead’s own spending raises what the asset costs. A large company that sits still through 2027 is not being slow. It is pricing an option that still has time on it.

There is a quieter consequence to waiting. Every program Arrowhead licenses changes what a future buyer can acquire. Exclusive development rights leave the company, while cash, milestones and royalty interests stay. Whether any given deal raises or lowers what the company is worth depends on its terms, and a buyer prices the retained economics rather than pretending they are gone. Novartis has already selected additional targets under its Arrowhead collaboration, so the portfolio available to a future buyer is changing before the next major readout.

Against that, these companies have shown how they would rather handle it. In the past two weeks Novartis committed 575 million dollars up front to license from a Chinese biotech, and Roche put up to a hundred million into an obesity program from Suzhou. Those are substantial commitments. Neither is an acquisition. Both show that a large company can buy exposure to promising science without buying the company that produced it, and the readout does not take that option away.

What may disappear is the chance to negotiate on the terms that existed before human validation. The next agreement will turn on the data, on who else is interested, and on which rights Arrowhead still controls. Nobody knows that price yet.

The option to wait still exists. Nobody gets it for free anymore.

That was the argument when this was written. Fifteen days later the largest company in RNAi made it for me, without being asked to.

On its third-quarter call, Alnylam was asked directly whether it would pursue a receptor-based approach for the central nervous system. The answer defended the spinal canal on terms worth reading closely: the company does not see intrathecal delivery as a barrier in this disease, with the infrequent administration it anticipates. Then it said that work is underway internally to find a brain shuttle that can deliver peripherally, and that an update would come in the not so distant future.

Put the two halves side by side. The defense is specific to Huntington’s disease, where patients face a fatal diagnosis and no approved disease-modifying treatment exists. The shuttle work is a platform investment, and a platform need not be limited to one indication.

A company that believes the spinal canal is the destination does not fund a way around it.

Alnylam did not say when that work began, and there is no basis for attributing it to October 14. The program may have been running for years. The two positions are not in conflict either. They are what sober portfolio management looks like when the route you have works today and another route may change the economics later. Arrowhead did not necessarily start Alnylam’s clock. It made the clock visible.

9. Who cannot wait at all

The buyers have a price problem. The programs have a different one, and theirs is harder to solve with money.

Novartis sits on both sides of the argument, which is the rarest position in this field. It holds exclusive rights to Arrowhead’s alpha-synuclein program and further collaboration targets, all built on subcutaneous delivery. It is also running its own tau silencer into the spinal canal, in a Phase 3 that has been enrolling since June, targeting three hundred patients, with primary completion expected in 2029. That is the same disease Arrowhead just told regulators it wants to enter, with a drug that would not require a lumbar puncture.

Different drugs, different proteins, but competing answers to the same question about how RNA medicine gets into the brain. Novartis is paying for both. That is an interesting place to be standing when the evidence starts to move.

The people who genuinely cannot wait are not the buyers. They are the programs that now have to explain themselves against a potentially less burdensome alternative.

October 14 did not make the existing drugs worse. It made the alternatives harder to ignore. Every future conversation about an intrathecal tau drug, with a regulator, a payer, a trial site or a patient choosing between two studies, now contains a question that did not exist on Monday. Asked about this directly, Boxer said the lumbar puncture is already a barrier to enrolling patients in trials, and sometimes a barrier to a patient accepting a drug after it is approved. For inherited tauopathy families scattered across countries with thinner health systems, he said a spinal route may simply put the treatment out of reach. There is a version of this that is a shot. That question does not go away, and it gets louder with every data release from the other side.

The most interesting clinical question of the day came from Adam Boxer, the UCSF neurologist Arrowhead invited to present. Boxer knows this field from the inside, including research on Novartis’s own intrathecal tau program and disclosed paid consulting for Novartis. His question was not whether tau can be lowered. It was about what might be limiting the benefit when it is.

Boxer pointed to neurological events reported during treatment with Biogen’s drug, including confusion and falls, most often in the week following an injection, and raised the possibility that they offset some of the benefit. What caused them was left open. The procedure itself, through inflammation or otherwise? The drug? The biology of removing tau? Some combination?

If the spinal route contributes materially to those events, it may be more than a burden on patients. It may limit the benefit a drug can safely deliver.

The two readings point in opposite directions. If the route contributed materially, a subcutaneous drug offers more than convenience. It may deliver the same biology without part of the tolerability cost. If the trouble came from lowering tau itself, Arrowhead meets the same ceiling, and changing the needle does not change the target.

Boxer said plainly that the data cannot separate those explanations. Neither can I. These drugs differ in far more than the needle, in chemistry, exposure, dose and the patients who got them, so comparing separate trials cannot isolate the route. What has changed is that the question can now be put to two very different ways of reaching the same target.

Two slides later Arrowhead’s chief medical officer reported no neurobehavioral adverse events, using the same word Boxer had used. Healthy volunteers over a few months is not the same test as patients over eighteen, and nobody should pretend otherwise.

Ionis shows this better than anybody. The company has built the deepest neurology franchise in this modality, and every medicine in it arrives through a needle between the vertebrae. All three approved drugs discussed above originated with Ionis. Zanvastro, their zilganersen for Alexander disease, was approved in September 2026 and became the first neurology medicine Ionis launched on its own. Obudanersen for Angelman syndrome and ulefnersen for FUS-ALS are both in Phase 3. The tau drug with Biogen is theirs as well.

Three approved medicines and fourteen investigational programs, every one of them into the spinal canal. Ionis is not standing still about it, though, and this is where the story turns.

Months before October 14, Ionis had already disclosed preclinical work on systemic delivery, including a collaboration with ABL Bio on a brain shuttle that binds the insulin-like growth factor 1 receptor rather than the transferrin receptor Arrowhead uses. Its own researchers also posted preclinical work on transferrin-receptor shuttles carrying both siRNA and antisense across the barrier after intravenous and subcutaneous dosing in animals. In monkeys, a tau-targeted construct of theirs reached better than seventy percent knockdown of MAPT across several brain regions after repeated intravenous dosing. That work is a preprint rather than a peer-reviewed paper, and none of it is human.

None of that is human validation, and none of it is a subcutaneous product. It establishes a different point. Arrowhead did not prove to the rest of the field that a second road was worth looking for. Some of them were already well down it.

A franchise built on one road is a strength. Building the second one before somebody else occupies it is how a company keeps that strength.

Which puts one line in their own annual filing in an interesting light.

Their own annual filing says they are not aware of any other medicine in clinical development for Alexander disease. That is very likely correct. Clinical competition is a snapshot, though, and the systemic delivery work now running across the industry shows how fast the picture outside that snapshot can move. The absence of a competing drug today says little about the delivery technology that might support one in a few years.

The route also keeps producing medicines. In September, Ionis and Otsuka reported positive Phase 3 results for ulefnersen in FUS-ALS, hitting a primary endpoint that combined functional impairment and survival. The spinal canal did not prevent that. Whatever systemic delivery eventually offers, convenience alone does not displace a drug that demonstrably helps people.

I should say what kind of pressure this is and is not. No trial has to be redesigned on this account, and a healthy-volunteer result does not establish a new regulatory comparator or standard of care. The pressure is on the next conversation rather than the current protocol.

The buyers can wait. The programs cannot. Sometimes both sit inside the same company, and the clock runs at different speeds in different rooms.

The strongest answer from the other side came nine days later, and it should be stated at full strength. Alnylam reported that brezosiran, delivered by lumbar puncture, lowered mutant huntingtin in spinal fluid by 60 to 64 percent at three months, with a maximum individual reduction of 83 percent, durability supporting twice-yearly dosing, and none of the three findings that ended an earlier huntingtin program. No rise in neurofilament, no inflammatory signal, no ventricular enlargement. A pivotal study follows in 2027.

In patients. For a fatal disease with no approved treatment. That is more clinically relevant evidence, because the knockdown happened in patients rather than in healthy volunteers. It is not yet evidence of clinical benefit, and it is not a basis for ranking the two drugs.

Convenience is an argument about who will take a medicine. It is not an argument about whether the medicine works.

10. The assumption inside the price

Every company running a gene-silencing drug into the spinal canal now holds an asset whose value rests on an assumption. The assumption is that the route does not matter, or that the systemic alternative will not reproduce in patients. That is a perfectly respectable position. It is also now a testable one, and it has a date attached, because Arrowhead’s patient cohorts report in 2027.

An investor holding those companies is pricing that assumption whether or not anyone has stated it. It pays to ask what has to stay true for each of these routes to hold its value.

Three assumptions hold the intrathecal position up. Each one is now testable. How much of that risk the market has already priced is a separate question.

Novartis is where the gap shows most plainly. Its Phase 3 runs to a primary completion in 2029 while it holds a license to the other route, and the assumption inside that is specific: that the first program keeps its value even if the second answer wins.

It may well. The trial may read out positive, the drug may help people, and the burden may prove irrelevant in a disease that kills within a decade. Those are the assumptions, and they are reasonable. They are also what an investor should be tracking rather than taking on faith.

The case overreaches without the other side of it, so here it is. No company owes the market an opinion on a competitor’s healthy-volunteer data. Forty-one volunteers is not a patient population, a biomarker is not an outcome, and Biogen has clinical signal in Alzheimer’s patients where Arrowhead has spinal-fluid tau in healthy people. A board that reads October 14 and concludes the route is a detail is not being dishonest. It is making a judgment.

The three, plainly. That systemic delivery will not reproduce in patients. That a lumbar puncture will not materially constrain adoption where an alternative exists. That efficacy and safety advantages will be large enough to outweigh the procedure if it does. The first begins to face a human test in 2027. The others take longer, and by the time they are answered a great deal of capital will already be committed.

The reason this matters is timing. Programs on a losing route do not get discontinued on the day the route loses. They get discontinued years later, after more capital and more patients enrolled, and the investors who exit worst are the ones who never knew which assumption they were holding.

An assumption with a date on it is not a risk until the date arrives. It is a risk the whole time.

11. What would make me wrong

The proof is narrower than the argument. Healthy volunteers are not patients, one target is not a platform, and the headline average rests on six people. The argument above assumes the route generalizes, and that has not been shown.

The competitor is closer than people think. Denali is also advancing DNL422, a systemically delivered oligonucleotide against alpha-synuclein, in IND-enabling work, so four companies now pursue that target across four delivery strategies, counting Ionis’s ION464 in multiple system atrophy. Ionis has disclosed preclinical work on systemic oligonucleotide delivery with ABL Bio using an IGF1R-targeted shuttle, and separate preclinical work of its own on transferrin-receptor shuttles.

The narrower version of that worry is the likelier one. DNL628 is expected to report human biomarker data in the first half of 2027, while Arrowhead expects patient data during that year. The order and strength of those two results could do a lot to shape how investors judge the platforms. If it comes in competitive on knockdown and tolerability, Arrowhead’s lead gets harder to define by the biomarker alone. Route, duration, brain distribution and the cost of giving the drug all move toward the middle of the comparison. A similar number in spinal fluid does not mean two drugs behave alike in the brain, and it does not mean patients experience them alike.

The open line may also be narrower than I think. Knowing a route works is a long way from working it. If Arrowhead’s specific chemistry, linker and manufacturing turn out to be the hard part, the open-line worry in Section 5 matters much less than I have made it sound.

The price argument can fail. Large companies have waited through stronger signals than this one, and no part of this forces a decision. A company spending hard on expansion can also get cheaper rather than dearer, if the market decides the spending is undisciplined. Appreciation is not urgency, and buyers have watched assets appreciate and sat still before.

More tau lowering may not be required, and nobody knows how much tau a person can spare. Boxer described early results for the Novartis drug in PSP where a far more modest reduction in spinal fluid tau came with encouraging neurofilament findings. Those are patients rather than volunteers, at different doses and times, in small numbers, so the percentages do not line up. The question does. Tau does real work in a neuron and ARO-MAPT lowers all six forms of it. Boxer called the therapeutic window the key question in the field right now, and said plainly that the Biogen results are producing questions nobody can answer yet.

Convenience is not the same as dosing frequency. Biogen studied its drug at intervals as long as twenty-four weeks. A less invasive procedure four times a year is not obviously better than a more invasive one twice.

A shot is not automatically a simple product. The dose that validated the route was substantial, and commercial development still has to solve formulation concentration, injection volume, manufacturing cost and the minimum dose that does the job. A quarterly injection that takes several syringes or carries a heavy cost of goods gives back part of the advantage the route appears to offer. The 6.4 mg/kg cohort reached a 69 percent mean reduction against 73 percent at 12.8, on different schedules, so the figures are not a controlled comparison. They are a hint that the top dose may not be the product.

The question is not how much tau Arrowhead can lower at the highest dose tested. It is how little drug it takes to matter.

The receptor may reach less of the brain than the regional data suggests. Bret Bostwick, who co-invented CNS-targeted RNA therapeutics at Alnylam, has said publicly that transferrin receptor shuttles will solve delivery for only a subset of the brain, because some cells worth targeting do not carry the receptor. Twelve regions is not every cell type inside them. If he is right, the route opens part of the brain rather than the whole of it, and the companies now looking at CD98, LRP1 and IGF1R are looking for the right reason.

The target is still unproven, though not untested. Biogen’s tau-lowering drug reduced tau on brain scans in patients and produced encouraging cognitive signals, and still missed its primary endpoint. That is more human evidence than Arrowhead has on whether lowering tau helps, and it remains unsettled. Tau genetics links strongly to the primary tauopathies and much less to Alzheimer’s, which is the reverse of where the money has gone. Failure in Alzheimer’s alone would not settle the question for MAPT-related frontotemporal dementia or progressive supranuclear palsy. If lowering tau fails across those too, this drug loses its rationale. The delivery system could still hold real value against other targets.

12. The file is open

A line opens once. After that the position is simply different, and every player on the board adjusts to a world where that line exists.

Arrowhead did the opening. It put in the years, took the risk, and produced a result that told an entire field what it did not know the day before. That deserves more credit than it will get.

One reader saw it immediately. Within an hour of the webinar, Bret Bostwick, who had co-invented CNS-targeted RNA therapeutics at Alnylam, called the durability profile best in class, named biodistribution rather than convenience as the true differentiator, and wrote that subcutaneous blood-brain-barrier-penetrating siRNA was officially validated in the clinic. A transformative milestone, he said, for the entire neurodegeneration field. He reached that judgment in sixty minutes.

One of the field’s best-placed readers called it transformative. The stock closed up 0.41 percent and the week moved on.

In the days that followed, the stock even traded below where it had closed before the data. It has since recovered. Neither movement settles the scientific argument. It is a reminder that proving a thesis and being paid for proving it are separate events, and that the second one runs on its own schedule.

The file does not belong to the player who opened it, however. It belongs to whoever has a rook on it.

Arrowhead has the only human data on this route, its own oligonucleotide manufacturing, and two rare diseases already in front of regulators. That is a reasonable claim to the file. It is not a permanent one.

The next twelve months come down to one question for Arrowhead: whether it occupies the line it opened, or simply shows everyone where it was. That is the smaller question, though, and it belongs to one company.

The larger one belongs to everybody else. A field spent thirty years treating the spinal canal as the price of reaching the brain. On October 14 that stopped being the only price. Nobody has to move. Everybody now has to explain why they are not moving, and the first company asked that question in public answered it by saying a brain shuttle is under research and an update is coming.

The file is open. Everyone can see it. The arguing from here is about who gets to stand on it.

A Note on Supporting Independent Research

If this white paper has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this white paper; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This paper is provided for informational and analytical purposes only. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security, and it is not a recommendation as to any corporate course of action. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results, and forward-looking analysis is inherently uncertain. The author and BioBoyScout are not registered investment advisors. The author assumes no obligation to update this paper. The characterization of what is and is not in the published literature, the probability judgments, and the chess analogy are the author’s own.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

1. The problem nobody solved for thirty years

siRNA has a delivery problem, and that problem is the whole problem. The molecule works. Put it inside the right cell and it will silence the gene you aimed at, reliably, for months. Getting it inside the right cell is where the field has spent its entire existence.

Chris Anzalone described the sequence in a BioCentury interview this month, and it is worth laying out, because the public conversation treats delivery as a single step.

Figure 1. The three problems that have to be solved together before any new cell type opens to siRNA.

Three problems, in order. You need a receptor that sits on the cell you want, that internalizes, and that recycles fast enough to carry repeated doses. Then you need a ligand that binds it and survives being conjugated to an oligonucleotide. Then, once inside, the payload has to leave the endosome and reach the silencing machinery, because a cell is not a bag of water and concentration in a tissue is not activity in a cell.

Solve the first two and fail the third, and you have a drug that arrives everywhere and silences none of it.

The liver came first because the biology cooperated. Hepatocytes already carried a high-capacity receptor for clearing circulating glycoproteins, one that internalized and recycled efficiently. A sugar called GalNAc gave the field a way to use machinery nature had already installed. Even with that head start the field spent the better part of a decade getting from idea to approved medicine.

The liver is opening theory. The moves are published, the position at the end is known, and anybody can play it. Past the liver the book runs out.

Every organ after the liver has been found rather than followed, and the brain is the hardest of them.

That is what made October 14 worth attention. Arrowhead reported that ARO-MAPT, given under the skin on Days 1 and 15, lowered spinal fluid total tau by a mean of 73 percent at Day 105, ninety days after the second dose, with a maximum individual reduction of 85 percent. No spinal injection to deliver the drug, and no infusion into the central nervous system. Lumbar punctures were still needed to draw the samples.

That is not proof that Alzheimer’s can be treated. It is narrower and prior to it: evidence that a subcutaneously delivered siRNA can engage a target in the human central nervous system. A working delivery system is not a working medicine. Without the first there is no second.

2. What Alnylam said when somebody asked

At a roundtable this morning on Brezosiran, its intrathecally administered siRNA for Huntington’s disease (also known as ALN-HTT02), Alnylam was asked directly whether dosing into the spinal canal is a commercial problem and what the company is doing about brain shuttles.

Christi Kelsey, Senior Vice President, Value & Pipeline Commercialization at Alnylam, took the first half and gave a good answer. In Huntington’s, efficacy drives treatment decisions rather than convenience, and specialists have indicated that dosing into the spinal canal twice a year is acceptable. In a fatal disease with no approved disease-modifying treatment, she is right.

Toby Ferguson, Senior Vice President, Neuroscience Therapeutic Area Head at Alnylam, took the shuttle question. He confirmed that Alnylam is working on a number of brain shuttle platforms across its CNS portfolio, said the company would talk about those in the future when it has data to share, and framed the choice between a shuttle and an intrathecal approach as a trade-off to be weighed target by target. Then he said the present focus is establishing proof of concept with brezosiran, after which Alnylam would be well positioned to optimize from there.

Plural platforms. No publicly disclosed shuttle results. No announced timeline. A company that would very much like to tell you about this if it had a result to show.

Read that against who is saying it. Alnylam has worked on CNS delivery for years and produced the C16 conjugate, which is a real piece of chemistry and the reason brezosiran reaches the brain at all. They have the people and the money. If a subcutaneous route into the brain were solved, or nearly solved, I would expect them to be presenting it rather than deferring. That is an inference about disclosure behavior rather than a fact about their laboratory.

Alnylam is not arguing that the spinal canal is the right route for every disease of the brain. It is arguing that intrathecal dosing is workable where patients will tolerate a great deal, and building a different route for the rest.

3. What each route has actually been shown to reach

Claims about brain delivery are simple to make and hard to check. I published the map below separately last week on X; it collects what has been measured, region by region.

Figure 2. Regional evidence map. Tau pathology by disease against measured knockdown by route, compiled from company presentations and published releases.

One caveat before the numbers. The regional knockdown percentages all come from monkey studies, and those studies differ in target, formulation, dose and measurement method. The pathology columns describe human disease. These are not interchangeable datasets. The human ARO-MAPT result is spinal fluid tau alone, so regional uniformity in a person remains an inference from the animal work rather than an observation.

Two findings matter. Arrowhead’s subcutaneous construct reached all twelve regions it was tested in, between roughly 63 and 83 percent on charts presented at TIDES, RNA Leaders and the CNS Delivery Summit, with no depth-dependent decline across the regions measured. Its intrathecal comparator reached 86 percent in thoracic spinal cord, 68 percent in temporal cortex, 23 percent in putamen and no measurable knockdown in caudate.

That second result is a comparison between two Arrowhead formulations, not a verdict on intrathecal delivery as such, and the distinction matters. Alnylam’s own intrathecal chemistry does reach the striatum. Roughly half of huntingtin protein cleared from caudate and putamen in monkeys three months after a single dose, with cortex above eighty percent. The route is not incapable. It is uneven, and the unevenness runs the wrong way for diseases that live in deep structures.

One limitation applies to Arrowhead as much as to anybody. Spinal fluid is an imperfect guide to what is happening inside brain tissue. The animal data suggest the regional advantage. The human data establish that the delivery system is pharmacologically active. How completely those two overlap is the open question, and it is the same question every company in this paper has to answer.

4. The honest case for the spinal canal

Intrathecal delivery bypasses the blood-brain barrier by putting the drug straight into cerebrospinal fluid. It still has to penetrate brain tissue from there, and distribution is not uniform, but it avoids the problem of carrying a payload across the barrier from the bloodstream. Lower doses, less systemic exposure, and no requirement that the drug survive a trip through the circulation. Alnylam reports no dose-dependent rise in spinal fluid neurofilament and no ventricular enlargement, which were among the safety concerns that troubled earlier huntingtin programs, and up to sixty percent mean reduction of mutant protein in its Phase 1b.

That matters more than it sounds, because Alnylam’s own framing of the field’s history is that exposure-related tolerability prevented anyone from exploring deep lowering. Earlier programs ran into rising neurofilament as doses climbed. That is one ceiling earlier programs ran into, and Alnylam’s argument is that its chemistry has raised it.

Systemic delivery carries a cost that intrathecal delivery does not. A drug circulating through the body can silence its target in tissues no one aimed at. Toby Ferguson named this directly as part of the trade-off and he was right to. Arrowhead’s answer so far is healthy-volunteer safety data showing no serious treatment-emergent events and no persistent anemia. Encouraging, and not evidence of long-term safety under chronic dosing.

The strongest argument for the spinal canal is not Alnylam’s, though. It is Biogen’s.

Diranersen is an intrathecal antisense drug against the same target Arrowhead is chasing, and in July it reported Phase 2 results in early Alzheimer’s. Spinal fluid tau down 50 to 65 percent. Tau on brain scans down in every region evaluated. Twenty-six percent slowing on the clinical dementia scale at the 60 milligram dose, with larger effects on the cognitive measures.

The trial missed its primary endpoint, which was dose response, and showed no separation on daily function. That miss is worth sitting with. Higher doses did not produce greater slowing, even though tau fell substantially across the dose groups. Perhaps there is a plateau. Perhaps distribution and exposure matter more than the percentage suppressed. Perhaps the clinical differences are less reliable than they look, coming as they do from secondary analyses after a failed primary. Nobody knows. What the result does establish is that deeper biomarker lowering cannot be assumed to carry greater clinical value, and 73 percent should not be read as automatically better than 60. The efficacy question is open, and Biogen intends to advance into registrational development regardless. Set the two side by side, though, and the comparison is uncomfortable. A drug delivered by lumbar puncture has produced clinical signal in patients. Arrowhead has produced a biomarker in healthy volunteers.

Convenience is an argument about who will take a medicine. It is not an argument about whether the medicine works.

Twice a year into the spinal canal is tolerable in a fatal disease. It is a different proposition in a disease with more than seven million patients in this country alone and a community neurologists managing most of them.

5. The counterexample worth taking seriously

Receptor-mediated transport into the human brain is no longer theoretical. Denali has an approved medicine that crosses using the transferrin receptor. The approval was accelerated and rests on a spinal fluid biomarker, with confirmatory evidence still being collected, which is worth noting before anybody treats it as settled.

What that validates is the crossing, and more than the crossing. The enzyme is taken into cells and trafficked to the lysosome, where it does its work. That is a real intracellular destination. An siRNA needs a different one: it has to escape the endosome and reach the silencing machinery in the cytoplasm. That is the third problem on the list above, and it is where most of this difficulty lives. Denali proved a door opens. It did not prove an siRNA can get from the doorway to the room it needs to reach.

6. Where everyone actually stands

Five positions, and not one belongs to a company that has decided the problem is solved.

Arrowhead. ARO-MAPT is the wholly owned brain program in the clinic. Two more are there through Sarepta, one intrathecal against ataxin-2 and one subcutaneous against huntingtin. The company has said it intends to put at least four more CNS candidates into the clinic by the end of 2027. It also holds the only clinical evidence yet produced that a shot under the skin can lower a target in the human central nervous system.

Alnylam. Brezosiran in the clinic by the spinal canal, real chemistry behind it, and brain shuttle platforms in the laboratory with no publicly disclosed data and no date attached.

Novartis. NIO752, an intrathecal tau drug, is in Phase 3 for progressive supranuclear palsy, a primary tauopathy rather than Alzheimer’s. Separately, Novartis paid Arrowhead to license a subcutaneous program against alpha-synuclein. One company, both routes.

Denali. An approved medicine shows receptor-mediated delivery into the brain works for an enzyme payload. DNL628 now tests whether the same transport concept can carry a tau-lowering oligonucleotide. It is given intravenously rather than under the skin, so the burden is an infusion rather than a shot, with human biomarker data expected in the first half of 2027.

Biogen. Intrathecal tau lowering demonstrated in patients, regional reductions on tau imaging, and clinical signals that are encouraging and not conclusive. A failed primary endpoint and a stated intention to go registrational regardless. The most advanced direct comparator anybody has.

Four of the five are building or buying a way past the spinal canal. Biogen is the exception, and Biogen is the one with clinical signal. One company has shown the subcutaneous route working in a person.

7. What would change my mind

The obvious one. Alnylam presents shuttle data. They have the chemistry group and the capital, and the day they show a subcutaneous construct reaching a primate brain, the technical part of the gap starts closing. It would not close the rest of it. The distance between discovering a delivery system and developing a medicine with it is measured in clinical studies rather than laboratory announcements.

The quieter one. Arrowhead’s patient cohorts read out in 2027 and the knockdown comes in materially below what healthy volunteers showed. A diseased brain may differ in barrier integrity and in distribution, and Arrowhead has not yet reported whether the same depth and durability reproduce in patients.

The longer-term one. ARO-MAPT turns out to be the exception rather than the rule. The chemistry works for tau and proves hard to reproduce against unrelated brain targets. Endosomal escape is not a property of the delivery vehicle alone; payload, sequence and conjugate chemistry all bear on it, so success against one target does not automatically carry to the next. That would leave Arrowhead with a promising drug rather than the reusable platform the argument here depends on, and the next distinct CNS target to reach human knockdown is the proof point.

The one that matters most. Arrowhead reproduces deep tau lowering in patients and the clinical benefit proves no better than what an intrathecal competitor achieves. Delivery can be a competitive advantage without being a clinical one, and the market would then have to decide what the easier route is worth on its own.

The nearest one. Denali's DNL628 produces deep, durable tau lowering in people after intravenous dosing. That would not erase a lead in subcutaneous siRNA, and it would show that a second delivery platform reaches the same destination, which is a different kind of problem than a competitor catching up on the same approach.

8. The part that is actually hard

Two of the largest pharmaceutical companies in the world ran RNAi delivery programs and sold them after deciding not to continue the work internally. Arrowhead bought both. That is a fact about the difficulty of this problem more than about anyone’s foresight, and I have written about the strategic reading of it in my other papers.

What the last month has added is a view of where everyone else is standing.

The field is not arguing about whether to reach the brain without a spinal needle. It is arguing about who gets there first.

Alnylam has intrathecal data and shuttle platforms it has not yet shown. Novartis is paying for both routes. Denali has crossed the barrier with a different payload and is now trying it intravenously with an oligonucleotide. Biogen has a spinal-dosed drug with promising clinical evidence.

Arrowhead has what none of them has publicly demonstrated with subcutaneous siRNA: substantial target engagement in the human central nervous system.

That result is not a medicine. It is a key that turned once, in a lock no one else has opened.

A Note on Supporting Independent Research

If this white paper has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this white paper; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This paper is provided for informational and analytical purposes only. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security, and it is not a recommendation as to any corporate course of action. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results, and forward-looking analysis is inherently uncertain. The author and BioBoyScout are not registered investment advisors. The author assumes no obligation to update this paper.

The three-step delivery description is as given by Chris Anzalone in a BioCentury interview of October 16, 2026. Alnylam’s remarks and the tolerability framing are from its brezosiran roundtable of October 2026, where the slide on technical challenges in the field refers to tominersen and WVE-003 rather than to brezosiran; the brain shuttle comments are Toby Ferguson’s and the intrathecal commercial remarks are Christi Kelsey’s. Brezosiran primate and Phase 1b figures are from that same presentation. Arrowhead regional knockdown figures are from its TIDES USA 2025, RNA Leaders USA 2025 and CNS Delivery Summit presentations and the ARO-MAPT release of October 14, 2026, and are read from published charts rather than tabulated values. Denali’s approved medicine uses transferrin-receptor-mediated transport of an enzyme and is not an oligonucleotide. DNL628 is an antisense oligonucleotide on an engineered Fc fragment, given intravenously, with first patient dosed in March 2026. The regional map was published separately by the author.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

1. A gate and a check are different events

In June and July I published four papers arguing that Novartis, Lilly and Roche might each be pushed into buying Arrowhead. The companion note put the mechanism in a sentence: they would be pushed not because they wanted to, but because the cost of letting a rival buy it first can be worse than the cost of buying it themselves.

That mechanism needs two separate events, and I have been careless about keeping them apart.

The first is a gate. A late-2026 readout had to show human pharmacodynamic activity consistent with the delivery platform reaching the brain. The companion note was explicit that a clear failure would knock out the most valuable part of the platform and deflate the urgency. The gate was a survival test, not a starting gun.

The second is a check, in the chess sense. Part Two introduced Lilly as the player who can simply outspend the others, and described its entry as the move that puts the whole board in check. The cascade begins when somebody moves. Until then the others are watching each other.

On Wednesday the gate opened. Mean reduction of 73 percent in spinal-fluid tau, measured ninety days after the last injection, from a shot under the skin. Six treated volunteers in that cohort, dosed twice where the lower cohorts were dosed three times.

Nobody has played the check.

More precisely: nobody has played a check the market can see. Whether somebody has made a private approach is not information I have, for reasons the sixth section gets into. The first check could also be a credible proposal rather than a signed agreement, and the forecast later uses the narrower, publicly observable standard.

A first bid would start the test of the game theory rather than prove it. The other two could bid, license around the new owner, build alternatives, or do nothing at all. The original papers asserted that losing Arrowhead would be too expensive to tolerate. The first bid is when that assertion finally becomes observable.

The gate was a test the thesis had to survive. The check is a move somebody has yet to make.

Figure 1. The Forced Move scientific gate, Arrowhead’s later clinical benchmark, and the results announced October 14, 2026.

The distinction decides what a quiet week means, though it must not become a way of never being wrong. If the first bid is what starts the cascade, a quiet week cannot show whether the cascade works. It does say how willing the potential first movers have been to begin it. The science cleared its gate. The acquisition mechanism is untested, and the one timing argument those papers did make, that a well-placed buyer would rather act before a positive readout, has not played out as I expected.

The science itself I covered in The Bishop Moved, and the market’s failure to reprice it upward in The Liver Got Paid. This note is about the board.

2. Where I was wrong

Three corrections first.

The bar was never mine. The 50 to 60 percent figure everyone quoted was Arrowhead’s, not mine. Hamilton named it on the August 4 earnings call, ten weeks before the readout, and it happens to match the range diranersen had reached. The result came in at 73, with clear dose-related activity, though the top two groups sit close together and were dosed on different schedules.

I missed a piece on the board. Novartis registered a Phase 3 of its own intrathecal tau drug in progressive supranuclear palsy in March, and started it on June 3. My first paper went out on June 22, nineteen days later, and the last on July 8. None of the four mentions the trial. It sat on a public registry for three months before I published a word.

I left a row off it too. The payoff grid had three outcomes: Novartis wins, Lilly wins, Roche wins. An independent Arrowhead appeared in that work as the baseline against which competitive losses were measured, but never as a strategic outcome anyone could choose. No row asked what happens if all three go on licensing, building alternatives or simply waiting. That is where the board sits today.

3. The contract that turned down the engine

The companion note built every number on two values. The floor is the denial value, the competitive damage a company avoids purely by keeping the most threatening rival from winning. The ceiling is that denial value plus the full worth of owning Arrowhead outright.

Denial is the engine. Take it away and a forced move stops being forced.

Which brings me to a document I had not read in June. Section 2.10.2 of the Arrowhead and Novartis agreement is titled Arrowhead Change of Control, and it anticipates exactly the scenario those papers were about. If somebody buys Arrowhead, Novartis may disband or restructure the joint committees and restrict what it shares. The clause addresses separating competing programs and walling off confidential information.

Read it for what it does to the floor. If a rival wins Arrowhead, Novartis keeps the programs it licensed, limits what the new owner learns, and carries on.

Be careful about how far that goes. The license removes one source of competitive exposure: Novartis cannot lose what it already controls merely because somebody else buys the company. It could still lose access to future programs and control of the unlicensed platform. The contract narrows the exposure. It does not tell us by how much, and recomputing the floor is work I have not done. The question is not whether the clause removes Novartis’s reason to bid. It is how much of the original denial value rested on exposure the agreement already protects. Until I separate that from the worth of future programs and control of the platform, I cannot say how much of the floor survives.

Two boundaries on all of this. The protection runs to Novartis alone. Neither Roche nor Lilly benefits from a clause they are not party to, though the rights Novartis already holds shape what either of them would be buying. It also covers the programs Novartis licensed, not the brain pipeline Arrowhead is building around them. The company intends to put three more wholly owned candidates into the clinic inside a year, which leaves substantial brain opportunity outside the existing licenses.

Denial is the engine of the whole thesis. For one of the three, the contract turned the engine down.

There is a further distinction the original numbers never settled, and it may be the more important one. The damage a company would suffer if a rival bought Arrowhead is not the same as the chance the rival tries. A very large problem conditional on somebody moving is not automatically a very large reason to move first. The model estimated the cost of losing. It did not establish how likely anybody was to start the contest.

Part One called Novartis the partner who knows too much, and argued that proximity creates urgency. The contract suggests proximity also bought insulation. The best-informed player is also the one holding contractual protection against part of the mechanism that was supposed to compel it.

It cuts the other way too, which is the more interesting half. The clause also contemplates an acquirer continuing its own competing programs, subject to those safeguards. The parties wrote down a sale without writing it off. Parts of the filed agreement are redacted, so this establishes what was anticipated rather than what anybody intends.

Which leaves Novartis with more than one move. It can run the spinal-canal program toward its 2029 completion and hold the license as a hedge against its own route being obsoleted. It can develop what it has already licensed, with whatever target-selection and substitution rights the agreement still allows. It can also bid for the rest of Arrowhead. The first two preserve choices already made. Only the third is a contest for control.

4. What the readout did, and what it did not

It may have raised the price Arrowhead would accept. The July note said a successful first readout from the brain program would lift the platform’s standalone value, and with it the price below which Arrowhead refuses to sell. That is not a new observation and I should stop presenting it as one. It was in my own work three months ago. Whether the board actually moved that number is not visible from outside.

It may also have strengthened Arrowhead’s standalone position. On Wednesday its chief executive committed to at least three new wholly owned brain programs entering the clinic within twelve months, two applications filed by year end or early next, and another partnered candidate behind them. He described the delivery platform as feeling like a company’s worth of value on its own. That is a man describing what he intends to build.

What it did not produce was a sustained repricing. Arrowhead reached 60.53 during Wednesday’s session, more than four percent above Tuesday’s close, and finished the day at 58.37. Thursday brought a rally of more than two percent in XBI, the biotechnology ETF, and thirteen cents for Arrowhead. By Friday it closed at 55.90, roughly four percent below where it stood before the readout.

I cannot tell you why. Expectations already in the price, doubt about clinical benefit, the cost of the expansion, a bad tape, or plain disagreement. The trading does not say. Any buyer still watching Arrowhead now has more information than it had on Monday and, for the moment, a cheaper quoted price. Whether the board raised the number it would accept is not visible from out here. Those are different prices set by different people.

Success can raise the acquisition price while lowering the incentive to sell.

Which suggests the odds do not rise steadily with the science. Early proof pulls buyers in by retiring uncertainty. More proof raises the price, the bargaining power and the minimum the board will accept. The window may be widest after the technology becomes credible and before independence becomes too valuable to give up.

5. Putting a number on it

A reader is entitled to ask how likely I actually think the check is. Describing a position is not an answer. Here are numbers through the end of 2027, when Arrowhead expects its first patient data and plans to move its two rare-disease brain programs into clinical development.

An acquisition here means a publicly announced definitive agreement transferring control of Arrowhead, signed by December 31, 2027. A license, a minority stake or the sale of individual programs does not count. The numbers that follow are judgments rather than calculations, and I have put the drivers beside each one so you can disagree with an input instead of an output.

Figure 2. Author’s estimates through December 2027. Not derived from a model.

Independent, 50 percent. My largest single outcome, for five reasons. No acquisition was announced in the four months before the readout, the window in which the Novartis paper argued a well-placed buyer would get a lower entry price. Chris Anzalone spent Wednesday morning committing to three new brain programs rather than a process. Licensing captures much of what a buyer wants without paying a premium. Novartis is protected from being shut out of what it holds. The next major patient data are expected in 2027, and those results could materially change the calculation.

Roche, 15 percent. The cleanest fit on the evidence I can see, which is a judgment rather than a ranking. Its shuttle reaches the brain by infusion, Ocrevus faces biosimilars in 2028 and 2029, and it holds no publicly disclosed contractual position in Arrowhead’s brain platform. It also put a hundred million dollars into Rona the day before Arrowhead reported, which shows continued appetite for external RNAi without being evidence it intends to buy anybody.

Novartis, 15 percent. Best informed and contractually protected, which is the paradox of the three. It has a cliff of its own that the June papers underweighted: Cosentyx, at 6.7 billion dollars of 2025 sales, faces estimated US patent expiration in 2029, the same window as Roche’s Ocrevus. Two of these three are staring into the same window. The change-of-control clause protects what it holds. Buying Arrowhead would mean paying for a platform that could eventually challenge the delivery route its own Phase 3 depends on. A defensive bidder rather than an initiator.

Lilly, 15 percent. Level with the other two, and I had this too low. Its chief executive called tau a tough target eight days before the readout, but skepticism about tau is not skepticism about a delivery platform. Lilly has repeatedly backed several approaches to a problem rather than committing to one, and a buyer who hedges across technologies may find ownership attractive precisely because the winning approach is still unknown. That makes Lilly a plausible owner of the technology, not evidence it intends to become one.

Its own exposure is real and differently shaped. Trulicity produced about 4.3 billion dollars in 2025 against a US compound patent expiring in 2027, and Lilly recognized roughly 3.4 billion from its Jardiance collaboration, whose US patent runs to 2029. Mounjaro alone produced nearly 23 billion with protection into 2036. Lilly has the deepest balance sheet in the room, a large new franchise, and less immediate need than its peers to buy a replacement revenue stream.

Figure 3. Capacity ranges as published in the Forced Move series, June and July 2026, on an enterprise value basis.

One more piece of history belongs here, because it involves two of the three. Arrowhead bought Roche’s entire RNAi business in 2011 and Novartis’s entire RNAi business in 2014. Chris Anzalone’s account of why is blunt: they did not believe the field could solve delivery.

Two of the companies in this note have owned this technology before and sold it, having concluded it would not work. The thesis is that they now have to buy it back at a very large multiple of what they let it go for.

That cuts both ways and both belong on the record. These boards can be wrong about RNAi. They are also willing to walk away from it.

One more piece of context applies to all three, and it cuts against me. Roche and Novartis are not alone. Several large franchises face patent and biosimilar exposure in the closing years of this decade, which widens the market for external innovation generally.

That does not help Arrowhead as much as it first appears. A company losing exclusivity in 2029 needs earnings, not merely interesting technology. An early-stage brain platform may be among the most valuable assets it could own for the decade after, and it does not fill the gap when the patents go. The same cliff that raises an acquisition budget can point that budget somewhere else entirely.

The patent cliff creates buyers. It does not select their targets.

That constraint sits under all three numbers. Each of these companies has reason to buy before the decade turns. None has an obvious reason to buy this.

The equal odds are not a claim that the three face equal pressure. They are an admission that I cannot reliably turn very different incentives into different probabilities. The last five points belong to somebody I have not modeled, which Merck KGaA demonstrated is not a hypothetical.

Fifty percent is the least precisely grounded number here. The science makes Arrowhead strategically interesting and several companies have reason to consider it. Neither establishes that any one of them bids. I cannot produce a reliable base rate fitted to these circumstances and will not pretend otherwise. The estimate reflects my judgment of the combined incentives, not evidence that a transaction is already under discussion. It is a forecast and it can be wrong.

One more boundary. These concern whether control changes hands, not what somebody pays for it. The valuations in the original papers are separate estimates, and the October readout validated none of them.

A word about those valuations, since the range in the companion note starts above the largest biotech acquisition ever completed and runs to roughly double it. Bristol Myers Squibb paid about 74 billion dollars for Celgene. Roche paid 47 billion for Genentech. Pfizer paid 43 billion for Seagen and its entire antibody-drug-conjugate platform. Against that record, 90 to 150 billion dollars is off the top of the chart, and anybody checking the number against precedent will find it there.

The defense is not that Arrowhead is special. It is that the number was never a price forecast. A ceiling is what a buyer could rationally pay in a contested situation, denial value plus the worth of owning the asset outright. What somebody would actually pay is a different question and a lower number.

One feature of the asset is genuinely different, though it is a category point rather than a superlative. A normal biotech acquisition prices a pipeline: molecules, indications, launch dates, probabilities. Arrowhead would be bought for the capability that produces pipelines, across seven cell types it can now address, five of them already in the clinic. Nobody has sold a validated multi-tissue delivery engine before, which is why there is no comparable transaction to anchor against.

A number with no precedent is not a high number. It is an unanchored one.

That cuts both ways, and the second way is the one shareholders should sit with. An unanchored number can land far below where I modeled it as easily as above.

A willing buyer is also not enough. A transaction needs Arrowhead’s board and an acquirer to agree on a number, and that may be the largest uncertainty in the whole exercise. It is the one variable none of the outside analysis can see.

If Arrowhead is still independent in January 2028, the original papers will have described pressure without producing the move they contemplated. That would not validate the 50 percent. One outcome never validates a probability.

6. Why you would not see it coming

I argued in The Liver Got Paid that the models pricing Arrowhead have no field for what it proved. This section asks a narrower question a reader put to me: what would acquisition interest look like from the outside, if it existed? The honest answer is that it might look like silence, and the reason is worth understanding.

A preliminary approach generally triggers no duty to announce it. Discussions with a prospective buyer and its advisers can stay confidential under appropriate confidentiality arrangements. Regulation FD does not impose a blanket twenty-four-hour deadline on them, and a preliminary approach is not one of the enumerated Form 8-K events. Nasdaq expects prompt disclosure of material information but allows delay for confidential negotiations, which is exactly what that carve-out exists for.

Talks can therefore sit in the dark lawfully until they are signed. A leak or unusual trading can force the issue sooner, at which point the company may have to respond on a day it did not choose. Neither is guaranteed to happen. The Silence deal announced on Monday, which the next section takes up, is one illustration: no leak I saw, no unusual tape, just a finished agreement.

You may see it in the tape. You may see no sign of it at all until an agreement is signed.

None of that is legal advice and I no longer practice. It explains why an absence of news is not evidence of an absence of interest, and why anyone waiting for a press release to tell them the auction opened has the sequence backwards.

7. Three sessions later, somebody moved

This note was finished last week. On Monday morning Merck KGaA announced an agreement, dated the day before, to acquire Silence Therapeutics, expected to close in the first quarter of next year, for $1.1 billion in enterprise value, $1.3 billion in equity, all cash, at a 130 percent premium to Friday’s close and 82 percent over the thirty-day average.

Silence is a liver company. The drug driving the deal silences a gene expressed almost exclusively in liver cells, in a rare blood cancer, and it has finished Phase 2 with a positive result. One principal value driver, with other pipeline behind it including a Phase 3-ready program against Lp(a). No approved medicines. No commercial organization.

Three details in the announcement matter more than the price.

It was competitive. Silence’s chairman called it the result of a competitive sale process. The announcement does not say how many bidders there were, or who, and leaves it there.

The buyer was outside my framework. I modeled Novartis, Lilly and Roche as potential buyers of Arrowhead. Merck KGaA was not among them, though it had bought SpringWorks the year before. Paying $1.1 billion for Silence does not establish that Merck would pay ten or a hundred times that for Arrowhead. It does establish what my framework never examined: the set of companies willing to own RNAi reaches past the three I named.

I did not see it coming. No warning, no leak I caught, no unusual tape I noticed. Three trading sessions after I argued you would not see one until it was done, Silence supplied the illustration. The negotiations were invisible to me. The agreement was not.

Now set the two companies beside each other, because the comparison is uncomfortable. Silence: a Phase 3-ready rare disease candidate, a second advanced cardiovascular program, an RNAi platform, no approved medicines. Enterprise value $1.1 billion. Arrowhead on Friday: an approved medicine on the market, positive Phase 3 data in hand for a label expansion, human data in five organ systems, two partnered brain programs with three more promised inside a year, the first reported clinical demonstration of substantial spinal-fluid tau lowering after a subcutaneous dose, and roughly $1.6 billion in cash and securities. Equity value near $7.9 billion at Friday’s close. Enterprise value around $7.5 billion once the cash, the convertible notes and the royalty obligations are netted, roughly seven times what Merck agreed to pay for Silence. That figure is approximate: the price is Friday’s, the balance sheet is June 30, and the treatment of the royalty obligations moves it either way.

That is not a claim that Arrowhead should be worth some multiple of Silence. The companies are not comparable and I will not pretend otherwise. It is an observation about what a buyer pays once it has decided, and about how little the public market appears to have rewarded what happened last Wednesday.

Merck put $1.1 billion of enterprise value on a liver RNAi business. It did not buy a license. It bought the company.

8. The best argument against all of this

There is a better objection than the one I used to lead with, and it is not that management sounds enthusiastic about going it alone. Executives say that whether or not a deal is possible.

The real objection is economic. The platform may be worth more to Arrowhead as a licensing and commercial business than any buyer is currently willing to pay to own it outright. Novartis showed in August of last year that substantial access can be bought without buying the company. Sarepta showed the same with the muscle programs. A buyer acquires the unpartnered pipeline, the research engine and the right to decide who gets access next. It does not acquire the ability to unwind rights already granted.

There is a point where renting stops being cheaper. One program can be licensed. The next ten bring upfronts, milestones, royalties, exclusivity limits and the standing risk that somebody else takes the target you wanted. Ownership wins when controlling the engine is worth more than the flexibility of buying what it produces. For these three companies, the public evidence does not establish that Arrowhead has crossed that line.

A further possibility is worth holding, and it is not bearish. There may be many buyers for Arrowhead’s technology and no buyer for Arrowhead at a price its owners would take. Those outcomes are not contradictory. They are what happens when the parts are worth different amounts to different companies and no single buyer can capture all of them. A platform can become indispensable without the company becoming an acquisition, and a decade of licensing revenue is not necessarily the worse outcome for anybody holding the stock.

Arrowhead does not look like a company preparing to sell either, and the expansion Chris Anzalone announced on Wednesday is the evidence. That counts for a little. It is the weakest of the three arguments in this section.

The recent behavior of the buyers points the same way. In the past two weeks Novartis committed $575 million up front to license from a Chinese biotech and Roche put up to a hundred million into an obesity program from Suzhou. Neither is an acquisition. Both are companies choosing access over ownership, which is the choice Novartis already made with this very platform fourteen months ago.

The papers themselves were careful on this point in a way the title was not. A forced move describes a position in which every alternative is worse. It does not promise a timetable. Players sit in difficult positions for a long time, and the position does not care.

What would argue the other way. Three results would shift the argument from licensing back toward ownership. Patient data showing clinical benefit rather than biomarker movement, because a working drug is harder to rent. A second brain target reaching the same knockdown, because that converts a result into a capability. Patent claims giving Arrowhead real leverage over a rival’s freedom to operate would strengthen the ownership case as well, because control of exclusion rights can be worth more than access to the technology. None has yet been established to a degree that would settle the ownership question.

9. What would make me wrong

The result is thinner than the headline. The 73 percent is the mean for six treated volunteers in an eight-person cohort, at the Day 105 assessment. Patient data are not expected until 2027, and healthy people are not sick people.

One brain target is not a brain franchise. ARO-MAPT has shown substantial activity on one biomarker against one target. Whether the same approach produces comparable knockdown against other brain targets is unresolved in humans. If the chemistry turns out to be target-specific, what I have been calling a company’s worth of value may be one exceptional drug with a much narrower delivery story. Arrowhead disputes this, and its claim is narrower and stronger than the one I just described. Chris Anzalone’s position is that once delivery into a cell type is validated, further targets in that same cell type follow, because the cell does not care which sequence it receives. Reaching a new cell type is the hard part; a second gene in a cell type already reached is not. By that account the brain is open and a second brain target should work. It is still a claim nobody has tested.

A competitor may close the gap before any buyer moves. Denali already has an approved medicine using receptor-mediated transport across the blood-brain barrier, and a separate tau program in patients reading out in the first half of next year. If that reads well, Arrowhead keeps its scientific first and loses the assumption that first means best placed.

The price argument can fail in both directions. Large companies have sat through stronger signals than this one. A company spending hard on expansion can also get cheaper rather than dearer, if the market decides the spending lacks discipline. Rising value is not the same as urgency.

The target is still unproven. Lowering tau has not been shown to change the course of anyone’s disease. Biogen reduced tau on brain scans, produced encouraging cognitive signals, and still missed its primary endpoint. If the mechanism fails, the delivery platform keeps real value against other targets and this particular drug does not.

The one that would retire the thesis. There is a way to be right about the platform and wrong about the rest of it. If patient data strengthen, if other brain targets validate the route, and the large companies keep licensing instead of buying, then what I got wrong was not the science. It was the assumption that anybody needs to own all of this. The technology can be exactly what I thought, and the argument for buying the company can still fail.

10. The clock runs while you think

In chess the clock does not stop for difficulty. A player in a hard position can think for forty minutes, and at the end of forty minutes the position is exactly what it was, minus forty minutes.

I said in June that three companies would be forced to move. The more precise claim was that the first buyer would put the others in check. Whether they answer is the part the model has yet to prove.

Three tests, then. The science passed the first. The second is whether somebody makes a credible bid. The third is whether that bid forces the competitive response my original model anticipated. Only the first has been completed.

The gate I named opened, inside the window I pointed at, and the result came through it clear of every hurdle anyone had named. The position that condition was supposed to create now exists. Three companies are sitting in it. One of them has a registrational trial running on the alternative route. None of them has to act at all.

A forced move is not a prediction that somebody moves. It is a description of what is left when they do.

A Note on Supporting Independent Research

If this white paper has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this white paper; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This paper is provided for informational and analytical purposes only. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security, and it is not a recommendation as to any corporate course of action. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results, and forward-looking analysis is inherently uncertain. The author and BioBoyScout are not registered investment advisors. The author assumes no obligation to update this paper. The characterization of what is and is not in the published literature, the probability judgments, and the chess analogy are the author’s own.

The Forced Move papers were published on June 22, June 29 and July 6, 2026, with the companion note on July 8. ARO-MAPT results are from Arrowhead's announcement and investor webinar of October 14, 2026. Arrowhead's acquisitions of the Roche and Novartis RNAi businesses in 2011 and 2014, and the platform and pipeline figures in Section 5, are as described by Chris Anzalone in a BioCentury interview of October 16, 2026. The Arrowhead and Novartis agreement was entered into on August 29, 2025; the change-of-control provision is at Section 2.10.2 and the target-selection procedures at Section 3.1.2, and portions of the filed agreement are redacted. Novartis's Phase 3 study of NIO752 is registered as NCT07498426.

Patent expiry years are estimates and vary by territory; sales figures are as reported for 2025 and, where a product is partnered, reflect the named company's recognized revenue rather than worldwide product sales. Arrowhead's enterprise value is approximate, derived from its October 16 closing price and its cash and securities position as of June 30, 2026. Merck KGaA's agreement to acquire Silence Therapeutics was announced on October 19, 2026, and the Novartis and Roche licensing transactions on October 2 and October 13. Diranersen results are from Biogen's announcements of May and July 2026. The probabilities in Section 5 are the author's own estimates and not the output of any model.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

1. The claim I am going to try to prove

Arrowhead rose 24 cents on Wednesday, four tenths of one percent, on the day it reported the first clinical evidence that a shot under the skin can silence a gene in the human central nervous system.

One point has to be made immediately, because leaving it out would be dishonest. Wednesday was the worst day for American stocks since July. A hot inflation print sent the ten-year Treasury above 5 percent, the S&P 500 fell 1.11 percent, and the Nasdaq fell 1.88. Against those, a gain of 0.41 percent looks respectable.

Biotechnology told a different story. The sector index finished the day essentially flat. Measured against its own industry rather than against technology stocks having a bad afternoon, Arrowhead’s outperformance was under half a percentage point.

One more detail from Wednesday belongs here. Arrowhead traded as high as 60.53 that session, more than four percent above the previous close. By the bell almost all of it was gone. The question is not whether investors noticed. It is why so little of what they did survived the afternoon.

The next day gave everyone more time. The webinar had run at 2:30 that afternoon, so Thursday was the first full session with the presentation, the dose curve and the scientific explanation all public. Biotechnology rallied more than two percent. Arrowhead added thirteen cents.

Across the two sessions the sector gained about two percent and Arrowhead gained less than one. The gap widened after the explanation rather than closing.

Hold that number. Under half a point on the day, and further behind by Thursday. The rest of this note is about what the same market has paid for comparable evidence on other days.

A lot of people found that insulting. Rather than simply agree, here is a falsifiable version of the complaint. The market has repriced companies violently on exactly this kind of evidence before. Twice in the last five years it moved roughly forty percent in a single session on an interim Phase 1 readout with single-digit patient numbers and no clinical outcome at all.

Both times, the organ was the liver.

2. Four firsts, four tapes

Figure 1. Compiled from company announcements, press coverage at the time, and the trading record for each date.

Intellia. In June 2021 Intellia reported that six patients had received a gene-editing drug through an intravenous infusion, and that the protein it targets had fallen by a mean of 87 percent at day 28. No clinical benefit was measured. The company called it proof of concept for its delivery platform. The shares closed up more than 55 percent. The forty in this note’s title is the figure the wires carried that morning, and the conservative one.

Verve. In November 2023 Verve reported the first base editing performed inside a human body. Nine patients evaluable, cholesterol down between 39 and 55 percent at the higher doses. One participant had a heart attack the investigators judged possibly related to treatment. The shares closed down about 41 percent.

Sarepta. In March of this year Sarepta reported the first clinical data on two siRNA drugs for muscle disease: drug concentrations in muscle tissue, suppression of a panel of genes downstream of the target in one program, a placebo-adjusted reduction of the target gene in the other, and favorable tolerability. The shares closed up about 35 percent.

Arrowhead. On Wednesday Arrowhead reported that six treated volunteers had a mean 73 percent reduction in spinal-fluid tau, measured ninety days after the last injection. That is pharmacodynamic evidence of silencing in the central nervous system rather than a measurement of gene expression in brain tissue, and the distinction is worth keeping. No serious treatment-emergent events, no discontinuations attributed to them, no persistent anemia. The shares rose 24 cents.

The market is not indifferent to this category of news. It priced three of these in double digits and the fourth at four tenths of one percent.

3. The March case is Arrowhead’s own technology

Start with Sarepta, because it is the most useful of the four comparisons.

SRP-1001 and SRP-1003 are Arrowhead drugs. Arrowhead’s own proxy statement lists them under partnered programs and gives their former names: ARO-DUX4 and ARO-DM1. The delivery chemistry that carries them into muscle is Arrowhead’s. Sarepta licensed the platform. The trade press covering the readout said so in the headlines, calling them Arrowhead’s siRNA assets and RNAi drugs from Arrowhead.

What Sarepta reported on March 25 was early, and it was not trivial. Drug concentrations in muscle well above a competitor’s, a dose-dependent rise, suppression of the gene panel downstream of DUX4 of roughly 90 percent against placebo in the FSHD program, and a 50 percent placebo-adjusted reduction of the target gene in the myotonic dystrophy program, which the company itself called limited given the numbers involved. No clinical outcomes in either.

Sarepta closed up about 35 percent.

In March the market added about a third to a company’s value for results built on Arrowhead’s technology.

Arrowhead moved too. It rose eight percent that same day. Biotechnology was strong, up about 3.7 percent, so call it four points of sector-relative gain. Not all of it belongs to Sarepta’s news and I cannot separate out what does. The point is simpler than attribution.

Investors had no difficulty repricing Arrowhead in March on evidence about its licensed delivery chemistry working in muscle. Seven months later, on evidence about its own delivery chemistry working in the brain, the sector-relative gain was under half a point. The same stock, the same engineering group, roughly a tenth of the response.

That needs one qualification. Sarepta holds the development and commercial rights, so most of the direct economics of those two programs belong to it, with Arrowhead retaining milestones and royalties. The market had a rational reason to reward Sarepta. What is harder to see is how much it assigned to the layer underneath, which was evidence that a targeted delivery chemistry works in people, and that chemistry is Arrowhead’s.

This is the hardest of the comparisons for a skeptic to wave off. It was this year, in this market, in this sector. The data was in patients rather than healthy volunteers, and it was thinner than Arrowhead’s. It was also not tau, so whatever the market thinks of that target cannot explain it.

4. The Verve case closes the other door

If the only comparison were Intellia, somebody would reasonably say that 2021 was a different market, that money was free and gene editing was a story stock, and that none of it carries over.

Verve answers that. November 2023 was not a bull market in biotech. The move was also violent in the other direction, which is the point. The market read an interim Phase 1 biomarker readout in nine patients, found one safety signal in it, and took forty percent off the company inside a session.

A market that can do that has not lost the ability to price early platform data. It was paying close attention in 2023. It paid close attention in 2021. On Wednesday its reaction was barely visible.

5. Eight examples are not a distribution. They are a rebuttal

A reasonable reader at this point says I have picked three days out of five years and arranged them to suit myself. That is fair, and these eight cannot establish how the market normally prices Phase 1 data. No such claim is being made. What they establish is narrower: investors have repeatedly assigned large changes in company value to early genetic-medicine evidence, sometimes with no clinical outcome, sometimes without the company reporting a result of its own. Whether the market knows how to react is not in dispute.

Figure 2. Single-session share moves following interim Phase 1 data releases in genetic medicine. Compiled from company announcements and press coverage at the time.

Wave is the extreme case. In October 2024 it reported the first therapeutic RNA editing ever performed in a human being, in two patients, on a single dose. The stock closed up about 74 percent. Eleven months later it reported more data from the same Phase 1b/2a study, the result came in below what investors wanted, and the stock fell about 17 percent.

One detail about that October makes it the closest parallel to Arrowhead of any case here. WVE-006 was already licensed to GSK, which held the global rights, with Wave keeping milestones and royalties. The market repriced the originating company by three quarters anyway. The clinical questions were not equivalent, and the protein Wave restored has a better established link to its disease than tau reduction has to slowing dementia. The licensing structure is what makes the comparison useful. Investors were willing to pay the originating technology company even when a partner held the global rights.

The September 2025 readout is the one worth sitting with, though, because of what happened to everybody else that day. Beam rose 15 percent and Korro rose 17 percent. Neither company reported a result that day. They moved because a competitor’s result changed where the value in a shared approach might end up, which is not quite the same as validating the approach.

That is the market this note is about. It will reprice a company by double digits because a rival published. It repriced Arrowhead by four tenths of one percent for the first gene silencing ever achieved in a human brain.

6. Where Arrowhead’s data is stronger, and where it is weaker

Honesty here cuts both ways, so take the weaker side first.

Against Arrowhead. Intellia and Verve dosed people who had the disease. Arrowhead dosed healthy volunteers. That is a real difference and I will not argue it away. A biomarker in a sick person carries information about treating that person which the same biomarker in a healthy one does not.

The reason for the difference is worth knowing, though. Exposing a healthy person to a potentially permanent change in their genome, with no prospect of benefit to them, is a risk-benefit calculation that rarely survives review, so those companies had little choice but to study patients. Silencing is reversible and a shot under the skin is routine, which is how Arrowhead got 41 volunteers through a study in the time it takes to enroll a handful of patients. What makes the data look weaker is downstream of what makes the drug interesting.

There is a further point against my own concession. For validating delivery specifically, rather than efficacy, healthy volunteers may offer the more controlled test. Sick brains vary. Disease stage, atrophy, comorbidity and concomitant medication all add noise to a measurement whose whole purpose is to establish whether the drug arrived. A clean dose-response in people whose biology is not confounded tells you more about the vehicle than a messier signal in patients would.

Then a qualification to the qualification. Spinal-fluid tau is an indirect measure, and nobody biopsied a brain. A diseased brain may differ in barrier integrity, in tau biology and in how the drug distributes. The healthy-volunteer result makes the delivery case stronger. The patient cohorts will show how much of it survives contact with the disease.

For Arrowhead. Now the stronger side.

Intellia reported its headline number at day 28. Verve used a time-weighted average from day 28. Wave saw a signal by day 15 and carried it to day 57 on one dose. Arrowhead’s 73 percent was measured ninety days after the last injection.

Ninety days does not simply beat twenty-eight, and it would be sloppy to claim it does. Intellia was editing DNA, aiming at a permanent change, so its short observation window was never the point. Arrowhead is silencing RNA, which wears off. The significance of day 105 is not that the number is larger. It is that substantial suppression persisted a quarter after the last injection from a drug that makes no permanent change at all, which is what an infrequent dosing schedule would require. That is a potential commercial advantage, provided efficacy and repeat dosing hold up.

Arrowhead showed rising mean suppression across three dose levels, 40, 69 and 73 percent, though the top two are close together and the highest cohort received two injections where the others received three. Verve’s safety signal cost it forty-one percent. Arrowhead’s interim safety observations were encouraging, including on the specific risk that attaches to its delivery receptor.

Then the organ.

7. The liver is the cooperative one

The next paragraph is the argument.

Lipid nanoparticles, the delivery vehicle in both of those gene-editing programs, reach the liver with the biology helping rather than resisting. Put them in a vein and the liver takes them up through a receptor it already uses for cholesterol. Getting that to work took real engineering and years of it. The point is that the organ was cooperating.

The brain is the opposite. Plenty of small molecules cross its barrier, which is why anesthetics and antidepressants exist. What that barrier excludes is large charged molecules, and an siRNA construct is exactly that. Oligonucleotide drugs that reached the human brain before this week generally required direct administration, most often a needle between the vertebrae.

Two companies demonstrated they could reach the organ where the biology cooperates, and the market repriced them by tens of points each.

8. What actually changed

Not the market’s appetite for platform data, as Verve shows. Not the quality of the evidence, which is stronger on durability and safety and weaker on population. What may have changed is how the company gets valued.

Intellia in 2021 and Verve in 2023 were primarily platform companies. Each booked some collaboration revenue, and neither had an approved product generating commercial sales. The platform dominated the investment case. Validate it and every number in the model moves, because there was little else in the model to anchor them.

Arrowhead’s chief executive, Chris Anzalone, called this a therapeutic holy grail on the call, and had the sense to flag that the term is overused before he used it. He is not wrong about the difficulty. Delivering an oligonucleotide into the brain from a shot under the skin is a problem the field has failed at for thirty years.

The trouble is that difficulty is not an input. A model has fields for market size and launch year and none for how long a problem went unsolved.

Which produces an odd result. An easy problem gets solved on the way to a product, so its value lands inside somebody’s forecast. A genuinely hard one gets solved before the business that would use it exists, so no forecast has been built. The harder the problem, the less a spreadsheet has to say about having solved it.

Chess engines are useful here. They used to judge a position by adding up terms a programmer could name: material, king safety, pawn structure, mobility, each weighted in advance by somebody who decided what mattered. Then in 2017 a program called AlphaZero, which had been given the rules and left to teach itself by playing, began handing over material for positions the old arithmetic had no term for, and winning. The arithmetic was not wrong. It was counting pieces at a moment when the position had become about what the pieces could reach.

A discounted cash flow model is an evaluation function. Somebody decided in advance which terms it contains.

A blank field is not an estimate of zero. It is a decision not to estimate.

Put plainly for anyone who skipped the chess: this is a limit of the instrument, not a judgment rendered by it. Discounted cash flow can be extended to value uncertain platforms, and real-options methods exist precisely for this. The question is whether the published models reviewed here do any of that.

Arrowhead has an approved drug, a Phase 3 readout, and 1.6 billion dollars. It is priced on discounted cash flow now, anchored on a cardiovascular franchise. Five of the commercial assumptions such a model runs on are market size, penetration, price, probability of success and launch timing.

A healthy-volunteer biomarker, against a target no regulator has ever approved a drug for, supplies too little to populate those inputs with any confidence.

9. A drug, and a method for making drugs

A drug is a bet on one molecule, one disease, one market. A delivery platform is a bet on the ability to place more of those bets.

If ARO-MAPT fails in Alzheimer’s, one therapeutic hypothesis failed. It does not undo the evidence that this construct crosses into the brain and lowers its target there. If the same chemistry carries a different payload, the consequences are not confined to tau.

One experiment changed the odds on experiments nobody has run yet. That is what separates a platform from a drug.

Though it is not one key. The chemistry carrying siRNA into muscle for the Sarepta programs is an integrin-targeting ligand. The construct going into the brain uses an antibody fragment against a different receptor entirely. These are not the same key.

That does not weaken the argument. It changes what the argument is about. Arrowhead is not demonstrating that it found a universal delivery molecule. It is demonstrating that its approach to engineering tissue-specific delivery keeps producing solutions for tissues that did not have one.

A key that opens one door is useful. A method for cutting keys to doors nobody could open before is a different asset.

A platform also creates choices, not only programs. Arrowhead does not have to pursue every target it can now reach. It can select, abandon, partner or keep, and revise as the biology comes in. Maintaining the capability costs money every year, so flexibility is not free and does not by itself imply a positive number. That flexibility may carry economic value even so, and a forecast built around individual drugs has no place to put it.

Opening a file does not require the rook to move. It gives the rook moves it did not have before.

Liver, then lung, then muscle, then fat, now brain. None of these opened the same way. The lung program used an inhaled route. The fat program showed suppression directly in tissue. The brain program gives pharmacodynamic evidence after a subcutaneous shot, with nobody biopsying a brain. Different problems, different routes, different grades of evidence.

Which is the point rather than a weakness in it. The common achievement is not that every organ has fallen. It is that the same group keeps finding ways to make siRNA work in tissues that had no way. None of that guarantees the next door opens. The list of doors already opened is what is being priced here, or not priced.

A portfolio of unrelated drugs is a set of separate bets. A portfolio built on shared delivery engineering has a common layer beneath it. Every new target still carries its own biology, but none starts from zero on whether the drug can get there.

There are two levels to this and they behave differently. Within the brain, programs using related machinery share technical risk directly. Across organs, what is shared is broader and looser: the engineering capability that keeps producing tissue-specific solutions.

The correlation cuts both ways at each level. A problem with the brain receptor would damage several brain programs together, and would say little about muscle, which uses a different mechanism entirely. One platform does not mean one risk. It means related capabilities whose risks overlap in some places and not others.

Correlation is not a gift. It is a property.

It also means the cause of any future failure matters. If tau turns out to be the wrong target, the delivery evidence survives more or less intact. If the construct proves toxic over time, or distributes worse in sick brains than in healthy ones, the platform takes the damage with the drug.

This is not speculation about targets Arrowhead might one day find. On Wednesday’s call Chris Anzalone said the company already has one wholly owned and one partnered brain program in the clinic, expects another partnered candidate there in 2027, and intends to put at least three more wholly owned candidates into the clinic inside twelve months. He described the platform as feeling like a company’s worth of value on its own.

A reader can discount all of that. Transferability to other targets is unproven. The doses are high. Manufacturing, long-term receptor safety and real clinical convenience are all open. One target is not a platform. Each of those argues for a discount, possibly a brutal one, and together they may fully explain why an analyst declines to put a figure on it today. That is a different claim from the capability being worth zero, and the narrower one is the only claim this note makes.

In chess, opening a file changes what every piece that can use it is worth. Arrowhead may have opened one. The models are still counting pieces.

10. At least three analysts said it out loud

Three banks published on Arrowhead this week, and these are only the notes I could read. All three are positive on the stock. None of the three identifies a material contribution from the brain program to its published target.

Figure 3. Compiled from the three published research notes available to the author, all dated October 14, 2026. Other banks cover Arrowhead and their models were not reviewed.

UBS is the most explicit, and the most useful, because it states the mechanism rather than hiding it. ARO-MAPT is not included in the valuation and represents upside. That is not a judgment that the program is worthless. It is a statement that the model has no field for it.

Stifel reaches the same place in plainer language, writing that there is no credit here and that severe hypertriglyceridemia remains what matters for the stock. Morgan Stanley’s risks to the target, up and down, are cardiovascular and obesity. The brain appears on neither list.

A caution about all of this. One limitation has to be stated plainly. Published analyst targets are not the market. They are evidence of how several influential participants are framing the problem, and no more than that. Private models, discretionary positioning and speculative premium could all carry CNS value that never appears in a price target, and the trading record cannot tell us how much of this was already discounted.

What the three notes do establish is narrower. Substantial new clinical evidence arrived, and explicit value for it is hard to locate in the models I could read.

11. What these numbers are actually made of

One more item from the UBS note, because it reveals what price targets are made of.

UBS raised its target from 63 dollars to 109, a jump of 73 percent, on assumption of coverage. A new analyst took the pen. The note is built on the cardiovascular franchise and explicitly excludes the brain, so whatever moved the number by three quarters, it was not the data that landed that morning.

That is not a criticism of the analyst, whose model is more thorough than most. It is a reminder of what a price target is: one person’s spreadsheet, which changes when the person does.

12. What would make me wrong

The populations differ. Intellia and Verve dosed patients. Arrowhead dosed healthy people. If the market simply weights that difference more heavily than I do, the whole comparison softens.

Perhaps the market expected it. Prices move on the distance between a result and what was already believed, not on how important the result is. Arrowhead had announced the readout in advance, booked a webinar, and discussed a benchmark of 50 to 60 percent beforehand. Seventy-three cleared it. Whether it cleared what investors had already priced is a different question, and management’s stated objective is not the same as the market’s expectation. I cannot rule this out, and it is the best argument against the whole of this note. It does raise a second question. If the market already expected systemic silencing in the brain to work, that expectation should be visible somewhere in what the brain is worth. In the three models I could read, it is not.

Not every biomarker is equal. Cholesterol is a validated treatment target with decades of outcome data behind it. Tau is biologically compelling and therapeutically unresolved. A 73 percent reduction in spinal-fluid tau establishes pharmacology, not a reduction in anybody’s risk of dementia, and a market discounting the commercial program on that basis is making a defensible judgment rather than an error.

Which leaves the question this note keeps circling. If tau turns out to be the wrong target, does the ability to deliver gene silencing into the human brain become worthless? Those are two risks, not one, and no rule requires them to be priced together.

Tau has a history. Biogen’s diranersen lowered tau substantially, reduced tau on brain scans, produced encouraging cognitive signals, and still missed its primary dose-response endpoint. An older Biogen antibody against extracellular tau failed outright. A market that has watched this target disappoint may be pricing target risk rather than ignoring delivery, in which case it is making a judgment rather than an omission.

The stock was already broken. Arrowhead traded above 95 dollars inside the last year and sits near 58 now. A stock already down by a third on commercial worries may be too preoccupied to listen, which would be a different failure from the one I am describing.

Size matters. These companies were smaller than Arrowhead is now, and a move of forty percent on an eight and a half billion dollar company is a different ask than on a two billion dollar one.

They may simply be right. The last one is the serious one. The models may be right. A Phase 1 biomarker in six people, against a target with no approval precedent, may genuinely deserve a zero until there is more. Analysts have declined to credit assets before and been correct to wait.

Here is how to tell which of these is right. Those are three different explanations and they imply three different tests. If the market is waiting for patients, the Alzheimer’s and tauopathy data in 2027 should move it. If it will not credit the platform until a second target works, the first non-tau brain readout is the one to watch. If the constraint is commercial visibility rather than science, the next informative event may not be a readout at all. It may be a transaction, because a licensing deal requires somebody other than Arrowhead to put a number on this. Upfront cash, the breadth of target access and where the milestones sit would say more than another biomarker. A single-asset license and broad platform rights are very different signals. The next eighteen months may begin to separate them.

13. Twenty-four cents

The liver is the organ where the biology cooperates. Two companies showed they could edit a gene in it, in a handful of patients, with a biomarker and no clinical outcome, and the market repriced them by forty points in one direction or the other. In March it paid a third company roughly a third of its value for reaching muscle, using chemistry Arrowhead invented and licensed out.

The brain is the organ that a hundred years of pharmacology has failed to reach without a needle in the spine. Arrowhead reached it with a shot, in six people, with a biomarker and no clinical outcome, and held the effect for three months.

Twenty-four cents.

The market did not decide the brain was worth less than the liver. It never got as far as deciding.

A Note on Supporting Independent Research

If this white paper has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this white paper; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This paper is provided for informational and analytical purposes only. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security, and it is not a recommendation as to any corporate course of action. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results, and forward-looking analysis is inherently uncertain. The author and BioBoyScout are not registered investment advisors. The author assumes no obligation to update this paper. The characterization of what is and is not in the published literature, the probability judgments, and the chess analogy are the author’s own.

Intellia’s interim Phase 1 results for NTLA-2001 were announced on June 26, 2021, covering six patients across two dose cohorts, with an 87 percent mean reduction in serum transthyretin at the higher dose by day 28, and were published in the New England Journal of Medicine. The share move is as reported at the time. Verve’s interim results for VERVE-101 were presented at the American Heart Association Scientific Sessions on November 12, 2023, covering ten dosed and nine evaluable patients, with time-averaged LDL-C reductions of 39 and 48 percent in the two patients at 0.45 milligrams per kilogram, and a serious cardiac event in one participant judged possibly treatment-related. The share move is as reported contemporaneously. Sarepta’s first clinical results for SRP-1001 and SRP-1003 were announced on March 25, 2026.

Arrowhead’s proxy statement lists both as partnered programs under their former designations, ARO-DUX4 and ARO-DM1, and Sarepta’s siRNA platform is licensed from Arrowhead. That share move is also as reported at the time. Sector-relative comparisons use XBI, the SPDR S&P Biotech ETF, as the benchmark, on closing prices. The additional moves shown in Section 5 are drawn from company announcements and press coverage at the time of each release: Wave’s first-in-human RNA editing result of October 2024, from the ongoing Phase 1b/2a RestorAATion-2 study, and its multi-dose update from the same study on September 3, 2025, together with the same-day moves in Beam Therapeutics and Korro Bio, neither of which reported results that day.

ARO-MAPT results are from Arrowhead’s announcement and investor webinar of October 14, 2026. Price targets, model contents and the change in the UBS target on assumption of coverage are from research notes published by UBS, Morgan Stanley and Stifel dated October 14, 2026. Arrowhead’s cash and securities position is from its quarterly filing for the period ended June 30, 2026.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

Updated. This note has been revised twice since publication, both times because readers supplied better information than I had. Section 3 now leads with the explanation given by Sacha Schermerhorn, founder and chief executive of Babylon Biosciences, of why the 98 percent figure was close to guaranteed. Section 7 has been corrected: Biogen did publish per-regimen clinical results and a tau range for the Phase 2, which I had treated as unavailable. The correction strengthens the argument rather than weakening it, and the section says so.

1. The number everyone is waiting for

On Wednesday morning, Arrowhead will report the first human data for ARO-MAPT, its brain drug. Somewhere in the presentation there will be a percentage: how much tau the drug removed from the spinal fluid of healthy volunteers. Management has said publicly it wants to see somewhere between 50 and 60 percent.

Within an hour, that number will be on every message board and in every analyst note, and it will be treated the way a test score is treated. Higher is better. A 60 is a triumph, a 45 is a disappointment, and the stock will move accordingly.

I want to make a narrower argument than that. Tau drugs have produced two impressive numbers in the past five years. Both were real and both were earned. In each case the inference the field drew from the number turned out to be wrong, and it was wrong in a different way each time.

This note is about those two mistakes, and what they should change about how you read Wednesday.

Three questions sit behind any drug like this, and they are easy to run together:

1. Did it reach its target?

2. Did it change the pathology?

3. Did it help the patient?

Each of the two trials below answered the first one cleanly and then came apart at a different point. Wednesday’s number speaks to the first question alone. That is not a retreat from what I have written before, which argued that evidence of central nervous system pharmacological activity after a subcutaneous dose would be a major event for this company. I still think so. The narrower point is that one percentage cannot answer three questions.

A bigger number on Wednesday is not a better result. It is a different result, and the difference has to be argued for.

2. The first number: ninety-eight percent

A few years ago, Biogen ran a trial of a drug called gosuranemab in progressive supranuclear palsy, a brutal disease in which tau builds up in the parts of the brain that control movement and balance. The drug was an antibody. It circulated in the fluid around the brain and grabbed loose pieces of tau floating there.

It worked. In the published results, unbound tau fragments in spinal fluid fell by 98 percent. In a field where getting any drug into the brain is the central problem, that is an extraordinary measure of target engagement. The drug found its target and removed essentially all of it.

The disease did not notice. On the rating scale used to track how fast patients decline, the treated group worsened by 10.4 points over a year. The placebo group worsened by 10.6. The p value was 0.85, meaning the difference was well within what chance alone would produce. With nearly 500 participants and almost identical outcomes between the groups, the trial provided no persuasive evidence of clinical benefit. That is not the same as proving the true effect was exactly zero, and it does not need to be. A drug cannot be developed on an effect that large a study cannot see.

The lead investigator published that conclusion himself, and his wording was careful. Neutralizing tau at that particular end of the protein, he wrote, does not translate into clinical benefit. Not that tau is the wrong target. That one way of reaching it fails.

Ninety-eight percent target engagement. A rating scale that moved from 10.6 to 10.4. In most fields, that ends the target.

3. Why it failed, which almost nobody writes about

Start with the number, because it is less impressive than it looks. Sacha Schermerhorn pointed this out after publication and it is the cleanest account of the 98 percent I have seen.

It turns on one word in the trial report. The test measured unbound tau, meaning tau floating free, with no drug attached to it. The drug’s entire job was to attach itself to tau.

The test therefore could not see the tau the drug had grabbed. That tau had not left the body. It simply had a drug stuck to it, and the test only counted the free ones. Give a drug that binds tau, then count tau that is not bound, and the number falls. That is the drug working, not the disease retreating.

It is tighter than even that. The antibody grabs tau at one specific spot near the end of the protein, residues 15 to 22, and the test was looking at that same spot. Drug and ruler were pointed at the same small stretch of the same molecule. A large drop was close to guaranteed before anyone enrolled a patient.

The Alzheimer’s trial shows what happens when you measure a different way. At week 76, the unbound tau figure was down 93 percent. Two other tau measurements, ones that do not care whether a drug is attached, were down 23.8 percent and 15.5 percent. Same patients, same drug, same day. Only the ruler changed.

This is Goodhart’s Law inside a clinical trial. A measure that becomes a target stops being a good measure.

The test counted only the tau floating free. The drug’s job was to grab hold of it.

A cleaner number would not have saved it either, and the reason is in the tissue.

Three patients who received gosuranemab were examined after they died. The antibody had clearly acted. Tau had accumulated inside the disposal compartments of cells wrapped around blood vessels, exactly where a protein ends up after an antibody tags it for removal. The machinery worked.

What had not changed was the pathology. Compared with untreated patients, tangle burden was unchanged in the regions examined. Three brains is a small window, and the finding is an absence of observed reduction rather than proof that no tangle anywhere was cleared. The drug cleaned out one pool of tau and the tangles stayed.

Here is the part that makes it almost painful. In progressive supranuclear palsy, unlike in Alzheimer’s, total tau in spinal fluid is not elevated. The protein that causes the disease sits inside neurons and inside the support cells around them rather than floating in the fluid. The various tau measurements are not interchangeable, so this is a statement about the pool the antibody could reach, not about every form of tau in the body.

The antibody therefore cleared almost all of a pool that turned out to be too small, or too far from the pathology, to change the course of the disease. That is not proof that loose tau plays no part in progressive supranuclear palsy. It is proof that removing it was not enough. The drug was fishing in a nearly empty pond, and it caught almost every fish in it.

The Alzheimer’s trial closes the argument. There the extracellular pool the drug targets is genuinely present, and spinal-fluid tau is elevated. The drug engaged its target again. It failed on the clinical endpoint, failed on every secondary endpoint, and left tau PET unchanged after a year and a half. The company ended the program.

The argument therefore does not depend on a quirk of progressive supranuclear palsy. Clearing loose tau outside the cell did not change the pathology in either disease, including the one where there was plenty of it to clear.

Ninety-eight percent of one pool of tau. No measurable reduction in tangles, in either disease.

4. The obvious fix, and why it is harder than it looks

The natural response is to build a better antibody, one that goes after the misfolded tau rather than the loose fragments. The chief executive of Eli Lilly made exactly this point in an interview last week: tau is essential, he said, and what you really want is the misfolded kind.

That instinct is right, and the execution runs into two walls that have little to do with effort.

The first wall is that a shape is not a sequence. Misfolded tau is not a different protein. It is the same protein, from the same gene, with the same sequence of amino acids, folded into a different three-dimensional shape. Misfolding happens after the protein is built. There is no misfolded tau gene and no misfolded tau message, so a drug that works at the genetic level has no target to aim at. A shape cannot be silenced.

The second wall is geography. Over the past decade, researchers in Cambridge imaged tau filaments pulled from the brains of people who died of different tauopathies. Alzheimer’s folds tau one way. Pick’s disease folds it another. Progressive supranuclear palsy, corticobasal degeneration and the dementia seen in former boxers and footballers each have their own fold. The folds are so distinctive that the field now classifies these diseases by structure rather than by symptoms.

As one of those researchers put it, different folds mean different chemical surfaces. A drug precise enough to recognize the misfolded shape in Alzheimer's has no guarantee of recognizing the misfolded shape in progressive supranuclear palsy, because it is a different surface. Some binding sites may turn out to be shared across diseases. The point is that cross-disease reach becomes a question to prove rather than a property you get for free.

Which produces a result nobody expects. The more precisely you aim at the bad tau, the harder it becomes to claim the rest of the board. Precision is usually free. Here it has to be paid for one disease at a time.

The more precisely you aim at the bad tau, the harder it becomes to claim more than one disease.

5. The other approach, and why it is cruder on purpose

The alternative gives up on telling good tau from bad. It lowers the production of all of it.

The logic rests on how tau pathology spreads. Misfolded tau does not sit still. It recruits normal tau and templates it into the same bad shape, and the pathology travels from region to region along the brain’s wiring. Lower the supply of normal tau and you starve the process of raw material.

If a fire spreads by catching nearby fuel, you can fight the fire or take away the fuel. Fighting the fire requires telling one shape from another. Removing the fuel does not.

It also works in the right place. These drugs act inside the neuron, on the message before the protein exists. That is the same compartment the tangles occupy. The antibodies were working primarily outside the cell, while much of the established pathology sits inside it.

Because every tauopathy is built from the same raw material, one drug has a claim on all of them. The crude approach keeps the whole board.

6. The second number: tangles, reduced

This is where the story gets genuinely good, and then genuinely complicated.

Biogen and Ionis built a drug called diranersen that does exactly this. It lowers the production of all tau. Because it is an antisense drug with no way of reaching the brain on its own, it has to be injected into the spinal canal.

In May, the Phase 2 study read out. Tau PET signal, which images aggregated tau in a living brain, fell in every dose group. The Alzheimer’s Association described this as the first Phase 2 evidence that a treatment can remove tangles from a living human brain, though a drop in imaging signal and the physical disappearance of individual tangles are related measurements rather than the same one. Decline slowed on multiple cognitive measures. Ninety-four percent of participants chose to continue into the extension study.

The trial also missed its primary endpoint.

7. How it missed, which is the whole point of this note

The primary analysis was designed to detect a dose-response relationship in clinical outcomes, not simply to determine whether any treatment group differed from placebo. It used a statistical method that compares the observed results against several pre-specified shapes a dose-response curve might take, measured on a standard dementia rating scale at week 76.

The trial did not establish that relationship. What it did instead is more interesting, which is why the miss is worth a section of its own.

Three regimens were tested over eighteen months: 60 milligrams every six months, 115 milligrams every six months, and 115 milligrams every three months. Against placebo, on the dementia rating scale, decline slowed by 26 percent, 14 percent and 9 percent respectively. On a cognitive test, 42, 32 and 29 percent. The lowest dose produced the largest effect on five of six measures, and most of its differences reached nominal significance. Biogen’s own language is that higher doses were not associated with greater slowing of decline.

Now put the biomarker beside it. Across all three regimens, spinal-fluid total tau fell by 50 to 65 percent. The company reported that as a range across the doses rather than a figure for each, so the exact pairing is not public. What is public is the shape: the biomarker moved within a narrow band while the clinical benefit nearly tripled in the opposite direction.

Tau fell across a band of fifteen points. Clinical benefit tripled as the dose came down.

That is not a study that could not test the relationship. That is a study that tested it and found it running backwards.

I want to be careful about what that does and does not prove, because the careless version of this is wrong. This is one Phase 2 with three arms and sixty patients in the group that did best. Most of its clinical differences were nominally significant rather than formally so, meaning they were not corrected for testing several endpoints at once. A larger trial could show a perfectly orderly relationship, and the inverse pattern could be an artifact of how the arms happened to fall out.

What it establishes is narrower and harder to argue with: across the doses tested, higher doses were not associated with greater clinical benefit. The relationship everyone assumes exists was examined directly in the only randomized trial of this mechanism, and the data came back pointing the other way.

Figure 1. Two biomarker successes with different limits.

8. What this changes about Wednesday

Put the two together. The first number was 98 percent, and it bought no benefit because clearing that pool was not enough to alter the course of the disease. The second number showed tau pathology genuinely falling on brain scans and decline slowing at every dose, and the clinical benefit still ran backwards against dose. Why is unsettled. The biomarker moved within a narrow band while the clinical effect did not.

On Wednesday a third number arrives. It will measure how much tau left the spinal fluid of healthy volunteers who do not have the disease, do not have tangles, and will not be followed for cognitive decline.

Figure 2. Compiled from the published trial results described above. The ARO-MAPT column describes what the study can and cannot measure, not a prediction.

Set the three programs side by side and the shape of the problem is visible. Two of them have been tried in people and neither settled the question. The third changes one variable, and it is the one nobody has solved.

I am not saying the number is meaningless. It is the first meaningful test of whether a shot under the skin can produce tau lowering in the human central nervous system, and that is a genuinely large question nobody has answered. It is the right question for this stage of development.

I am saying the number answers the first of the three questions and leaves the other two alone. It tells you a shot under the skin can lower tau in the human central nervous system. It does not tell you how widely the drug reached the neurons that matter, how much pathology would change, or whether a patient would be better off. A 60 would demonstrate greater tau suppression than a 50, and that is a real pharmacological result. It would not establish greater clinical benefit.

One corollary is worth stating plainly, because it cuts against the way this will be covered. ARO-MAPT could fail as an Alzheimer’s drug and still matter enormously to Arrowhead. If a shot under the skin produces real pharmacological activity in the human central nervous system, that result belongs to the delivery system rather than to tau, and the delivery system is what the company has spent a decade building. Whether it carries to other brain targets would still have to be shown, one target at a time. The competition sharpens the point.

Novartis has an antisense drug against the same gene, NIO752. In a Phase 1 trial in progressive supranuclear palsy, spinal-fluid neurofilament light held steady in treated patients while it climbed on placebo. That was presented at a conference rather than published, and I have not seen whether it was a prespecified endpoint or an exploratory one. A Phase 3 is planned, with a motor rating scale as the primary measure. It is delivered into the spinal canal. The point is that the two questions can be answered differently, and most coverage will treat them as one.

The target is not what separates these programs. The needle is.

The drug could fail and the delivery system still succeed. Most coverage on Wednesday will treat those as the same result.

9. Six readings worth more than the percentage

If the headline number carries less information than it appears to, the rest of the presentation carries more. Here is what I will be reading.

Figure 3. Author’s list, drawn from the trial registration, the primate data Arrowhead has published, and the two trials described above.

The study day matters more than most people realize. Tau is a long-lived protein and the pool turns over slowly. In Arrowhead’s primate work, knockdown took three to four months to reach its floor, though an animal timeline is a hypothesis about humans rather than a schedule. If Wednesday’s sample was drawn before the effect reached its maximum, the reported figure understates where the drug was heading. A 50 percent reduction on a curve still descending may be more informative than a 60 percent reduction that has already flattened.

The dose question is the direct lesson from the Phase 2 above, and it is worth setting out the possibilities before the data arrives rather than improvising at eleven in the morning.

The strong version. Cohorts separate on dose, the reduction holds at a later study day, and safety is clean. That is strong evidence the delivery system works, and the best case available from a study of this design.

The ambiguous version, which will be misread. Cohorts converge on a similar reduction regardless of dose, with clean safety. That looks like a disappointment and may not be one. It resembles the pattern the antisense data showed, where the biomarker moved within a narrow band across a wide dose range, and it would still establish pharmacological activity in the central nervous system from a subcutaneous dose.

The bad version. A small reduction, or one that fades by the later sampling points. That raises a specific question about whether the primate results translate, or about whether the dosing schedule is right, and it is the version that would actually matter.

The middle case is the one to prepare for. It will look like a miss and may be the same ceiling the antisense drug approached.

10. Why the speakers tell you more than the slides

One more observation, and it is the kind that has served this newsletter well before.

Arrowhead did not book a generic expert for Wednesday. It booked Adam Boxer of the University of California, San Francisco. Boxer ran the trial described in section two. He published its failure and wrote the sentence concluding that neutralizing tau at the N-terminus does not work. He also leads the research program that established spinal-fluid neurofilament light as a measure of how fast these diseases progress, and he runs two government-funded platform trials where the next generation of tau drugs will be tested.

When the first results from the antisense approach appeared, Boxer called it a landmark study of human tau therapeutics, the first to target tau at the genetic level. The man who published the obituary for one approach called the other one a landmark.

His talk on Wednesday is titled Silencing MAPT in Alzheimer’s Disease and other Tauopathies. The last three words are the ones to notice.

In November, the full scientific data goes to a different conference, presented by Catherine Mummery of University College London. Mummery was first author on the first human study of the antisense drug and presented its Phase 2 results in July.

Between them, these two people ran the defining tau-lowering programs in the world. Their participation says a good deal about how seriously the field takes this drug. It does not establish that the drug works, that a particular indication is coming, or that any specific plan exists. Credentials are evidence of standing, not of outcome. Still, a company that books these two speakers has made a choice, and the choice is legible.

Arrowhead did not book a generic expert. It booked the man who buried the alternative.

11. What would make me wrong

The lowest-dose finding may not replicate. The dose-response result came from one Phase 2 with three arms. Statistical noise explains a great deal in studies that size, and a larger trial could show a perfectly orderly relationship between dose and benefit. If it does, the central argument here weakens considerably.

Antibodies are not dead. The first generation of antibodies aimed at the wrong end of the protein. A second generation aimed at the middle, and one of them slowed the rate of tau accumulation on brain scans by roughly a third to nearly 60 percent, with cognitive signals in some subgroups. It still missed its primary endpoint, and so did a competitor, but the selective approach is not finished. It may have needed a better target, not a different philosophy.

The crude approach has not won either. No tau-lowering drug has yet produced an unambiguous clinical win. Diranersen slowed decline and missed its primary. That is a result worth having, and it is not the same as proving that lowering tau helps people.

The seeding model could be wrong. The argument in section five depends on misfolded tau recruiting normal tau. If pathology propagates some other way, lowering the supply accomplishes little and only clearance matters.

Somebody may solve the selectivity problem. Targeted degraders, which hand misfolded proteins to the cell’s own disposal machinery, could eventually crack conformational selectivity from the other direction. They are early and the brain-penetration problem is real, but the geography argument in section four assumes nobody cracks it.

Lowering tau is not free. Reducing a protein the brain normally makes, by half, for years, is untested. Animals missing tau entirely do reasonably well, which is reassuring, but the data are not perfectly consistent and no human has lived decades with less of it.

Receptor-mediated delivery carries its own questions. Carrying a drug into the brain by binding a receptor on the blood-brain barrier raises questions outside the brain, because those receptors are rarely confined to it. Depending on which receptor a program uses and how the molecule is built, effects on blood counts and iron handling have been a live concern for others working in this area. This note does not establish that the same applies here. A clean tau number alongside a blood-count signal would be a different story than it first appears.

12. The third number

There is a habit in chess worth borrowing here. Beginners count material. A queen is nine, a rook five, a bishop three, and the position gets judged by adding. Stronger players know the count is only the beginning. They read where the pieces sit, whether the king is safe, which files are open, who moves first. Counting is easy and reading is hard, and reading is what decides the game. A player can be a piece up and completely lost.

Ninety-eight percent was a material count. The position never changed.

The field has been handed two impressive tau numbers in five years. One cleared almost all of a pool, and clearing it was not enough to alter the course of the disease. The other lowered tau pathology in living brains and slowed decline across every dose, and then produced its largest clinical effect at its smallest dose.

Both drugs did what they promised. Both numbers were real. Neither number carried the information the field read into it, and in each case the reason was only obvious afterward.

On Wednesday, a percentage will appear on a slide and a great many people will decide what it means before lunch. The honest position is that if the number shows meaningful tau lowering, it establishes pharmacological activity in the human central nervous system from a shot under the skin, and that alone. If it does not, it raises a specific question about translation or dosing. Either way, that is the question Arrowhead has spent years and a great deal of money trying to answer, and nobody has answered it before.

The rest is for next year, when the patient cohorts can measure tau on a brain scan, track cognition, watch the nerve-damage marker, and run long enough for any of them to move. None of that is available from healthy volunteers, by design.

Two numbers, two wrong inferences. The third tells you whether a shot under the skin can produce meaningful tau lowering in the human central nervous system, and no more than that. It is still the only question worth asking this week.

A Note on Supporting Independent Research

If this white paper has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this white paper; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This paper is provided for informational and analytical purposes only. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security, and it is not a recommendation as to any corporate course of action. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results, and forward-looking analysis is inherently uncertain. The author and BioBoyScout are not registered investment advisors. The author assumes no obligation to update this paper. The characterization of what is and is not in the published literature, the probability judgments, and the chess analogy are the author’s own.

The gosuranemab results, including the 98 percent reduction in unbound N-terminal tau and the PSP Rating Scale outcome, are from the Phase 2 trial published in Nature Medicine in 2021. The postmortem findings in three treated patients are from a separate 2021 neuropathology report. The observation that spinal-fluid tau is not elevated in progressive supranuclear palsy appears in published reviews of tau-targeted therapy.

The cryo-EM filament structures and the structure-based classification of tauopathies are from work published by the Medical Research Council Laboratory of Molecular Biology between 2017 and 2021. Diranersen results are from Biogen’s topline announcement of May 14, 2026, the detailed presentation at the Alzheimer’s Association International Conference on July 14, 2026, and the Alzheimer’s Association summary of that presentation. Biogen reported mean spinal-fluid total tau reductions of 50 to 65 percent across all studied doses in the Phase 2, and reported that range across the doses rather than a value for each. The per-regimen clinical figures are from the same announcement.

The earlier Phase 1b tau PET findings are from Biogen’s 2023 conference disclosures and the subsequent publication in Nature Aging. Bepranemab results are from UCB’s Phase 2 presentations in 2024 and 2025. Adam Boxer’s role, publications, and research programs are from his university profile, the published trial, his comments to Alzforum, and public trial registrations.

The NIO752 Phase 1 neurofilament result and Phase 3 plan are from Alzforum’s conference coverage of the program in 2025, which reproduced the neurofilament figure courtesy of Gunter Hoglinger. I have not located a peer-reviewed publication of that result. The ARO-MAPT trial design and endpoints are from its ClinicalTrials.gov registration. The gosuranemab binding site at tau residues 15 to 22, and the week 76 values for unbound tau, phosphorylated tau and total tau from the Alzheimer’s trial, were supplied by Sacha Schermerhorn of Babylon Biosciences and are credited in Section 3. The interpretation throughout is the author’s own.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

1. The second wave

A new siRNA company seems to show up every month. One Chinese brokerage counted more than thirty small nucleic acid deals worldwide in 2025, worth more than thirty-six billion dollars, and Chinese biotechs have become one of the main sources of them. Argo Biopharma of Shanghai struck a pact with Novartis with a headline value of $5.2 billion.

SanegeneBio, founded in 2021 with labs in Boston and China, signed with Lilly for up to $1.2 billion, then with Genentech in February for $200 million upfront plus milestones of up to $1.5 billion. Big pharma, which once walked away from this field, is writing checks to companies that did not exist five years ago. Call them the second wave: the siRNA companies founded since about 2020, many of them Chinese, building on the published playbook. Avidity and Dyne, which appear later, came earlier and are not part of it.

Readers keep asking me whether these newcomers threaten Arrowhead and Alnylam. The honest answer has two halves. In the liver, the newcomers are real competitors, and I will explain why. Beyond the liver, and in the brain above all, they are about to play a game whose middlegame nobody has written down.

A quick word on what these companies make. An siRNA is a short strand of genetic material that tells a cell to stop making one protein. Much of the core chemistry of the strand itself is well understood. The hard part has always been delivery: getting the strand into the right cells, in the right tissue, in enough quantity to matter, without doing harm along the way.

The newcomers can buy or hire the answers to yesterday’s problem. The next problem has no answer key.

The gap between knowledge that can be copied and knowledge that has to be earned is the whole argument of this paper.

2. The first wave

This has happened before, and how it ended is the most useful lesson in this paper.

Between 2006 and 2010, the biggest companies in medicine decided siRNA was the future and bought in. Merck paid $1.1 billion for Sirna Therapeutics in 2006. Roche paid Alnylam $331 million in 2007. Novartis partnered with Alnylam. Pfizer, Abbott and others built programs of their own.

Then they left, one after another. Roche shut down its RNAi research in 2010 after spending roughly half a billion dollars on it over three years. Novartis declined to extend its Alnylam partnership the same year, triggering layoffs at Alnylam. Pfizer closed its 100-person RNAi unit in early 2011, and Abbott quit too. Merck sold Sirna to Alnylam in 2014 for $175 million, about one-sixth of what it had paid, explaining that it wanted less emphasis on platform technologies. Novartis exited the field that same year, citing ongoing challenges with formulation and delivery, and in 2015 sold what it had kept to a small company in Pasadena called Arrowhead.

Figure 1. Sources: company filings and contemporaneous reports. Dates are the public announcements.

Here is the part that matters most. The first wave did not fail somewhere exotic. It failed at the liver. Early trials were confounded by inflammation from the fatty particles used to carry the drugs, and it was hard to even prove the effects came from silencing the target. The science was getting better fast. Pfizer’s own former chief scientist for its RNAi unit said liver knockdown improved about a hundredfold between 2008 and 2011. The companies left anyway, because the improvement was not arriving on the clock their boards were watching.

Alnylam’s president at the time called big pharma a miserable barometer of new platforms, and pointed out that it had made the same mistake with antibodies a generation earlier. He was right. By 2019, Novartis, Regeneron and Roche were all buying back in.

The last time everyone entered this field, the entrants were the richest companies in medicine. Nearly all of them left, and the problem that beat them was the liver.

3. What it took to survive

The two survivors did not win because they never failed. They won because they failed at the worst possible moment and kept going.

In October 2016, Alnylam halted revusiran, its second most advanced drug, after 18 patients died in a 206-person trial and the data showed more deaths on the drug than on placebo. The stock fell 48.5 percent in a day. A month earlier, it had stopped another program after liver enzyme rises in healthy volunteers.

Seven weeks later, Arrowhead discontinued all three of its clinical programs. Its intravenous delivery vehicle had caused deaths in a primate toxicology study, at doses higher than those planned for people, and regulators made clear the questions would take a year and a half or more to answer. The stock fell more than 65 percent in a day.

Both companies came back. Alnylam’s first drug was approved in 2018, sixteen years after the company was founded. Arrowhead already had a new system, given by a shot under the skin, working in animals at lower doses with good safety margins. That system, the one it uses today, reached the clinic within about two years.

What each company carried out of 2016 was not a drug. It was a record: which sequences caused trouble, which chemical changes made the difference, what the monkeys showed before the people did, and how to read early warning signs the next time. Fragments of that record show up in papers and patents. The complete failure history does not, and it is the main asset a newcomer cannot buy.

The survivors are not the ones who never failed. They are the ones who failed in 2016 and kept the notes.

4. In the book: the liver is open

Chess players call published opening theory the book. Anyone can study it, and strong players know it cold. A decade ago the liver was out of book. Today it is in it.

The reason is a sugar tag called GalNAc, which steers an siRNA to liver cells, plus a set of chemical changes that let the drug survive in the body for months. Alnylam worked that out over years of trial and error. The methods have been published for a long time, the core patents are aging, and the rest of the field has learned them. A well-funded newcomer with experienced hires can now build a competent liver drug far faster than the pioneers could. The deal flow shows it. The Argo programs Novartis licensed are liver-delivered drugs for heart and metabolic disease, and some are already in mid-stage trials.

The clearest American example went public in late September. ADARx was founded in San Diego in December 2019 and is run by Arrowhead veterans. Its chief executive, Zhen Li, worked on siRNA chemistry at Merck and later ran chemistry and nonclinical development at Arrowhead. Its chief technology officer, Rui Zhu, was a key inventor on the programs that became Arrowhead's Redemplo.

The company's name comes from ADAR, the enzyme behind RNA editing, and in its early years it described a platform for silencing, degrading and editing RNA. By the time of its IPO, its filing described a next-generation siRNA company, and its three drugs in human trials all silence genes in the liver. It raised $446 million in an upsized offering, after AbbVie paid $335 million upfront for options on its next drugs. Its programs beyond the liver are still preclinical, and its brain program is not expected to enter a first trial until late 2027 or early 2028.

The company has not said why its emphasis changed, and I will not guess. The record shows what reached the clinic first. Veterans carry the book with them, and what they build first is what is already in it.

The pattern holds at the very top of the field. John Maraganore, who built Alnylam, co-founded City Therapeutics in 2024 to take RNAi beyond the liver. Its first two drugs, one already in human trials and one about to start, both work through the liver.

I want to be straight forward about what that means for Arrowhead, because it is not comfortable. The company’s approved drug and most of its near-term revenue come from the liver. Its nearest competitor there today is Ionis’s Tryngolza, not a Chinese copy, and Chinese liver drugs are still years from an American or European label. When they arrive, they will press on prices and on what Arrowhead can charge partners for liver programs. That pressure is coming. It is not here yet, and any paper that pretends it will never come is not worth your time..

The liver was the moat. It is becoming the commons. The moat did not disappear. It moved.

Notice the shape of the history, though. The first wave failed at the liver because the liver was out of book. The newcomers can succeed at the liver because they arrived after the book was written. Beyond the liver, they face a problem structurally similar to the one Merck and Roche faced in 2008.

The important point, then, is not that Arrowhead and Alnylam still own the liver. Increasingly, they do not. It is also not that every tissue beyond the liver is equally unknown. The board now has five parts. The liver is becoming a commons.

Muscle already has an opening, written by someone other than Arrowhead or Alnylam. Fat cells have an early opening, first sketched by Arrowhead. The lung has a more developed one, also Arrowhead’s, reached by inhaler. The brain has no book yet for anyone, the incumbents included, and neither do the eye or the heart. The advantage has moved toward the parts of the board where the field has not standardized the answer: getting into new tissues, knowing early when a program is going wrong, and having the history to prove a chemistry is safe.

Patients, the barrier that grows after success. This one does not fade as the book gets written. It grows. Once a drug is approved for a disease, the next one has a harder time finding patients. Doctors and ethics boards are reluctant to give a placebo to patients who could take a drug that works, so later trials usually test the new drug on top of the approved one, or against it. That takes more patients, a bigger effect and more time. In rare diseases, the few centers that see these patients are often already running the first company’s trials. The chemistry of the liver is a commons. The patients are not.

This barrier does not favor incumbents. It favors whoever is first in a disease, and Arrowhead knows it from the losing side, following Ionis’s Tryngolza into severe hypertriglyceridemia. For the second wave, it compounds the problem. Many of the liver genes it is going after, such as PCSK9, APOC3 and Lp(a), already have approved drugs or late-stage rivals. A newcomer can build a competent liver drug quickly and still spend years filling the trial that proves it. China offers a partial way around, with large numbers of untreated patients and fast trial startup, but American regulators have been reluctant to approve drugs on Chinese data alone, so the global trial still has to be run.

The same logic runs in reverse in the brain. No drug is approved to slow PSP or inherited frontotemporal dementia. Whoever gets there first will not just win the first approval. It will make every trial after it harder to fill.

5. Out of the book: five barriers

The second wave is not entering the field to stay in the liver. Its ambitions extend to the brain, muscle, fat and lung, because those are among the major remaining frontiers. Those tissues are not equally open, though, and the incumbents are not only Arrowhead and Alnylam. Ionis has decades of experience with antisense, a cousin technology, in many of the same tissues, and Novo Nordisk owns Dicerna.

Muscle already has an opening. Avidity, now part of Novartis, delivered siRNA into human muscle with an antibody. Dyne uses a similar antibody to carry exon-skipping drugs into muscle, and the FDA accepted its first application in July, with a decision due January 21, 2027. A newcomer that reaches muscle in the next few years will mostly be learning an opening Avidity and Dyne have already demonstrated.

Fat needs a definition. The word does two jobs, so it needs pinning down. Some obesity drugs, including Arrowhead’s INHBE program, silence a gene in the liver and change how the body stores fat. Those are liver drugs, and they stay in the book. Others deliver the drug into fat cells themselves, and in this paper, fat means that second kind. Here an early opening exists, and Arrowhead sketched it.

In January, it reported that its ALK7 drug cut the target gene in fat cells by a mean of 88 percent at the top dose, in four people at week 8, with a 14.1 percent placebo-adjusted drop in visceral fat after one dose. The company called it the first RNAi drug to silence a fat-cell gene in humans. It is small and early, a first page rather than a book. It shows the drug can reach the fat cell, and it has not yet shown how long the effect lasts. SiranBio’s SA030, licensed to GSK in May, is the first second-wave attempt to follow.

The lung has a short book. Arrowhead wrote this one too, by inhaler rather than injection, and it is further along than fat. Its inhaled drug ARO-RAGE was tested in a randomized trial in healthy volunteers and people with asthma, published in Nature Medicine in September. A single dose cut its target protein by a mean maximum of about 90 percent in fluid washed from the lungs, with silencing still deep weeks later, and asthma patients showed a matching drop in the blood. One company, one target, inhaled rather than injected, and not yet copied. That is closer to a short book than a first page.

The brain has no book yet. Here everyone is out of book, the incumbents included. Alnylam’s most advanced brain drug is still given by spinal injection, and Arrowhead’s shot under the skin gets its first human test on October 14. The same is true further out. Arrowhead lists the eye and heart muscle cells as preclinical delivery targets, though an unannounced eye drug, given by a shot under the skin, has been enrolling on the public trial registry since June. Nobody has shown either tissue reached from a shot under the skin in people yet.

The five barriers below apply most to the brain. They still slow anyone trying to copy the newer openings in fat and lung, where only one company has human data so far. They are not the same height, so I have listed them from tallest to shortest.

Figure 2. Author’s summary of what published science and patents teach a newcomer, and what they only partly reveal.

Failure memory, the tallest. A newcomer can hire veterans, and the best ones have, as ADARx shows. What it cannot hire is the shared record of what did not work, because that record lives in the group, not in any one person. I made this argument at length in The Seconds, and the second wave is its real-world test. Artificial intelligence does not automatically close the gap. The models learn from failure data, and much of that data is exactly what the incumbents never published. I should be honest that this is also the barrier I can least prove. Nobody outside a company can inspect its failure file, and the difference will only show when a new chemistry runs into a 2016style surprise.

Safety history. Regulators get comfortable with a chemistry slowly, one trial at a time. Arrowhead and Alnylam each have years of human safety data across thousands of people, counting their partners’ large trials. They also learned some lessons the hard way, as 2016 showed. A newcomer introducing a materially new chemistry starts much closer to zero, and the clock runs in years.

Monkeys, tall but changing. Delivery beyond the liver is hard to work out fully in mice. Blood-brain barrier crossing, muscle uptake and fat distribution differ between species, so for several tissues beyond the liver, and especially the brain, primate studies remain one of the most informative bridges between mice and people. Monkeys are scarce and expensive. In 2026 the price of a research-grade cynomolgus monkey in China reached about 200,000 yuan, roughly 30,000 dollars, close to its all-time high and more than double what it cost a year earlier.

For programs that lean heavily on primate testing, preclinical costs have run past twenty million yuan, with the monkeys as much as half of it. One Chinese brokerage projects a shortfall of fifteen to twenty thousand animals between 2026 and 2028. Well-funded companies lock in supply in advance. Biotechs with less cash have to choose which programs to delay.

It is not easier in the United States. China halted primate exports in 2020, and in 2021 the national primate research centers could not meet two-thirds of researcher requests. Arrowhead and Alnylam have more than a decade of primate data on their own chemistries. That history does not let them skip the studies for a new delivery handle.

Arrowhead’s brain drug still needed its own primate package. What the history buys is a shorter conversation with regulators about the backbone chemistry, and a trained eye for reading what the animals show. A newcomer gets neither, and has to queue for animals that cost far more than they used to. It is less a time machine than a head start. This barrier could also shrink as regulators push toward non-animal methods, a point I come back to in Section 8.

Patents, a middle barrier. The tricks for reaching new tissues are patented, and the incumbents hold many of them. A newcomer has to design around them or license them, and has to be ready for a fight if it guesses wrong. Alnylam has shown it will go to court over chemistry, suing Pfizer and Moderna in 2022 over lipid technology it says their COVID vaccines used. That case was about a different technology, though, and the patent estates that matter beyond the liver have not been tested in court against a newcomer. Determined competitors can sometimes design around them. I am asserting this barrier more than showing it, which is another reason it sits in the middle, and mapping those estates properly is a paper of its own.

Manufacturing, the shortest. This is the shortest barrier, and I want to be clear about why. Nobody needs their own factory to make clinical supply. Contract manufacturers exist, and some of the biggest are Chinese. That has turned from a convenience into a risk. The BIOSECURE Act became law in December 2025. In June 2026, WuXi AppTec, which makes drug substance for many American biotechs, including at least one oligonucleotide company, was added to the Pentagon’s list of Chinese military companies.

On August 7, a federal judge blocked the Pentagon from enforcing that designation while WuXi’s lawsuit proceeds, though a separate route onto the BIOSECURE list remains open and the first list is due by December. Existing contracts get a five-year grace period, and the law restricts federal contracts and funding rather than drug sales. Legally, it is a complication rather than a wall, and a shorter one than the June headlines suggested. The telling part is what happened anyway. Within weeks of the June listing, customers canceled projects or moved programs to other suppliers. Supply chains move faster than courts.

Arrowhead built its own 160,000-square-foot plant in Verona, Wisconsin, for about 250 million dollars, designed for commercial-scale production of its drugs. That is an advantage in control, supply and insulation from politics, not knowledge nobody else has. It matters most at scale, and the biggest-volume programs, such as liver-acting obesity drugs, sit in the part of the board that is becoming a commons. The plant protects the commoditizing business. It is not the brain moat.

A monkey costs thirty thousand dollars. The trained eye that reads the study does not come with the animal.

6. What the odds actually look like

I want to be careful here, because the easy version of this argument is wrong. Across all of drug development, experienced sponsors do only somewhat better than new ones. One study of trials across this century found the top twenty pharmaceutical companies took drugs from first human trials to approval 9.2 to 9.8 percent of the time, against 8.0 to 9.0 percent for biotechs. Sponsor track record does matter, and the BIO study of the last decade found it significantly tied to late-stage success, but it is a nudge, not a cliff.

The broad statistics, then, do not justify assuming the newcomers will fail. This field’s own history supplies a more specific warning. The first wave had more money, more chemists and more monkeys than any newcomer today, and nearly all of it left. The two survivors nearly died. That is a small sample from a different era, and I am not going to pretend it is a statistical base rate. It is a warning: when delivery moves beyond what is already solved, money and talent have not been enough to make development predictable.

The time it takes is just as telling. Alnylam was founded in 2002 and got its first approval in 2018. Even now, after more than twenty years, its most advanced brain drug is still given by spinal injection. If the company that wrote most of the liver book is still working out the brain, a five-year-old company should not be expected to do it on schedule.

The exception came before the second wave, and it proves the point. Avidity, founded in 2012, used an antibody rather than a sugar to carry siRNA into muscle. It announced the first delivery of siRNA into human muscle in December 2022, a decade after it started. In October 2025, Novartis agreed to buy the company for twelve billion dollars, a forty-six percent premium. The lesson cuts both ways. A newcomer can open a new tissue, given ten years and a book of its own. When one does, the prize is the whole company. That is the real claim of this paper. It is not that newcomers cannot succeed beyond the liver. It is that they cannot copy that success on the timetable the liver allowed.

The Avidity sale also sets up a choice for any company that wants into a tissue nobody else has opened. It can wait a decade for someone to write the book, or buy the company that already has.

Notice, too, how pharma itself is pricing the second wave. Most of every headline value is paid only if the drugs work. Argo’s 5.2 billion dollar Novartis pact came with 160 million dollars upfront. A 160 million dollar upfront payment against a 5.2 billion dollar headline looks less like full conviction than a relatively inexpensive option on future success. GSK’s deal for SiranBio’s fat-cell drug is starker still: 55 million dollars upfront against about a billion in milestones.

Here is how I would set the odds. In the liver, newcomers can win, and some will. They can be cheaper, and that is part of what pharma is buying. In the brain, the one tissue where nobody has an opening for a drug given outside the spine, they face most or all of these barriers at once. I expect most of those programs to arrive years later than planned, cost more than budgeted, and run into safety questions the incumbents have more practice reading. Whether their drugs will be worse is unknowable today, because no second-wave company has yet established a durable human opening outside the liver. That they will often be slower and more expensive is the part I would bet on.

The newcomers will be judged where their own book ends. For many of them, that is still the liver.

7. What to watch

This argument is testable, and the evidence will arrive over the next few years. Here is what I will be watching.

Copies of the existing openings, and the brain. Muscle data from a second-wave company would mostly show that the Avidity and Dyne opening can be learned. Fat-cell or lung data would show the same about Arrowhead’s openings. SiranBio’s ALK7 program for GSK is the first such test, and its Phase 1 data could arrive soon. Note how long each copy takes, because that is the real measure of a head start. The dataset that matters most is different: silencing in the human brain from a drug given outside the spine, by anyone other than Arrowhead. Nobody has shown it yet.

How much is paid upfront. If upfront payments start to rise as a share of headline deal values, pharma is gaining confidence in the newcomers. If they stay small, it is still buying options.

Monkey prices. Prices rising further means the barrier is getting taller. Prices falling, or new supply coming online, means it is shrinking.

The BIOSECURE list. Whether WuXi AppTec and others land on the government’s first list of companies of concern, due by December, and how quickly newcomers move their supply.

The first liver approval and its price. The first Chinese-origin liver siRNA approved in the United States or Europe, and the price it launches at, will tell you how much pressure Arrowhead’s liver franchise faces.

October 14. The first human data from Arrowhead’s brain drug, in healthy volunteers, arrives on October 14. It will show whether a shot under the skin gets the drug into the human brain and lowers its target. It will not show whether the drug helps anyone with Alzheimer’s. Patient data comes later.

8. What would make me wrong

Four results, in order of how much they would hurt the argument.

A newcomer reaches the brain in people, quickly. If a second-wave company shows lasting silencing in the human brain within the next two or three years, from a drug given outside the spine, especially with a pharma partner supplying the monkeys and the manufacturing, the barriers were lower than I have made them. That is the result that would hurt.

Monkeys stop mattering. The FDA published a roadmap in 2025 to reduce reliance on animal testing in preclinical safety studies. If lab-grown tissue models and computer simulations become acceptable substitutes for primate work faster than I expect, the monkey barrier shrinks, and so does the value of a decade of primate data.

The liver erodes faster than I think. If Chinese liver siRNAs reach approval and win share at prices Arrowhead cannot match, the liver section of this paper turns out to be understated, and the company’s near-term revenue is in more trouble than its platform story suggests.

A newcomer copies an existing opening, quickly. A second-wave company that matches Avidity and Dyne in human muscle, or Arrowhead in fat cells or the lung, within a few years would be mildly damaging. It would show that a written book can be learned fast, which shortens how long any head start lasts.

9. Out of book

When a chess player leaves published theory, the commentators say the game is out of book. From that moment every move has to be found at the board, on the clock, with no book to copy. Strong players prepare for this. They know the book, and they also know what happens after it ends, because they have been there before, lost, and written down what they learned.

In 2008 the liver was out of book, and the richest companies in the world could not find their way through it. The newcomers arrived after that book was written. In the liver they are already playing the middlegame, and pharma has paid for their seats. In muscle, one company wrote a book of its own and sold it for twelve billion dollars. In fat cells, Arrowhead has written the first page. In the lung, by inhaler, it has written a short book. In the brain, everyone is out of book, the incumbents included.

That is the honest shape of the advantage. It is not a locked position. It is a head start and a file of failures, in the part of the board where nobody has written a page. Arrowhead went out of book in 2016 without wanting to and has been playing at the board ever since. On October 14 it will show, for the first time in people, whether a shot under the skin can reach the brain. Whether that helps anyone with Alzheimer’s is a later question.

The opening is for sale now. The middlegame still has to be earned.

A Note on Supporting Independent Research

If this white paper has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this white paper; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This paper is provided for informational and analytical purposes only. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security, and it is not a recommendation as to any corporate course of action. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results, and forward-looking analysis is inherently uncertain. The author and BioBoyScout are not registered investment advisors. The author assumes no obligation to update this paper. The characterization of what is and is not in the published literature, the probability judgments, and the chess analogy are the author’s own.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

1. A number that should not be possible

At an R&D day in 2023, Chris Anzalone said something I went back and listened to twice, because the number sounded wrong. In 2017 the company had optimized its TRiM platform for liver delivery and had not yet advanced a single TRiM candidate into the clinic. By the end of 2023, six years later, it expected to have advanced eighteen.

Eighteen drugs into human studies in six years. Call it one every four months, from a company with a fraction of the people and the money that the big firms in this field have.

That was three years ago and the count has kept climbing. Chris put the number at twenty-one or twenty-two candidates in clinical studies at a conference on September 16, and the company guides to two or three new clinical programs a year. The cumulative total since 2017 is higher still, since programs have entered while some of the original eighteen finished, stopped or went to partners. I have not tried to add it up.

The clock starts in 2017 for a reason, and skipping past it would make this story tidier than it deserves to be. Arrowhead’s first delivery approach was a different chemistry entirely, and it had candidates in human trials years earlier. Those programs were discontinued in late 2016 after a safety finding in a primate study. The company then rebuilt around the platform it has now.

The eighteen were therefore not built on an unbroken run. They were built after an approach that reached the clinic had to be abandoned, which is worth remembering when reading anything about accumulated knowledge. Some of what accumulates is the knowledge of what did not work.

The standard explanation is that RNAi is somehow easier. It is not. Every one of those eighteen went through the same work any drug goes through. What changed is how much of that work had to be done from scratch. The difference is not speed. It is repetition avoided.

2. What actually happens

Start with the part everybody assumes is hardest, which is finding the molecule in the first place.

Say you want to switch off a gene. A computer reads the message that gene puts out and lists every spot along it where a short piece of RNA could grab on. For an ordinary gene that is hundreds of spots.

Figure 1. Funnel from a published academic effort against PCSK9, shown to illustrate the shape of the process.

Then you start throwing them out. Most get discarded because the same sequence appears somewhere else in the genome, and a drug that switches off your target plus two genes you were rather fond of is not a drug. A handful actually get built and tested in cells, because making these drugs is not cheap. The best of those go into animals.

Then comes the real filter, which is less elegant than everything before it. You give rats far more drug than any person would ever receive, and then you go look at their livers.

3. The forty percent that is not what it looks like

Alnylam has published its experience with this step. Roughly forty percent of sequences fail the rat screen, typically with liver damage showing up as elevated enzymes and dead cells under a microscope.

Forty percent sounds like a disaster. It is not, and the reason is the best thing about this whole business.

They can routinely find both toxic and non-toxic sequences against the same gene. In those experiments the damage was not generally caused by silencing the intended target. It was sequence-dependent, and came from the particular sequence hitting something it should not.

Which means the failure costs you a sequence. It does not cost you the target. You go back to your list of ten and pick another one.

Sit with that for a second, because it is genuinely unusual. In most of drug development, a toxicology failure can end the program. The molecule is the program. Here the molecule is one of several shots at the same target, and what you actually care about, the gene, is untouched by the failure.

That one property changes the whole shape of the risk. You are not betting on a molecule and hoping. You are betting on a target and running a search, and searches you can run again.

4. What gets built fresh and what gets inherited

Here is the part that actually explains the four months.

Every one of these drugs passes through the same stations. Pick the target, design the sequences, screen for what else they might hit, animal work, toxicology, manufacturing, the regulatory filing. Nobody skips any of it.

What changes is how many of those stations you have to build yourself.

Figure 2. Author’s grouping of which development steps recur and which carry over.

The chemistry is the clearest example, and Alnylam has documented its own version of this more openly than anybody. Bare RNA falls apart in the bloodstream within minutes, so the molecule has to be armored first. Alnylam arrived at its pattern through what the literature describes as a comprehensive screening effort across both strands of the duplex, optimizing where to place each modification.

That work was enormous and it was done once. Every drug after it inherits the template. Nobody sits down and works out where the fluorines go all over again. Arrowhead runs different chemistry on a different platform, and the principle is the same. The hard optimization happens at the start and is then applied.

Same story with the piece that finds the tissue. A little cluster of sugar molecules called GalNAc latches onto a receptor that sits on liver cells and almost nowhere else. Working that out took years. The twentieth liver target does not require working it out again, because it is the same chemistry attached to a different sequence.

The platform is not a shortcut through the work. It is knowing which work does not need doing again.

Chris put it more bluntly at a conference this September, when somebody asked whether artificial intelligence lets a newcomer leapfrog a company like his. Arrowhead has made hundreds of thousands of RNAi molecules over the years, he said, and has learned a great deal about what makes some potent and some not. An engine is only as good as the data fed into it. Brute force, in his phrasing, is a hell of a thing.

There is a third category the figure above does not capture. Every so often the platform does not simply produce another drug. It acquires a capability, and the capability itself becomes inheritable.

ARO-DIMER-PA is the current example. Getting two silencing triggers onto one molecule and showing that both work in a person took years and had never been done. Arrowhead reported it on September 15. Chris said the same day that several more dimers are already in development and some should reach the clinic in 2027, including work on both of the obesity and liver targets the company has been running.

He was also unambiguous about whether it worked. The goal going in was LDL lowering in the range of the existing PCSK9 drugs and triglyceride lowering in the range of plozasiran.

His verdict on whether they got there was that they hit both in spades, which is not the language of a man hedging.

The first dimer was expensive. The ones behind it inherit what the first one paid to learn.

The output of the first program was therefore not just a drug. It was a method.

5. Nobody sets out to build a platform

Worth pausing on how a platform actually comes into existence, because the word platform suggests somebody drew it up first.

They did not. You have a drug to make. You solve the delivery problem because that drug needs solving, and the solution turns out to work for the next one. You settle the chemistry because this molecule falls apart in blood, and the pattern holds for everything after. Each piece gets built to finish a specific job, and only later does anybody notice it keeps getting reused.

A platform is not designed. It accumulates, and you find out you have one.

Which means it is a ratio rather than a status. Look back at the two columns. Five things built fresh, six inherited. Early on that split runs the other way and almost everything is bespoke, and you are a company with a drug. Somewhere along the line the right-hand column outgrows the left, and the label starts to mean something.

The efficiency lands somewhere people usually miss, too. It is not that any single drug moves faster, because Chris was not claiming that and neither am I. It is that the twentieth program asks far less of the organization than the first one did. Less bespoke chemistry, less novel safety interpretation, less arguing with a regulator about a class nobody has seen.

That is why twenty-odd programs can run at once. Not because each one is quick, but because each one costs the company less of its attention than the one before it.

A company where every program needs its own delivery system cannot carry twenty. It does not have twenty programs worth of bespoke effort to give.

Which raises the question nobody asks about platforms. If they are this useful, why does almost nobody have one?

Look at the shape of the cost. You pay for that right-hand column years before it starts paying you back, by running program after program at full bespoke price while the ratio is still pointed the wrong way. Most companies cannot survive that stretch. They run one asset, or two, and get bought or run out of money long before the inherited column outgrows the other one.

A platform only becomes cheap after you have paid for it many times over, and the paying comes first. That window is where most of them die.

Arrowhead nearly did. Nine years in, with candidates already in human trials, the whole delivery approach came apart and everything built on top of it went too. What makes the eighteen worth noticing is not only the pace. It is that they came after that.

It runs the other way too, and this part gets missed. The inherited column only grows while programs are moving through it. The first nineteen tell you how to read the twentieth. Only running the twentieth gives you something new to learn. Stop running programs and the accumulating stops with them, which makes all this a flow rather than a stock.

6. Which is why you cannot start with one

Turn that around and you get the problem facing anybody trying to enter this field now, and there are a great many of them. Chris counted roughly a dozen Chinese siRNA companies at one point, and said several are fast.

They can buy speed. What they cannot buy all at once is history. Every item in that right-hand column was paid for by somebody, and a company standing up its first program pays for all of them at once while also doing the work in the left-hand column.

The obvious objection is that the chemistry is published, and it is. Alnylam has been unusually open about where the modifications go and why. You can read it this afternoon.

What gets published is what worked. Nobody publishes the two hundred thousand molecules that did not, and those are most of the dataset.

Chris describes the accumulating end of this less delicately than I would. Fifteen years of banging their heads against the RNAi wall, in his phrase, and no substitute for history to get there.

The literature hands you the answer. It does not hand you the map of wrong answers that had to be eliminated to find it, or tell you which of your own ideas are already on that map.

I would not oversell this. A newcomer can rent manufacturing from a contract shop, license chemistry, hire people who have done it elsewhere, and patents expire on a schedule. What is hard to buy is the accumulated record of failure, and even that is a lead measured in years rather than a wall. Chris said as much himself, and the qualifier he attached to it is worth more than the claim.

7. Why the safety package moves faster

This is where the months usually disappear, so it is worth walking through.

For programs like these, reaching a person has typically required formal toxicology in two species, rats and monkeys, running about a month with a recovery period after. That does not go away.

What changes is what the findings mean. Read a published tox package for one of these drugs and the same phrase keeps turning up. The changes observed in kidney and liver were in line with previously described effects for this class. Known. Expected. Already characterized.

A regulator looking at a novel chemistry has to work out which findings matter. A regulator looking at the twentieth molecule from a characterized class is comparing against a picture they already have.

The same logic runs through the primate work. Published work suggests the mechanism producing months-long silencing is conserved across rodents, monkeys and people. That is why the monkey number tells you something useful about the human one, and it is why a company that has run the comparison twenty times has a better sense of what its primate data is worth.

8. Where the preparation runs out

None of this helps you with a new tissue, and that is where the argument stops.

Change the destination and most of the right-hand column moves back to the left. You need a new ligand, which means finding a receptor that is abundant on the cells you want and scarce everywhere else. You need to prove it carries a payload inside. You need new safety work, because the class effects you have characterized were characterized in a different organ.

Chris has put the cadence at a new cell type every eighteen to twenty-four months. Seven are addressable by the company's account, and he said in September that clinical programs were running in five. The public trial registry already shows a sixth, an eye program that the company has not yet announced. That is the number that matters for anyone thinking about how far this extends, and it is a very different number from four months.

9. An and company, not an or company

There is a wrinkle here that makes that cadence less orderly than it sounds. Arrowhead does not wait for the validating result before building what comes after it.

Chris has a phrase for this and he uses it often enough that it is plainly not improvised. Arrowhead is an and company rather than an or company.

An or company picks. An and company builds the next drug while the current one is still being tested, and finds out afterward whether it needed to.

He said it again in September, then went further. The follow-on brain programs are being built right now, without waiting to see the tau data, exactly the way the later dimers were built before the first one had reported anything.

Which means the clock on the next tissue starts before the current one is proven. The two clocks overlap rather than queue.

That is real compression, and it comes with a bill the company has already had to pay once. Developing on the assumption that a bet lands is why the pipeline fills quickly. It is also why the collapse of the first delivery approach in 2016 cost more than one program. Everything built on top of an assumption goes when the assumption does.

Four months buys you another drug. Two years or so buys you another organ, and the second one is the expensive purchase.

It is also why the brain readout carries the weight it does. Not because one Alzheimer’s drug is worth more than the others, but because opening a tissue is the slow, costly part of this business and the brain is among the hardest tissues to reach.

Chris is also clear about the shelf life of all this. Asked in September about the number of Chinese companies now working in RNAi, he said Arrowhead holds multi-year head starts across these capabilities, then added the qualifier that matters. Multi-year, not forever.

10. What the clock actually looks like

Before you look at the chart, be clear about where it comes from. Arrowhead has never published a stage-by-stage timeline and neither has anybody else here. This is my reconstruction. A few durations have published sources and are marked. The rest are my estimates, and any given program can look wildly different depending on how well understood the target already is.

Figure 3. Author’s reconstruction, not a company disclosure. Teal bars have published sources. Brown bars are the author’s estimates. Any individual program can look quite different.

Two things jump out.

The first is that almost everything before the candidate is chosen runs in sequence. You cannot rank sequences before you have settled on the gene. You cannot test in cells until you have synthesized. You cannot run the rat screen until you have something worth screening. That whole stretch is a queue, one thing after another.

The second is what happens after. Formal toxicology and manufacturing start at the same moment and run alongside each other, because both need the same thing, which is a chosen molecule. The dosing and recovery periods are published at about three months, and call it five by the time the analysis is done. One large contract manufacturer advertises around nine months to deliver the first material made to clinical standard.

Which means the critical path between a finished candidate and a first patient can run through the manufacturing plant rather than the toxicology lab.

Treat that the way you would treat any conclusion built on estimates. It follows from the durations above, and if those are materially wrong, so is it.

That reframes a decision I have written about before. Arrowhead built its own plant in Wisconsin rather than renting capacity. Read as real estate that is a cost line. Read against this chart it is the company taking ownership of a potential bottleneck, on a platform designed to keep twenty things moving at once.

Arrowhead’s own chief medical officer handed me the limit on all of this, and I would rather quote him against my argument than tiptoe around it. Asked in September whether artificial intelligence would speed things up, James Hamilton said there is no substitute for running the clinical trial. Shaving a few months off discovery is fine, he said, but you still have to grind through every stage of development.

He is right, and it puts a fence around this entire paper. Everything described here compresses the path to the clinic. None of it compresses the path through one.

There is a harder version of that point, and it is the one I would put to myself. Eighteen candidates into the clinic is a count of entries, not of finishes. Some of those programs are no longer running. Getting to the starting line quickly and cheaply does not make a drug more likely to work once it is there, and on that question Arrowhead gets graded the same way everybody else does.

What the platform changes is how many times you get to take the test, and how early you can sit down for it. Those are worth a great deal. They are not the same as passing.

A Phase 3 cardiovascular outcomes trial takes the years it takes whether the molecule arrived in eighteen months or sixty. What the platform buys is more shots on goal and an earlier start on each. Development time cannot be recovered later, so that earlier start compounds across a pipeline.

11. Opening preparation

Chess has a version of this, and it is the closest analogy I have found to what is actually going on.

Two grandmasters sit down across from each other. Twenty moves in, one has burned four minutes on the clock and the other has burned an hour. Same board, same position, same rules. One of them prepared this line at home, knows the critical branches, and has been playing from memory. The other has been calculating.

The prepared player is not smarter and is not thinking faster. They did the work earlier, once, and are now collecting on it.

What preparation actually buys is not memorized moves. It is knowing which of the thirty legal options are worth thinking about. The unprepared player burns an hour eliminating possibilities their opponent eliminated last year.

Arrowhead is not designing drugs faster than anyone else. It is arriving at move twenty with most of the clock still on it.

Eighteen drugs in six years is what that looks like from the outside. From the inside it is a company that already answered the questions everybody else is still sitting with, and now spends its time on the handful that are genuinely new each time.

Every one of those eighteen ran the same race. Most of them started somewhere near the finish.

A Note on Supporting Independent Research

If this white paper has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this white paper; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This paper is provided for informational and analytical purposes only. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security, and it is not a recommendation as to any corporate course of action. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results, and forward-looking analysis is inherently uncertain. The author and BioBoyScout are not registered investment advisors. The author assumes no obligation to update this paper.

Several of the load-bearing facts here come directly from Arrowhead and from its executives speaking publicly. The eighteen clinical candidates through 2023, the count of twenty-one to twenty-two candidates in clinical studies as of September 16, 2026, the cadence for opening a new cell type, the count of seven addressable cell types with clinical programs in five, the description of the company as an and rather than an or and the practice of building follow-on programs before the validating data arrives, the multi-year head start and its limits, the hundreds of thousands of RNAi molecules made to date, and James Hamilton’s point that nothing substitutes for running the clinical trial are all Arrowhead’s own statements, from a 2023 R&D day and from public appearances in September 2026.

The ARO-DIMER-PA results, the assessment of them, and the timing of the dimers behind it are from the company release of September 15, 2026 and from Chris Anzalone speaking the same week.

The sixth clinical tissue is the ocular program ARO-033, taken from its public registration on ClinicalTrials.gov under NCT07662096, which lists Arrowhead as sponsor and describes subcutaneous administration. The company has not announced it. Everything stated here about ARO-033 comes from that public registration.

Several phrases in the text are Chris Anzalone's own language from those appearances rather than mine, and their repetition here is deliberate: brute force is a hell of a thing, banging their heads against the RNAi wall, no substitute for history, in spades, an and rather than an or, and multi-year, not forever.

What is not Arrowhead’s. The sequence funnel numbers come from a published academic program against PCSK9 and illustrate the shape of the process rather than any one company’s. The attrition rate, the toxicology findings and the chemistry descriptions are drawn from the published literature, much of it Alnylam’s. The manufacturing duration is one contract manufacturer’s advertised figure. The grouping of which development steps recur is the author’s own, and so is the development timeline, including the sequence of stages, which run in parallel and how long each takes. Arrowhead has not published a stage-by-stage timeline. None of that chart should be read as company guidance, as a description of any specific Arrowhead program, or as a forecast of how long any future program will take.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

1. The scoreboard

Count the tissues where a company has an RNAi drug in a person, and the list is short.

Figure 1. Author’s reading of public pipelines as of September 2026. Spinal injection is marked separately because it is a different problem with a different burden on the patient.

Alnylam is the closest. It got its second tissue by a shot under the skin this year, putting a fat program into Phase 1 alongside its liver franchise, and its brain programs go in through the spine. Ionis works with antisense rather than RNAi, so it is not strictly on this board, but it is the nearest mature comparison and its picture looks the same.

Everybody else is in the liver or not yet anywhere, including the well-funded newcomers whose programs outside the liver have not reached a person yet. One company is in six. Liver for everything the liver does, muscle for a rare wasting disorder, fat for obesity, brain for Alzheimer’s, and the retina for macular degeneration, all five by an injection under the skin. Lung for cystic fibrosis and other pulmonary disease, which goes in by inhaler, straight to the airway, and never has to survive the bloodstream at all.

The sixth one has not been announced. ARO-033 sits on the public trial registry, recruiting since June for macular degeneration, first in healthy volunteers and then in patients. The registration states the route four separate times. It goes in as a shot under the skin, which means Arrowhead is trying to reach the retina from the arm, with the drug traveling through the bloodstream rather than being placed in the eye. Every approved drug for that disease goes in through a needle in the eye.

Chris Anzalone said in September that the company can address seven cell types with clinical programs in five. The registry entry had been updated the day before.

Six tissues against three, and on the harder route, the one where the drug has to travel through the blood and find its way, five against two. That is not a small gap and it is not a permanent one either. Alnylam is doing the work. What separates them right now is years.

2. Why everybody else stayed in the liver

The obvious question is why. If getting outside the liver is so valuable, and it is, why did the biggest and best-funded companies in the field not do it?

Because the liver was enough.

A sugar cluster called GalNAc grabs a receptor that sits on liver cells in enormous abundance and almost nowhere else. The pairing was not discovered by any of these companies. Academics worked out that the liver had this receptor and that the sugar would stick to it decades before anybody put RNA on the end of it. In that sense the handle was lying on the table.

Picking it up was a different matter. Getting from a known sugar to a drug that silences a gene for six months took years of chemistry, and Alnylam did most of that work. What matters is that it only had to happen once. The pattern got published, the patents eventually run out, and now anyone entering the field starts with the basic liver-delivery problem already solved for them.

There was also a scientific reason. The liver is forgiving. It filters blood, so anything you inject ends up passing through it. It has a receptor that recycles fast. It tolerates a lot of drug. Every other tissue is worse on at least one of those counts, and most are worse on all of them.

Staying in the liver was not a failure of ambition. It was the right call for anyone who already had a liver franchise. Which is precisely the point.

3. Why Arrowhead went looking anyway

Arrowhead did not have a liver franchise. In 2011 it had a Madison operation it had picked up from Roche for almost nothing, a delivery chemistry that had just been abandoned by its previous owner, and no approved drugs. Alnylam was years ahead in the liver and better funded.

Competing head-on in the liver meant fighting the incumbent on its home ground with fewer resources. Chris Anzalone said as much in September, looking back. Early on, he said, they decided that to extract real value from the technology they needed to get outside the liver, and that starting around 2010 they began building delivery for other tissues.

Worth being precise here, because the shorthand gets this wrong. Arrowhead never left the liver. It is still there, and the only drug it has on the market is a liver drug. What it did was refuse to be only there, at a moment when it had no approved product and every reason to concentrate on the one tissue that already worked.

The tissue record everybody admires now started as the second front opened by a company that could not win the first one on resources alone.

I want to be honest about what that means, because it is a better story than genius. Arrowhead went looking elsewhere because the good ground was already occupied. Necessity picked the direction. What happened after that is the part worth understanding.

4. What opening a tissue actually takes

Here is why the gap on the scoreboard is as wide as it is.

Figure 2. Simplified. Each step has its own literature and its own graveyard.

Opening a tissue is not one problem. It is six, in sequence, and an attempt can die at any of them.

You need a receptor that sits on the cells you want and almost nowhere else, and for most tissues that receptor is not obvious. You need a handle that grabs it, small enough to attach to RNA without wrecking either one. You need proof the receptor actually carries the whole package inside rather than just holding onto it at the surface. You need the package to escape the bubble it gets trapped in once inside, which is where most of what enters a cell stays. You need the silencing to last months rather than days. Then you need to find out where else that receptor lives, because it lives somewhere you did not choose, and whether that matters.

Six steps. No textbook covers all of them together, because no discipline does. The people who can do this learned by failing at each step in order, more than once.

That is the real reason the list is short. The chemistry to hit a target is something you can hire for. The ability to open a tissue is something almost nobody has, because the training does not exist and the only way to acquire it is to spend a decade at it.

5. The people who can do this

Which brings me to the part of this that does not appear in any model and that I think matters more than any single program.

A delivery scientist is not a chemist, though they have to know chemistry. Not a cell biologist, though the bubble that traps the drug inside a cell does not care what your degree says. Not a pharmacologist, though durability is a pharmacology question. It is all three at once, applied to a problem that most of the world has been content to leave alone because the liver was enough.

The number of people who can do that end to end is small. I would guess a few dozen, worldwide, and I am not confident of the second digit. There is no graduate program in it. There is no textbook. You become one by working on it for a long time alongside other people who are working on it, and a surprising number of the people who fit that description have spent their careers in one building in Wisconsin.

I wrote about that building in an earlier note. The short version is that these people came up at a Madison company called Mirus Bio, founded out of university research in the 1990s. Roche acquired Mirus Bio in 2008 and ran the site as part of its own RNAi effort. When Roche abandoned the field two years later, the operation went to Arrowhead. The group stayed together through both changes of owner because there was nowhere local to go. Two of Roche’s own site leaders were put back in charge within a month of Arrowhead taking over. Arrowhead brought aboard thirty-seven employees from the operation.

The platform everyone talks about as if it were a machine is a few dozen people who have been failing at the same six steps together for longer than most biotech companies have existed.

Here is why that word together matters more than it looks. A competitor could go out tomorrow and hire excellent delivery scientists from a dozen companies. It still would not get what Madison has, because a lot of what Madison has does not sit inside any one of them.

Failure makes information, and most of that information never becomes a paper or a patent. It becomes a conversation somebody remembers twelve years later. We tried that receptor. We tried that linker. Here is what happened, and here is why nobody has bothered since. One person remembers the handle that behaved strangely with a particular chemistry. Another remembers the toxicity signal from a receptor that looked perfect on paper. A third remembers the animal result that was going to be a program until somebody looked at where the drug actually ended up.

The clearest example is one the company would rather not be remembered for. In 2016 the delivery chemistry the team had inherited from Roche, which had already put candidates into human trials, came apart after a safety finding in a primate study. The programs were discontinued. Everything built on that chemistry went with them.

Within about two years the same people had a different delivery approach in the clinic. Every tissue on the scoreboard was opened with the one that came after the one that failed, by a team that knew exactly why the first one failed, in a level of detail no publication could capture.

You can hire a scientist. You cannot hire twenty years of shared memory one person at a time.

That makes this a stranger kind of moat than the usual one. Some of it sits in patents and molecules and databases, the way a normal moat does. Some of it sits between people, in the accumulated record of what was tried, what failed, and what was quietly set aside years ago for reasons never written down.

You cannot copy what you cannot see.

6. What six tissues in the clinic actually proves

Be careful here, because the scoreboard is easy to over-read.

Six tissues with a drug in human trials proves that the route into each one works well enough to dose a person. It does not prove that any drug in those tissues will work. Getting into muscle and fixing muscle are different problems, and the second one is not a delivery problem at all.

It also does not prove the six-step process is now routine. Chris puts a new tissue at every eighteen to twenty-four months. Brain and eye both reached the clinic this year, which is faster than that, and one fast year is not a trend. Each one is still a project with its own receptor to find and its own ways to fail.

What it does prove is narrower and still unusual. A group of people has solved the delivery problem in six tissues, five of them by the harder route through the blood. The closest competitor is in three tissues, two by that route. The second of the two arrived this year.

A drug proves a target. A tissue proves a team. Arrowhead has six of the second kind of proof, and the market only knows how to price the first.

There is a consequence of that which most models miss. Investors tend to value the tissues one at a time. Lung is worth something, muscle is worth something, the brain is worth something, add them up. If the argument here is right, that undercounts, because each tissue contains information about the next one.

Not about which receptor will work, or whether the biology will cooperate once you get there. About whether the people looking for that receptor know how to find one. That is what a platform is supposed to mean, if the word means anything. Success in one program changes the odds you should assign to a program that does not exist yet.

7. Where this can go wrong

Three ways, and I would take the first one seriously.

The people can leave. Everything above argues the asset is a team. Teams age, retire, and get recruited. The Madison group stayed together through two changes of owner partly because the labor market kept them there, and a very successful brain readout is exactly what would make that labor market noisier. If the delivery scientists are the platform, then retention belongs on the same page as the science. Most models treat it as boilerplate, the same key-person language every company files.

The next tissue may not open. Six tissues are now in the clinic. Whatever comes next remains unproven, and nobody publishes the attempts that did not.

The route can work and the drugs can still fail. This is the one the scoreboard hides. Six tissues is six opportunities for the biology to disappoint after the delivery succeeds. That would not invalidate the team. It would mean the team solved the part it controls and the disease did not cooperate.

8. The seconds

Chess used to have a custom that computers have mostly made obsolete.

In the era of adjournments and world championship matches that ran for months, a top player brought seconds. These were strong players in their own right, sometimes grandmasters, whose job was to prepare. They analyzed the opponent’s repertoire. They found the novelties. When a game was adjourned overnight with a sealed move in an envelope, the seconds stayed up until dawn working out the position while the champion slept.

The champion walked in the next morning with the winning line already in hand. The public saw the champion. The seconds sat in the back.

Every serious player knew the truth. The name on the trophy was the one who could afford the best seconds.

Chess engines, the programs that now play better than any person alive, ended most of that. Analysis that took a team a night takes a laptop a minute, and the second’s craft became one more job a machine does better.

There is no engine for opening a tissue. No program finds the receptor, builds the handle, and works out why the package will not get out of the bubble. The craft still lives in people, the way it did before the machines, and the number of people who have it is small in the way the number of world-class seconds was always small.

Arrowhead’s seconds have prepared more positions than anyone else in the field. It has had them since before it owned them. When the brain data lands in the next few weeks and everybody looks at the number, the number will belong to the company.

The position was prepared by people who have spent their careers in the back of the room, and who have now opened six doors before the rest of the field.

The champion gets the trophy. Somebody prepared the position.

A Note on Supporting Independent Research

If this white paper has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this white paper; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This paper is provided for informational and analytical purposes only. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security, and it is not a recommendation as to any corporate course of action. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results, and forward-looking analysis is inherently uncertain. The author and BioBoyScout are not registered investment advisors. The author assumes no obligation to update this paper.

The tissue count is the author’s reading of public company pipelines and trial registries as of September 2026 and counts tissues with at least one RNAi program in human trials. The ocular program ARO-033 is taken from its public registration on ClinicalTrials.gov under NCT07662096, which lists Arrowhead as sponsor, describes subcutaneous administration in both the healthy volunteer and macular degeneration cohorts, and was last updated September 15, 2026. The company has not announced it. Everything stated here about ARO-033 comes from that public registration. Route of administration is marked because it matters: an injection that has to reach a tissue through the bloodstream is a different problem from an inhaled or spinal dose that is placed at or near the target.

Arrowhead’s pulmonary programs are inhaled by nebulizer, and the company has separately shown subcutaneous delivery to lung in animals. Statements attributed to Chris Anzalone are from public conference appearances in September 2026. The Madison history, including the 2008 Roche acquisition of Mirus Bio, the 2011 transfer of the operation to Arrowhead, and Arrowhead’s hiring of thirty-seven employees from the operation, is from contemporaneous Arrowhead announcements and is detailed in a prior BioBoyScout note. The six-step description of tissue delivery is a simplification and is the author’s own. The estimate of how many people can do this work end to end is a guess and is labeled as one. The chess custom described is historical and the analogy is the author’s.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

The question I get more than any other about ARO-MAPT is not how much tau it will lower. It is how quickly this could reach patients, and whether it could qualify for accelerated approval.

This note is an attempt to answer it properly.

The conventional answer is grim. Alzheimer’s trials measure how fast a patient declines, and demonstrating a convincing difference generally takes many months to years, with eighteen to twenty-four months typical for pivotal programs. A program built that way puts approval somewhere in the middle of the next decade. Fast Track designation does not change that. It buys more meetings with the FDA and can make a program eligible for rolling review, meaning the application is submitted in pieces rather than all at once. It does not, by itself, turn a conventional efficacy trial into a shorter one.

There is a faster route, and it is not hypothetical. The FDA can approve a drug based on a biomarker that is reasonably likely to predict clinical benefit, with the trial proving it actually helps patients finished afterward. Two Alzheimer’s drugs have come through that door. A neurology drug almost nobody outside the field has heard of came through the same door.

The difference between how those cases went is the whole subject of this note, and it points at a number that is not currently being discussed.

1. A word on who actually decides

One thing has to be explained first, because both stories below turn on it.

When the FDA reviews a drug, it can convene an advisory committee. That is a panel of outside experts, clinicians, statisticians and often a patient representative, who read the application, hear the company and the agency present, and then vote in public on specific questions.

The vote is advice. The FDA is not bound by it and has gone against it before.

There is a second detail that matters more than it sounds. The agency writes the questions. It decides what the committee is asked to vote on and what stays off the agenda. Hold onto that.

2. How it goes wrong

On June 7, 2021, the FDA approved aducanumab for Alzheimer’s on the basis of reduced amyloid plaque.

Its own advisory committee had been unenthusiastic to the point of hostility. On the central question, whether it was reasonable to treat the one positive trial as primary evidence of effectiveness, the vote was 0 yes, 10 no, 1 uncertain. Its own statistical reviewers had rejected the application. Within days of the approval, three members of that committee resigned, one describing it as probably the worst drug approval decision in recent United States history.

The detail that matters most is procedural rather than scientific. None of the four questions put to the committee asked whether reducing amyloid plaque met the standard for accelerated approval. According to committee members writing afterward, the lead FDA scientist told them during the meeting that the agency was not using amyloid as a surrogate for efficacy. Seven months later the agency approved the drug under the accelerated approval pathway on the basis of amyloid reduction.

What followed was worse for the company than the controversy. The Centers for Medicare and Medicaid Services restricted coverage to patients enrolled in clinical trials. Major hospital systems declined to administer it. The drug was eventually withdrawn.

An approval that leaves the vast majority of eligible patients without coverage is not much of a commercial approval. The lesson of aducanumab is not that the surrogate was wrong. It is that a surrogate never argued in the open does not survive contact with the people who decide what gets reimbursed.

3. How it goes right

On April 25, 2023, the FDA approved tofersen for a genetic form of ALS under accelerated approval, based on a drop in a blood marker called neurofilament light chain, or NfL.

The Phase 3 trial had missed its primary endpoint, and not narrowly. The measure was a functional rating scale covering things like speech, swallowing, walking and breathing. Drug and placebo separated by 1.2 points on it, with a p-value of 0.97.

That last number deserves a translation. A p-value estimates how often a result this size would show up by chance if the drug did nothing. Below 0.05 is the conventional threshold for calling a result real. At 0.97, the trial was not close to the line. It was about as far from it as a result can get.

The advisory committee, meeting a month earlier, was asked two questions rather than one. On whether the drop in NfL was reasonably likely to predict clinical benefit, the vote was 9-0 in favor. On whether the clinical results were convincing evidence that the drug worked, the vote was 5-3 against, with one abstention.

Read that again. The committee rejected the clinical evidence and endorsed the biomarker, in two separate recorded votes, and the FDA approved on the biomarker. Nobody resigned. The review team’s own document notes that it identified no issues precluding accelerated approval.

The confirmatory trial, running in people who carry the mutation but have not yet developed symptoms, has a primary completion date in 2027 and runs into 2028.

4. The difference

Aducanumab and tofersen offer two sharply contrasting accelerated approval precedents, less than two years apart. One collapsed commercially. The other remains intact while its confirmatory trial runs. The distinction runs along two lines, and both matter for tau.

The first is what the biomarker measures. Amyloid plaque reduction tells you the pathology the drug was aimed at has changed, and the FDA does treat plaque reduction as reasonably likely to predict clinical benefit. It sits close to the therapy, in the same compartment the drug was designed to act on. NfL sits further out. Nerve cells release it when their fibers are damaged, so a falling NfL suggests the rate of neuroaxonal injury is coming down. It is not a measure of whether the drug hit its target. It is a measure of what is happening downstream of it.

Tofersen had a target engagement measure available. Its developers tracked the SOD1 protein in spinal fluid, which tells you directly whether the drug hit its target. That is not what the approval rested on.

The FDA did not approve tofersen because the randomized trial established clinical benefit. It did not. It approved tofersen because the evidence taken together supported NfL as reasonably likely to predict that it would.

There is a third case that belongs here, because it complicates the neat version of this story.

Lecanemab received accelerated approval in January 2023 on the same amyloid surrogate that had gone so badly for aducanumab. Six months later it converted to traditional approval, because its confirmatory Phase 3 demonstrated clinical benefit. Same biomarker, same pathway, opposite outcome.

Which means the lesson is not that pathology biomarkers fail and injury biomarkers succeed. The lesson is that a surrogate has to sit inside an evidentiary package that makes the clinical inference credible. Aducanumab had a contested surrogate, conflicting trials and a regulatory process that drew extraordinary criticism. Lecanemab had the same surrogate and a clean confirmatory result. Tofersen had a downstream marker, a coherent mechanistic story and a public committee endorsement.

The second difference is procedural. Tofersen’s surrogate was written into the questions, argued in public, and won a unanimous vote on the record. Aducanumab’s surrogate was never put to the committee as a question, and then became the basis for approval. One approval had a public record of expert endorsement behind it. The other did not. That does not mean a committee endorsement would have changed the reimbursement decision, and CMS grounded its restriction in insufficient evidence of improved health outcomes rather than in anything procedural. It does mean the approval entered the reimbursement debate without a public expert record validating the surrogate the FDA had ultimately relied on.

5. What CELIA just did to the tau surrogate

Which brings this to July, and to a result that has been read almost entirely as good news for tau. It is good news for the mechanism. It is bad news for the simplest version of the surrogate argument, and almost nobody has said so.

Diranersen, a drug that lowers tau, reported eighteen-month Phase 2 results in 416 patients with early Alzheimer’s. Total tau in spinal fluid fell 50 to 65 percent across all three dosing schedules. Tau imaging showed reductions across all doses while placebo rose. On the cognitive measures, the lowest dose arm slowed decline by 26 percent on one clinical scale, 42 percent on another, and 50 percent on a third. Worth noting immediately that this arm had 60 patients in it. Impressive percentages from small groups deserve to be read with the group size attached.

Caveats aside, that is the strongest randomized evidence yet that lowering tau might change the course of Alzheimer’s disease. The trial did not prove it, and it missed the endpoint it was built around. It is still the most encouraging thing this mechanism has produced, and it de-risks the biology for everyone working in it, including Arrowhead.

Now the problem. Higher doses produced greater tau reduction without producing greater clinical benefit. The cognitive measures favored the drug across all doses, but more tau lowering did not buy more slowing. The trial’s primary endpoint was an assessment of dose response, and on that measure it failed.

Sit with what that means to a regulator. A drug lowered tau robustly, in a dose-dependent way, confirmed by imaging. The strongest clinical signal came from the lowest-dose group, even though the higher doses produced greater tau reduction. Whether that reflects an optimal dosing window, a non-linear exposure relationship, a difference between the tau being measured and the tau doing damage, or simply noise in a 416-patient study, nobody yet knows.

If somebody asked the FDA today to accept the size of a spinal fluid tau reduction, by itself, as evidence that a drug will help patients, CELIA is the obvious counterexample, and there is currently no good answer to it.

Tau reduction, on this data, behaves like target engagement. It tells you the drug reached the brain and did its job. It does not, on its own, tell you the patient will be better off. That is one reason the tofersen precedent is particularly interesting for a tau-lowering program.

6. What Arrowhead would need

All of which produces a specific checklist rather than a general hope. Six things, roughly in order of how hard they are.

Deep tau reduction that lasts. The obvious one, and the one everybody is watching. It is necessary and nowhere near sufficient.

Two things make it harder than it sounds. A 50 percent reduction in healthy volunteers does not guarantee the same magnitude in somebody with established tau pathology, so the healthy volunteer number cannot simply be assumed to carry over. A reduction that fades between doses is also worth much less than one that holds, because a patient spends the back half of every dosing cycle drifting back toward where they started.

Figure 1: Where the evidence for each link currently comes from. Only the first is what September tests.

The NfL trajectory bending, and considerably more than that. This is the item nobody is discussing, it is the center of the whole case, and the tofersen file shows the bar is far higher than simply getting the number to move.

A surrogate is a measurement that stands in for the thing you actually care about. What anyone actually cares about in Alzheimer’s is whether the patient can still recognize their family in three years. You cannot wait years for that outcome every time you test a drug, so you look for something that moves earlier and reliably predicts it.

Tau reduction is not quite that, on the current evidence. It tells you the drug got in and did its job.

Chess has a word for the position tau is now in. A piece is pinned when it cannot usefully move, because moving it would expose something more valuable sitting behind it. The piece is still valuable. It simply cannot do the work by itself, and the reason has nothing to do with the piece.

That is where the tau number stands after CELIA. It is the figure management benchmarked, the figure September reports, and the figure the market will trade on. Sitting behind it is the ultimate question that matters, which is whether patients end up better off. Tau does not answer that question on its own, and diranersen just demonstrated it by lowering tau further without producing greater clinical benefit.

The consequence matters more than the metaphor. A bigger tau number does not fix this. Pushing harder on a pinned piece accomplishes nothing, because the problem was never how hard you pushed. What breaks a pin is bringing another piece to bear, and the pinned piece then becomes useful again.

NfL is the different piece. It is a marker of axonal injury and neurodegeneration, released when nerve fibers are damaged. When NfL falls, it suggests the rate of neuronal injury is falling. It is not a measure of whether the drug hit its target. It is a measure of what is happening downstream, in the disease itself. Tofersen’s accelerated approval centered on a blood-based biomarker, NfL, which is why the file matters so much here.

One caveat belongs up front. In SOD1-ALS, axons die quickly and in large numbers, so the NfL signal is loud and moves within months. Alzheimer’s is slower and the elevation is milder. The FDA accepting NfL in one disease does not commit it to accepting NfL in the other, and the agency will say so. Other markers have done it, amyloid in Alzheimer’s and dystrophin in muscular dystrophy among them. NfL is unusual because it measures downstream neuroaxonal injury rather than target engagement.

Now the complication, and it is a real one. The only reported human trial of a tau-lowering drug that I am aware of measuring NfL did not find what this argument needs.

In the Phase 1b study of diranersen, published in 2023, CSF NfL was tracked as an exploratory measure. Eight weeks after the last dose it showed no dose-responsive effect. NfL fell in the placebo group and in the lowest dose group, and rose slightly in the higher dose groups. The authors said plainly that the changes were not dose responsive and not concordant, and that assay variability and small sample size limited what could be read into them.

Anyone building a case on NfL has to deal with that, so here is the case.

The study enrolled 46 people across five arms. Individual dose groups had six to thirteen participants. It looked eight weeks past the last dose. That is a small, short experiment, and its own investigators said so.

More importantly, it may have been asking the wrong question. In somebody who already has Alzheimer’s, substantial neuronal and axonal injury has already occurred, and NfL is elevated because of it. A drug working upstream, at the level of tau production, would not be expected to reverse damage that has already happened. The relevant signal may therefore be a reduction in the rate of new injury rather than an immediate fall below baseline.

The right question is therefore probably not whether NfL falls. It is whether the climb slows.

Picture two lines over eighteen months, in illustrative indexed units rather than real values. On placebo, NfL runs 100, then 112, then 124, then 136. On drug, it runs 100, then 104, then 107, then 110. NfL never drops below where it started. That would still be one of the most important results this field has produced, because it would suggest that the rate of ongoing neuroaxonal injury had slowed.

One further caveat belongs here. NfL is not specific to Alzheimer’s disease. It rises with many kinds of neurological injury, climbs with age, and is affected by kidney function among other things. That raises the bar for using it as a surrogate, though a randomized design with repeated within-patient measurements helps mitigate those problems far better than a single absolute reading does.

Stated precisely, the question is whether the longitudinal slope differs from placebo, not whether the treated group’s absolute NfL value falls. Answering it requires a long trial with repeated measurements, which is exactly what the Phase 1b was not. The longitudinal experiment this hypothesis needs has not actually been reported.

One practical note follows from all of it. NfL can be measured in blood as well as spinal fluid. Plasma carries the practical advantage, because it can be drawn at ordinary study visits and repeated as often as the schedule allows, which lets investigators estimate an individual patient’s trajectory rather than relying on a handful of lumbar punctures. A program serious about this question collects plasma NfL longitudinally and treats CSF as complementary.

What the tofersen file actually required. Biogen’s advisory committee materials are public, and they are the clearest statement available of what the FDA wanted before accepting a novel surrogate. The agency’s own guidance, quoted in those materials, says a reasonably likely surrogate depends on two things: the biological plausibility of the relationship between the disease, the endpoint and the desired effect, and the empirical evidence supporting that relationship.

Biogen met the second requirement with roughly a hundred published citations spanning 1996 to 2023. That literature established, independently of any drug, that NfL is elevated in ALS above nearly every other neurodegenerative disease, that it distinguishes ALS from conditions that mimic it, that it correlates with the rate of decline across multiple separate cohorts, and that it predicts survival. Decades of work by people with no stake in the outcome.

They then did something more demanding than showing the marker moved. They built a model estimating how much clinical benefit each unit of NfL reduction bought. For every 10 pg/mL fall in plasma NfL at Week 16, the model predicted 0.77 points of preserved function on the ALS rating scale at Week 28, with a p-value of 0.0038, alongside parallel estimates for quality of life and for the risk of death.

The bar was not that the biomarker moved. It was a quantified relationship between how far it moved and how much the patient benefited, sitting on top of thirty years of independent literature.

There is a mirror-image piece of evidence in the same materials, and it is the kind of thing that makes a regulator believe a marker. A different antisense drug, aimed at a different ALS gene, raised CSF NfL by 37 percent. The patients receiving it did worse. A biomarker that moves the wrong way and drags outcomes with it is powerful confirmation that it tracks something real.

One process detail completes the picture. Biogen held a formal meeting with the FDA in April 2022 specifically to discuss the utility of NfL for accelerated approval, three months before filing. The surrogate was negotiated with the agency in advance and then ratified in public by the committee. It was not sprung on anybody.

Several markers agreeing, not one. The strongest version of this argument is not a single impressive number.

CELIA’s real problem was disagreement. Tau went down, imaging confirmed it, but the strongest clinical signal came from the lowest-dose group. When the biology and the clinical results point different directions, a regulator has no way to know which one to believe.

The fix is not a better single measurement. It is having tau, NfL, imaging and the cognitive scores all move the same way at the same time. Any one of them can be a fluke. Four of them agreeing is a story.

A dose-response that behaves. Regulators look for an exposure-response relationship that makes biological sense. It does not have to be a straight line, and more drug does not have to produce endlessly greater benefit, since real drugs plateau and therapeutic windows exist. What it does have to be is interpretable.

CELIA is hard to interpret on exactly that basis. Across the doses studied, increasing tau reduction did not translate into increasing clinical benefit. That single fact is the hardest thing in its dataset to explain and it is why the trial formally failed. A program that shows benefit rising with exposure has an argument available to it that diranersen currently does not.

The surrogate argued in public. The lesson from aducanumab, where the committee never voted on the surrogate the approval ultimately rested on, is not optional. It is also cheaper to follow than to skip.

For the strongest possible regulatory and reimbursement case, a tau surrogate should be written into the questions put to an advisory committee, debated openly, and endorsed on the record. The FDA is not obliged to convene a committee at all. The argument here is not that it cannot approve without one, but that after aducanumab, nobody should want a contested surrogate approval without transparent outside validation behind it. Approving first and explaining later is what happened in 2021, and the people watching most closely were not at the FDA at all.

They were at the Centers for Medicare and Medicaid Services, which decides whether Medicare pays. CMS is a separate agency with a separate process, and after aducanumab it restricted coverage to patients enrolled in clinical trials. An approved drug that Medicare will reimburse only under highly restrictive conditions, in a disease of the elderly, is not much of a commercial product. Winning the FDA argument and losing the CMS one is the worst outcome available.

The confirmatory trial already running. Accelerated approval is conditional. The company gets to sell the drug while it runs the study that proves the biomarker was telling the truth, and if that study fails, the approval can be withdrawn.

For years, companies collected the approval and let the confirmatory work drift. Congress has since given the FDA explicit authority to require that the confirmatory study be underway before accelerated approval is granted, and current agency policy strongly favors starting that work early rather than waiting until after approval. That pulls a great deal of expensive work forward, which is exactly the point.

The opportunity is not to replace tau with NfL. It is to connect them. Tau shows that ARO-MAPT is doing what it was designed to do. NfL could show that what it is doing matters to the disease.

7. What the current trial is not designed to do

Worth being clear about where things actually stand.

Public trial registries require a company to state, in advance, what a study is designed to measure. For the ongoing ARO-MAPT study, the single primary measure is side effects, tracked through day 270. The secondary measures are twelve readings of how the drug moves through the body, meaning how much gets absorbed, how long it lasts, how it clears, plus three routine safety checks on spinal fluid: total protein, glucose, and cell count.

Neither tau nor NfL appears in that list. That is a statement about what the study is formally designed to prove. It is not a statement that either biomarker is going unmeasured.

That is not a criticism. This is a first-in-human safety and pharmacokinetics study, and it is registered as one. Management has said the update will include tau knockdown in healthy volunteers, so tau is presumably being tracked as an exploratory measure. That is entirely normal, and exploratory biomarker measurements do not necessarily appear among a registry’s primary and secondary outcome measures.

The point is what it tells you about the number the market will trade on. It will arrive as an exploratory result, meaning a measurement taken out of interest rather than one the study was built to prove, from a trial designed to answer a different question, quite possibly in a small number of participants. It is the beginning of the regulatory argument, not evidence that can settle it.

Which also means the question worth asking is forward-looking. Once adequate target engagement is established, whether NfL is being collected now, and whether Arrowhead plans to carry it into the patient cohorts and the Phase 2 design, tells you more about the timeline to approval than the precise magnitude reported in September.

8. The faster door is not Alzheimer’s

There is a route to an accelerated approval that runs around the Alzheimer’s problem entirely, and Arrowhead’s own language already gestures at it. The program is described as being for Alzheimer’s disease and other tauopathies.

The other tauopathies may come first.

Progressive supranuclear palsy is a primary 4R tauopathy. Amyloid is not a defining pathology, unlike in Alzheimer’s disease. It moves fast and you can measure it. It is rare enough that trials run in the low hundreds instead of the thousands. There is no approved disease-modifying treatment. The protein the drug silences is the defining pathological protein in the disease, which makes it an unusually clean test of the mechanism.

Tofersen is the useful analogy here, though the analogy is regulatory rather than biological. A rare, fast-moving, well-defined neurodegenerative disease with major unmet need, approved on a biomarker after a Phase 3 that missed, is a far more applicable precedent for progressive supranuclear palsy than anything in the amyloid history. The disease biology, the biomarker kinetics and the trial endpoints are not interchangeable between the two, and the regulatory argument would still have to be built from scratch.

A tau drug that changes the course of a rare tauopathy could give the FDA a much stronger human precedent for accepting tau biology as part of the regulatory case in the common one. The rare disease is not the consolation prize. It is the argument.

9. The odds, and what would change them

Making a case for something is not the same as predicting it, so here are the odds as I actually see them.

Accelerated approval for ARO-MAPT in Alzheimer’s disease is unlikely. My estimate before CELIA was somewhere around ten to fifteen percent, and CELIA moves it in both directions at once, strengthening the mechanism while weakening the simplest version of the surrogate argument. I would leave it roughly where it was.

That number is not arbitrary, and it is worth showing the parts. Getting there requires deep and durable tau knockdown in patients, which I would put at better than even. It requires a measurable separation in the NfL trajectory, which I would put below even, given the limited human evidence to date rather than because the biology argues against it. It requires the FDA to accept NfL as a surrogate in Alzheimer’s specifically, having only ever accepted it in ALS, which I would put well below even. It requires the biomarkers and the cognitive data to point the same direction. It requires the confirmatory program to be underway early enough to satisfy the FDA’s accelerated approval expectations.

One distinction is worth drawing inside that list. The scientific probability and the regulatory probability are not the same thing, and the second is lower. Even a convincing NfL result would still leave Arrowhead having to establish that NfL is a valid surrogate in Alzheimer’s disease specifically, which is a separate argument from having produced good data.

The chain is long enough that even reasonably plausible probabilities at each step would produce a low-teens result overall. That is a conceptual probability tree rather than a calculated model, and it is offered as one. Any one of those links failing could close this particular route, which is why the number stays small even though several of the individual steps are more likely than not. It would not necessarily close every route, since a different biomarker package, unexpectedly strong clinical data, or a different indication could each open another.

A convincing NfL dataset in patients would move that number more than anything else, plausibly doubling it. That is a real if, given that the one reported tau-lowering trial I am aware of that measured NfL did not deliver it, and it is the single most important thing to watch over the next three years. Convergence across several markers and a clean dose-response would matter nearly as much.

An accelerated approval in progressive supranuclear palsy may be a materially better opportunity than the Alzheimer’s version, and could arrive years earlier if pursued in parallel from the start.

The reimbursement question sits behind all of it. The FDA approving a drug is not the same as patients getting it, and aducanumab is the reason that sentence has to appear in any honest note on this subject.

10. Where this leaves the September readout

The September number is a first step and will be treated as a verdict.

What it can establish is human central nervous system target engagement after subcutaneous dosing, meaning that systemic dosing produced a measurable pharmacodynamic effect within the central nervous system. If that had not worked, nothing else would have mattered. That is worth a great deal, and it is worth more to the platform than to this particular drug.

What it cannot establish is whether lowering tau helps a patient, because CELIA has just demonstrated that the two questions come apart.

The most credible path I can see to patients getting this drug early runs through a biomarker that was not in the headline, in a disease that is not Alzheimer’s, argued in front of a committee that has not yet been convened.

The case for early approval is real. It simply does not run through the number everyone will be looking at in September.

A Note on Supporting Independent Research

If this white paper has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this white paper; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This paper is provided for informational and analytical purposes only. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security, and it is not a recommendation as to any corporate course of action. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results, and forward-looking analysis is inherently uncertain. The author and BioBoyScout are not registered investment advisors. The author assumes no obligation to update this paper.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

Two Arrowhead readouts land in September. One of them will get all the attention, and it deserves attention. ARO-MAPT is Arrowhead’s first human test of subcutaneous delivery to the brain, and a companion paper of mine argues at length that it could reprice the company.

The other readout has been treated as a footnote. ARO-DIMER-PA is a single molecule built to silence two genes at once, and its first clinical data are expected in the same month. Far less has been written about it. This paper is about why that is a mistake, and about what the readout actually tests, which is not what a conventional preview would say it tests.

Chess has a name for a move like this. A zwischenzug is an in-between move, played in the middle of a sequence the opponent has already worked out. Its power is not that it is stronger than the expected continuation. Its power is that nobody was looking at it, so the evaluation of the position changes before the main line resumes.

One distinction organizes everything below. The brain program tests whether the engine can reach a new place. The dimer program tests whether the engine can build a new kind of thing. Those are different questions, they fail in different ways, and one of them does not appear in the sum-of-the-parts breakdown this paper examines at all.

1. What ARO-DIMER-PA is

Start with the molecule. Conventional RNAi drugs silence one gene. A patient who needs two genes silenced takes two drugs, which means two prescriptions, two co-pays, two prior authorizations, and two regulatory approvals. ARO-DIMER-PA is one molecule carrying two different silencing payloads, called triggers, aimed at APOC3 and PCSK9. Silencing APOC3 lowers triglycerides. Silencing PCSK9 lowers LDL cholesterol. One injection, two lipid abnormalities.

The target population is patients with mixed dyslipidemia, meaning elevated LDL and elevated triglycerides at the same time, which is a common combination and a poorly served one. The trial is a Phase 1/2a study running in patients with mixed hyperlipidemia rather than in healthy volunteers, which matters because it means lipid effects are measurable in the relevant population from the first study, not years later. The company describes the target indication as atherosclerotic cardiovascular disease arising from mixed hyperlipidemia.

Arrowhead’s own framing, from its June webinar, repays a close look, because the company chose the words carefully. The dimer is described as a single chemical entity to silence two gene targets, with regulatory advantages over two co-dosed drugs. That phrase, single chemical entity, is doing regulatory and commercial work as well as scientific work. Two separately approved drugs taken together remain two drugs, each with its own approval and its own label. Building them into one product would mean developing a fixed-dose combination, with its own program and its own approval. A single molecule is neither. It is one drug from the start.

2. Seven years in plain sight

The first thing to know about this program is that it is not new. Arrowhead has been building the capability behind it, and disclosing the progress, since 2019.

At an R&D Day in New York on October 18, 2019, the company told investors it was presenting data demonstrating that a new dimer structure, delivering multiple siRNA sequences together, could achieve high levels of knockdown of two different genes. Note the framing. The dimer was described as an addition to the delivery platform, not a drug program. It was announced as a capability, nearly seven years before its first human data.

The critical update came at the R&D Day of June 1, 2023, and it was significant enough to earn its own headline bullet. The improved hepatic dimer platform, Arrowhead reported, achieved equivalent or better knockdown of two target genes with longer duration than a monomer mixture, in non-human primates. A monomer mixture, in this context, means the two conventional single-target drugs administered together, which is the comparison that matters.

Set that against the problem described in the next section and its importance becomes clear. Equivalent or better answers the concern that one address label carrying two payloads ought to be less efficient than two labels carrying one each. Longer duration is the genuinely unexpected part, since nothing about combining two triggers obviously extends how long they keep working.

From there the sequence is public and dated. Preclinical data on the named candidate, ARO-DIMER-PA, was presented at the National Lipid Association 2025 Annual Scientific Sessions. A clinical trial application was filed on October 7, 2025. The first subjects were dosed on January 27, 2026. In June 2026 the program received flagship billing at the company’s cardiometabolic webinar, with its own section presented by the chief medical officer and a cardiology key opinion leader closing the event around it. Arrowhead expects to release early Phase 1 data in September.

Nearly seven years from platform disclosure to first human data, with the decisive preclinical result reported in 2023 and the candidate named in 2025. This is not a program that appeared opportunistically. It is a capability that was built deliberately, in public, while almost nobody was watching.

The June webinar is the last beat in that sequence and the most recent tell. Management gave a Phase 1 asset flagship billing three months before its first human data, which is a statement about internal conviction, disclosed through behavior instead of a forecast. Behavior is the more reliable of the two.

3. The real question the readout answers

A conventional preview might frame the September data as a test of whether APOC3 and PCSK9 silencing works. That framing is wrong, and getting it right is the whole point of reading this paper before the data lands.

Both targets are already validated in humans, extensively. PCSK9 silencing by RNAi is an approved medicine: inclisiran achieves roughly 50 percent sustained LDL-C reduction, with maintenance dosing every six months. APOC3 silencing by RNAi is an approved medicine: Arrowhead’s own plozasiran reduced APOC3 by up to 85 percent in early studies, and delivered triglyceride reductions in the range of 56 to 62 percentage points at 24 weeks in the mixed hyperlipidemia population studied in MUIR. Nobody needs September to learn whether these two targets are druggable.

The unvalidated element is the molecule. Specifically, whether one construct can deliver two triggers into the same cell and have both load into the silencing machinery efficiently enough to match what the two separate drugs achieve.

There is a concrete reason to think this is hard. Getting a drug like this into a liver cell depends on a targeting ligand, which works like an address label: it binds a receptor on the cell surface and gets the whole molecule carried inside. A conventional construct of this type carries targeting functionality for one payload. A dual construct asks the same targeting architecture to deliver two. The effective ligand-to-cargo ratio therefore falls.

This is not theoretical. Published work on dual-targeting antisense oligonucleotides, a related class carrying the same kind of address label, found that the dual versions worked but were less potent, and attributed the shortfall to precisely this change in the label-to-cargo ratio. The evidence comes from a neighboring chemistry, not from siRNA directly, so treat it as a caution and not a prediction. It is still the tax the architecture has to overcome.

The second constraint comes from how the two triggers are arranged. In Arrowhead’s construct, and in the competing construct now in clinical development, the triggers sit in sequence rather than side by side: the ligand attaches to the first, and the second attaches behind it. Section 7 takes up that geometry in full. It creates a different failure mode from the one just described. A broad shared-ligand penalty would be expected to weaken both triggers. A positional penalty in the chain could preferentially weaken one.

Arrowhead has two pieces of evidence that these can be overcome, and they arrived three years apart. The first is the 2023 platform result described in the previous section. The second is specific to this candidate: in cynomolgus primates, a single 6 mg per kg subcutaneous dose produced roughly 50 percent reductions across non-HDL cholesterol, LDL cholesterol, and triglycerides, with potency matched to the two single-target drugs given together.

Matched to the monomers is the phrase that matters. It means the animal data showed no meaningful penalty from combining the triggers, and the earlier platform work suggested there might even be an advantage. September asks whether either finding survives the move into humans.

4. A scorecard, written before the data

What follows is a grading rubric, published in advance so it cannot be adjusted afterward to fit whatever arrives. Readers can hold it against the press release.

It has two levels, and keeping them apart is the point. The first asks whether the architecture worked. The second asks whether the resulting drug competes. Those are different questions with different evidence, and commentary can easily collapse them into a single lipid number.

Level one, the architecture test. The cleanest measure of whether two triggers both loaded and functioned is the suppression of the two proteins themselves, PCSK9 and APOC3, not the lipid changes downstream of them. Arrowhead describes its own preclinical work in exactly that order, reporting that the construct lowered serum PCSK9 and APOC3 before discussing what happened to cholesterol and triglycerides. Watch four things at this level: the depth of suppression on each target, whether the two are symmetric or one lags, the dose-response relationship, and how long suppression persists.

Level two, the product test. Then the downstream lipid profile, which is what determines whether this becomes a competitive medicine: LDL cholesterol, triglycerides, non-HDL cholesterol, and the dosing interval those effects would support.

Management has named its own bar. At an investor conference in June, the chief medical officer said a total ApoB reduction of roughly 40 percent would feel competitive against existing PCSK9 inhibitors, that the construct should produce inclisiran-like effects on PCSK9, and that combining the two mechanisms should add to the ApoB reduction. That is the number to grade against, because it is the one the company chose. For reference, inclisiran achieves roughly 50 percent sustained LDL-C reduction with maintenance dosing every six months, and plozasiran produced triglyceride reductions in the range of 56 to 62 percentage points at 24 weeks in the mixed hyperlipidemia population studied in MUIR. Arrowhead’s own primate benchmark was roughly 50 percent across non-HDL cholesterol, LDL cholesterol, and triglycerides from a single dose, with potency matched to the two single-target drugs given together.

Full success. Both proteins suppressed deeply and symmetrically, with a lipid profile that lands near the single-agent benchmarks and a tolerability picture resembling the parent compounds. That result would say the architecture works and the ligand-to-cargo constraint has been engineered around.

Partial success. One target suppressed to a depth consistent with its single-target reference while the other materially lags. This is the most informative outcome and the one least discussed, because it narrows where the problem is likely to sit. Asymmetric knockdown would be more consistent with a positional or trigger-specific problem than with a general failure of the shared targeting element, since a broad ligand-to-cargo penalty would be expected to affect both triggers. That would be potentially more tractable than a general potency shortfall, because it would implicate one trigger’s position or design rather than the viability of unimolecular delivery.

Miss. Both targets materially below their relevant single-target references, or a tolerability signal that points to the combined construct instead of either target. That would suggest the ligand-to-cargo constraint is real in humans in a way it was not in primates, which is a platform-level finding rather than merely a drug-level finding.

Duration, the item most likely to be overlooked. The 2023 platform data reported longer duration than a monomer mixture, which would be a commercial advantage independent of potency. Any signal about how long suppression persists deserves as much attention as the depth of it, because dosing interval is where this molecule would compete.

The pairing does real work. The construct carries two separate engineering risks, and the two level-one measurements help distinguish them. Depth primarily informs the shared targeting constraint. Symmetry informs whether a positional effect is emerging. Read together, the two measurements can say not only whether the construct worked but where the problem may lie, which is a more useful thing to know in September than a single verdict.

One caution on all of the above. This is an early dose-ranging study, so the relevant comparison is what the dimer achieves at its selected dose against what the monomers achieve at theirs, not a raw number-to-number contest. Read the dose alongside the effect. Note too that a Phase 1 disclosure may report lipid changes without the underlying protein data, in which case level one will have to be inferred from level two, and inference is weaker than measurement.

5. The asymmetry nobody is positioned for

The September pair diverges most sharply here, and not in the way most readers would guess.

The brain program carries a placeholder. In the sum-of-the-parts breakdown JPMorgan published with its $95 target, the line covering the brain platform was carried at $1 a share. Small, but present.

The dimer program has no line at all. It does not appear in the breakdown. That absence need not be an oversight or a verdict that the program is worthless. The cited model was built without an explicit line for this asset, and management has since provided the outline of a strategy without the inputs a conventional forecast requires: no detailed Phase 2 design, no outcomes-trial size or timing, no registrational assumptions, no commercial forecast. Direction is not the same as a model. There is still no row to reprice.

The consequence runs against intuition. If there is no line for the dimer, a clean result adds nothing to the sum of the parts, since there is no line to increase. An analyst who wanted to credit the result would first have to create one, and doing that credibly requires development and commercial assumptions that have not yet been disclosed. A disappointing result subtracts nothing either, for the same reason. Against the model, this readout is symmetric at zero.

The model is symmetric at zero. The narrative is not. Everything therefore runs through sentiment and through the platform narrative, and sentiment is not symmetric. A clean result confirms the direction already suggested by the public primate data and by the validation of both targets, so the immediate surprise may be limited. Confirmations generally carry less surprise than failures. A miss does something larger. It would end a near-unbroken translation record that the platform argument leans on, and it would raise the possibility that the ligand-to-cargo constraint described in Section 3 was deferred rather than engineered around.

Note the precision required here, since this paper has argued that the two September readouts test different things. A construct that fails is a failure of architecture, not of tissue delivery, and the two are genuinely separable on the science. Whether investors separate them in September is a different question, and many will not.

There is no line for the dimer, so a good result has nothing to raise in the existing model. The readout cannot help the model, and it can still hurt the narrative. That is the reverse of how a validated-target program is normally held, and the reverse of the brain program reporting the same month, where a placeholder at least exists and the surprise runs the other way.

There is a second-order consequence that nobody appears to be pricing, and it is the reason to hold the two September readouts together. The two events share a dependency. Arrowhead’s translation record, the claim that virtually everything it has taken into the clinic has translated from animal models to humans, is load-bearing for both programs and for the platform argument generally. A dimer miss would blemish that claim in the same month the brain program reports, which would ask the market to evaluate the hardest delivery frontier the company has attempted while the translation record had just taken a visible hit. That the two failures would be of different kinds is a distinction the science supports and the tape may not honor.

The reverse holds as well. A clean dimer result strengthens the translation claim going into the brain data, and strengthens it on a molecule of entirely new construction, which is a more demanding version of the claim than another liver target would have supplied. Treating the two readouts as independent events understates both the risk and the value. They are correlated through a shared premise, and the smaller one reports on the premise the larger one depends on.

6. One readout, a multiplied design space

This is where the readout starts to matter more than the drug it is testing.

A pipeline grows by addition. Each new program adds one asset, and the arithmetic is linear. A capability grows differently. If a dual-trigger construct shows the architecture can work as a reusable method rather than as a one-off success with two particularly cooperative targets, then what has been unlocked is not one drug but a design space.

The change runs deeper than the number of possible combinations. It changes the unit of design. The starting point no longer has to be one gene that yields one drug. It can be a disease mechanism requiring two coordinated interventions, engineered as a single molecule from the beginning.

In concrete terms: Arrowhead has built a substantial roster of liver programs over more than a decade, many of them carried into or through the clinic. Proving the dual architecture does not add one program to that set. It establishes the first human-validated member of a potentially combinatorial design space, in which clinically sensible pairings among those targets become candidate molecules. The arithmetic stops being additive and starts being combinatorial.

Two limits belong on that claim. Most pairings are not clinically rational, since two targets have to make sense in the same patient at the same time to justify a combined molecule. Every real combination also needs its own development program, its own trial, and its own approval. The design space expands; the work does not disappear.

A second multiplication sits behind the first, and it is the one that connects this readout to everything else Arrowhead has built. Tissue reach and construct type are independent capabilities. The first answers where a molecule can go. The second answers what kind of molecule can be built.

One clarification belongs on that. The delivery technology is an architecture rather than a single ligand, and the targeting chemistry differs by tissue. Management has said so directly, noting that the brain program uses a transferrin-targeted Fab while the adipose work uses a small-molecule lipid, and that a result in one does not de-risk the other. Generalization is a claim about the architecture, not about one ligand working everywhere. A company that has taken that architecture into five tissues clinically, and that can also assemble multi-target constructs, holds something closer to the product of the two than to their sum, since a dual-trigger design is in principle applicable in any tissue the platform already reaches.

The qualification in that sentence is load-bearing. A successful hepatic dimer would establish the architecture in one tissue, with one delivery chemistry and one pair of triggers. It would not establish that the same construct works equivalently in lung, muscle, adipose, or brain delivery, each of which uses a different targeting approach. What it would establish is that the architecture is real somewhere, which is the precondition for asking where else it travels.

That is where the competitive statement belongs, and it needs to be made carefully, because the obvious version of it is wrong. Silencing two genes with one product is not new and is not unique to Arrowhead. Sirnaomics has been running a dual-target siRNA in human trials since roughly 2017, and has taken it through Phase 2 in skin cancer and into early trials in adipose tissue, using a nanoparticle platform aimed at skin, fat, and muscle alongside a separate liver-directed one. Anyone claiming that dual-target silencing in extrahepatic tissue is unprecedented has not looked.

The distinction that matters is structural, and it is the same one Section 3 turns on. Sirnaomics’ product consists of two separate siRNA molecules packaged together in one nanoparticle, a co-formulation, not a single chemical entity. The academic literature treats those as a different category from unimolecular constructs for good reason. A nanoparticle carrying two payloads does not face the same ligand-to-cargo constraint, because it is not relying on one targeting ligand to haul twice the cargo through a single receptor. That constraint appears only when the two triggers share a single conjugate, which is exactly Arrowhead’s design and exactly what makes the September readout a question rather than a formality.

Stated at the level the evidence supports: dual-target products have been in the clinic for years, unimolecular dual-trigger conjugates are only now entering the clinic, and Arrowhead is attempting one while also holding clinical delivery across five tissues. Whether anyone else is doing both is a harder question than it looks, since several Chinese developers advertise multi-target platforms alongside extrahepatic delivery without disclosing which of their constructs are single molecules and which are mixtures.

The temptation here is to convert that into a claim about the quality of the people, and it is worth resisting, because it would be the weakest version of the argument. Every company in this industry describes its scientists as excellent, the claim cannot be checked, and a shareholder making it sounds like a shareholder. The timeline in Section 2 is the better evidence, because it describes a property of the organization rather than of any individual in it, and that is the property a buyer would actually be purchasing.

Even with those limits, the point stands. One Phase 1 readout in September either opens a combinatorial design space or calls into question whether Arrowhead has unlocked it, and conventional asset models have no obvious row for either implication. The market may initially process the event as news about one cardiometabolic drug, because a drug is the only unit of analysis a conventional model has.

7. The architecture question

Arrowhead is not alone in attempting this, and the two programs are closer in construction than a first look suggests.

Rona Therapeutics, with operations in Shanghai and California, filed in December 2025 to begin a Phase 1 study of RN5681, a GalNAc-conjugated dual-targeting siRNA designed to silence PCSK9 and Lp(a) simultaneously, with dosing slated for early 2026. No clinical data from that study appear to have been published. The company described it as the first bi-valent siRNA from its platform and framed multi-valency as a strategic direction. Arrowhead, for its part, has titled its own announcements around the first dual functional RNAi therapeutic. Two companies are claiming the same ground, which is usually a sign that a category is being defined in real time.

The structural detail has gone unremarked in coverage of either program, and it is not a difference. Both constructs arrange their two triggers in sequence, not side by side. The targeting ligand attaches to the first trigger, and the second trigger attaches behind it, forming a chain. Two companies arrived at the same structural answer to the same problem, and both inherit the same question along with it.

Both molecules are chains. That is not merely a detail of assembly. It creates a specific failure mode worth watching, and it is the reason one line on the scorecard deserves particular attention.

A chain raises a positional question. One trigger sits close to the ligand and the other sits behind it, which creates a plausible route to asymmetric release, or to asymmetric loading into the silencing machinery, meaning one target silenced well and the other less so. The concern is not invented for this paper. It is a plausible consequence of the geometry, and it is why the scorecard treats symmetry between the two targets as a first-order measurement and not a footnote.

Read Arrowhead’s primate result against that concern and it becomes more informative than it first appears. Potency matched to both co-dosed monomers, rather than to one of them, is precisely the outcome a chain architecture does not guarantee. Something in the design, the linker chemistry, the trigger order, or the spacing, appears to have kept the distal trigger from paying a penalty. September asks whether that holds at clinical doses in people.

The competitive picture changes with it. If both companies have chosen the same gross geometry, architecture at that level is not where the differentiation lies. What separates them sits elsewhere: Arrowhead has clinical delivery across five tissues and a construct already dosed in humans, while Rona’s platform, on its own materials, is liver-directed. Geometry is common ground. Reach and timing are not.

One caveat belongs here. Published academic work on unimolecular dual-targeting scaffolds compared linear and branched configurations in the central nervous system and found the linear form performed equivalently, evidence that linear geometry is not necessarily penalized, at least in that experimental setting. That is encouraging for both programs. It is also a reason to treat symmetry as a question September should answer rather than a problem already known to exist.

8. The population, and why it is still unserved

Any commercial case starts with how many patients there are, and this one has an unusually well-documented starting point. It also has a warning attached to it that enthusiasm about the market tends to ignore.

The raw count first. National survey data covering 2007 through 2014 found that 25.9 percent of United States adults, roughly 56.9 million people, had fasting triglycerides at or above 150 mg per deciliter. Among adults already taking a statin, the figure was 31.6 percent, or about 12.3 million people. Those numbers are more than a decade old and obesity and diabetes have both risen since, so they are more likely to understate the present population than to overstate it.

The subset that matters here is narrower than either figure, and Arrowhead has defined it in its own trial protocols. The company describes mixed dyslipidemia as a patient on stable optimal statin therapy who still has cholesterol above target, meaning LDL at or above 70 or non-HDL at or above 100, and who also has fasting triglycerides between 150 and 499. That is a patient failing on both axes despite treatment. Working from the statin-treated figure above, that population plausibly numbers several million in the United States alone, though the precise intersection is an estimate, not a directly measured survey result.

What makes this a real market rather than a theoretical one is that the unmet need has been quantified in events, not just in prevalence. Analyses of the same survey data project more than three million cardiovascular events over ten years among adults with triglycerides at or above 150, including roughly one million among people already taking statins. Mean ten-year cardiovascular risk in statin users rises from about 11 percent to about 19 percent as triglycerides climb. These are patients under treatment who continue to experience cardiovascular events, which is the cleanest definition of residual risk there is.

A population of that size, in a disease this well studied, does not remain unserved by accident. It remains unserved because it has defeated nearly everything aimed at it.

That is the warning, and it belongs in any serious version of this argument. Residual triglyceride risk is one of cardiology’s most thoroughly failed targets. Fibrates lowered triglycerides and did not reduce events when added to statins. Niacin raised HDL, lowered triglycerides, and failed twice in large outcomes trials. Cholesteryl ester transfer protein inhibitors failed repeatedly, one of them with evidence of harm. The most recent and most damaging result came from a modern fibrate that lowered triglycerides by roughly a quarter in a large outcomes trial and produced no reduction in cardiovascular events at all.

The lesson from those failures is narrower than the headline version, and the difference matters here. In that fibrate trial, triglycerides fell while ApoB, the measure of atherogenic particle burden, did not. What failed was not the idea that triglyceride-rich lipoproteins contribute to risk. What failed was lowering a measured triglyceride number without reducing the particle burden that carries the risk. Triglyceride concentration, remnant-particle biology, and atherogenic particle count are related quantities and not interchangeable ones. Note where that leaves September. Management has named ApoB as the measure it expects to move, which means the readout speaks directly to the variable that the modern fibrate trial failed to move.

That history changes what the market size means. The mixed dyslipidemia population is not a large untouched opportunity waiting for someone to notice it. It is a large population that has absorbed several billion dollars of failed development, which is why regulators are unlikely to accept triglyceride lowering alone as evidence of benefit, and why payers are unlikely to reimburse a branded injectable on a biomarker claim in a population where biomarker improvement has repeatedly failed to translate.

The counterargument, and the reason this molecule is not simply the next entry in that list, rests on the mechanisms, not on the market. Half of the dimer is a PCSK9 inhibitor, and lowering cholesterol through that pathway is validated by completed outcomes trials, not by inference. The other half targets APOC3, where the supporting evidence is human genetics: people carrying loss-of-function variants have lower triglycerides and lower cardiovascular risk across their lifetimes. Genetic validation is not the same as an outcomes trial, and it should not be sold as one. It is nonetheless a different and stronger evidentiary basis than the fibrates and niacin ever had, both of which lowered a number without any comparable genetic support for the pathway.

One further point on arithmetic, because large populations invite lazy multiplication. The commercial case does not require the whole population, or anything close to it. At pricing consistent with an established cholesterol-lowering injectable, a few hundred thousand patients is a substantial business, and a million is a very large one. That is low single-digit penetration of the statin-treated residual-risk population described above. The relevant question is therefore never the size of the market. It is what fraction converts, at what price, under what label, and all three depend on evidence that does not exist yet.

9. The comparator Arrowhead chose

Assume the readout comes in clean. The company has already told the market how it intends to position this molecule, and the framing is more specific than the coverage has generally registered.

Arrowhead’s June materials describe the dimer as a single chemical entity to silence two gene targets, and claim regulatory advantages over two co-dosed drugs. The deck goes further, laying out the logic against a combination of an approved cholesterol-lowering RNAi drug and Arrowhead’s own triglyceride-lowering one. The sentence names the comparator. Arrowhead is not positioning this molecule against any single existing product. It is positioning it against a two-drug regimen.

Much of the analysis around this program compares the dimer to one drug. Arrowhead is comparing it to two. That single choice changes the pricing math, the regulatory argument, and the definition of the addressable patient, and it is stated plainly in the company’s own materials.

Follow the consequence. A patient with both elevated cholesterol and elevated triglycerides, treated to guideline on each, takes two medicines. That means two prescriptions, two prior authorizations, two co-pays, two reimbursement decisions, and two injection schedules that may not align. The dimer’s claim is to collapse that regimen into one injection, and its regulatory claim is that one molecule is one drug rather than a fixed-dose combination of two, which could offer a simpler regulatory path than developing two agents for co-administration.

The pricing implication follows directly, and it is where the common analysis goes wrong. Measured against a single cholesterol drug priced near $6,500 a year, a dimer priced anywhere close to Arrowhead’s approved cardiometabolic product would look indefensible. Measured against a two-drug regimen, the umbrella is higher and the argument shifts from the price of a medicine to the total cost of treating a patient. Whether payers accept that argument is a separate and open question. It is nonetheless the argument the company has set up, and it deserves evaluation on its own terms rather than against a comparison Arrowhead never made.

A second signal sits in who Arrowhead chose to make the case. The June webinar closed with Dr. Steven Nissen of the Cleveland Clinic building the argument for mixed hyperlipidemia and atherosclerotic cardiovascular disease. Nissen is among the most prominent cardiovascular outcomes trialists in the field, a different kind of expert from a lipid specialist, and he is simultaneously directing several competing outcomes programs in the lipid space. Bringing an outcomes trialist to introduce a lipid-lowering molecule is consistent with a company thinking about a cardiovascular endpoint instead of a biomarker label.

That reading is an inference, not a disclosure, and it should be held loosely. The choice of speaker is not random, though, and the ambition it implies is considerably larger and more expensive than a lipid-lowering approval.

What remains genuinely hard, because the paper would be dishonest to skip it. The comparator argument only works for patients who would actually receive both treatments, and today many patients with mixed dyslipidemia are managed with a statin plus inexpensive generics, not two branded injectables. An outcomes trial, if pursued as management has described, would be a multi-year and expensive undertaking. The commercial organization Arrowhead has built serves a specialist population with acute risk, which is not the same organization that sells into broad cardiovascular practice.

On cannibalization of the approved triglyceride franchise, the concern is smaller than it appears. Patients with severe hypertriglyceridemia frequently have low or normal cholesterol, and standard cholesterol calculation is unreliable at very high triglyceride levels, so the dual mechanism offers that population little. The overlap sits in the moderate-triglyceride expansion territory, which is years away and where a dual molecule would simply be the better product. Obsoleting your own drug with a superior one is the version of cannibalization worth having.

Management has already sketched the path, which changes what September tests. In June the chief medical officer described adding a Phase 2 segment to the existing study, dosing patients for about a year, and then an outcomes study in mixed hyperlipidemia, with the stated intention of reaching it as fast as possible. The chief financial officer said separately that no out-licensing was planned. Management’s stated plan is therefore to keep the asset wholly owned and advance it toward a cardiovascular outcomes endpoint rather than stop at a biomarker program.

That makes the September disclosure a test of the plan rather than a reveal of it. An outcomes trial in mixed hyperlipidemia is the expensive, slow, and historically unforgiving route described earlier, and the data will determine whether the company still wants it.

10. What would make me wrong

Five ways the argument in this paper breaks.

The construct underperforms in humans. Primate data is encouraging and it is not human data. The ligand-to-cargo constraint described in Section 3 has been documented in related oligonucleotide chemistry, and it may show up at clinical doses in a way it did not at 6 mg per kg in cynomolgus monkeys. That would be a platform-level finding, not merely a failed program.

The disclosure is thin. No conference venue has been identified for this readout, which suggests a press release and possibly an interim dataset, not a full presentation. A sparse disclosure would leave the central question unanswered and the scorecard in this paper ungraded, which is a real possibility readers should hold.

The fixed ratio proves limiting. A dual construct commits to a trigger ratio at the design stage. If the clinically optimal balance between LDL lowering and triglyceride lowering turns out to differ across patients, a fixed-ratio molecule is less flexible than two drugs that can be titrated separately. That is an advantage of the combination approach the single-entity framing does not address.

The chemistry does not scale elegantly. A construct that works clinically still has to be manufactured reproducibly and economically. A single molecule carrying multiple triggers may be more demanding to synthesize, purify, characterize, and control for impurities than either monomer, and those challenges could increase further as additional triggers are added. A platform whose design space expands faster than its manufacturability would be worth less than the combinatorial argument implies.

The capability is less scarce than it looks. Rona has advanced a dual construct into clinical development, and the academic literature already contains published dual-targeting scaffolds. If unimolecular dual targeting becomes a general technique available to everyone, then proving it works is valuable to medicine and much less valuable to any one company’s competitive position.

11. The test inside the test

One closing observation turns September into something more interesting than a data event. There is the engine’s side of it and the market’s side, and the two are worth keeping apart.

A framework I set out elsewhere proposes four observable tests for a genuine discovery engine, as against one good drug with a story attached. Does it translate, meaning does laboratory work reliably reach humans. Does it generalize across more than one setting. Does it run efficiently, producing more per research dollar than peers. Does it keep a beat, producing on a schedule instead of in bursts.

A clean result in September would speak directly to translation and broaden a second criterion, generalization. It would provide another successful translation by showing that a construct that performed in primates also performs in people. The beat is different, because the September timing already supports it. A capability disclosed in 2019, demonstrated in primates by 2023, and dosed in humans by 2026 arrived roughly when an engine running on schedule would deliver it, whatever the data show.

There is a stronger version of that cadence point, and it likewise does not depend on the September data. Two distinct programs, one solving where a molecule can go and the other solving how it can be built, are set to reach first-in-human readout in the same month. Whatever the results turn out to be, running two distinct delivery and construction problems to that stage simultaneously is a statement about throughput rather than about either molecule.

The revision to generalization is the more interesting of the two, since a revision teaches more than a confirmation. That framework treats generalization as a question about places, meaning whether a delivery technology can move from one tissue to the next. This readout tests generalization along an entirely different axis, asking not where a molecule can go but what kind of molecule can be built. If the answer is favorable, then the criterion has two dimensions rather than one, and an engine that generalizes across both is a wider thing than the framework describing it assumed.

Be precise about what that would and would not establish, because the distinction carries the argument. Evidence that an engine deserves a premium is not the same as the market having paid one. A clean dimer result would strengthen the first and would say nothing whatever about the second. Which brings the question back to the market’s side of it.

Then the market’s side. A separate paper of mine argues that conventional valuation can price the drugs a company has made but has no explicit way to price the engine that keeps making them. The absence described in Section 5 tests that claim unusually directly. With no explicit DIMER asset value in the cited model to reprice, a clean result asks whether investors will pay for what the architecture implies beyond this one molecule, which is to say for the capability and not the drug.

The experiment is unusually clean, though not perfectly so. Investors could begin assigning value to this asset directly, ahead of any analyst building a line for it, and a flat reaction could reflect anticipation of the brain readout, or uncertainty about the cost, timing, and execution of the development path, rather than an inability to price a capability at all.

Watch the reaction as carefully as the data. If the construct performs and the price barely moves, that would be evidence consistent with the blind spot operating in public, on a live example. If instead the reaction reflects what a proven dual architecture would mean across the whole liver portfolio, then the market can price a capability after all, and the thesis in that other paper is weaker than I think.

Either outcome teaches something. That is a rare property for a catalyst, and it is the reason to pay attention to the readout nobody is discussing.

The brain readout asks whether the engine can reach somewhere new. The dimer readout asks whether it can build something new. September runs both tests at once, and only one of them is on anybody’s calendar.

Everyone is calculating the main line. The move that changes the evaluation is the one nobody wrote down.

A Note on Supporting Independent Research

If this white paper has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this white paper; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This paper is provided for informational and analytical purposes only. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security, and it is not a recommendation as to any corporate course of action. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results, and forward-looking analysis is inherently uncertain. The author and BioBoyScout are not registered investment advisors. The author assumes no obligation to update this paper.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

I have written about Arrowhead’s engine before, in The Execution Engine, in Zero, in the platform pieces, and each time I tried to value it carefully and kept the numbers conservative. I now think I undervalued it every single time. Not because the analysis was wrong, but because the engine keeps proving itself faster, and in more places in the body, than any careful model would dare to assume in advance. Every quarter Arrowhead adds another target, another tissue, another program that made the jump from animals to humans, and every quarter it reminds me that the thing worth valuing was never the drugs on the board. It is the machine that keeps putting them there. This paper is my attempt to fix that mistake, to value the engine itself instead of its output, and to explain why the market has had the same blind spot I did.

This paper makes one argument, then tests it. The argument is simple: the market knows how to model a list of drugs, but it has no explicit way to model the machine that produces them. Any company whose real asset is a proven, repeatable discovery engine will therefore tend to be undervalued by output-based models, in a way that is not a mistake anyone makes on purpose but a blind spot built into the math. Arrowhead is the clearest living example. The first half of what follows builds the idea on neutral ground, using nothing about Arrowhead at all. The second half holds Arrowhead up against it.

1. A list of drugs is not an engine

Start with a distinction most investors skip past. A pipeline is a list of drugs. You can name each one, count them, guess each one’s odds and market size, and add it all up. Analysts are good at this, and it is exactly what a sum-of-the-parts model does, SOTP for short: put a value on every drug on the board, total it, and call that the company.

An engine is a different animal. It is not a drug. It is the thing that makes drugs. Its real output is a stream of future programs, most of which do not exist yet and have no name today. What makes an engine valuable is not any one medicine it has produced but its proven ability to keep producing them, in new tissues, against new targets, year after year. The value is in the repeatability, not in any single result.

The market has good tools for the first thing and much weaker ones for the second. Markets price intangible things all the time, through multiples, sentiment, and the premium paid for a good story. What they cannot do is model an engine explicitly. When a company’s main asset is the engine rather than the list, the standard model has nowhere to put it, and whatever credit the engine receives arrives indirectly, as a multiple nudged by mood rather than a number anyone has built. The result is not that the engine is valued at zero. The result is that it is valued by accident.

2. Why the math cannot see the engine

The reason is mechanical, not a knock on any analyst, and it is worth walking through slowly because it is the heart of the paper.

A sum-of-the-parts model values things it can name, with odds and markets it can defend. That is its strength. It is also its cage. An engine’s value lives in drugs that have not been invented yet. They have no name, no trial, no disease, no odds you could write in a footnote and defend to a skeptic. A careful analyst therefore cannot put a line in the model for a drug that does not exist, and the value of the ability to create that drug quietly rounds to zero. Not because anyone decided it was worthless. Because there is no row to write it on.

This is the key idea. The engine is not underpriced because the Street is lazy. It is underpriced because the ruler cannot measure it. A model that paid in advance for drugs it could not yet name would be a fantasy, not a model. The very discipline that makes SOTP trustworthy is the same discipline that blinds it to the engine.

The chain of reasoning is worth keeping in this order, because each link is much harder to argue with than a blanket claim about market blindness. An SOTP model cannot explicitly value assets that do not yet have names. Public markets lean heavily on that method for companies like this one, so they systematically underprice the engine rather than ignore it outright. A strategic buyer, whose whole purpose is to own the future output, can explicitly value the engine’s expected productivity. That is the argument. Companies whose worth is mostly the visible list of drugs can at least be modeled explicitly. Whether the market gets those models right is a separate question, and often it does not. Companies whose worth is mostly the engine get priced on a placeholder plus whatever sentiment supplies, and the more of the value that sits in the machine instead of the list, the wider the gap between the price and the truth.

3. The Jordan Premium

There is a version of this you already understand, from a completely different world, and it makes the whole thing click.

When a team drafts a generational talent, it is not paying for next season’s points. Next season’s points you can estimate, and a decent role player who scored the same total would cost a fraction as much. What the team is paying for is the near-certainty of greatness it cannot spell out yet, year after year, in forms nobody can predict. The extra money, the amount over and above the projected stat line, is the price of proven repeatability. It is rational precisely because the greatness has already been shown, not just hoped for.

Call that gap the Jordan Premium: the difference between what an engine is worth and what its current, visible output is worth. It is the value of the machine on top of the value of what the machine has made so far. For a generational athlete, the premium is huge and the market pays it without blinking, because sports learned long ago to price proven repeatability. The stock market, handed a company whose real asset is a repeatable discovery engine, has not learned the same lesson. It pays for the box score and hands you the player for free.

One rule keeps this honest, and the rest of the paper leans on it. The premium is only earned when the repeatability is proven, not just promised. Most prospects scouts call can’t-miss do miss. The reason a true generational talent earns the premium is a real track record, not the hype in the scouting report. For a company, it is the same. The premium is earned by evidence, and by nothing else. A story about a platform is not an engine. The next section is how you tell them apart.

4. How to spot a real engine

Most companies that call themselves platforms are, when you look closely, one good drug wearing a costume. The jump from animal studies to human results is hit-or-miss, every new program is a fresh gamble, and the platform talk is marketing draped over what is really a short list. The real job, then, is telling a genuine engine from a good story, and it can be made concrete. A real engine leaves four marks you can actually check.

It translates. Does what works in the lab reliably work in people? A real engine turns targets into human-stage drugs at a rate well above the industry average, and it does it again and again, not once. This is the hardest mark to fake, because it shows up in the clinic, where stories cannot follow.

It generalizes. Does the same core trick work in more than one place? One drug in one tissue is an asset. The same technology working in tissue after tissue is proof that the underlying ability is general, not a fluke. Each new tissue, moreover, is not just one more market. It is a multiplier, because every tissue holds dozens of new targets to aim at.

It is efficient. Does it make more per dollar than its rivals? A better engine turns the same research budget into more drugs than the competition. That is the number-based fingerprint of a superior machine, and you can check it against public spending.

It keeps a beat. Does the output arrive on a schedule, or in random bursts? An engine produces. A story goes quiet between press releases. A steady, rising count of new drugs entering trials, year after year, is the mark of a process rather than a lucky streak.

A company that scores high on all four has earned the Jordan Premium, and the next question is whether the market has paid it yet. A company that scores high on one or two has a good drug and a good story, which is common and much cheaper. These four marks have nothing to do with any particular company yet. They are just the measuring stick. Now it is fair to pick a company up and hold it against the stick.

5. How rarely anything passes this test

The four marks are common one at a time and rare together, and that gap is the entire reason a premium exists. If proven repeatability were ordinary, it would be priced the way ordinary things are priced. Plenty of companies translate well inside a single modality. Plenty run cheaply, usually because they are small rather than because they are productive. Some keep a decent cadence for a while. What almost none of them do is generalize, meaning take the same core capability into domain after domain, which is the mark that separates a machine from one good drug with a story attached.

Set the bar at all four marks together, held over years, and the historical list gets short fast. Genentech’s recombinant protein method generalized from insulin to growth hormone to a clot-dissolving drug, and for years the market bought the products rather than the method. Regeneron’s antibody-generation platform produced a cholesterol drug, then an immunology drug that grew into one of the largest in the industry, then an oncology franchise, and a string of others behind them. Through much of that stretch the stock was discussed primarily as a bet on the company’s eye franchise, even while the antibody engine was quietly producing assets behind it. Alnylam’s liver-targeting approach generalized across a series of approved medicines, and it too was talked about as a rare-disease company well after it had become a delivery platform. In each case the engine is obvious in hindsight and was priced late.

Moderna is the case worth studying most closely, because there the frontier fell all at once. The generality of the platform was the entire thesis, and the market paid something for that promise. A pandemic then supplied the demonstration, and the repricing arrived in months rather than years. The sequel is just as instructive. When the demonstrated use case faded, much of the premium went with it. A Jordan Premium can be awarded and then withdrawn, which is a useful corrective for anyone inclined to read this paper as a one-way argument.

Now the warning that belongs on that list, because leaving it off would be the same error this paper keeps trying to avoid. Every company named above is an engine that worked, which is precisely why anyone remembers it. For each of them there were companies with equally confident platform stories whose generalization never arrived, and they are missing from the list because they failed and were forgotten. The base rate of platform claims in biotech is enormous. The base rate of platform claims that turn out to be engines is small. That asymmetry is not a reason to discard the framework. It is the reason the framework needs a test at all, and it is why the four marks insist on demonstrated behavior rather than stated ambition.

The honest scale, then, is a few per generation rather than a few per year. Note also where Arrowhead sits relative to that list, which is not on it. The companies above had already demonstrated substantial generalization by the time their platform value became impossible for the market to ignore. Arrowhead is a candidate standing at the moment before its defining test, which is a less comfortable position than membership, and also the only position in which the premium has not already been priced.

6. Arrowhead against the stick

Run the four marks in order.

It translates. Arrowhead’s own line is that just about everything it has taken into the clinic has made the jump from animal models to humans. Treat that as a claim to be checked, not swallowed, and it is still a strong one, because a false claim like that gets exposed fast, failed translation shows up as failed trials for everyone to see. A translation rate near the top of the industry, held across many programs, is the first and hardest mark, and Arrowhead appears to carry it.

It generalizes. Here the record is plain. The same delivery technology has reached the liver, then the lung, then muscle, then fat, and the brain program is in the clinic now, with its first data expected shortly. That is not one trick used once. It is one trick that keeps working in a new place each time, and each new place widens the field of targets by a large multiple. Generalization is the mark that most cleanly separates a real engine from a single lucky drug.

Arrowhead has taken this one into the clinic across more tissues than any other RNAi company. Competitors are working on the same frontier, and Alnylam in particular has clinical programs aimed at the central nervous system and adipose tissue, so this is a lead rather than a monopoly. On that record, Arrowhead has a strong claim to being the leading extrahepatic siRNA developer, which is the more useful way to state it: every approved siRNA drug to date targets the liver, and Arrowhead has gone furthest in leaving it.

It is efficient. The numbers were the subject of an earlier paper and they are blunt. Arrowhead has advanced more clinical programs per research dollar than either Alnylam or Ionis, its two closest peers, spending roughly $607 million on research and development in fiscal 2025 against their $1 billion and $916 million.

That comparison is rough, and it is worth saying why rather than leaving a skeptic to say it. Both peers carry heavier late-stage and commercial spending, and a single Phase 3 program can consume more cash than several discovery programs combined, so part of the gap reflects where each company sits in its life cycle rather than how good its engine is. Fiscal periods do not line up perfectly either. The gap is wide enough that the direction survives those adjustments. That is the claim being made here: not that the ratio is precise, but that more output per dollar is the number-based signature of a better machine, measurable rather than asserted.

It keeps a beat. The count tells the story. The clinical portfolio has climbed steadily toward a guided twenty-three drugs, owned and partnered, entering trials on a schedule rather than in fits and starts. There is a concrete reason the beat holds, and it is worth knowing, because it is the least glamorous item in this paper and one of the most important. Arrowhead built its own manufacturing plant. RNAi timelines across the industry have often been gated by waiting for batch slots at contract manufacturers, which means a rival’s program can sit idle for reasons that have nothing to do with its science. Owning the plant takes that queue out of the schedule. That is production, not luck. Arrowhead scores high on all four marks at once, which, measured against the record in the previous section, is the unusual case rather than the normal one.

7. The tell that the engine is still accelerating

Here is the part that should stop an investor cold, because it turns the engine from a story about the past into a story about the future.

Arrowhead is not done adding tissues. Behind the brain, two more are already in the works at the preclinical stage: the eye and the heart. The eye program aims at glaucoma, delivered by a small injection into the eye itself. The heart program, aimed at the heart muscle cell, the cardiomyocyte, is the one to sit up for, and it was not even on the company’s public pipeline slides until recently.

Reaching heart muscle with a gene-silencing drug is close to a holy grail. Heart muscle has been one of the great locked rooms in medicine, enormous numbers of patients, and until now almost no way to switch off a disease-causing gene inside those cells. Cardiovascular disease is the largest cause of death in the world. A delivery engine that reaches the heart muscle would not open one more drug. It would open a whole new front in the biggest disease category there is, at the genetic root. Two words of restraint belong on that sentence: this program is preclinical, years from a human test, and it may not work. What it demonstrates today is not a heart drug. It is the engine picking its next locked room.

Count the tissues: liver, lung, muscle, fat, brain, eye, heart. Seven, and the last two were added while nobody was pricing the first five. That is not a company with a platform. That is a machine that reaches a new part of the body on a schedule.

Here is the real point, the one that matters most and gets priced least. The named tissues are not the prize. The prize is the increasingly credible expectation that the engine keeps reaching new ones. A machine that has gone from the liver to the lung to muscle to fat to the brain in a decade, and is now engineering toward the eye and the heart, gives no good reason to assume seven is the limit. The reasonable expectation for an engine with that record is that it reaches an eighth tissue, and a ninth, in places nobody has named yet. Those unnamed tissues, the ones not on any slide, not in any model, not in anyone’s price target, are where the largest and least-priced value of all is hiding. You cannot write them into a spreadsheet. That is precisely why they are free.

8. What the market pays for all of this today

The framework predicts that conventional asset-by-asset valuation will pay almost nothing explicitly for a discovery engine, however good, until evidence forces that engine into the model. Arrowhead gives you the cleanest proof of that prediction you could ask for, and the number is worth saying out loud.

In the sum-of-the-parts breakdown JPMorgan published with its $95 target, the line covering the brain platform, the central nervous system programs and the delivery technology behind them, was carried at $1 a share. Not a billion. One dollar. JPMorgan has since raised its target to $100, on a quarter driven by commercial and cardiometabolic progress rather than any human brain data, so there is no reason to think the extra value reflects a new credit for the platform. Most of what any sane person would call the engine, the proven, generalizing, efficient, steady machine described above, sits in that model at a placeholder next to zero.

The preclinical tissues, the eye and the heart, sit inside the same platform line, which is to say they are carried at very close to nothing at all.

The stock does not trade at exactly the sum of those parts, and sentiment supplies some credit the model omits. The point is narrower and sturdier: the one part of the company that most deserves an explicit valuation is the one part no analyst has a row for.

The $1 is not an insult to the engine. It is the math doing exactly what the math does. An SOTP model cannot explicitly value a discovery engine, so it parks it at a placeholder, and given the method, the placeholder is honest. Arrowhead is not the exception that breaks the framework. It is the framework’s clearest proof.

9. What the premium is worth

The fair question is how big the premium should be, and the honest answer is a range with its assumptions visible, not a single number pretending to a precision it cannot have.

The premium is the gap between the engine-inclusive value of Arrowhead and its SOTP value. Its lowest layer is visible, and its highest layer is not. The lowest layer is revealed strategic value: what buyers have already shown they will pay for the engine’s output. Novartis put up $200 million up front and committed to as much as $2 billion in milestones for one program and a few targets built on this platform, before a shred of human brain data existed. In just the most recent quarter, Madrigal paid $25 million up front and committed to up to $975 million for a single clinical-stage liver program. Read those numbers precisely. The upfronts are cash that changed hands. The milestone figures are contingent, payable only if the programs succeed, so they are not money in the bank, but they do establish that sophisticated counterparties were willing to contract around substantial future economics for slices of this engine. That is observable evidence in signed contracts, not hypothetical value invented by a model.

The ceiling is the value of all the drugs and tissues the engine has not reached yet, including the ones with no name. It cannot be itemized, which is the exact reason the market leaves it out, and it is also potentially the biggest part of the premium. It is the value of the machine’s future, the same thing a team pays for when it drafts a generational talent instead of a year of projected points. No honest analyst can type it into a model. That same analyst can nonetheless see that its absence from the model is the mispricing, not a verdict on its worth.

Between that lowest layer and that ceiling the premium separates further, and naming them is more useful than pretending the whole can be reduced to a single figure. The bottom layer is revealed strategic value: the cash paid and the milestone economics sophisticated counterparties have already committed to for slices of the engine. Above it sits demonstrated platform value, implied by the fact that several independent partners have each chosen to build on the same architecture rather than on anyone else’s. Above that is unmodeled option value (targets in tissues already proven), the future programs inside tissues the engine has already reached, which are real, foreseeable, and still nameless. Higher again is frontier option value (tissues not yet proven), covering the eye, the heart, and whatever comes after them. At the top sits strategic control value, which is what an acquirer gains by owning the machine outright rather than renting pieces of it.

Each layer is progressively harder to defend with a number, even as the potential value it captures expands, which is exactly why conventional valuation stops at the first one and sentiment does uneven work on the rest. The point of this paper is not to squash the layers into a single figure, which would be false precision painted over an honest range. The point is that the premium is real, that its lowest layer is already visible in signed deals, and that its largest layers sit outside what the standard method measures. That is why it has never been priced in full. That is why it is still there for the taking.

One caution belongs on all of this, and it is the objection a valuation specialist would raise first. Platform confidence does not only live in a line labeled platform. It can also sit quietly inside the rest of a model, in a probability of success set a little higher because the technology has worked before, in a terminal assumption made a little friendlier, in a multiple that drifts up because the company is respected. To the extent that credit is already there, some of what this paper calls the premium is being counted a second time. The honest equation is not the sum of the parts plus the whole premium. It is the sum of the parts plus whatever engine value is not already embedded elsewhere.

Two things suggest that overlap is small rather than large. The first is the $1 itself. A model that had quietly folded substantial engine value into its other assumptions would have little reason to carry the explicit platform line at a placeholder, and the placeholder is what the published breakdown shows. The second is that the credit which does arrive through sentiment and multiples is unstable by nature, since it moves with mood rather than with evidence, which is a different thing from value a model has actually assigned. Neither observation proves the overlap is zero. Both suggest that the great majority of what is described here is genuinely incremental, and the premium in this paper should be read as the incremental portion rather than the whole.

10. The one buyer who can see it

There is one kind of buyer for whom the premium is not invisible at all, and this is where the argument completes itself. A strategic acquirer does not value a company with a public-market spreadsheet and a $1 placeholder. Its deal team values exactly the thing the spreadsheet excludes, the future programs, the tissues still to come, the repeatability itself, because the future output is precisely what an acquirer is buying. The blind spot this paper describes is a public-market artifact, not a universal one. The one participant structurally equipped to price the engine is the one that intends to own it.

Look again at the partner deals through that lens and they change meaning. Novartis contracting around as much as $2 billion for one program and a few targets, Madrigal around up to $975 million for a single liver asset, those are not just evidence that the engine has value. They are the premium being paid, in fragments, by the actors structurally equipped to price it. Each license is a strategic buyer pricing a slice of the machine that the public market has no explicit way to price. The fragments are already trading. Only the whole is not.

Follow that one step further and you reach the scenario where the premium gets priced most completely: a competitive buyout. In a contested acquisition, rival bidders do not converge on the sum of the visible parts, which any of them could assemble more cheaply elsewhere. They bid up the one thing that cannot be assembled elsewhere, the proven machine, which means a bidding war for Arrowhead would be, almost by definition, an auction for the Jordan Premium itself. Earlier papers of mine walk through who those bidders would be and why each may be cornered into competing. This paper deliberately does not re-argue or price that scenario, for the same reason the Keystone kept the control premium outside its numbers: the case here does not need a deal to work. The engine is underpriced today, on the evidence already in hand. A buyout is simply the venue where the premium would be priced most completely, and in public. The market prices the box score. An acquirer prices the player.

11. What would make me wrong

A paper that only accumulates reasons to agree with itself is advocacy, not analysis. Here are the four ways this thesis breaks, stated as plainly as I can manage, because a reader deserves to know where the load-bearing walls are.

The translation record could break. Everything above rests on a track record, and a track record is a statement about the past. The first mark, that the engine translates, is exactly the kind of claim that a single high-profile failure in a new tissue would damage badly, and the newer the tissue, the thinner the evidence behind it. Liver delivery is proven many times over. Brain delivery has not yet been proven once in a human. A miss in September would not merely disappoint on one drug. It would put the generalization claim itself back in question, which is the mark the whole premium leans on.

The engine costs money, and shareholders have paid for it. This is the counterweight I would want raised against me, so I will raise it myself. More tissues mean more programs, more programs mean more spending, and Arrowhead’s share count has roughly doubled over the past decade. The engine described in this paper was not free. It was funded, in significant part, by diluting the very shareholders who own it. An engine that requires continuous financing can produce wonderful science and still deliver ordinary returns, because the value created gets divided across a growing number of shares. Anyone paying a premium for repeatability should be honest that repeatability has a running cost, and that the cost has historically been paid in equity.

The premium may be structurally unpayable. Here is the deepest objection to this paper, and it deserves to be stated at full strength rather than waved at. If the public market genuinely cannot price a discovery engine, as Section 2 argues, then perhaps it never will, in which case the mispricing is not an opportunity but a permanent condition. A gap that never closes is not value waiting to be captured. It is simply how the asset trades. The honest answer is that this objection is largely correct about the public market and is the reason the strategic buyer matters more to this thesis than a framework paper would like to admit. The historical record cuts both ways here. In the cases from Section 5 the gap did eventually close, which is encouraging, and in every one of them it closed late and only when something forced it, which is not. Recognition tends to arrive when something forces it, proof across a doubted frontier, or a buyer willing to pay for what the spreadsheet omits. Absent one of those, an investor can be right about the engine and wait a very long time to be paid for it.

Someone else could solve delivery. The premium assumes scarcity. If a competitor demonstrates its own route into the brain or the heart, the engine stops being the only one of its kind and the pricing power that comes with being alone at the frontier erodes quickly. Nothing in the record guarantees Arrowhead stays ahead. It guarantees only that it has been ahead so far.

None of these dissolve the argument, and I do not think any of them is more likely than not. Taken together, though, they mark the boundary of the claim. The engine is real and it is underpriced. That is not the same as saying the gap closes on a convenient schedule, or that the shareholder captures all of it when it does.

12. When the market will finally see it

A framework is only useful if it tells you when the gap closes. This one does.

The pattern is this: an engine’s premium expands when it proves itself somewhere the market believed it might not reach. Not every engine has a single hardest job, and it would be convenient rather than true to invent a universal law that happens to point at this September. What is true is narrower. Doubt attaches to specific frontiers, and when a frontier falls, the doubt attached to it is released, along with some of the doubt attached to every frontier still ahead.

For Arrowhead, the brain is the frontier that carries the most doubt today, because it is a room the field has historically entered with a needle in the spine. That makes the September readout the highest-information event this engine has faced. It also means the same logic applies again later. If the brain falls, the heart becomes the next frontier the market doubts, and clearing that one would expand the premium a second time, on the same principle rather than on a new one.

This is where this paper shakes hands with the last one. The case that Arrowhead’s brain readout reprices the company, argued in full in The Keystone, is just this general idea in one specific instance. That paper is about the trigger. This one is about the machine the trigger reveals. A good readout does not merely add a brain drug to the model. It forces the market to face the Jordan Premium it has never been able to price. Proving the engine across a frontier the market doubted it could reach is the moment the engine stops being a story a skeptic can wave off. It becomes a fact a model can no longer park at a dollar.

The timing, finally, is close. Arrowhead announced initiation of the Phase 1/2a study of its lead brain program in December 2025, and management has guided to topline data from the healthy-volunteer portion in September. Note what that readout is and is not: management has described it as primarily safety and total tau knockdown in healthy volunteers, not evidence of benefit in patients. The argument here does not hinge on it, the engine is underpriced today on the evidence already in hand, but September is the moment the market is most likely to be forced to look.

Notice there are two doors the recognition can walk through, and September could open either. The first is the data itself, which forces the public market to reprice what it can now no longer dismiss. The second is a bid, because a proven engine invites the one buyer who can price it, and nothing teaches a market the value of something faster than watching someone else pay for it.

13. The bigger lesson

Step back from the ticker, because the durable idea is larger than any one stock.

Any company whose real worth is a proven discovery engine will be underpriced by output-based valuation, in biotech and well beyond it. The pattern is old enough to have a history, as Section 5 shows, and it has repeated across four decades and several modalities. The very thing that makes SOTP trustworthy, that it prices only what can be named and defended, is the thing that makes the engine invisible. This is not a bug you fix with a better spreadsheet. It is baked into the act of pricing the nameable, and it hands a standing opportunity to anyone willing to tell an engine from a list and put a value on the difference.

The rule that keeps this from being wishful thinking is the stick from Section 4. An engine is not a company that calls itself a platform. It is a company that translates, generalizes, runs efficiently, and keeps a beat, all at once and over years. Hold every hopeful up to that stick, and the premium is earned by evidence instead of handed out on enthusiasm. Arrowhead is today’s clearest case, scoring on all four marks while the market carries its engine at a placeholder and its next two tissues inside it. The rule, though, is the thing to keep. It will outlast this one example.

You do not draft a generational talent for the games you can already put on the schedule. You draft him for the ones you cannot imagine yet. That is what Arrowhead’s engine is, and it is the one thing a spreadsheet built to price the nameable can never fully capture.

Here is the whole paper in a sentence. The market is happy to pay for the drugs Arrowhead has already made, and it will hand you, for free, the machine that keeps making them and the tissues that machine has not reached yet.

The market prices the box score. An acquirer prices the player.

Learn to see the engine, and you learn to see the value the market cannot. That is the Jordan Premium. It is sitting in plain sight, priced at a dollar.

A Note on Supporting Independent Research

If this white paper has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this white paper; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This paper is provided for informational and analytical purposes only. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security, and it is not a recommendation as to any corporate course of action. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results, and forward-looking analysis is inherently uncertain. The author and BioBoyScout are not registered investment advisors. The author assumes no obligation to update this paper.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

JPMorgan’s sum-of-the-parts model for Arrowhead assigns $1 per share to the company’s brain program. Not 1 billion. $1.

That number is not an insult. It is an accounting convention. Analysts price what has been proven and hold a placeholder for what has not, because a model that pays in advance for unproven platforms has stopped being a model. The placeholder is honest.

The question, then, is not whether the Street has overlooked the central nervous system platform. It has not. It has explicitly chosen not to value it yet, and that choice is internally consistent: there is no human evidence to price, so a placeholder is the disciplined answer. The argument of this note is not that the choice is wrong today. It is that the choice is about to be overtaken by the exact evidence it has been waiting for.

It is also the most important number in the model, because the thing it is holding a place for is not one drug.

1. What the market is actually pricing

When the SHASTA readout landed, the market rerated Arrowhead in a hurry. The stock rose roughly 19 percent in a single session, its best day in nearly eight months, to a fresh 52-week high. Analysts moved with it: Morgan Stanley lifted its target to $120, Piper Sandler to $126, Chardan to $115, with others following. The cardiometabolic data was real, and the Street repriced it enthusiastically and fast.

That is exactly what makes the next observation so striking. Look at what those same, freshly raised targets still assign to Arrowhead’s brain program. In JPMorgan’s sum-of-the-parts model, it is $1. The analysts who had just moved their targets $15 to $40 higher on the cardiometabolic franchise did not move the platform, because there was nothing new to move it on.

That is the structure worth holding in mind. The market prices Arrowhead’s drugs readily, and repriced them the moment SHASTA gave it something to model. What it will not price is Arrowhead’s platform, and it declines for a defensible reason: the platform’s central claim has never been proven in a human brain. This September, the first data that could prove it arrive. The drugs already have their catalyst. The platform is still waiting for its.

2. A keystone, not a brick

An arch is not built like a wall. Every stone leans on the others, and none of them carries load until the last stone, the keystone, is set at the top. Before it goes in, the structure is scaffolding and intention. After it goes in, every stone locks into place and the arch carries weight it could not carry a moment earlier.

ARO-MAPT is the keystone of this thesis. It has been dosing subjects since December 2025, and management has now guided topline data from the healthy-volunteer cohort to September, so the readout is an imminent result from a trial already underway, not a distant event. Beyond that timing, it is not testing one proposition. It is testing four, at the same time, in the same patients.

The drug question. Does lowering tau in the human brain accomplish anything? Tau is the protein whose tangles track most closely with cognitive decline in Alzheimer’s disease. One tau-lowering drug, Biogen’s diranersen, has produced a suggestive clinical signal, but it missed its primary endpoint and did not reach statistical significance, so whether removing tau changes the course of the illness remains unproven.

The delivery question. Can an injection under the skin silence a gene inside the brain? This is the one that matters most, because nobody has done it. Every genetic medicine for the brain in the clinic today is delivered by lumbar puncture, a needle placed into the spinal canal.

The pipeline question. Arrowhead has guided a substantial expansion of its central nervous system pipeline at the end of 2026, contingent on encouraging data, and on the earnings call management tied that expansion directly to a successful MAPT readout, noting it would validate the platform for numerous additional CNS programs including partnered ones. Today that expansion is a promise. A good readout converts it into a plan.

The platform question. Does the engine that reached liver, lung, muscle, adipose tissue, and now the brain keep converting delivery capability into clinical programs at the pace it has managed so far?

Four propositions. One readout.

3. Why a good result would compound rather than add

Here is the part that models handle badly, and it is worth walking through slowly because it is the analytical core of this note.

When several uncertain propositions must all be true, their probabilities multiply rather than add. Give each of the four above an even chance and the joint probability is not one half. It is one sixteenth. That is roughly how a platform ends up valued at $1: not because anyone believes it is worth $1, but because a chain of individually reasonable discounts produces a number near zero at the end of the chain.

Now run it in the other direction. A readout that provides the first human validation of the delivery platform does not remove one term from that chain. It removes the condition every other term was hanging from. The drug question, the pipeline question, and the platform question were all discounted for the same underlying doubt, which is whether Arrowhead can put a silencing molecule where it needs to go. Answer that doubt once, and three other discounts collapse alongside it.

This is why the repricing would be nonlinear. The model does not move from $1 to $2. The model changes category, from a pipeline of separately discounted drugs to a validated platform, and platforms are valued on an entirely different basis. One clarification keeps this honest: a good readout would be the first human proof of concept for the delivery architecture, not a guarantee that every future central nervous system program built on it will succeed. What it validates is the route. Each program still has to earn its own approval. That is enough to move the platform off a placeholder, because the market is not pricing certainty on every program; it is pricing whether the architecture works at all.

4. The precedent nobody is citing

There is a temptation to treat all of this as theory. It is not. The most important part of the argument has already been tested in the market, in the same organ, against the same modality, delivered by the same route.

In 2016, Biogen launched Spinraza, an antisense oligonucleotide for spinal muscular atrophy delivered by lumbar puncture. It was the first treatment ever approved for the disease, and it became the standard of care.

In 2020, Roche launched Evrysdi. It works on the same underlying biology, the splicing of the SMN2 gene, toward the same therapeutic goal. The meaningful difference is that patients drink it.

By 2024, Evrysdi was the global market leader in spinal muscular atrophy, with more than 16,000 patients treated and revenue growing 18 percent. Spinraza’s revenue fell roughly 10 percent to $1.57 billion. Roche’s own explanation for the gain was that Evrysdi is the only noninvasive treatment for the disease. Trade coverage put it less delicately: the oral drug removes the need for painful lumbar injections.

Figure 1. Reported annual revenues. Evrysdi converted from Swiss francs; 2023 figures derived from reported year-over-year changes. The incumbent was first, effective, entrenched, and backed by a large company. It lost its lead in roughly four years, and it lost on route of administration.

Read that sequence carefully, because it is this entire thesis in miniature. Nothing about Spinraza stopped working. What changed is that patients were offered the same biology without the needle in the spine, and they took it. That is what a delivery shift looks like when it arrives. It is neither gradual nor polite.

5. What the precedent implies for the incumbents

Every genetic medicine for the brain in clinical development today is delivered into the spinal canal.

Ionis, the pioneer of the field, describes a neurology franchise that addresses all major brain regions, with 13 investigational medicines in clinical development. Spinraza for spinal muscular atrophy and Qalsody for SOD1-ALS are on the market. ION582 for Angelman syndrome is in Phase 3 with Breakthrough Therapy designation. ION717 targets prion disease, zilganersen has cleared its pivotal study in Alexander disease, and further programs address Huntington’s disease, multiple system atrophy, Parkinson’s, and Alzheimer’s. Diranersen, the tau program partnered with Biogen, belongs to the same family. Every one of them is administered by lumbar puncture.

Those are real medicines, and several of them are genuinely important advances for patients who had nothing. Spinraza alone still generates over $1.5 billion a year, and the broader intrathecal neurology franchise across these companies runs to billions more in current and projected revenue, all of it delivered by lumbar puncture. The argument here is not that they stop working. The argument is that their long-term value quietly assumes the route survives, and a validated subcutaneous alternative would not compete with them one drug at a time. It would date the route they all share.

Two honest limits belong on that claim. Antisense chemistry reaches targets and cell types that RNA interference may not, so the two approaches are not perfectly substitutable, and not every brain target will yield to a silencing molecule delivered under the skin. A first-in-human readout also proves biology rather than commercial displacement, which takes years to play out.

There is a further wrinkle that makes the route question sharper than mere convenience. Diranersen’s own trial produced an inverse dose response, in which the lowest dose performed best, alongside a confusional state that climbed from 5 percent on placebo to 28 percent at the highest dose. The chief executives of both Voyager and Denali publicly attributed that pattern to delivery rather than to tau biology. The same trial appears twice in this note, once as evidence that tau-lowering is not yet proven and here as evidence that the route may be the problem, and both readings can hold at once: the drug missed, and the delivery is a plausible reason it did. If that reading is right, the intrathecal route is not simply inconvenient. It may be the constraint on the dose.

6. Value does not appear, it moves

Markets reprice shifts of this kind abruptly, and the mechanism is worth understanding. In the clinic, a transition from one delivery route to another takes years. In a model it takes an afternoon, because an analyst does not gradually shade down an incumbent’s terminal growth rate. The analyst changes the assumption.

A validated subcutaneous route into the brain would therefore do two things simultaneously. It would create a platform premium where a placeholder used to sit, and it would begin subtracting terminal value from franchises built on the older route. The total value of treating brain disease would not change much on the day of the readout. The ownership of that value would start to.

That is the difference between a good clinical result and a repricing event.

7. How large a repricing, and why the number is conservative

The natural question is how large. This note will not answer it with a single price target, because a point estimate on an unproven readout is false precision. What it will do is build the number from the model already on the Street, state every assumption, and then show that the result is conservative against what buyers have actually paid. A skeptical analyst should be able to rebuild it and land in the same range.

Begin with the model itself, since the argument requires no new one. JPMorgan's sum-of-the-parts is a discounted-cash-flow build on roughly 134 million shares. In the breakdown published with its $95 target, the components were approximately $48 a share for Redemplo in severe hypertriglyceridemia, $5 for Redemplo in familial chylomicronemia, $5 for zodasiran, $10 for the obesity programs, $12 for partner milestones, and the balance in cash and tax assets. The brain platform, meaning ARO-MAPT plus the entire central nervous system pipeline plus the delivery technology, was carried at $1. JPMorgan raised the target to $100 the day after the third-quarter print. That raise followed a quarter dominated by cardiometabolic and commercial progress, the priority review voucher, the SHASTA strength, the accelerated sHTG path, rather than any human brain data, so there is no reason to think the extra value reflects a new credit for the platform. Absent a fresh readout, the platform remains the placeholder this section reprices. That single dollar is the line the argument turns on. Everything else is left as JPMorgan has it.

The four components of a repriced platform

A good readout does not lift the platform line by a few dollars. It forces an analyst to build a line item that does not currently exist, out of four distinct value pools. Each is estimated separately below, deliberately, so that a reader can dispute any one without collapsing the rest.

One: ARO-MAPT itself. Value the lead asset the way an analyst values any de-risked clinical program, with a risk-adjusted net present value. Assume a peak-sales estimate for a subcutaneous tau therapy in early Alzheimer’s that is deliberately modest by the standards of the indication, on the order of $4 to $6 billion, reflecting a large patient population against meaningful competition and pricing pressure. Assume an unadjusted program value of roughly 1.5 to 2 times peak, standard for a durable therapy with a decade of exclusivity. Then apply a probability of success that a positive biomarker readout would support but not inflate, in the range of 15 to 20 percent, which respects Alzheimer’s long history of late-stage failure. The product lands near $12 to $18 a share. Note the discipline in that figure: it already assumes most versions of this drug fail.

Two: the wholly-owned central nervous system pipeline. Arrowhead has guided a substantial expansion of its own central nervous system programs contingent on encouraging data, a linkage management restated on the earnings call. A positive readout converts that guidance into credible, separately valuable programs beyond tau. Ascribe only a few risk-adjusted dollars to each of a small number of them and the pool is worth roughly $10 to $15 a share. This is distinct from the value of ARO-MAPT and distinct from the platform’s licensing value below, and it is priced as option value, not as certainty.

Three: the delivery platform as a business asset. Separate from any drug Arrowhead develops itself is the value of a proven subcutaneous route to the brain that other companies will pay to use. This is not speculative. Novartis has already paid $200 million up front and committed up to $2 billion for one program and a few targets built on this platform, before any human brain data. That is the observed price of a single slice. Assigning the entire platform’s licensing potential $12 to $20 a share, roughly $1.5 to $2.5 billion, values the whole at less than what Novartis committed for a fraction. A conservative anchor by construction.

Four: validation of the existing partner licenses. JPMorgan already carries $12 a share for partner milestones. A positive readout raises the probability of the central nervous system portion of those milestones, the Novartis synuclein program and the Sarepta ataxia and Huntington’s programs, all of which ride the same architecture. Marking up only that portion adds roughly $5 to $10 a share. This is an increase to an existing line, not a new invention, which makes it the least disputable of the four.

Summed, the four pools rebuild the platform line from $1 to roughly $40 to $55 a share. Since that line entered JPMorgan’s target at $1, replacing it means adding roughly $39 to $54 of platform value on top of the rest of the model. Set against JPMorgan’s current $100 target, that points to a base case in the rough vicinity of $140 to $155. The precise figure depends on JPMorgan’s latest component split, which is not the point. The point is the shape of the move: a repricing of $40 to $55 a share, or something over 40 percent, off a target that still prices the platform at nothing.

Figure 2. Illustrative, not a forecast. The scenarios reprice only JPMorgan’s $1 platform line; every other component of JPMorgan’s target is held fixed. Figures illustrate magnitude and are not price targets.

Why this is the conservative case, not the bullish one

The test of any target is what informed buyers pay for comparable assets, and here the comparison is unusually direct. In October 2025 Novartis agreed to acquire Avidity Biosciences for approximately $12 billion, an $11 billion enterprise value, for a platform that delivers RNA to one tissue, muscle, with three late-stage assets. Novartis described the capability as one competitors had struggled to replicate and paid a 46 percent premium for it. The comparison is not exact, since Avidity also carried three late-stage clinical assets that Arrowhead’s early brain program does not yet match, but it remains informative on one point the debate turns on: what a proven single-tissue delivery platform commands in a real transaction. Alnylam, whose platform remains concentrated in the liver, carries a market capitalization in the tens of billions and is itself now pushing RNAi into Alzheimer’s, which tells you where the field believes the value is going.

Set the base case against those marks. It implies a platform worth roughly $45 a share, about $6 billion. Novartis paid twice that for a single-tissue platform. The base case therefore values Arrowhead’s entire multi-tissue platform, liver, lung, muscle, adipose, and a validated route to the brain, at half of what one tissue fetched in a real transaction months ago. Either the base case is too low, or Novartis materially overpaid for Avidity. Both cannot be true, and a buyer paying an $11 billion enterprise value in cash is the harder number to dismiss.

The right way to read the base case, then, is as a floor rather than a midpoint. It is built from deliberately conservative inputs at every step, a modest peak-sales figure, a low probability of success, a licensing value set below what a partner has already paid for a fraction of the platform, and it still lands beneath the price a real buyer paid for a narrower asset months ago. A base case that sits below the observable market-clearing price is doing its job as a floor. The honest implication is that the expected value most likely sits above the stated base range, not at its center, and the numbers are kept low on purpose so that the case does not depend on the optimistic end of any single assumption.

One source of upside sits entirely outside these figures and is worth naming precisely because it is not in them. The four pools value Arrowhead as a standalone platform. They contain no control premium. A positive readout would raise the market’s implied probability of an acquisition, and an acquirer would pay above the standalone value, that is what a control premium is. That premium is real and it skews the entire distribution to the upside, but it is left out of the modeled numbers on purpose, because quantifying it would mean stacking a guessed probability of a deal on top of a guessed premium, and a case that needs a takeover to work is a weaker case than one that does not. The repricing above stands on fundamentals alone. The acquisition premium is additional upside on top of it, directional rather than modeled, and it widens the right tail well beyond the bull case.

The magnitude is not an aggressive assumption laid on top of the model. It is what the model produces once the zero is filled in, and it still values a proven multi-tissue platform below what a single tissue sold for this year.

The bull case, and what it requires

The bull case, roughly $185 to $210, is not a larger version of the same arithmetic. It requires the category switch described earlier to actually occur: the market stops valuing Arrowhead as a pipeline of risk-adjusted drugs and starts valuing it as a platform company, on the higher multiple those command. That is where the pipeline expansion, the partnered licenses, and a live acquisition premium all begin to carry value at once, and it is the softest of the three scenarios because it depends on a change in how the market frames the company, not only on the data. It is included for completeness and flagged as the least certain.

The objections a careful reader will raise

Three are worth answering directly.

1. That Alzheimer’s always fails: conceded, which is why the probability of success above sits at 15 to 20 percent rather than higher, and why the platform’s value does not depend on ARO-MAPT’s clinical success alone, since the delivery proof validates the route regardless of the drug’s eventual outcome in dementia.

2. That a biomarker is not clinical benefit: also conceded, and it is why the readout is a repricing trigger rather than a settlement, with full value accruing over years as later data matures.

3. That the drug value and the platform value double-count: they do not, and the four pools above are defined to be mutually exclusive, one drug, other drugs, licensing to third parties, and an uplift to an existing milestone line. On share count, the analysis uses JPMorgan’s own 134 million throughout, so a larger diluted figure would lower every per-share number proportionally while leaving the percentage move, which is the quantity that matters, unchanged.

8. Why proof, not price, has been the obstacle to a deal

The most common objection to the acquisition thesis is that Arrowhead has become expensive. That has the logic backwards.

A large acquirer cannot justify paying platform multiples for a platform that has not been proven. That is a governance problem before it is a financial one, since the board that approves the premium has to defend the evidence behind it. The obstacle was never the price of the asset. It was the absence of the evidence that would make the price defensible in a boardroom.

Proof removes that obstacle, and it removes it in the direction of urgency. A de-risked delivery platform that reaches the brain would be the scarcest asset in an industry facing the largest patent expiration cycle in two decades, and there would be exactly one of them. It would also carry a defensive motive that does not exist today, because whoever owns the successor route owns an option on every franchise built on the route it replaces.

Novartis has already partially voted. In 2025 it paid $200 million up front, with up to $2 billion in milestones, for a preclinical Arrowhead brain program and access to the platform, before any human brain data existed at all. That is what a sophisticated buyer pays for an unproven platform. Novartis is not the only buyer paying, either: within the most recent quarter Madrigal licensed a clinical-stage Arrowhead liver program for $25 million up front and up to $975 million in milestones, one more sophisticated buyer paying to rent the engine rather than build one. The interesting question is what a buyer pays for a proven platform, and what a rival pays to keep it from happening.

Novartis is not the only one exposed to the readout. The same subcutaneous delivery platform ARO-MAPT is about to report on in humans is the one that carries a row of already-licensed brain programs. Novartis holds the rights to ARO-SNCA for Parkinson's disease, described in the deal itself as subcutaneous delivery to the central nervous system, plus options on further targets. Sarepta has licensed a set of central nervous system programs run on the same architecture, covering ataxias and Huntington's disease, with the right to add more.

Every one of those licenses was written on the belief that a subcutaneous injection can silence a gene in the brain. ARO-MAPT is the first clinical test of that belief, now dosing patients with topline data guided to September. A positive readout does not just validate Arrowhead's own programs; it validates every partner's license at once, and confirms that the companies which paid for early access were paying for something real.

None of this makes a transaction certain. It makes the specific thing that has been preventing one go away, which changes both the probability and the timeline.

9. The honest asymmetry

Everything above is conditional, and the condition may not be met.

If ARO-MAPT disappoints, the sequence runs in reverse. The platform premium does not appear. The pipeline expansion guided for the end of 2026 reverts to a hypothesis. The intrathecal incumbents receive a reprieve, because the route everyone criticizes remains the only route that works. The delivery question, the keystone, stays unanswered, and the discount stays applied.

What does not change is the floor. SHASTA-3 and SHASTA-4 have already read out, plozasiran is approved and launching in five geographies, the cardiometabolic franchise is real revenue rather than a projection, and the balance sheet holds roughly $1.57 billion in cash and investments even after the company committed $215 million to a priority review voucher to pull the sHTG approval forward. Management has put the peak sales of that broader approval in the $3 to $4 billion a year range. A disappointing brain readout does not touch any of that.

Underneath that floor, the company is compressing the approval timeline on two separate fronts, and the distinction between them is worth getting right. The priority review voucher shortens the review clock itself, taking the FDA standard review from ten months down to six once the clock starts. Per JPMorgan, management has already told the FDA of its intent to use the voucher, a step required ninety days before filing, and separately intends to request the agency’s Split Real-Time Application Review, or STAR. STAR does not obviously shorten the six-month clock further. It works on a different segment of the timeline, letting a sponsor split the submission into two parts filed roughly two months apart so the agency can begin reviewing the first part before the complete package arrives, with the formal clock starting on the second.

The benefit is front-loading rather than a shorter clock, so the honest way to hold it is as a second, smaller accelerator on the submission-to-clock-start window, not as further compression of the six months the voucher already buys. Two caveats keep it grounded: STAR is a limited pilot with a small number of slots, and it carries eligibility conditions, including a disqualifier tied to foreign manufacturing sites, so an intent to request is not the same as an acceptance. The signal that matters is directional. A company does not pursue two independent acceleration mechanisms at once for an approval it is unsure it wants to reach quickly.

It is worth naming the pattern in these moves, because it is the same quality the platform thesis depends on. Management treated time as a quantified asset and acted on it. It paid for the voucher in cash rather than issuing stock, it timed the regulatory communication to the ninety-day requirement rather than improvising, it layered a second acceleration request on top, and the chief financial officer put the company’s own arithmetic on the decision, describing the four-month pull-forward as worth more than three times the price of the voucher on present value alone, before any competitive benefit from reaching the market ahead of a rival. Read together, these are the actions of a team that knows precisely what its time is worth and spends to protect it. That disposition is not incidental to this note. The value in the sections above depends on execution, on a company that converts capability into approved, launched, partnered programs at a consistent pace, and the way management handled this approval is one more piece of evidence that the execution is real.

The asymmetry is the actual investment observation in this note, and it is more useful than any target price. The downside is bounded by a commercial franchise that already exists. The upside is not a higher number in the same model. It is a different model.

One caution belongs here on what would count as success. A first-in-human readout of this kind is a biomarker and safety event. It shows whether the drug reaches the brain, how much tau it removes, how long the effect persists, and whether patients tolerate it. It does not show that patients get better, which requires years and far larger trials. Reading a strong biomarker result as proof of clinical benefit would be the same error as pricing the platform at $1, made in the opposite direction.

10. What to watch when the data arrives

Five things will separate a good headline from a result that confirms the thesis.

Depth of knockdown. In primates, Arrowhead reported roughly 70 to 80 percent reduction of tau messenger RNA across brain regions, and 50 to 60 percent reduction of tau protein in cerebrospinal fluid sustained for months. The two figures measure different things, and the distinction matters for reading the human data. Messenger RNA knockdown cannot be measured directly in a living human brain, so the number a first-in-human study reports is the cerebrospinal fluid tau protein reduction.

Management has now named its target explicitly, guiding to a 50 to 60 percent knockdown and anchoring that level to the degree of tau lowering associated with clinical improvement in the reference literature. That is the benchmark to hold the September data against, and it lines up with the primate cerebrospinal fluid figure rather than the higher messenger RNA number. A reader who remembers the 70 to 80 percent primate mRNA figure and expects it in humans is measuring against the wrong yardstick, the gap between species is where optimism usually goes to die, and the honest comparison is the cerebrospinal fluid number the company has itself put forward.

Regional distribution. This is the most important item on the list and the least discussed. A drug delivered into spinal fluid diffuses inward from the surface, so it reaches superficial cortex more readily than the deep structures beneath, and those deep structures carry much of what patients and families actually care about. Cerebrospinal fluid tau cannot show this; only imaging can, which is why the exploratory tau-PET readout, if the company reports it, matters more than the headline knockdown number. Whether Arrowhead shows the drug reaching deep structures, rather than an aggregate figure alone, is the difference between reaching the brain and reaching the part of the brain that matters. A leading tau imaging researcher raised exactly this question about the Biogen data, and Biogen did not answer it.

Durability. Duration of effect per dose determines dosing frequency, and dosing frequency is where a subcutaneous route turns a scientific advantage into a commercial one.

Safety, specifically its absence. The signature that follows oligonucleotides in spinal fluid includes inflammation of the cerebrospinal fluid, rising neurofilament light as a marker of neuronal injury, and ventricular enlargement. A clean profile on those measures would not merely reassure. It would be the affirmative case that changing the route solves the problem rather than trading one problem for another.

What the company chooses to disclose. A company confident in its regional data shows regional data. The shape of the disclosure will say almost as much as the numbers inside it.

11. The position, and the move

Chess players recognize positions like this one. Every piece is developed, the center is prepared, and the entire game reduces to a single break in the middle of the board. Until that break is played, the position is only potential, and the stronger player is usually the one who understood several moves earlier that everything had already been arranged.

Arrowhead has spent more than a decade arranging this position: seven tissues, 19 clinical programs, its own manufacturing plant, an approved and launching medicine, partners who pay it for hitting deadlines, and a balance sheet that lets it refuse a low offer.

The readout in September does not create that position. It reveals whether the position was real.

A Note on Supporting Independent Research

If this white paper has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this white paper; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This paper is provided for informational and analytical purposes only. Forward-looking analysis of an unannounced readout. Nothing here is a prediction of clinical results. Revenue and franchise figures are drawn from company reports and public disclosures. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security, and it is not a recommendation as to any corporate course of action. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results, and forward-looking analysis is inherently uncertain. The author and BioBoyScout are not registered investment advisors. The author assumes no obligation to update this paper.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

Robert Toczycki, JD, MBA
bioboyscout.com
bioboyscout@gmail.com
847.227.7909
X: @BioBoyScout

About This Series

This is the third and final paper in a series imagining how three large pharmaceutical companies, Novartis, then Lilly, then Roche, would approach acquiring Arrowhead Pharmaceuticals, and how Arrowhead would respond. As with the first two, this paper is a strategic thought experiment built entirely on the public record: each company’s actual acquisition history, its publicly stated strategy, the way it has behaved in past deals under its current leadership, and the public facts about Arrowhead. It is not a prediction, and not a claim that any deal is under discussion. I have no knowledge of any such discussions. Part One introduced Novartis, the partner that knows the value, and sounded the warning the old chess players called “en garde”. Part Two introduced Lilly, the giant that can simply pay, whose entry was the “check” that forced the whole board to respond. This paper introduces the last and most reluctant suitor, and with it the position the entire series has been building toward, the one in which a player is compelled to move and every move is bad.

Executive Summary

Roche is the suitor with the deepest claim of all to the science Arrowhead is built on, and the strongest temperamental reluctance to do anything dramatic about it. That combination is what makes it the right subject for the finale. The depth of the claim is almost literal: the platform Arrowhead built its company on came from Roche, which sold its RNA interference business, the technology, the Wisconsin site, and the scientists, to Arrowhead in 2011. Roche also pioneered the delivery of medicines across the blood-brain barrier using the transferrin receptor, the same fundamental strategy Arrowhead now uses to carry its tau therapy into the brain. No potential acquirer has more of its own history embedded in the company it would be buying.

Roche is nonetheless the most disciplined and most price-sensitive of the three. It does fewer deals than its peers, it puts science at the center of every decision, it has publicly chosen to sit out the recent industry acquisition spree rather than overpay, and it relies on partnerships and licensing more heavily than any of its rivals. It has even told its investors, in plain language, that it faces no patent cliff and needs no rescue from dealmaking. Everything about how Roche prefers to operate argues against being drawn into a large, contested acquisition.

This is the setup for the position the series has been building toward, the one chess calls “zugzwang”, in which a player would prefer to do nothing but is compelled to move, and every available move worsens his position. Roche’s preferred move, to license rather than buy, no longer protects it once a rival might buy the whole platform. Walking away means watching a competitor capture the very science Roche pioneered. Bidding means abandoning the disciplined, no-cliff identity it has spent years projecting. This paper lays out why Arrowhead fits Roche more deeply than it fits anyone, how Roche actually does deals, and why, in this one case, the most disciplined player on the board is the one with no good move left.

I. The Position the Series Has Been Building Toward

Two warnings have already sounded on this board. In the first paper, Novartis heard “en garde”, the old courtesy that announced an attack on the queen, and recognized that the company best positioned to understand Arrowhead’s value was not the company that could most easily afford it. In the second, Lilly’s entry delivered a “check”, the forcing move that stripped every other suitor of the freedom to wait. Each paper tightened the position. This one closes it.

Chess has a word for the position in which a player would most like to pass, to do nothing and keep his advantages intact, but is not allowed to, because the rules require him to move, and every move he can make damages his own position. The word is “zugzwang”. It is one of the strangest and most instructive ideas in the game, because it describes a situation in which the obligation to act is itself the disadvantage. A player in “zugzwang” is not losing because his pieces are weak. He is losing because it is his turn, and every legal move makes things worse. The player who could simply sit still would be fine; the player who must do something is undone by the doing.

This is the position Roche faces in the contest for Arrowhead, and it is why Roche belongs at the end of the series rather than the beginning. Roche is, by temperament and by stated strategy, the player who would most prefer to pass. It is disciplined, it is science-first, it is the most price-sensitive of the three and the most reliant on partnership rather than acquisition, and in neuroscience it has consistently chosen the patient path of licensing over the dramatic path of buying. It has gone out of its way, publicly, to stand apart from the industry’s recent rush of dealmaking. The drama of this final paper is the spectacle of the one suitor who most wants to stand still being compelled, by the presence of the other two, to move, and discovering that every move available to it costs something it did not want to pay. The most disciplined player makes the most painful forced move, because he has the most to give up by abandoning his discipline, and the most to lose by clinging to it.

II. Why Arrowhead Fits Roche

The depth of the fit between Arrowhead and Roche is greater than for either other suitor, and it carries an irony so complete that it almost defies invention. Roche is not merely interested in the science Arrowhead practices. Roche built the foundation of it, owned it, and sold it to Arrowhead.

The history is a matter of public record. In 2011, Roche decided that RNA interference, the gene-silencing technology that is the entire basis of Arrowhead’s platform, was not a business worth keeping. It sold that business to Arrowhead: the research site in Madison, Wisconsin, the foundational delivery technology, the intellectual property, and a team of more than forty RNAi scientists who became the nucleus of Arrowhead’s research engine. Arrowhead was then worth less than $50 million. It took what Roche discarded and made it the seed of everything that followed. The science Roche would now have to pay an enormous price to acquire is the science it once owned outright and let go for a pittance, to the very company it would now be trying to buy. No rival can claim a connection to Arrowhead’s platform anything like this one, because no rival gave it away.

The brain is where the fit turns from history into live competition. Crossing the blood-brain barrier, the biological wall that keeps most drugs out of the brain, is the central obstacle in treating Alzheimer’s and most other neurological diseases, and for fifteen years Roche has been one of the world’s leaders in solving it. Its proprietary brain-delivery technology, the foundation of its flagship Alzheimer’s antibody trontinemab, works by attaching the drug to a fragment that latches onto a specific docking point on the cell surface, the transferrin receptor, and uses it as a shuttle to ferry the drug across the barrier. That is, at the level of fundamental strategy, the same approach Arrowhead uses to deliver its tau therapy: a fragment that binds the same receptor and carries a payload into the brain. The difference is the point of complementarity. Roche’s shuttle carries an antibody that clears amyloid, one of the two toxic proteins that accumulate in the Alzheimer’s brain; Arrowhead’s carries a genetic medicine that lowers tau, the other principal driver of the disease. Two companies, the same delivery strategy, aimed at the two halves of the same illness. No potential acquirer is better equipped to understand exactly what Arrowhead’s brain platform is worth, because Roche has spent fifteen years building the closest thing to it that anyone else owns.

The RNA platform tells the same story in reverse. Having sold its RNA interference business in 2011, Roche has spent recent years trying to buy and partner its way back into the field it walked away from, reaching for a capability Arrowhead has spent those same years compounding into a mature platform. To acquire Arrowhead’s RNA engine now would be to pay a vast premium to stand where Roche could have stood all along.

Obesity completes the picture, and here the fit is not a contrast but a direct synergy with a program Roche already owns. Roche has declared an ambition to become a top-three player in obesity, anchored by CT-388, a weight-loss drug from the same mechanistic family as the market-leading injections, acquired in its Carmot purchase, that produced weight loss in mid-stage testing comparable to the market leaders and is advancing into Phase 3. The difficulty Roche faces is the one its own executives and outside analysts have named: CT-388 enters a crowded field years behind the leaders, so its differentiation will have to come from combinations and from novel mechanisms layered onto the GLP-1 backbone, including approaches that preserve lean muscle and improve the quality of weight lost rather than simply the quantity. That is precisely the gap Arrowhead’s obesity programs are built to fill. They work through mechanisms entirely different from the GLP-1 drugs, aimed at exactly the next-generation questions, muscle preservation, fat quality, durability, on which the obesity market’s next phase will be decided. For Roche, Arrowhead is not a competing obesity bet to be weighed against CT-388; it is the differentiating layer that could make Roche’s own franchise the one that wins the second act of the weight-loss era. A company racing to catch the leaders has the strongest possible reason to want the mechanisms that leapfrog them. Across all three areas, the brain, the RNA platform beneath them, and obesity, Roche is not entering a new field but returning to one it once occupied, pioneered, or is now racing to lead.

One feature of the platform sits less comfortably with Roche than with the others, and it foreshadows the bind to come. The platform does not confine its output to areas Roche already knows; it will keep generating programs across many tissues, some far from Roche’s focus. For a company that prides itself on selectivity, on developing only what clears its bar and walking away from the rest, that open-ended generativity is a genuine complication, because it asks Roche either to broaden beyond its chosen lanes or to license away what it will not pursue. The very thing that makes Arrowhead most valuable, its endless capacity to generate new programs, is the thing that fits least comfortably with how the most disciplined suitor prefers to operate.

III. The Cliff Roche Says It Does Not Have

Each paper in this series has treated the patent cliff differently, because each company stands in a different relation to it. Novartis faces a real and arriving cliff and acquires openly to fill it. Lilly faces no present cliff and buys from strength to front-run a distant one. Roche presents the most interesting case of the three, because Roche has told the world, in plain terms, that it has no patent cliff at all.

This is not an inference; it is Roche’s own stated position. In its investor presentations the company has declared, in so many words, that there is no patent cliff ahead, that its on-market portfolio will deliver growth through the latter part of the decade, and that its margins will hold. It is a confident, even proud posture, and it is central to how Roche presents itself: a science-driven company strong enough that it does not need to chase rescue deals the way its more exposed peers do. The message to investors is that Roche can afford to be disciplined precisely because it is not desperate.

The fuller picture is more nuanced, and the nuance matters for what follows. Beneath the no-cliff confidence, Roche does face real erosion of some older products as biosimilar competition arrives, the lower-cost copies that rivals can sell once a biologic drug loses its patent protection. Several long-standing biologics are exposed over the second half of the decade, among them the breast-cancer drugs Perjeta and Kadcyla, and, most significantly, Ocrevus, the multiple-sclerosis blockbuster that generates on the order of $8 to $10 billion a year and begins losing exclusivity toward the end of the decade. Roche’s position is not that nothing is eroding; it is that its growth drivers and deep pipeline more than offset the erosion, so that the net effect is continued growth rather than a cliff. That is a defensible claim, and quite possibly an accurate one. The important point for this paper is what it does to Roche’s room to maneuver. A company that has publicly staked its identity on having no cliff, and on not needing transformational acquisitions, has boxed itself in. It has told the market it does not need to do a big, dramatic deal, which makes doing one a reversal of its own narrative. Roche’s confidence is real, but it is also a constraint, because it raises the cost of being seen to act out of necessity. This is what sets up the cruelty of the final position. Roche is the one suitor for whom a large acquisition is not just expensive in money but expensive in identity.

IV. How Roche Actually Does Deals

Roche’s dealmaking style is the most disciplined and the most distinctive of the three suitors, and understanding it is essential to understanding why the forced move costs Roche more than it would cost anyone else. Where Lilly has become the industry’s most aggressive acquirer and Novartis signs deals by the dozen, Roche moves rarely and deliberately. It completes only a couple of acquisitions in a typical year, it places science at the center of every decision, and its leadership speaks consistently of discipline, of refusing to overpay, of maintaining a high bar. In 2026, as its peers pursued an acquisition spree, Roche’s chief executive publicly explained why the company was sitting it out, with not overpaying high among his reasons. Roche is proud, with cause, of being the disciplined one.

This does not mean Roche never does a large deal; it means it does them rarely and on strict terms. It has shown it will act decisively when the science and the price both clear its bar, paying around $7 billion for one late-stage asset in 2023 and acquiring its way into obesity the same year. The point is not that Roche cannot write a big check, it plainly can, and it keeps roughly $10 billion of dealmaking capacity available each year. The point is that it does so reluctantly, selectively, and on its own terms, and that it has deliberately chosen to stand apart from the kind of competitive bidding its rivals embrace.

On the question of how large a check it could write for Arrowhead specifically, Roche has more room than its restraint suggests. Working from its own filings, with net debt near $19 billion, earnings before depreciation and amortization on the order of $28 billion, and the highest credit ratings of the three suitors, Roche carries the largest borrowing capacity of the group, enough to fund perhaps $60 to $85 billion of an acquisition before straining its balance sheet. Combined with its own stock, that capacity reaches to something on the order of $120 billion without undue strain, and can stretch to roughly $155 to $160 billion, very roughly $1,000 to $1,030 a share, through a cash-and-stock structure with a contingent value right to bridge the clinical uncertainty. These are estimates from public filings rather than precise limits, but the implication is the one that makes Roche the finale: its capacity is ample, and its need, the Ocrevus revenue gap opening in 2028 and 2029, points at the same asset on the same timeline. Roche has both the reason to bid near the top of that range and the room to do it. It is the bidder forced in the strongest sense of the word, because the usual excuses, cannot afford it, do not need it, are both unavailable to it.

In one area that discipline takes a specific and telling form, and it is the most important fact for what follows. Roche relies on partnerships and licensing to an unusual degree; its own leadership has noted that a partnership underlies roughly sixty percent of its research pipeline and drug sales. In neuroscience especially, the field where Arrowhead’s lead program sits, Roche has favored licensing specific programs and technologies over buying companies outright, partnering for what it needs while keeping its commitments measured. This is a rational approach to a high-risk field: licensing lets Roche gain access to a promising asset without betting the company on it, preserving the discipline and optionality it prizes. For years it has been exactly the right way for a science-first, price-sensitive company to engage with the hardest area in drug development.

This preference for partnership is the key to the whole finale, because it is Roche’s natural move, and the position about to be described is precisely the one in which Roche’s natural move stops working. Everything in Roche’s history says that, confronted with an asset like Arrowhead’s tau program, it would reach first for a license: take the program it wants, structure a partnership, avoid the cost and the contested-auction dynamics it has spent years avoiding. That is what Roche does. The trap, as the next section shows, is that the one thing a license cannot do is keep the platform out of a rival’s hands, and in a contested situation that is the only thing that matters.

V. The Roche Playbook, and Why It Breaks

Put Roche’s deep fit, its no-cliff confidence, and its licensing preference together, and its preferred approach to Arrowhead is easy to predict. Roche would license. It would identify the program it most wants, most likely the tau therapy that complements its own brain-delivery work, and it would seek a partnership: rights to that program, perhaps to a few others, structured to give Roche access without forcing it into a transformational acquisition that violates its discipline and contradicts its no-cliff narrative. For a company that prizes selectivity and has spent years telling investors it does not need big deals, a targeted license is the obvious, comfortable, in-character move.

In a quiet world, that move works beautifully. A license gives Roche the one program it most wants, at a fraction of the cost and risk of buying the whole company, while leaving Roche free to remain the disciplined, science-first house it presents itself as. If Roche were the only suitor, licensing would be not just adequate but optimal, the textbook way for a risk-aware company to engage a promising platform without overcommitting.

The world of this series, though, is not quiet, and that is what breaks the playbook. The first two papers put two other suitors on the board, and at least one of them, Lilly, can buy the entire company without strain. This is the fact that turns Roche’s natural move into a trap. A license secures one program; it does not secure the platform. If Roche licenses the tau program and a rival then buys Arrowhead outright, Roche is left holding rights to a single asset while its competitor owns the engine that generates all the others, including the future brain programs that would compete directly with Roche’s own. Worse, an acquirer of Arrowhead might be able to disrupt or renegotiate the very license Roche was relying on. The licensing strategy, which is safe and smart when Roche is the only player, becomes the opposite of safe the moment the whole platform is in play, because it leaves the thing Roche most needs to prevent, a rival owning the science Roche pioneered, entirely unprevented. Roche’s preferred move does not lose gracefully. It fails at the one job that matters in a contest: keeping the asset away from the competition.

VI. “Zugzwang”

Now the position is complete, and it is worth stating with precision, because it is the destination of the entire series. Roche, the most disciplined and most reluctant of the three suitors, faces a board on which it would prefer above all to do nothing dramatic, to license quietly or to wait, and on which every move actually available to it worsens its position. This is “zugzwang”, and Roche is in it.

Consider the moves and what each one costs. Roche can license, its preferred move, but as the previous section showed, a license secures one program while leaving the platform for a rival to buy whole, so the move that feels safe is the one that fails at the only task that matters in a contest. Worse for Roche, the option may not even be on the table. A company fielding acquisition interest from two or three of the largest players in the industry has little reason to carve off a piece of its platform when a sale of the whole captures far more, so Arrowhead may simply decline to license its core science into the middle of a bidding process. Roche's safest move could be foreclosed not by its own hesitation but by the target's refusal to offer it. Roche can walk away, staying disciplined and preserving its no-cliff narrative, but walking away means standing aside while a competitor captures the transferrin-receptor brain-delivery science that Roche itself pioneered, watching its own frontier pass into a rival's hands. Roche can instead bid to win Arrowhead outright, which secures the asset but requires the one thing Roche most avoids: paying a contested premium in exactly the kind of bidding war it has publicly refused to join, against rivals with deeper pockets and fewer scruples about overpaying. Three moves, three different costs, and not one of them leaves Roche as well off as it would be if it could simply pass. That is the definition of the position. The obligation to respond is itself the trap.

The cruelty is sharpest for Roche precisely because Roche is the most disciplined player. For Lilly, winning Arrowhead is no reversal; aggressive acquisition is its stated strategy, so a winning bid is simply Lilly being Lilly. For Novartis, a stretch acquisition is unusual but not identity-breaking; it has stretched before. For Roche, every path violates something it values. Licensing violates its security, walking away violates its strategic interest, and winning a contested auction violates the disciplined, no-overpay identity it has spent years cultivating and has just publicly reaffirmed by sitting out the industry’s deal spree. The player with the most rigid discipline has the most to lose from being forced off it, which is why the forced move falls hardest on the suitor that most prizes its discipline. A less disciplined company would feel this position as a hard choice. Roche feels it as a genuine bind, because there is no move consistent with everything Roche wants to be.

There is a further twist hidden inside Roche’s own discipline. Years of restraint have left Roche with the means to act: a conservative balance sheet, ample deal capacity held in reserve, and a chief executive who has said plainly that the company retains the strategic flexibility for large acquisitions when the science and the price justify them. Discipline did not leave Roche unable to bid; it left Roche eminently able to. That removes the one excuse a forced player most wants, the comfort of incapacity. A company that genuinely could not afford the asset could walk away with its head high, pleading necessity. Roche cannot. It has the capital, it has the strategic rationale, and it has the deepest claim of anyone to the asset. Its discipline bought it the very capacity that now denies it the easy exit, because no one will believe Roche walked away because it could not act. They will know it chose not to. The disciplined player saved its strength for a moment exactly like this one, which is why the moment is so unforgiving.

VII. The Far Side of the Forced Move

Everything to this point has described the discomfort of the move itself, and that discomfort is real. A forced move, though, is defined only by the compulsion to make it, not by where it leads, and this is the place to say plainly what the language of traps can obscure: for Roche, of all three suitors, the move it is forced toward leads somewhere genuinely glorious. Lilly and Novartis are pushed toward Arrowhead largely by what they stand to lose. Roche is pushed toward the one asset on the board whose acquisition could become the proudest chapter in its modern history. It is at once the suitor with the most to lose by being forced and the most to gain by winning, and the second half of that sentence has gone understated for too long.

The redemption is the heart of it, and it is unique to Roche. The 2011 sale is the source of the bind, but it is equally the source of a story almost no acquisition can offer. To buy Arrowhead would be for Roche to reclaim the platform it invented and let go, to walk back into the field it abandoned and lead it, to convert what looks in hindsight like one of the costliest divestitures in its history into the foundation of its next era. Most corporate acquisitions are spreadsheets and synergies and integration plans, and no one writes songs about them. This one would be different. It would be the pioneer returning for the science it created, and finishing the work it once decided was not worth keeping. There are few stories in this industry a company could be prouder to tell, and fewer still that would fit so completely with how Roche likes to see itself, as the patient, science-first house that backs the hardest problems and stays for the long arc. Winning Arrowhead would not contradict that identity. It would vindicate it.

The strategic prize matches the symbolic one. An acquisition of Arrowhead would not, by itself, make Roche the largest company in the industry; the lead Lilly built on the obesity wave is not closed by a single deal, and it would be a mistake to claim otherwise. What it would do is arguably more durable than a change in the rankings. It would hand Roche the one validated genetic-medicine engine no competitor can match, secure its growth deep into the next decade with a pipeline that renews itself across tissue after tissue, and re-establish it as the leader of a field it helped create and then watched others build. There is a particular sting, and a particular prize, in the data beneath that engine. As a separate analysis in this body of work argues, the deepest moat Arrowhead holds is the proprietary, compounding record of fifteen years of experiments, a dataset no rival can buy or rebuild, that, fed into AI-driven design, makes its discovery faster and surer with every program. The moat is the data, not the software that reads it: AI models are available to everyone, but the proprietary record that makes them useful is available to no one else. Roche began that dataset. The experiments it ran before 2011, and the platform it sold, were the first entries in the very record that now cannot be reconstructed at any price. To acquire Arrowhead would be to buy back, vastly enlarged, the compounding advantage Roche itself started and then let another company spend fifteen years widening. Scale can be bought by anyone with enough cash, and the obesity wave lifting Roche’s rivals will eventually crest. A self-renewing, data-compounding platform that generates new medicines across the body for years is the rarer and more lasting advantage. Roche would be acquiring not a higher rung on a list, but the thing most likely to keep it near the top of the list for a generation, which is the prize a science-first company should want above almost any other.

None of this makes the act of bidding comfortable. A disciplined company does not relish paying a contested premium in a public auction, and Roche would feel that cost as sharply as the zugzwang describes. The discomfort, though, is the entry price, and Roche is the one player on the board for whom the destination so plainly justifies it. The forced move remains forced. It may also be the luckiest compulsion in Roche’s history, the push that carries the most disciplined company in the industry toward the best decade it could have written for itself. A player does not always choose the moment it is made to move. Sometimes the position that leaves it no comfortable choice is the very one that leads, against its own caution, to its finest hour.

VIII. How Arrowhead Plays It, and the Auction Resolves

From Arrowhead’s side of the table, the resolution of the series is not really about any single suitor’s tactics anymore. It is about the structure that the three suitors together have created, and Arrowhead’s role within it is the one developed across the whole BioBoyScout series: the company that does not need to sell, holding the position that lets it wait while others are forced to act.

By the final paper, the leverage analysis assembles itself. Arrowhead owns its manufacturing, has an approved product and revenue, and runs a platform deep enough to fund its own future, which means it is never forced to accept a disappointing offer; it can always choose to continue alone. Around that unforced center, three suitors now circle, each unable to let the others win. Novartis cannot lowball, because it knows the value too well. Lilly can pay the most and is the hardest to outbid. Roche cannot afford to let either rival capture the science it pioneered. That configuration, three players who cannot all win and at least one of whom cannot bear to lose, is the precise condition that turns a buyer’s market into a seller’s auction. Arrowhead does not need to manufacture the contest. It needs only to hold its position and let the suitors’ awareness of one another do the work, because the moment any one of them moves seriously, the others are compelled to respond, and the bidding rises not to the level any single buyer would have offered in isolation but to the level required to win a contested prize.

Roche’s role in that dynamic deserves a closer look, because its incentive does not disappear even in the case where it loses. Roche would, of course, prefer to win, to reclaim the science it once owned and to secure its own next decade. If it cannot, though, it is not reduced to a passive bystander. As the most informed party at the table, the one with the deepest claim and the clearest view of what the platform is worth, Roche is well placed to bid aggressively for a rational reason that has nothing to do with spite: to force a rival to pay the full, foreclosure-inclusive price rather than acquire the asset cheaply. A disciplined company does not bid past its own estimate of value to inflict pain. It can, however, bid up to that estimate without flinching, and its estimate is higher and better founded than almost anyone’s, which means Roche can push a competitor close to the true ceiling before stepping aside. There is a measure of cold consolation in that outcome. If Roche cannot keep the science it invented, it can at least ensure that the rival who takes it pays dearly, and that the technology Roche developed and once owned is carried off not at a bargain but at the hard-won price of a genuinely contested auction. Losing the asset is a defeat. Letting a competitor steal it cheaply would be a larger one, and that, at least, Roche has the standing and the knowledge to prevent.

This is the deepest expression of the foreclosure logic that runs through the series. The value of Arrowhead to each acquirer is not just what the platform is worth to that buyer; it is that amount plus the cost of letting a rival have it instead. In a quiet sale, only the first number is paid. In a contested auction, the second number, the value of denial, is dragged into the price, and it is captured by Arrowhead’s shareholders. The three-suitor structure is, in effect, a machine for converting the strategic value of foreclosure into realized acquisition value, and Roche’s predicament is what proves the machine is running, because the most disciplined player being forced to participate is the clearest possible sign that standing aside has become more expensive than bidding.

There is an affirmative side to this that the language of traps and forced moves can obscure, and it is the consideration most likely to make a winner of any of the three. Foreclosure explains why none of them can let a rival win; it does not capture how much the winner actually gains. The eventual owner of Arrowhead does not simply acquire a pipeline of programs to be tallied against the price. It acquires the only validated, multi-tissue genetic-medicine platform of its kind, with its own manufacturing, an approved product, and a roadmap of programs stretching across the liver, muscle, lung, fat, and the brain in the clinic, with the eye and the heart already emerging behind them and more tissues to follow, for years to come. Whichever company wins, if the platform performs as the series assumes, is likely to look back on the purchase not as the deal that strained its discipline but as the best acquisition it ever made, possibly the best any large drugmaker has made in a generation. The premium that looks shocking on the day of the announcement is measured against the wrong baseline; measured against a decade of compounding output and the franchises it will seed, even a record price can prove modest. The cruelest part of the position, then, is not merely that each suitor is forced to act. It is that each is forced to compete, at a punishing price, for what may turn out to be the prize of the era, which means the pain of bidding and the scale of the reward are the same fact seen from opposite sides. A player does not fight hardest to avoid a loss; a player fights hardest when the thing on the table is the best it will ever have the chance to buy.

IX. The Honest Counterweight

Honesty requires a clear statement of the ways this entire series could be wrong, and the caution belongs here, at the end, because it applies to all three papers at once. The scenario rests on a structure of rational actors competing for an asset, and there are several ways that structure might not form.

The first and most important caveat is that all three suitors might simply exercise discipline at the same time. Each of these companies prides itself, to varying degrees, on walking away from deals that do not meet its bar, and it is entirely possible that the price Arrowhead would accept exceeds what any of them judges rational, in which case no auction forms, no foreclosure premium is paid, and the contest this series imagines never materializes. A thought experiment about how suitors would behave in a contest is not a promise that a contest occurs. The second caveat is that an auction, even if it begins, can resolve quietly: a single suitor might move early and decisively, preempting the others with a friendly offer that Arrowhead’s board accepts before any bidding war develops, which would mean a sale but not the dramatic escalation the structure permits. The third and deepest caveat is the one this series has returned to throughout: all of it depends on the platform performing. Every suitor’s interest, every foreclosure calculation, every forced move, assumes that Arrowhead’s science continues to deliver, above all that its central nervous system program reads out well. No one competes for a platform whose lead program has just failed. The entire edifice of suitor interest rests on a clinical foundation that has not yet been fully proven, and if that foundation cracks, the contest dissolves with it.

There is also the open question, taken up earlier, of whether Roche would experience a forced acquisition as a defeat or a triumph, and honesty requires admitting that no outside analyst can settle it. The same facts support both readings. The bind is real: Roche would be pulled past its stated discipline, in public, at a contested price it has spent years refusing to pay. The vindication is equally real: it would be reclaiming the science it pioneered and securing its next decade in the process. Which feeling would dominate is a matter of how Roche chooses to see the moment, not something a spreadsheet decides, and the series has tried to give both their due rather than flatten the most interesting suitor into a single note.

These cautions and alternatives do not undo the analysis; they bound it. The series describes the conditions under which a contest forms and the dynamics that would govern it if it did, and it argues that those dynamics favor Arrowhead more than a simple sum-of-programs valuation would suggest. It does not claim the contest is inevitable, or that any deal is coming, or that the author knows anything about the private intentions of any company. Whether Roche’s forced move ends in defeat or vindication, the structural point holds either way: if Arrowhead’s platform delivers, the strategic logic facing these three suitors is the logic this series has described, and that logic favors the company being courted.

X. Conclusion: The Whole Board

Three suitors have now crossed the board, each for its own reasons and in its own style. Novartis is the partner who knows the value too well to lowball and too well to ignore. Lilly is the giant whose resources let it pay what others cannot, and whose mere entry forces everyone else to hurry. Roche is the disciplined pioneer, drawn against its own nature toward the science it helped invent, caught in a position where every move costs it something, and yet pulled toward the one prize that, once won, could become the proudest acquisition any of them ever makes. The styles differ, the motivations differ, the patent-cliff pressures differ, but the conclusion each reaches is the same: Arrowhead is a prize none of them can comfortably let another have.

That shared conclusion is the engine of the whole story. A single buyer, however motivated, negotiates against a seller. Three buyers, each unable to tolerate the others winning, negotiate against each other, and the seller who holds a strong enough position to wait becomes the one who sets the terms. This is why the series has insisted, across all three papers, that the number of suitors matters more than the identity of any one of them. One suitor is a negotiation. Three suitors who cannot all win is an auction, and an auction over an asset that cannot be allowed to fall to a rival is the most favorable situation a seller can occupy. The price such an auction produces will look enormous, and the commentary will call it an overpayment. The likelier truth, if the platform delivers, is the opposite: the winner will have bought one of the defining strategic assets of the decade, and in time the only regret on the board will belong to the two who let it go.

The series began with a warning and ends with a bind. “En garde” announced that the queen was under attack. The “check” forced the board to respond. “Zugzwang” is where it arrives: the position in which the most disciplined player of all, the one who most wished to stand still, is compelled to move and finds every move costly. That is the truest measure of how valuable the queen has become. You can learn more about a piece from how the players around it behave than from any tally of its worth, and when even the most patient, most disciplined player on the board cannot afford to wait, the piece at the center is worth more than any of them would have admitted while the game was still quiet.

Roche supplies the final irony, and it is the one that lingers. Fifteen years ago, Roche held the seed of this entire platform in its hands, the RNA business, the Madison scientists, the delivery technology, and judged it not worth keeping. It sold that seed to a company worth less than $50 million. The seed is now a forest, and Roche may have to pay tens of billions to walk back into woods it once owned and gave away. No fact in this series says more plainly what Arrowhead has become, or why the players who once let it go can no longer afford to let it pass to anyone else. The market is still counting the trees. Arrowhead is the queen who became a player, and the player who cannot be forced is the one who decides how the game ends.

A Note on Supporting Independent Research

If this white paper has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this white paper; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This paper is provided for informational and analytical purposes only. It is a strategic thought experiment based entirely on publicly available information, including company acquisition histories, public strategic statements, earnings disclosures, and trade press reporting, as of the date of publication. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security, and it is not a recommendation as to any corporate course of action. It is not a prediction of any transaction, and the author has no knowledge of any actual deal discussions among any of the companies described. Scenarios involving how companies would behave are analytical interpretations grounded in documented past behavior, not statements of fact about any company’s intentions or any individual’s thinking. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results, and forward-looking analysis is inherently uncertain. The author and BioBoyScout are not registered investment advisors. The author assumes no obligation to update this paper.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

Robert Toczycki, JD, MBA
bioboyscout.com
bioboyscout@gmail.com
847.227.7909
X: @BioBoyScout

About This Series

This is the second of three connected papers imagining how three large pharmaceutical companies, Novartis, then Lilly, then Roche, would approach acquiring Arrowhead Pharmaceuticals, and how Arrowhead would respond. As with the first, this paper is a strategic thought experiment built entirely on the public record: each company’s actual acquisition history, its publicly stated strategy, the way it has behaved in past deals under its current leadership, and the public facts about Arrowhead. It is not a prediction, and not a claim that any deal is under discussion. I have no knowledge of any such discussions. Part One looked at Novartis, the partner that knows Arrowhead from the inside, and ended on a warning: the company that understands the value best is not the company that can most easily afford it. This paper introduces the one that can.

Executive Summary

If Novartis is the suitor that knows Arrowhead’s value, Lilly is the suitor that can least be stopped from paying it. Lilly enters this story transformed by the most powerful financial engine in the industry. Its weight-loss and diabetes franchise, built on Mounjaro and Zepbound, has lifted the company toward revenue in the mid-eighties of billions of dollars a year, growing more than fifty percent in its most recent quarter, and that windfall has funded a deliberate, aggressive campaign to diversify the company beyond obesity through acquisition. Lilly is not shopping with a careful budget. It is shopping with the deepest pockets in the business and a stated intention to use them.

Lilly also fits Arrowhead across more of its franchises than any other suitor. Its obesity empire could absorb Arrowhead’s differentiated, non-GLP-1 weight-loss mechanisms as a complement rather than a competitor. Its committed Alzheimer’s franchise, anchored by an approved amyloid-clearing antibody, gives it a direct strategic reason to want Arrowhead’s complementary tau-lowering, brain-delivery platform. Its appetite for cardiometabolic innovation, already demonstrated by other recent deals, lines up with Arrowhead’s approved cardiometabolic product and pipeline. Where Novartis fits Arrowhead on strategy, Lilly fits it on strategy and can pay without strain.

This paper lays out why Arrowhead fits Lilly, how Lilly has actually behaved as a dealmaker (a historically disciplined buyer that has, on the strength of the obesity windfall, deliberately widened its aperture and become the industry’s most active acquirer), how a rational Lilly would approach Arrowhead, and how Arrowhead would respond to the richest bidder at the table. The chess idea that organizes it is “check”: the move that does not win the game by itself, but forces every other player to respond. Lilly’s entry onto the board is a “check.” From the moment the giant is in the game, neither Novartis nor Roche can proceed as though it were not.

I. The Move That Forces a Response

In the first paper, Novartis heard the warning, “en garde,” the old courtesy that announced an attack on the queen. A warning, though, is not yet a threat. It tells the other players that the queen is in danger without forcing anyone to do anything about it. What turns a warning into action is the arrival of a move that cannot be ignored, and in chess that move has a name everyone knows: “check.” A “check” is the move that attacks the king directly and compels an answer. A player in check cannot pursue his own plans, cannot develop a distant piece, cannot wait. He must respond to the threat in front of him, on this move, before anything else. It does not by itself win the game. What it does is take the initiative away from the opponent and hand it to the player giving check, forcing the whole board to reorganize around a single threat.

Lilly’s entry into the contest for Arrowhead is a “check.” Not because Lilly is guaranteed to win, it is not, but because once a company with Lilly’s resources is plausibly in the game, no other suitor can behave as though it were not there. Novartis’s comfortable plan, to deepen its partnership gradually and acquire on its own timetable, is a plan that assumes the freedom to wait. Lilly removes that freedom. A disciplined buyer can take its time only when no one is about to take the asset away from it, and the arrival of a giant that can pay any plausible price is exactly the event that ends the waiting. This paper is about the player whose mere presence puts the others in check, and about why the richest suitor changes the game for everyone even before it makes an offer.

II. Why Arrowhead Fits Lilly

Lilly fits Arrowhead on more fronts than any other suitor, and the breadth is the point, because it is what justifies a larger number than any single-franchise rationale could. Begin with the franchise that defines Lilly: obesity. Lilly is the dominant force in weight-loss medicine, with a franchise built on the GLP-1 drugs, the class of injections, sold as Mounjaro and Zepbound, that have reshaped the industry. Arrowhead’s obesity programs do not compete with that franchise; they complement it. They work through mechanisms entirely different from the GLP-1 drugs, aimed at the quality of weight lost, the preservation of muscle, the reduction of visceral and liver fat, the kinds of improvements that the next phase of obesity medicine will be judged on. A company that already leads in obesity has the most to gain from owning the differentiated mechanisms that extend the franchise into its next era, and the most to lose from letting a competitor own them instead.

The Alzheimer’s fit is just as direct, and it is documented. Lilly is committed to neurodegeneration; it won approval for its Alzheimer’s antibody Kisunla, known generically as donanemab, and has launched it globally. That commitment is exactly what makes Arrowhead’s central nervous system platform valuable to Lilly, because Kisunla works by clearing amyloid, one of the two toxic proteins that build up in the Alzheimer’s brain, while Arrowhead’s approach lowers tau, the other principal driver of the disease, using a delivery technology Lilly does not possess. A company already selling an Alzheimer’s drug, already carrying the commercial and medical infrastructure for the disease, is the natural home for a complementary tau program delivered by a platform it would otherwise have to build from scratch.

The cardiometabolic fit completes the picture. Lilly’s recent dealmaking shows a clear appetite for cardiometabolic innovation beyond its weight-loss drugs, including approaches that aim to treat with durable, infrequent dosing. Its acquisition of Verve Therapeutics, a gene-editing company pursuing a one-and-done approach to cardiovascular risk, is the clearest signal of that appetite. Verve’s programs are still in development rather than on the market, which is precisely the point: Lilly was willing to buy the capability years ahead of any approved product, because the strategic logic of durable, infrequent cardiometabolic therapy was compelling enough on its own. Arrowhead’s approved cardiometabolic product and the pipeline behind it speak to exactly the same appetite, with the added advantage of being further along. Taken together, the fit spans obesity, neurodegeneration, and cardiometabolic disease at once. Arrowhead is not a single-franchise bet for Lilly. It is three strategic fits in one company, and a buyer evaluating three fits at once can justify a price that no single fit would support.

Even three fits understates it, because the three visible franchises are only what the platform produces today. Arrowhead’s delivery system reaches across the liver, muscle, lung, fat tissue, and the central nervous system in the clinic, and it has already extended to two more, an ocular program for glaucoma with non-human primate proof of mechanism and an early heart-muscle program, with more tissues to follow. It will keep generating programs in those tissues and others for years. An acquirer is buying not three franchises but the exclusive right to that entire future output, much of which will land in therapeutic areas beyond the three that fit Lilly now. For most acquirers that open-ended reach is a mixed blessing, because a platform that keeps producing drugs in unfamiliar areas forces a choice each time, build a presence in that area or license the program away, and not every buyer wants to be pulled into territory it does not already occupy. Here Lilly is the exception, and this is the heart of why Arrowhead fits Lilly better than it fits a more focused buyer. Lilly’s entire stated strategy is to broaden, to use its windfall to become a wide innovation engine across many therapeutic areas rather than a single-franchise giant. A platform whose output sprawls across tissues is not a burden to a company that wants to sprawl; it is fuel. Where a disciplined, focused acquirer would see the platform’s open-ended reach as a series of awkward obligations, Lilly sees the raw material of exactly the diversified company it has already announced it intends to become. The multi-tissue engine that complicates the calculus for everyone else is, for Lilly, a feature aligned with its deepest strategic goal.

III. The Cliff Lilly Is Not Facing, and the One It Is Front-Running

Lilly’s relationship to the patent cliff is different from Novartis’s, and the difference matters, because it changes why Lilly buys. Novartis acquires to replace revenue it is about to lose. Lilly is not in that position. Far from staring at a cliff, Lilly is enjoying the steepest upward climb in the industry, its obesity and diabetes franchise driving revenue growth of more than fifty percent in its most recent quarter and full-year revenue guided well into the eighties of billions of dollars. Lilly does not need to buy Arrowhead to plug a hole, because there is no hole. It buys from strength, not from need.

That distinction is worth stating plainly, because it would be easy and wrong to lump all three suitors into a single cliff-driven story. Lilly’s motivation is not desperation; it is diversification. A company whose fortunes are concentrated in a single therapeutic area, however spectacularly successful, carries a concentration risk, and Lilly’s leadership has been explicit about wanting to broaden the company into a wider innovation engine rather than remain a one-franchise giant. The acquisitions it has made across oncology, immunology, neuroscience, and cardiometabolic disease are the visible expression of that intent, and the growth of those newer areas, rising sharply as a share of the company’s key-product revenue, shows the diversification is real and deliberate.

There is a cliff in Lilly’s future, even so, and the company is wise enough to be front-running it. Every blockbuster eventually faces competition and the loss of exclusivity, and a franchise as large as Lilly’s obesity business will one day face both. Buying now, while the windfall is at its peak, lets Lilly diversify from a position of overwhelming strength rather than scrambling later from weakness. Lilly’s acquisitiveness is therefore not cliff-replacement in the way Novartis’s is; it is cliff-prevention. For Arrowhead, the implication is what matters: Lilly is the one suitor whose interest does not depend on a deadline, which means it can move whenever it chooses, including early, and can pay a price that reflects the asset’s full value rather than one disciplined by the urgency of a closing window.

IV. How Lilly Actually Does Deals

Lilly’s dealmaking style has changed, and understanding the change is the key to understanding how it would approach Arrowhead. Historically, Lilly was a disciplined and relatively cautious acquirer. Its largest acquisition for many years was a roughly $8 billion purchase of an oncology company, and most of its deals were smaller and earlier-stage. By the standards of its largest peers, Lilly was not a big-game hunter. It focused on early science and bolted on selectively, and its average deal was modest.

The obesity windfall changed the company’s posture deliberately and visibly. Lilly’s leadership widened the aperture, sharpened its business development function, and turned the company into the industry’s most active dealmaker. In a single recent stretch it announced a rapid series of acquisitions across multiple therapeutic areas, committing many billions of dollars upfront and far more in total potential value, an intensity of dealmaking that would have been out of character only a few years earlier. The strategy was stated openly: to use the windfall to become a backbone of the broader innovation ecosystem, not merely a single-franchise leader. The honest reading of Lilly’s style, then, is that its old discipline was never really about reluctance to pay; it was about capital. Lilly was disciplined because it had to be. The windfall removed the constraint, and the behavior changed accordingly.

This is the crucial analytical point about Lilly as a suitor, and it distinguishes Lilly sharply from Novartis. Novartis stretches beyond its stated discipline only for assets at the dead center of its strategy, and even then it frames the stretch as exceptional. Lilly has simply raised its whole ceiling. A company that has chosen to deploy its windfall aggressively across many areas, and that fits Arrowhead on three franchises at once, is a company for which a large acquisition is not an exception to the strategy but an expression of it. The platform’s tendency to generate programs across many tissues, awkward for a focused buyer, is the same tendency that serves Lilly’s announced ambition to broaden, which means Lilly can value the open-ended future of the platform more comfortably than a more disciplined rival can. Where Novartis would have to talk itself into a number, Lilly has already decided, as a matter of policy, that large numbers are how it intends to grow.

V. The Lilly Playbook for Arrowhead

Put the breadth of fit, the absence of a deadline, and the deep pockets together, and Lilly’s characteristic approach to Arrowhead takes shape. It is the approach of a buyer who can afford the asset, wants it for several reasons at once, and is not forced by any clock to hurry, which is a genuinely powerful combination, and a different kind of threat from Novartis’s.

Lilly’s central advantage is the simplest and the hardest to counter: it can pay. The price that would force a disciplined buyer to hesitate is, for Lilly, comfortably within reach, which means Lilly can win this contest on the one dimension where being a price-taker hurts the other suitors most. A buyer that can comfortably absorb the full value of the asset does not need clever tactics to suppress the price; it can simply meet the price and rely on its rivals’ inability to follow. That is the purest form of the “check”: a threat the others cannot match on the merits, only respond to.

The numbers behind that advantage are worth stating, because they are what set the ceiling for everyone else. Lilly's market value has lately ranged from roughly $900 billion to above $1 trillion, its balance sheet carries modest net debt against rapidly growing cash generation, and it can use its richly valued stock as acquisition currency in a way no rival can match. The scale of that advantage is easy to miss: even a $150 billion acquisition would amount to only about a sixth of Lilly's market value, financeable through a blend of debt and stock with far less strain than the same price would impose on any competitor. Working from its own filings, Lilly is therefore comfortable across essentially the entire range a sale of Arrowhead would plausibly occupy, to roughly $150 billion, on the order of $970 a share, a price that would strain its rivals but that Lilly can absorb with room to spare, and its premium-valued equity provides a further lever well beyond that, toward $200 billion or more. These are estimates drawn from public filings, not precise figures, but they make the central point unmistakable: for Lilly, the binding constraint is never whether it can afford Arrowhead. It is only whether it judges the asset worth winning. That is precisely why Lilly sets the ceiling of the contest, and why the prospect of Lilly setting it pressures every other participant to act.

The timing question for Lilly is more interesting than for the others, precisely because Lilly has the luxury of choosing. A buyer with a deadline acts when the deadline demands. A buyer without one acts when the strategic logic is best, and for Lilly the strategic logic argues for moving early rather than late. Arrowhead’s value is poised to jump sharply when its central nervous system program reads out, and a buyer that intends to pay full value anyway has a reason to act before that jump rather than after, capturing the platform while the price still reflects uncertainty the buyer is willing to bear. Lilly is uniquely able to take that risk, because it can absorb a disappointing readout more easily than a smaller, more concentrated buyer could. The deep-pocketed, diversified giant is precisely the player best positioned to buy before the proof, which makes Lilly not only the suitor that can pay the most, but potentially the suitor that moves the soonest.

Underneath the question of whether Lilly can pay sits a larger one of whether Lilly should, and here the answer is not merely yes but emphatically so. Lilly is not a company trying to survive a hard decade; it is a company having the best decade in its history, and the deepest question facing any business at such a height is whether the height will last. The windfall is enormous, but it is also, by Lilly’s own admission, finite: the franchise generating most of its revenue today will eventually face its own competition and its own loss of exclusivity. Windfalls fade, and the companies that turn a golden moment into permanent stature are the ones that spend the moment’s resources on something the moment itself cannot provide. For Lilly, Arrowhead is that something, a self-renewing platform whose value keeps compounding long after the obesity wave that paid for it has crested. If the platform delivers, and that condition governs everything in this series, a record price would not be an extravagance; it would be the single highest-return use of money that will not keep coming forever. The want here is not for another franchise to add to a crowded desk. It is for the one asset that converts a spectacular but finite run into lasting institutional dominance.

That dominance is not only a matter of scale; it is a matter of identity. Acquiring Arrowhead would not merely diversify Lilly; it would help define what Lilly becomes. The company that already reset the treatment of obesity could enter the 2030s as the company that also owns the most productive genetic-medicine engine in the industry, extending its reach from metabolic disease into the brain, the muscle, and tissue after tissue beyond. That engine is more than a delivery platform; it sits on a proprietary dataset that, fed into Arrowhead’s own AI-driven design, makes each new program faster and surer than the last. A separate analysis in this body of work argues that no newcomer can rebuild that advantage, because AI models are available to everyone while the data that makes them useful is available to no one else, and the edge only widens the longer the platform runs. That is the difference between being the dominant company of a single era and being the company that carries its dominance into the next one. For the most ambitious organization in the industry, holding more capital to deploy than any rival, that is precisely the prize the ambition was built for, and if the platform delivers, the kind of acquisition a company is remembered for making.

The honest qualification is that breadth of fit can also dilute urgency. A company spending aggressively across many therapeutic areas at once has many priorities competing for attention and capital, and Arrowhead, however good a fit, is one opportunity among many on Lilly’s desk. The same diversification strategy that makes Arrowhead attractive to Lilly also means Lilly is not depending on Arrowhead the way a more focused buyer might. A giant with many options can pay for any one of them; it can also walk away from any one of them, because none is essential. Lilly’s strength, the breadth that lets it pay, is also the reason its desire may be wide rather than deep.

VI. What Lilly’s Entry Does to the Others

The most important effect of Lilly is not what it does to Arrowhead but what it does to the other suitors, because this is where the “check” reorganizes the whole board. Recall Novartis’s position from the first paper: the informed partner, content to move on its own disciplined timetable, confident that its inside knowledge gave it an advantage. That confidence depended on a quiet board. The moment Lilly is plausibly in the game, Novartis’s patience becomes a danger rather than a virtue, because the thing Novartis cannot afford is to wait politely while a buyer it cannot outspend takes the asset away. The “check” forces Novartis to choose: move now, ahead of its preferred timetable and possibly above its preferred price, or risk losing Arrowhead entirely to a richer rival. Either way, Lilly has taken the initiative away from Novartis without making a single offer.

The same logic will fall, in the next paper, on Roche. For now it is enough to see the structure. A single disciplined suitor can dictate the pace of a negotiation, because it is the only buyer in the room. Two suitors cannot, because each must now act with one eye on the other, and the more powerful of the two sets the tempo. Lilly’s deep pockets do not merely make Lilly a strong bidder; they convert the entire situation from a patient bilateral negotiation, in which Arrowhead deals with one suitor at a time, into a contested one, in which every suitor must move faster and offer more for fear of being outbid. That conversion, from a calm negotiation into a contested race, is the single most valuable thing that can happen to a company being courted, and it is Lilly’s mere presence that triggers it.

This is why the giant matters even if the giant never wins. A “check” does not have to lead to checkmate to change the game; it only has to force a response. Whether Lilly ultimately acquires Arrowhead or not, its plausible interest is enough to put Novartis, and soon Roche, in a position where waiting is no longer safe. The suitors are no longer deciding whether to pursue Arrowhead on their own schedules. They are deciding how to respond to each other, which is exactly the condition under which a target stops being a price-taker and starts setting the terms.

VII. How Arrowhead Plays It

From Arrowhead’s side of the table, the arrival of a suitor like Lilly is, in the plainest terms, good news, and the leverage analysis is the most straightforward of the three papers. The richest bidder is in some ways the easiest counterpart for a confident seller, because the price that satisfies Arrowhead is the price Lilly can most easily pay. There is no need to talk a reluctant buyer into a number it cannot reach. The number Arrowhead believes its platform is worth is a number comfortably within Lilly’s means, which removes the most common obstacle in a large acquisition, the gap between what the seller wants and what the buyer can bear.

Arrowhead’s deeper advantage, developed throughout this series, is that it does not need to sell at all, and Lilly’s presence makes that advantage more valuable rather than less. A company that can credibly continue alone, and that now has a demonstrably willing and able acquirer, holds the strongest possible position: it can decline anything short of full value, knowing that a buyer exists who can meet full value, and knowing that the existence of that buyer pressures the other suitors to do the same. Arrowhead does not have to choose Lilly. It only has to let Lilly’s presence remind every other suitor that the price floor has risen. The richest bidder sets a number the others must approach, and Arrowhead benefits whether or not that bidder is the one it ultimately accepts.

The honest qualification on Arrowhead’s side mirrors the one on Lilly’s. A diversified giant that can walk away from any single opportunity is a buyer whose interest, while real, may not be urgent, and Arrowhead cannot simply assume Lilly will pursue it to the end. The leverage comes not from any certainty that Lilly will buy, but from the credible possibility that it could, which is enough to discipline the other suitors regardless of what Lilly ultimately does. As always in this series, the point is not that Arrowhead should hold out for Lilly, or for anyone. It is that a company holding a strong position, with a credible path to independence and more than one able suitor, negotiates from a position of command rather than need.

VIII. Conclusion: “Check”

Lilly is the suitor that can simply pay. It fits Arrowhead across obesity, neurodegeneration, and cardiometabolic disease; it buys from overwhelming strength rather than from the pressure of a cliff; it has deliberately become the industry’s most aggressive acquirer; and it can absorb a price, and a risk, that would give a more disciplined or more concentrated buyer pause. On the merits of resources alone, Lilly is the most formidable of the three suitors, because the one thing a price-taker cannot do is out-pay a giant, and Lilly is the giant.

The deeper significance of Lilly, though, is structural. Its entry is the “check” that forces the board to reorganize. The moment a buyer with Lilly’s resources is plausibly in the game, no other suitor can act as though the game were uncontested. Novartis can no longer wait on its comfortable timetable. The quiet bilateral negotiation that the first paper imagined gives way to a contested field in which every player must move with one eye on the others. That is what a “check” does. It does not end the game; it ends the freedom of everyone else to ignore the threat.

One player, though, has still not been heard from, and it is the one with the deepest claim of all to the science Arrowhead is built on, and the strongest temperamental reluctance to do anything about it. Lilly’s “check” forces a response from everyone on the board, including the most disciplined, most science-proud, most acquisition-averse suitor of the three. What happens when a company that prefers never to be forced is finally forced, when the only player who would rather license than buy discovers that licensing no longer protects it, is the subject of the final paper. The warning has sounded. The “check” has been given. The position that leaves the last player with no good move is what remains.

A Note on Supporting Independent Research

If this white paper has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this white paper; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This paper is provided for informational and analytical purposes only. It is a strategic thought experiment based entirely on publicly available information, including company acquisition histories, public strategic statements, earnings disclosures, and trade press reporting, as of the date of publication. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security, and it is not a recommendation as to any corporate course of action. It is not a prediction of any transaction, and the author has no knowledge of any actual deal discussions among any of the companies described. Scenarios involving how companies would behave are analytical interpretations grounded in documented past behavior, not statements of fact about any company’s intentions or any individual’s thinking. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results, and forward-looking analysis is inherently uncertain. The author and BioBoyScout are not registered investment advisors. The author assumes no obligation to update this paper.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

Robert Toczycki, JD, MBA
bioboyscout.com
bioboyscout@gmail.com
847.227.7909
X: @BioBoyScout

About This Series

This is the first of three connected papers. Each imagines how one large pharmaceutical company, Novartis here, then Lilly, then Roche, would approach acquiring Arrowhead Pharmaceuticals, and how Arrowhead would respond. The exercise is built entirely on the public record: each company’s actual acquisition history, its publicly stated strategy, the way it has behaved in past deals under its current leadership, and the public facts about Arrowhead. It is a thought experiment about strategic mechanics, not a prediction, and not a claim that any deal is under discussion. I have no knowledge of any such discussions. The purpose is to understand how a deal like this would actually unfold, and why the presence of three suitors rather than one changes everything. The three papers escalate: this one looks at a single acquirer’s calculus; the later two show how the suitors, aware of one another, reshape each other’s choices until the most disciplined of them is forced into a move it never wanted to make.

Executive Summary

Of the three companies most likely to want Arrowhead, Novartis is the one that already knows it from the inside. The two companies are partners, joined by a licensing agreement, which means Novartis has worked directly with Arrowhead’s science and understands the platform more intimately than a cold outside bidder ever could. That familiarity is the theme of this paper, because it cuts in two directions at once. It makes Novartis the suitor best equipped to recognize what Arrowhead is worth, and the suitor least able to pretend it is worth little.

Novartis also has a clear and documented reason to want it. The company is facing a genuine wave of patent expirations, it has built its entire recent dealmaking strategy around filling that gap, it remains one of the few large pharmaceutical companies still committed to neuroscience, and in October 2025 it paid roughly $12 billion for Avidity Biosciences, a company whose core technology delivers RNA into tissue using the same cell-surface docking point, and the same delivery approach, that Arrowhead uses, applied to a different and easier tissue. Novartis has, in other words, already written a $12 billion check to validate the precise class of technology Arrowhead is built on. That single fact frames everything that follows.

This paper lays out why Arrowhead fits Novartis, how Novartis actually does deals (a stated philosophy of disciplined, small acquisitions that coexists with a proven willingness to pay up when the strategic fit is right), how a rational Novartis would approach Arrowhead given that history, and how Arrowhead, holding the leverage described elsewhere in this series, would respond. It closes on the dilemma that sets up the rest of the trilogy: the partner who knows the value best is also the partner who can be outbid by a rival with deeper pockets, and that possibility is what turns a patient strategy into an urgent one.

I. Why This Is a Deal Worth War-Gaming

Before turning to Novartis specifically, it is worth being clear about why three of the largest companies in the industry would want Arrowhead at all, because the whole series rests on it. The short version, argued at length across the other BioBoyScout papers, is that Arrowhead is not a single drug or even a collection of drugs. It is a platform: a delivery system that has been extended into tissue after tissue, that generates new drug programs on a predictable cadence, and that has now produced an approved product and owns its own commercial-scale manufacturing. A company that acquires Arrowhead is not buying a pipeline. It is buying the machine that makes the pipeline.

The reach of that machine is the part most easily underestimated. Arrowhead’s platform already operates in the clinic across the liver, muscle, lung, fat tissue, and the central nervous system, and the map is still growing: the company has extended the platform to two further tissues, an ocular program targeting the eye for glaucoma, with deep gene knockdown already demonstrated in non-human primates, and an early program aimed at the heart muscle itself. Seven tissues, five in the clinic and two advancing behind them, and the roadmap extends further still. An acquirer is therefore not buying three wholly owned franchises, the cardiometabolic, obesity, and central nervous system programs that are visible today. It is buying the exclusive right to whatever the platform generates next, in every tissue it has reached and every tissue it will reach. That distinction changes the nature of the asset. A pipeline is a finite list of programs that can be counted and valued. A platform that reaches across the body is an open-ended generator of programs, many in therapeutic areas the acquirer may not even occupy yet, and each one arriving with a choice attached: enter that area to develop and sell the drug, or license it out to someone who already operates there. Owning Arrowhead means owning that stream of future choices, which is worth far more than the three franchises on the table today, and is the part of the value that a program-by-program tally can never capture.

There is a second engine sitting on top of the first, and it is the one most likely to define the next decade. Every molecule Arrowhead has designed, synthesized, and tested across fifteen years and all of those tissues has produced data: a proprietary record of which sequences, chemistries, and delivery approaches work, and, more valuably, which ones fail. That record cannot be bought, scraped, or licensed, because it does not exist anywhere outside Arrowhead, and the failures, the most useful part for designing the next molecule, were never published. As a separate analysis in this body of work argues at length, this is the real moat in an age of artificial intelligence: the models that turn data into faster discovery are increasingly available to everyone, but the proprietary data that makes those models useful is available to no one else. A company that pairs that dataset with a serious internal artificial-intelligence capability, which Arrowhead is now building, does not simply make drugs; it makes drugs faster, cheaper, and with a higher hit rate than a competitor starting without the data, and it improves at doing so with every new experiment.

The two engines compound each other, and that interaction is what an acquirer is truly buying. Because the underlying biology of the platform is modular, what Arrowhead learns designing a liver drug informs the next muscle drug, and what it learns in the lung informs the next program in the eye or the heart. The data advantage therefore does not merely deepen within one tissue; it broadens across every tissue the platform reaches, so that each expansion of the map makes the discovery engine smarter everywhere at once. A buyer acquiring Arrowhead is acquiring not a fixed rate of drug output but an accelerating one, a machine that produces more programs across more tissues, and gets better and faster at producing them the longer it runs. That is the difference between a valuable asset and a compounding one, and it is the part of Arrowhead’s value least visible on any pipeline chart and least possible for a rival to reconstruct.

That distinction matters enormously for the largest companies right now, because they are all bracing against the same generational wave of patent expirations late in this decade. They can replace lost revenue slowly and expensively by buying one drug at a time, or they can buy a platform that generates drugs for years. A validated, multi-tissue platform is the rare asset that addresses the replacement problem structurally rather than one molecule at a time, which is exactly why it commands attention from companies that can normally fill their pipelines with bolt-on purchases. How sharply that logic applies to Novartis in particular is the subject of a later section.

There is a second reason these companies cannot be indifferent to Arrowhead, and it is the engine of this entire series. Whatever Arrowhead is worth to any one of them, it is worth more once a rival might take it instead. A platform that strengthens whoever owns it also weakens whoever lets a competitor own it, and in a small field of giants chasing the same therapeutic areas, that second effect can matter as much as the first. The multi-tissue reach just described makes this sharper still, because a rival who lets a competitor buy Arrowhead is not ceding three programs; it is ceding an engine that will keep producing drugs across tissue after tissue for years, some of which may land in the loser’s own core franchises. Worse, it is ceding the one advantage no amount of money can rebuild, the irreplaceable data accumulated over fifteen years, and handing a rival a discovery engine that only widens its lead the longer it runs. The question, then, is never simply what Arrowhead is worth to Novartis. It is what Arrowhead is worth to Novartis given that Lilly and Roche are looking at the same board. This first paper sets that aside to focus on Novartis alone, and the later two bring the rivals back in. The reader should keep them in the corner of the eye throughout.

There is a name for this situation, and it comes from chess. When I was a kid learning the game, I was taught a small piece of etiquette that has since fallen out of use. When you attacked your opponent’s queen, you were supposed to announce it, the way you announce check on the king, by saying “en garde.” The phrase is obsolete now; modern players are expected to notice their own queen is under threat without being told. I have always been fond of it anyway, and it turns out to be the right phrase for this series, because an earlier paper in this body of work argued that, on the board of biopharmaceutical acquisitions, Arrowhead is the queen, the single most valuable and most decisive piece in play. This trilogy is the story of three players closing in on that queen. “En garde” is the warning that the attack has begun, and Novartis, as we will see, is the first player on the board with reason to hear it.

II. Why Arrowhead Fits Novartis

Novartis is an unusually natural fit for Arrowhead, on more fronts than any casual observer would guess, and the fit is documented rather than speculative. Start with neuroscience. As large pharmaceutical companies retreated from brain diseases over the past decade, frustrated by repeated clinical failures, Novartis stayed. It is one of the few giants that kept building in neuroscience, and it has been explicit that genetically defined neurological diseases with high unmet need are central to its long-term strategy. Arrowhead’s lead central nervous system program, a tau-lowering therapy for Alzheimer’s and other tauopathies, the family of brain diseases driven by buildup of the tau protein, sits squarely in that priority.

The cardiovascular fit is just as real, and on close inspection it is the sharpest of all, because it is not merely additive but defensive. Novartis built a major cardiovascular franchise, and one of its anchors is now facing the patent expiration discussed in the next section. Less obvious, and more pointed, is that Novartis owns Leqvio, the first and only approved gene-silencing therapy, an siRNA drug, for lowering LDL, the so-called bad cholesterol. Novartis paid nearly $10 billion to acquire it and has worked hard to turn it into a multibillion-dollar blockbuster. Leqvio works by silencing a single gene, called PCSK9, that controls cholesterol. Arrowhead now has in the clinic a dual-target therapy, its dimer program, designed to silence that same PCSK9 gene and a second one, APOC3, in a single molecule, lowering both LDL cholesterol and triglycerides, a second type of blood fat, at once. In the large population of patients who have elevated levels of both, a single Arrowhead injection could do what Leqvio does and cover a second axis of cardiovascular risk that Leqvio does not touch.

That is not a distant or speculative threat, and the reason is the part most worth understanding. Arrowhead’s dimer is early, in a Phase 1 and 2a study, but early does not mean unproven here, for two reasons. First, the platform’s defining strength is the reliability with which it knocks down its genetic target; across a deep liver-focused franchise, with four separate programs already advanced into Phase 3, Arrowhead has consistently achieved the deep, durable target silencing its technology is built to produce. Second, the dimer’s two targets are not gambles. PCSK9 is validated by Leqvio itself and by the approved antibody drugs; APOC3 is validated by Arrowhead’s own first commercial product. The dimer is therefore not reaching for unproven biology; it is combining two clinically established targets, in the liver, where Arrowhead’s delivery is most validated. The mechanism risk is unusually low, which means the threat to Leqvio is unusually credible.

For Novartis, this transforms the cardiovascular fit into something more urgent than opportunity. The other suitors would see Arrowhead's cardiometabolic pipeline as a promising set of assets. Novartis would see, more sharply than anyone, the program most likely to leapfrog the cholesterol-lowering franchise it acquired at great cost and has worked for years to establish. The company that understands the platform best is also the incumbent with the most to lose if a rival, rather than Novartis, ends up owning the drug that could leapfrog Leqvio. Owning Arrowhead would let Novartis defend its hard-won leadership in cardiovascular RNAi by acquiring the next generation of it, rather than watching that next generation arrive in a competitor's hands. Arrowhead's approved cardiometabolic product and the broader pipeline behind it only deepen a fit that, on this front, Novartis would find difficult to ignore.

Then there is the platform itself, and here Novartis’s history with Arrowhead runs deeper than almost anyone remembers. Novartis worked in RNA interference for more than a decade and built its own portfolio in the field. In 2015, amid an industry-wide retreat from the technology, Novartis judged that portfolio not worth keeping and sold the whole of it to Arrowhead: the underlying patents and the freedom they gave Arrowhead to operate, an exclusive license to its other RNAi patents, three preclinical candidates, and an assignment of its own license to foundational Alnylam intellectual property covering thirty gene targets. The price was about $35 million. Part of the ground Arrowhead now stands on, in other words, Novartis once owned and handed over for a sum neither company would notice today. A company that once gave a competitor part of its own foundation understands, better than any outsider could, what that foundation has become.

What Novartis did next is the part that should sharpen its attention now. Four years after walking away, it paid $9.7 billion for The Medicines Company to acquire inclisiran, the cholesterol-lowering RNAi medicine now sold as Leqvio, re-entering the field for nearly three hundred times what it had been paid to leave it. A company that has lived that whole arc, underestimating the modality, selling its position cheaply, then paying billions to buy back in, does not need convincing what a mature RNAi platform is worth. It has already paid, twice, to learn. There is a closing irony in it as well: the company Novartis sold its RNAi assets to in 2015 is the same company whose dimer now threatens the very franchise it bought to return. Arrowhead is not a stranger to Novartis. It is, in part, what Novartis let go, grown into the rival best positioned to leapfrog its expensive way back in.

The obesity angle is the most interesting, because it is the one where Novartis has deliberately stayed out. Unlike most of its peers, Novartis chose not to chase the GLP-1 weight-loss market, and its leadership has said plainly that it does not regret skipping what it views as a crowded field of similar drugs. That stance is not indifference to obesity; it is a refusal to enter with a me-too. It actually makes a differentiated, non-GLP-1 mechanism more interesting to Novartis, not less, because a genuinely novel approach is the only kind of obesity entry consistent with its stated reluctance to join the herd. Arrowhead’s obesity programs, which work through mechanisms entirely different from the GLP-1 drugs, are precisely that kind of differentiated entry. The fit, taken together, spans neuroscience, cardiovascular, the RNA platform, and even the one major area Novartis has pointedly avoided.

These are the fits visible today, and the platform’s reach described earlier means they are not the end of it. Even a company as broad as Novartis does not operate everywhere the platform does, so owning Arrowhead would mean inheriting a stream of future programs in areas where Novartis has no franchise at all, each one posing the same build-or-license question. Here Novartis is better placed than most of its rivals: one of the broader footprints in the industry can absorb that demand more comfortably than a focused buyer could. The reach is still an obligation as much as a prize, but it is one Novartis is unusually equipped to carry, which only deepens the fit rather than complicating it.

III. The Cliff Novartis Is Actually Facing

The reason Novartis is a motivated buyer, and not merely an interested one, is a patent cliff that is real, large, and already arriving. This is not speculation; it is the stated driver of the company’s own strategy. Entresto, the heart-failure drug that has been one of Novartis’s biggest sellers, lost United States market exclusivity in 2025 and loses European exclusivity in 2026. It is not alone. Several other major Novartis products, including Xolair, Cosentyx, and others, face loss of exclusivity before the end of the decade, and the company saw a trio of big-selling drugs lose protection in the final quarter of 2025 alone. The exposed revenue runs well into the tens of billions of dollars.

Novartis has been candid that this is the problem its dealmaking is meant to solve. Its leadership frames acquisitions explicitly as building growth for the 2030-and-beyond period, the years when the cliff bites hardest. By its own account, the company has executed more than thirty strategic deals over the past two years, capped by the roughly $12 billion agreement to acquire Avidity, all aimed at strengthening the pipeline against the revenue the expirations will take away. This is a company shopping with a deadline, and a deadline changes how a buyer behaves. It makes waiting expensive and it makes a structural solution, a platform that generates revenue for years rather than a single replacement drug, especially attractive.

For Arrowhead, this is what shapes Novartis’s urgency. The cliff is the reason Novartis cannot treat the company as a small bolt-on to consider at leisure: the same clock running against its franchises is the clock that rewards moving decisively on a structural fix rather than waiting. That urgency also reframes how Novartis would weigh the price.

There is a further point here that reframes the entire question of price, and it deserves to be stated plainly, because it is the consideration most likely to push a disciplined buyer past its stated limits. The price of acquiring Arrowhead looks large only when it is measured against the wrong thing. Measured against today’s pipeline or today’s revenue, a record premium looks expensive. Measured against the problem it solves, the tens of billions of dollars in exposed revenue that the cliff will strip away, and the decade of new programs a working platform would generate to replace it, that same premium can look like the cheapest available answer to the most expensive problem Novartis has. A single replacement drug solves one year of the cliff; a platform that produces drugs across many tissues for years solves the structural problem itself. If Arrowhead’s platform delivers, and that conditional governs everything in this series, the buyer who wins it will not be remembered as the company that overpaid. It will be remembered as the company that bought, at a price that seemed steep for a single afternoon, the engine that carried it through its hardest decade. The right way to judge the number is not against what Arrowhead earns now, but against what it would cost Novartis to face the cliff without it.

There is something this defensive framing leaves out, though, and it is the part Novartis would feel most keenly. A company facing the largest patent wave in its history is a company on defense, managing decline and patching revenue holes one deal at a time. What Arrowhead offers Novartis is not merely a patch but a way off defense entirely. A platform that generates new programs across the body on its own cadence does not just replace what the cliff takes away; it changes the kind of company Novartis is, from one bracing against expirations into one with a self-renewing source of growth it owns and controls. For a management team that has spent years explaining how it intends to survive the cliff, the chance to stop talking about survival and start talking about expansion is worth more than any single figure can express.

That is the version of this deal Novartis would want, not the grim arithmetic of cliff-filling but the reinvention its recent dealmaking has been reaching toward. Arrowhead would let Novartis enter the 2030s not as a company that weathered its hardest decade, but as one that used the decade to remake itself around the genetic-medicine engine it has been assembling piece by piece and could instead own whole. The cliff is the reason Novartis must act. The platform is the reason it would want to. A buyer pushed by a problem and pulled by a prize is the most motivated buyer there is, and that pairing, the need underneath and the ambition on top, is what would carry Novartis past the limits it sets for itself.

IV. How Novartis Actually Does Deals

To understand how Novartis would approach Arrowhead, look at how Novartis has actually behaved, because its real record complicates its stated philosophy in a revealing way. The stated philosophy is discipline. Novartis leadership has said repeatedly that its strategy is bolt-on acquisitions, that it is best when it sticks to deals in the low-single-digit-billions range, often below $2 billion, and that over many years it has done only a small handful of larger deals. The public message is consistent: small, frequent, disciplined, science-first.

The revealed behavior is more interesting, because Novartis has shown that when an asset is strategically important enough, the discipline yields. In October 2025 it agreed to acquire Avidity Biosciences for roughly $12 billion, many times its stated comfort range, to gain a late-stage RNA pipeline for neuromuscular disease. The company justified the price by pointing to multibillion-dollar opportunities with launches planned before 2030, the cliff-replacement logic in action. The honest reading of Novartis, then, is not that it is cheap. It is that it is disciplined by default and willing to stretch dramatically when an asset hits the center of its strategy. The stated range describes the average deal; it does not describe the ceiling, and the ceiling is far higher than the rhetoric suggests.

The Avidity deal is not just evidence that Novartis will pay up. It is almost a blueprint for an Arrowhead acquisition, because the technology is closely related. Avidity’s platform delivers its RNA medicine into tissue by attaching it to an antibody that latches onto a specific docking point on the cell surface, the transferrin receptor, the same receptor, and the same attach-and-deliver concept, that Arrowhead uses to carry its tau therapy into the brain. The two are not identical, and the difference favors Arrowhead. Avidity delivers to muscle; Arrowhead crosses the blood-brain barrier, which is a substantially harder delivery problem, and one Arrowhead is solving across multiple tissues rather than one. Novartis, in other words, has already paid $12 billion to own a transferrin-receptor-targeted delivery platform aimed at the easier tissue. Arrowhead applies the same fundamental approach to the harder one, with a wider footprint across the body and an approved product already in hand. The most expensive part of evaluating a novel platform is conviction that the mechanism works and the price is justified, and Novartis has already reached that conviction once, with its checkbook. That makes Arrowhead not a leap for Novartis but a logical next step along a path it has already chosen to walk.

Willingness, though, is not the same as capacity, and on capacity Novartis is the most constrained of the three suitors. Working from its own filings, Novartis ended 2025 with net debt near $22 billion, annual free cash flow of roughly $18 billion, and operating earnings before depreciation and amortization on the order of $24 billion. Prudent borrowing alone might fund somewhere around $50 to $75 billion of an acquisition; reaching $100 billion would require Novartis to combine aggressive borrowing with a substantial issuance of its own stock, and stretching toward $140 to $150 billion, very roughly $900 to $970 a share, would pile real balance-sheet strain on top of that. Novartis can finance a transaction of this size, since cash-and-stock deals are routine, but it, alone among the three, would feel the strain of a top-of-range price most acutely, because its balance sheet is the tightest and its need the most pressing. These are estimates derived from public filings, not precise thresholds, yet the shape is clear: Novartis is the bidder most motivated to win and least equipped to prevail in a long contest. That combination argues for bidding early and firmly rather than waiting, because every additional round of an auction works against the participant with the least room left to maneuver.

V. The Novartis Playbook for Arrowhead

Put the fit, the cliff, and the deal style together, and a characteristic Novartis approach to Arrowhead takes shape. It would be the approach of a disciplined buyer who already knows the asset, faces a deadline, and has a proven willingness to pay for the right platform, which is a specific and somewhat constrained set of moves.

The defining feature is that Novartis cannot play the usual opening move of a platform acquisition, which is to suppress the price by professing uncertainty about whether the technology works. Novartis has already removed its own ability to make that argument, several times over. It is Arrowhead's existing partner, so it has worked with the science directly and cannot credibly claim to doubt it. It has publicly paid $12 billion for a closely related mechanism, and it already owns Leqvio, an approved gene-silencing medicine of exactly this kind, so it cannot pretend the technology class is unproven. A buyer who has partnered on the science, validated the mechanism class with its own money, and already sells an approved drug built on it has forfeited the argument that the platform might not work. This is the paradox of the informed acquirer: familiarity that helps it recognize value also strips away its ability to argue that value down by feigning doubt.

A rational Novartis would therefore more likely compete on relationship and certainty than on outright price suppression. Its natural pitch to Arrowhead would emphasize fit and trust: we already work together, we understand your platform, we have the neuroscience and cardiovascular and RNA infrastructure to make the most of it, and we can offer a clean, certain transaction without the friction of educating a less-informed buyer. The existing partnership is Novartis’s strongest card, because it offers Arrowhead a known quantity. This does not mean Novartis would negotiate softly. An informed buyer that cannot plausibly claim the asset is weak can still bargain hard on everything else, the timing of its approach, the structure of the consideration, the use of milestones and contingent payments to bridge a gap on headline value. The point is narrower: Novartis cannot win on the argument that the platform might fail, so it must compete on other ground. The place it would most try to gain an edge is timing. As the partner with the closest view, Novartis is well positioned to judge when to move relative to Arrowhead’s pivotal data, and a disciplined buyer would prefer to act before a positive readout sends the price sharply higher rather than after.

VI. What Novartis Knows About the Other Two

No acquirer evaluates Arrowhead in isolation, and Novartis least of all, because its inside knowledge of the platform is also inside knowledge of how badly a rival would want it. The same diligence that tells Novartis what Arrowhead is worth tells it what Lilly or Roche would gain by taking it, and that second calculation is where the partner’s comfort turns into the partner’s anxiety.

Consider what Novartis can see. It knows Arrowhead’s central nervous system platform would hand Lilly, already committed to Alzheimer’s with an approved drug, a delivery technology Lilly does not have. It knows Arrowhead’s obesity programs would give Lilly a differentiated complement to the most valuable weight-loss franchise in the industry. It knows, too, that Roche, which pioneered the brain-delivery science Arrowhead competes in, would treat losing Arrowhead to anyone as a strategic wound. Novartis, precisely because it understands the platform, understands that it is not the only one who will covet it, and that the others can bring resources Novartis has chosen not to match.

This is what converts Novartis’s patient, disciplined strategy into something more urgent. Left alone, Novartis might prefer to deepen the partnership gradually, license additional programs, and acquire only if and when the timing suited its cliff calendar. The presence of rivals removes that luxury. A partner who waits too long risks watching a better-funded competitor buy the company outright, taking not just a future asset but the existing partnership with it. The informed buyer’s knowledge, which makes it confident, is the same knowledge that tells it confidence is not safety.

This also answers the most obvious objection to the whole scenario. A skeptic could fairly point out that Novartis’s actual behavior toward Arrowhead has been to license, not to buy, and that its stated strategy favors small bolt-on deals over transformational acquisitions, so why assume it would ever acquire the entire company? The answer is precisely the foreclosure logic. Licensing works beautifully when no one else is bidding, because it lets Novartis acquire what it wants, one program at a time, at modest cost, while leaving the rest on the shelf. The moment a rival might buy the whole platform, that calm approach becomes a liability. A license secures one program but leaves the platform, and every future program it will generate, available for a competitor to take entirely. Against a serious rival bid, the disciplined licensing strategy stops protecting Novartis and starts exposing it, because the thing it most wants to keep out of a competitor’s hands is exactly the thing a license does not secure. This is the first appearance of a tension that runs through the whole trilogy, and that becomes decisive in the third paper: the strategies these companies prefer in calm conditions are the strategies that fail them in a contested one. The next paper introduces the rival whose resources Novartis most has reason to fear.

VII. How Arrowhead Plays It

From Arrowhead’s side of the table, an approach from Novartis is in some ways the most manageable of the three, precisely because the informed partner cannot lowball, and in one way the most delicate, because the existing relationship could be used to encourage a quiet, early deal before the platform’s full value is visible to the market.

Arrowhead’s central advantage, developed at length elsewhere in this series, is that it does not need to sell. It owns its manufacturing, it has an approved product and revenue, and it has a platform deep enough to fund its own future, which means it can decline any offer that fails to reflect the platform’s full value and simply continue building. Against Novartis specifically, that strength is amplified by the fact that Novartis cannot credibly argue the platform is worth little. The partner who has worked with the science and paid $12 billion for a cousin technology is in no position to plead ignorance of the value. Arrowhead can hold firm knowing its counterpart privately understands the platform as well as it does.

The sharper move available to Arrowhead is to make Novartis’s awareness of the other suitors work in Arrowhead’s favor. A company that can credibly continue alone, and that has more than one potential acquirer, is never obligated to accept a first mover’s terms. The mere fact that Lilly and Roche exist, and that Novartis knows they exist, raises the floor on what Novartis must offer to preempt them. Arrowhead does not need to orchestrate a bidding war to benefit from one being possible; the possibility alone disciplines the offer. The honest limit on this, which Arrowhead’s leadership would weigh seriously, is that an early, certain, generous offer from a trusted partner carries real value too, certainty and a known counterpart are worth something, and a credible offer that fairly reflects the platform’s value might rationally be accepted rather than gambled against an auction that may or may not materialize. The point is not that Arrowhead should refuse Novartis. It is that Arrowhead, holding a strong position and more than one option, sets the terms on which any conversation proceeds.

VIII. Conclusion: The Partner’s Dilemma

Novartis is the suitor that knows Arrowhead best, wants it for the most documented reasons, and has already proven, with the Avidity deal, that it will pay a price far beyond its stated discipline for exactly this kind of platform. On the surface, that makes Novartis the most natural acquirer of the three. Underneath, it makes Novartis the most exposed, because everything that lets it see Arrowhead’s value clearly also lets it see how much a rival would gain by taking it, and how little Novartis can do to stop a better-funded competitor from trying.

That is the partner’s dilemma, and it is where this first paper hands off to the second. Novartis would prefer to move on its own timetable, disciplined and patient, acquiring to fill its cliff when the moment is right. The trouble is that the moment may not be Novartis’s to choose. The deepest knowledge of the asset does not confer the deepest pockets, and the company that can simply outspend everyone is not the careful Swiss partner but the American giant flush with the proceeds of one of the most successful drug franchises the industry has ever seen. Novartis knows the value. The next suitor can pay it without blinking. What happens when the giant enters the board is the subject of Part Two.

The queen is under attack, and Novartis is the first to know it. “En garde” was always a courtesy, a warning offered to an opponent who might not yet have seen the danger. The irony of this trilogy is that no such courtesy will be extended here. Each player can see the queen, each knows the others can see it too, and none will wait politely for the rest to notice. Novartis hears the warning first because it stands closest to the board. It will not be the last to hear it.

A Note on Supporting Independent Research

If this white paper has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this white paper; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This paper is provided for informational and analytical purposes only. It is a strategic thought experiment based entirely on publicly available information, including company acquisition histories, public strategic statements, earnings disclosures, and trade press reporting, as of the date of publication. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security, and it is not a recommendation as to any corporate course of action. It is not a prediction of any transaction, and the author has no knowledge of any actual deal discussions among any of the companies described. Scenarios involving how companies would behave are analytical interpretations grounded in documented past behavior, not statements of fact about any company’s intentions or any individual’s thinking. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results, and forward-looking analysis is inherently uncertain. The author and BioBoyScout are not registered investment advisors. The author assumes no obligation to update this paper.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

Robert Toczycki, JD, MBA
bioboyscout.com
bioboyscout@gmail.com
847.227.7909
X: @BioBoyScout

Executive Summary

Almost every clinical-stage biotechnology company shares a quiet weakness: it cannot survive on its own. It can discover a promising drug, but it cannot manufacture at commercial scale, navigate approval, build a salesforce, and fund years of late-stage trials without a larger partner. That dependence makes such a company a price-taker. When a buyer comes, it negotiates from need, and the buyer knows it.

Arrowhead Pharmaceuticals is the rare exception, and the reason is its platform. The same delivery platform that lets Arrowhead reach new tissues and generate drug after drug also gives it the things most biotechs lack: a commercial-scale manufacturing facility it already owns, a regulatory organization that has already won an approval, a balance sheet and revenue base to fund development, and a pipeline deep enough that the cost of going alone is spread across many programs rather than one. The platform is not just how Arrowhead makes drugs. It is what makes independence possible.

This paper introduces a term for the move that this capability unlocks: the Platform Gambit. It is the decision a company can make to forgo the certain, immediate premium of an acquisition in order to keep the platform’s entire compounding future for its own shareholders. It is a gambit because it gives up the certainty of a sale. It is playable, and rational, only for a true platform company, because only a platform supplies what independence requires. Most biotechs cannot play it. They have no platform to stand on, so they are forced to sell. Arrowhead can, because the platform is the board it plays on.

The argument proceeds in stages. First, that going it alone with ARO-MAPT, Arrowhead’s lead central nervous system program, is genuinely difficult, and that Arrowhead nonetheless clears each requirement from an unusual position of strength. Second, that a proven commercialization strategy, entering through a rare, fast indication and expanding into a large one, exactly as Arrowhead has done with plozasiran, applies directly to ARO-MAPT and shrinks the hardest part of going alone. Third, that a positive ARO-MAPT readout would set off a self-reinforcing cascade, validating the platform, lowering the cost of capital, expanding the pipeline, and generating early revenue, that makes independence easier precisely when the data would prove the drug. Fourth, that the ability to choose among independence, partnership, and sale is itself a valuable asset and a source of negotiating leverage that most biotechs simply do not have.

The conclusion is the most important point. When a platform company sells, the buyer captures the platform’s entire future output, every program it will ever generate, while the selling shareholders receive a single premium. An acquisition therefore caps shareholder value at the premium and hands the compounding machine to someone else. For a genuine platform company, the future the platform will produce may be worth more than any premium a rational acquirer will pay. That is why the capability to walk away is the most valuable and most mispriced thing about Arrowhead, and why any acquirer must pay extraordinarily to take the Platform Gambit off the table. It is also why, should the platform perform, the independent path leads not to a larger biotech but toward the ranks of major biopharmaceutical companies, the trajectory that Regeneron, Vertex, and Alnylam followed by declining to sell. The alternative to being acquired is not staying small. It is becoming the kind of company that acquires.

I. The Price-Taker Problem

To understand why Arrowhead’s position is unusual, start with the ordinary case. A typical clinical-stage biotechnology company is built around one promising idea, a molecule, a target, a mechanism. It can run early trials and generate data. What it almost never has is the full apparatus required to turn that molecule into a marketed medicine, the manufacturing, the regulatory experience, the commercial organization, and the capital that bringing a drug to market demands. Building all of that takes a decade and enormous sums, far more than most biotechs can raise or justify for a single drug, which is why most never build it at all.

The consequence is structural dependence. The typical biotech must partner its drug to a larger company or sell itself outright, because those are the only ways to access the apparatus it lacks. This is not a failure of ambition; it is the economics of the industry, and it has a price. A company that must partner or sell negotiates from need, and the larger company on the other side of the table knows the smaller one has no alternative. The smaller company is a price-taker. It accepts the terms it can get, because the only other option is to let the drug languish unfunded.

This is the position nearly every biotech occupies, and it is worth holding the image in mind, because it is the board on which the rest of this paper is played. In chess, a player who has only one legal move is at the mercy of the position; the move is forced, and a forced move is rarely a good one. Most biotechs play the whole game in something close to that state, their options narrowed to a single path that runs through a larger company’s checkbook. The interesting question, the one this paper exists to answer, is what changes when a company is not forced, when it has more than one good move and can choose the moment and the terms. That freedom is rare, it is valuable, and in Arrowhead’s case it comes from a single source: the platform.

II. What Independence Actually Requires

Before claiming that Arrowhead can go it alone, it is only fair to lay out honestly what going it alone demands, because the bar is high and pretending otherwise would prove nothing. Taking a central nervous system drug like ARO-MAPT from where it is today to a marketed product, without selling or partnering, requires clearing five distinct hurdles, each of which defeats most companies that attempt it.

The first is late-stage clinical execution. Pivotal trials in neurological disease are among the largest, longest, and most expensive in all of drug development, often enrolling hundreds or thousands of patients, running for years, and relying on sophisticated cognitive, biomarker, and imaging endpoints. Running them well requires deep clinical operations and a great deal of money.

The second is manufacturing. A genetic medicine must be produced at commercial scale under demanding regulatory standards, in facilities that take years and hundreds of millions of dollars to build and qualify. Most biotechs never build this and must rely entirely on partners or contract manufacturers, which is one of the principal reasons they cannot go alone.

The third is regulatory capability. Winning an approval requires an organization that knows how to design a registrational program, engage with the Food and Drug Administration, and shepherd a submission to a successful decision. This expertise is learned by doing, and a company that has never done it carries real execution risk.

The fourth is commercial infrastructure. Selling a drug requires a salesforce, market access and pricing teams, medical affairs, and distribution, all specialized by therapeutic area. A neurology commercial organization is a large and particular thing to build, and it is the piece most often cited as the reason a biotech cannot commercialize independently.

The fifth is capital. All of the above must be funded through years of spending before a single dollar of the new drug’s revenue arrives. The company needs either a large balance sheet, a reliable revenue base, or access to financing on terms that do not cripple existing shareholders.

These five requirements are the reason independence is rare. They are also, not coincidentally, exactly what a large acquirer brings to the table: the manufacturing, the regulatory machinery, the salesforce, and the capital that the small company lacks. An acquisition is, in essence, a way of renting all five at once, in exchange for the company itself. That is why the question of whether a biotech can go alone is really the question of whether it already possesses these five things, because a company that does has no need to rent them. The honest question for Arrowhead is not whether the five requirements are hard, they are, but whether Arrowhead, uniquely, already holds most of what they demand. The next sections take them in turn and show that it does, and that the reason it does is the platform.

III. The Capability Audit

Consider each requirement as a ledger: what going alone needs, what Arrowhead already has, and what would remain to be built. The striking pattern is that Arrowhead already holds the hard, slow, expensive pieces, the ones that take a decade to build, and that what remains is the faster, more assemblable kind.

Manufacturing: already built.

This is Arrowhead’s strongest card, and it is the one most biotechs lack entirely. Arrowhead owns and operates a commercial-scale manufacturing facility in Verona, Wisconsin, which already produces an approved drug. The capability that takes most companies the better part of a decade and hundreds of millions of dollars to create, and that most never create at all, Arrowhead already has, running and validated. For going alone, this removes the single most common structural barrier before the question is even asked. What might remain is incremental capacity expansion as the pipeline grows, an addition to an existing capability rather than the creation of a new one.

Regulatory: already proven.

In November 2025, Arrowhead won Food and Drug Administration approval for its first product. That fact matters far beyond the single drug, because it means Arrowhead now possesses something most clinical-stage companies do not: a regulatory organization that has actually carried a submission across the finish line. The institutional knowledge of how to design a registrational program and win an approval is present and demonstrated. A central nervous system program brings its own specific regulatory questions, but the core capability has been proven rather than assumed.

Clinical execution: already operating.

Arrowhead is not a single-trial company. It runs a broad clinical operation across many programs and multiple disease areas, and it is already conducting the ARO-MAPT study. Scaling to pivotal central nervous system trials is a real undertaking, but it is a matter of expanding an existing, functioning clinical organization rather than building one from nothing.

Capital: a position of strength.

Arrowhead carries a substantial balance sheet, now supplemented by revenue from its approved product and by income from its partnerships. This is a fundamentally different financial position from the typical pre-revenue biotech that must sell simply to survive. The distinction is not merely one of degree. A company with no product revenue has a finite runway and a clock running against it, which is itself a reason it becomes a price-taker, because time pressure forces a deal. Arrowhead, with a marketed product generating revenue and partnership income flowing in, has removed that clock. It can fund development from a combination of cash, product revenue, and partnership proceeds, and it can choose the timing of any capital raise rather than being forced into one. That revenue base is, moreover, set to grow rather than hold steady, because the approved product’s expansion into a far larger indication, examined in a later section, would lift it substantially. Funding independent late-stage development remains a serious commitment, and later sections explain why a positive ARO-MAPT readout would make that funding markedly easier to secure on good terms. The starting point, though, is strength and patience, not desperation and a deadline.

Selective licensing: the lever that pays for independence.

There is a further capability hiding inside the platform’s breadth, and it is the one that most directly answers the cost of going alone. Because Arrowhead’s platform generates far more programs than any single company could develop itself, Arrowhead does not face an all-or-nothing choice between selling the whole company and funding every program from its own pocket. It can license out the parts of the platform it does not need to own, a tissue it does not intend to commercialize, a target outside its core focus, a program in a region it will not serve, and use the upfront payments, milestones, and royalties from those deals to fund the independent development of the programs it most wants to keep, above all ARO-MAPT and the core central nervous system franchise. This is not a hypothetical. It is already how Arrowhead operates, through partnerships with companies including Sarepta, Amgen, Takeda, and GSK, each of which licenses a defined slice of the platform’s output while leaving the platform itself, and its most valuable programs, in Arrowhead’s hands.

The strategic point is that a single-drug company cannot do this, and that is precisely the difference the whole paper turns on. A company with one asset that licenses that asset has licensed the entire company; partnering, for the price-taker, is surrender. A platform company licenses one of many outputs and keeps the engine that made it, along with everything the engine will make next. The breadth that makes Arrowhead a platform is exactly what makes selective licensing a tool of independence rather than a step toward losing it. The non-dilutive capital it generates is the funding mechanism that pays for the manufacturing, the regulatory organization, and the commercial build that independence requires, without selling equity cheaply and without selling the core. In the language of the board this series keeps returning to, selling Arrowhead means giving up the queen. Licensing a non-core program is trading a pawn: a deliberate, modest concession that strengthens the position and keeps the queen, ARO-MAPT and the franchise around it, exactly where Arrowhead wants it, on the board and in its own hands.

Design knowledge: the hidden capability.

There is another asset that does not appear on the standard list of what independence requires, and it quietly lowers the risk of everything else. Over more than a decade of making and testing molecules across many tissues, Arrowhead has accumulated a deep proprietary understanding of how to design drugs on its platform, which chemistries work, which sequences silence their targets, which approaches reach which tissues. This accumulated knowledge, examined at length elsewhere in this series, is what allows the company to advance new programs with unusual speed and reliability. For the question of going alone, it matters because it reduces the execution risk of the independent path. A company designing its next central nervous system drug from a deep base of empirical experience is less likely to stumble than one designing from scratch, which means the pipeline that justifies the independent infrastructure is itself more likely to deliver. The platform does not only supply the factory and the balance sheet. It supplies the know-how that makes each new program a better bet than the last.

Commercial infrastructure: the honest gap, and why it is smaller than it looks.

Here is the one requirement Arrowhead does not already fully hold. It does not today operate a neurology salesforce. It would need to build commercial infrastructure specific to the central nervous system. This is the real gap, and intellectual honesty requires naming it plainly. Two things, though, make it far smaller than it first appears. The first is that Arrowhead is already building a commercial organization for its approved cardiometabolic product, so it has the nucleus of commercial capability and, just as important, the institutional experience of standing one up from scratch. The second is the subject of the next section: the way Arrowhead can enter the central nervous system market does not require a large salesforce at the outset, and follows a path the company has already walked once before.

IV. The Team That Has Done It Before

A capability audit can list assets, but assets do not execute themselves. The credible question behind going alone is whether this particular organization, under this particular leadership, has shown it can do hard things. The honest answer, read from the public record rather than asserted, is that it has, repeatedly, and that the relevant evidence is a track record rather than a set of adjectives. The case for the team is not a case about charisma or vision in the abstract. It is a case about what this group of people has actually built and shipped, which is the only evidence that matters when the question is whether they can do it again, alone.

Chris Anzalone has led Arrowhead as chief executive since 2007, which is to say through an entire arc that most biotech leaders never complete: from a small research-stage company, through a near-death experience, to a commercial enterprise with an approved product and a deep pipeline. Longevity alone is not the point. The point is what that longevity contains, because the most instructive chapter is also the most painful one.

In 2016, the delivery chemistry on which Arrowhead’s entire clinical pipeline depended showed safety problems in the clinic. The company faced the defining choice that confronts every platform-stage biotech sooner or later: defend the sunk investment and push the existing programs forward, or accept that the approach was flawed and rebuild. Chris chose to discontinue the entire clinical pipeline and rebuild the company around a new and better delivery platform. It is difficult to overstate how hard that decision is in practice. It meant writing off years of work and capital, telling investors the programs they had funded were being abandoned, and starting substantially over. Most leaders, faced with that choice, rationalize continuing, because continuing defers the pain and preserves the story. The willingness to destroy flawed work rather than ship it is the single most important quality in a drug developer, because the alternative, advancing a compromised approach because it is already paid for, is how companies waste a decade. The platform Arrowhead runs on today, and the entire argument of this paper, exists because the company’s leadership made the hard call in 2016 rather than the comfortable one.

What followed is the part that bears most directly on the capability to go alone, because it is the part that demonstrates not judgment but execution. From a standing start after optimizing the rebuilt platform for liver delivery in 2017, Arrowhead advanced eighteen drug candidates into clinical studies across multiple tissue types within roughly six years, and reached its first product approval in November 2025. That pace is itself the evidence. A company does not move from a rebuilt platform to eighteen clinical candidates and a marketed drug in under a decade unless it has built, along the way, the full set of organizational muscles that independence requires: discovery, chemistry, clinical operations, regulatory affairs, manufacturing, and now commercialization. The leadership case for going alone is not that the team is gifted. It is that the team has already assembled, function by function, the very apparatus that the price-taker biotech lacks, and has done it in plain view, on a public timeline, with results anyone can check.

Chris has described the platform’s output in language worth pausing on: that the company can develop drugs in a way that is predictable and reproducible, with each new program building on the ones before. Those are the words of manufacturing, not of research gambling. They describe an organization that has turned drug discovery, at least at the delivery and chemistry layer, from an artisanal gamble into something closer to an engineering discipline, where the next program is a controlled variation on a solved problem rather than a leap into the dark. An organization that can produce clinical candidates predictably and reproducibly is, almost by definition, an organization that can sustain an independent pipeline, because the thing that makes going alone frightening, the fear that the well will run dry after the lead program, is precisely what a predictable, reproducible engine answers.

The same pattern shows up beneath the chief executive, which matters because a company cannot go alone on the strength of one person. The manufacturing organization conceived, built, and now operates a commercial-scale facility, a capability most biotechs never develop in their entire existence. The regulatory organization designed a registrational program and won an approval. The scientific organization extended a single delivery platform across tissue after tissue on a steady cadence, a feat of sustained technical execution. The commercial organization is being assembled now, in real time, for the approved product. Each of these is a demonstrated competence, evidenced by something the company has actually delivered, not a competence promised in a slide deck. Independence asks a company to do many hard things at once and to keep doing them for years. Arrowhead’s record is precisely a record of doing those things, in sequence, on schedule, and through at least one existential setback that would have ended a lesser organization. That is the strongest evidence there is that it could do them again, on its own, for ARO-MAPT and the programs that follow.

V. The Plozasiran Playbook

The most concrete reason to believe Arrowhead could commercialize ARO-MAPT itself is that the company is, right now, executing the analogous strategy with another drug. The pattern is worth naming, because it recurs and because it directly answers the commercial-infrastructure question raised earlier.

Arrowhead’s first approved product, plozasiran, did not launch into the largest possible market. It entered through a rare, severe disease, familial chylomicronemia syndrome, a small and well-defined patient population that can be reached with a focused, specialized commercial effort rather than a vast salesforce. From that beachhead, the company is expanding toward the much larger severe hypertriglyceridemia population through its later-stage trials. Enter through the rare indication, build a focused commercial capability, generate revenue and real-world experience, then expand into the large market. This is a repeatable strategy, and Arrowhead has shown it can run it.

That expansion is no longer a future hypothesis; it is underway and close. Arrowhead is completing the Phase 3 studies that support the severe hypertriglyceridemia indication and intends to file for approval with the Food and Drug Administration by the end of 2026, which points to a likely approval in 2027, helped by the Breakthrough Therapy designation the agency has already granted to speed the review. The significance is a matter of scale. Familial chylomicronemia syndrome, the rare disease through which plozasiran entered, affects only a few thousand patients in the United States; severe hypertriglyceridemia affects on the order of millions, a large share of them untreated, in a market measured in the billions of dollars and growing. Even at a modest share of a population that large, and at the lower net prices a volume market commands rather than rare-disease pricing, the indication could generate revenue an order of magnitude beyond the rare-disease launch, plausibly reaching blockbuster scale over time. That is what makes it matter for the question of going alone. The severe hypertriglyceridemia expansion would convert plozasiran from a modest rare-disease product into a major internal source of non-dilutive capital, a growing revenue base that helps pay for the pivotal trials and commercial build-out of the independent central nervous system path without selling equity cheaply or selling the company. The plozasiran playbook is not only a template ARO-MAPT can follow; it is, in its own right, part of the engine that funds ARO-MAPT’s independence.

ARO-MAPT fits the same template with unusual neatness, because tau, the protein ARO-MAPT lowers, drives not only Alzheimer’s disease but a family of rarer neurological diseases known as the primary tauopathies, among them progressive supranuclear palsy and corticobasal degeneration. These are smaller, more sharply defined populations than Alzheimer’s, with high unmet need and far less competition, exactly the kind of rare, fast entry point that familial chylomicronemia syndrome represented for plozasiran. Crucially, these diseases have no approved disease-modifying therapies at all; the available care is supportive, not curative. A drug that meaningfully altered their course would enter a vacuum, which tends to mean a more receptive regulatory posture, faster uptake, and pricing power, the same dynamics that make rare-disease entry attractive in the first place. Arrowhead’s chief medical officer, James Hamilton, made the underlying logic explicit on the company’s second-quarter fiscal 2026 earnings call, noting that even setting aside Alzheimer’s, the company retains the option of pursuing the other tauopathies, because a tau-knockdown approach should help any condition driven by tau pathology.

A second feature of ARO-MAPT makes the commercial path easier still, and it is one that distinguishes it sharply from the competition. ARO-MAPT is administered by subcutaneous injection. The other serious efforts to lower tau in the brain rely on far more burdensome routes: repeated injections into the spinal fluid, or intravenous infusions that require a clinic visit and infusion time. The history of the recent Alzheimer’s antibodies is instructive here, because their uptake has been slowed substantially by exactly this kind of administration burden, the need for infusion centers, scheduling, and monitoring. A subcutaneous injection sidesteps that bottleneck. It can be given in a community setting rather than a specialized infusion center, which widens the prescriber base and lowers the infrastructure a commercial organization must support. For a company weighing whether it can commercialize alone, a drug that is genuinely simple to administer is a drug that needs a smaller, less complex commercial apparatus to reach patients. The convenience of the route is not only a clinical advantage. It is a commercial one, and it lowers the bar for going alone.

The strategic implication is significant for the question of going alone. Reaching a rare tauopathy like progressive supranuclear palsy requires only a small, specialized neurology salesforce, the kind of focused commercial effort Arrowhead is already proving it can build, not the enormous infrastructure that competing in Alzheimer’s from day one would demand. The rare-indication entry shrinks the one genuine gap in the capability audit to a manageable size. It also does something more: it can generate central nervous system revenue earlier, from a faster, smaller approval, while the long and expensive Alzheimer’s program runs in parallel. The first central nervous system approval becomes a source of capital for the programs that follow rather than a drain on them, which begins to suggest a larger point about the economics of going alone, one the next section takes up directly.

VI. Why a Good Readout Makes Independence Easier

There is a feedback effect at the center of this paper that is easy to miss, and it is the reason the capability to go alone is not static but grows stronger at the decisive moment. A positive ARO-MAPT readout would not merely be good news for one drug. It would set off a self-reinforcing cascade that makes independence more affordable precisely when the data would prove the drug is worth pursuing.

Start with what the readout validates. Arrowhead has been explicit that the ARO-MAPT readout is a test of the platform, not only of a single drug. If the company can show that it silences a target gene in the brain after a simple subcutaneous injection, that result speaks to every other central nervous system program the platform can produce, because they all rely on the same delivery approach. A good readout therefore de-risks the entire central nervous system pipeline at once, not just the lead program. The market would be repricing a platform, not a molecule.

That repricing matters for a concrete financial reason. The practical question in any go-it-alone decision is the cost of capital, the terms on which a company can raise the money to fund independent development. A company whose platform has just been validated by a strong readout, and whose shares have risen sharply as a result, can raise capital far less dilutively than before, more dollars for each share issued. In this way a positive readout is partly self-financing: the same event that proves the drug works is the event that makes funding the independent path materially cheaper. The better the data, the cheaper independence becomes.

The pipeline expansion compounds the effect. Arrowhead has signaled that a positive early ARO-MAPT result would trigger a substantial expansion of its central nervous system pipeline, with additional subcutaneous central nervous system programs expected to enter the clinic. Each new program is another opportunity the market can recognize and value, so the repricing is not a one-time event tied to a single drug but a sustained climb in value as the breadth of the platform becomes visible. A wave of new programs entering the clinic builds momentum that, for a company funding itself, translates directly into a stronger balance sheet and better financing terms.

There is also a quiet improvement in unit economics hiding in that expansion. The expensive pieces of going alone, the manufacturing, the regulatory organization, the central nervous system commercial build, are largely fixed costs. The first central nervous system drug must bear them alone, but every subsequent program rides the same infrastructure at little additional cost. As the pipeline grows from one program to several, the per-program cost of independence falls. The first drug justifies the infrastructure; the programs that follow inherit it nearly for free. The very pipeline expansion a good readout would unlock is what turns the commercial build from a one-drug burden into a franchise-wide investment that pays for itself many times over.

The expansion does something more subtle as well, and it answers the most serious objection to going alone. The natural worry about independence is concentration risk: that going alone means betting the company on a single drug surviving a single readout, which is precisely the kind of all-or-nothing wager a sale would let shareholders avoid. A validated platform dissolves that worry, because it converts the bet from one drug to a portfolio. If the platform works, ARO-MAPT is not a lone gamble but the first of many central nervous system programs, each a separate shot on goal, each able to fail without sinking the others. The independent path is therefore far less risky than it first appears, because the thing being funded is not a single molecule but a diversified franchise in which no single failure is fatal. Platform validation does not only lower the cost of going alone. It lowers the risk of it, by ensuring that the company walking the independent road carries many shots rather than one.

VII. The Option Itself Has Value

Everything to this point establishes that Arrowhead can go it alone. The next two sections turn to what that capability is worth, and the first point is one that finance understands well but the market routinely overlooks in cases like this. The ability to choose is itself a valuable asset, separate from whichever choice is ultimately made.

In finance, an option, the right but not the obligation to do something, has value precisely because the future is uncertain. The holder of an option can wait, watch how events unfold, and then act in whichever way turns out best. That flexibility is worth money, and it is worth the most exactly when uncertainty is highest, which is to say right before a major, binary event resolves. Arrowhead, heading into the ARO-MAPT readout, holds precisely this kind of option. Depending on what the data show and what offers materialize, it can pursue independence, strike a partnership, or sell. It is not committed in advance to any of them. It can let the uncertainty resolve and then choose the best available path.

This is exactly what the typical biotech does not have. The price-taker company described at the outset effectively holds only one path, partner or sell, and must take it on whatever terms are available. It has no option, only an obligation. Arrowhead has a genuine choice among several credible paths, and that choice has value in its own right, because it guarantees the company can never be forced into a bad outcome. If the offers are poor, it walks and goes alone. If an offer is extraordinary, it can accept. The mere existence of a real alternative protects the company from ever having to accept a weak one.

Return for a moment to the chessboard. The player who is not forced to move holds what is, in practice, a luxury, the ability to wait, to improve the position, to make the opponent commit first and reveal their hand. The player with options acts last and acts best. Arrowhead, alone among most of its peers, can afford to wait, because it has somewhere to stand if it chooses not to deal. That patience is not passivity. It is the most active source of leverage there is.

There is a timing point worth drawing out, because it bears on how the market should value this today rather than someday. Option value is greatest before the uncertainty resolves, which means Arrowhead’s optionality is worth the most right now, in the window before the ARO-MAPT readout, when the range of possible futures is still wide. Once the data are known, the option collapses into whatever choice the result dictates, and much of its value is realized or lost in an instant. The market, which prices the disclosed pipeline and waits for the readout, is precisely the kind of observer that misses option value, because an option does not appear on any pipeline chart and pays nothing until it is exercised. The capability to walk away is therefore not only valuable; it is valuable now, and it is invisible now, which is the exact combination that defines a mispriced asset.

VIII. The Asymmetry of Who Can Walk Away

Optionality protects Arrowhead from a bad deal. The next step is to see how it actively improves every deal, because the capability to go alone changes the balance of power in any negotiation Arrowhead might enter.

The principle is simple and universal: in any negotiation, the party that can walk away holds the advantage. A buyer facing a seller who must sell will offer little, because there is no need to offer more. A buyer facing a seller who is content to keep what they have must offer enough to overcome that contentment, which means offering full value. The willingness to walk is what forces a fair price.

Consider the position of a strategic acquirer evaluating Arrowhead, one of the small number of large pharmaceutical companies for whom a validated subcutaneous central nervous system platform would be strategically valuable. Such an acquirer is trying to fill a gap it cannot easily fill any other way, because the platform, as the companion analyses in this series argue, cannot be quickly replicated. The acquirer, in other words, has a real need. Arrowhead, holding a credible independent path, does not share that need in the same way. The usual biotech dynamic, in which the small company is desperate to be bought and the large company holds all the leverage, is inverted. Here it is the acquirer who needs the deal more than the target needs to sell.

This asymmetry sets the floor on any transaction. Because Arrowhead can credibly choose independence, no acquirer can win it with a modest premium; the offer must clear the value of the standalone path, or Arrowhead simply keeps that path for itself. The capability to walk away does not merely protect Arrowhead from a bad deal. It raises the price of every good one, and it connects to a larger competitive dynamic, developed elsewhere in this series, in which rival acquirers cannot afford to let one another win the platform. When the suitors are compelled to act and the target is not, the target names the terms.

IX. Who Keeps the Future

The deepest reason the Platform Gambit matters has not yet been stated, and it is the most important point in this paper. It concerns a question that pipeline-by-pipeline valuation never asks: when a platform company is acquired, who captures the value of everything the platform will go on to produce?

When an ordinary single-drug company is acquired, the calculation is relatively clean. The buyer pays for the drug, plus a premium, and the selling shareholders receive a fair price for the asset they held. The future being transferred is bounded, because the company’s value was always bounded by that drug and a few others. A platform company is different in kind. Its value is not its current pipeline but its capacity to generate pipeline, program after program, for many years, each new drug riding the same delivery system, each adding to the same compounding store of data and know-how. When a platform company sells, the buyer does not merely acquire the disclosed programs. It acquires the entire future output of the platform, every drug it will ever produce, the whole compounding franchise, for as long as the platform endures.

This reframes what an acquisition premium actually represents. The selling shareholders receive a single payment, generous perhaps, but one-time and fixed. The acquirer receives a machine that will produce value for decades. In effect, an acquisition transfers the platform’s entire compounding future from the seller’s shareholders to the buyer’s. The premium is the price of giving away that future. For a single-drug company, this is a reasonable trade, because there is not much future to give away. For a genuine platform company, it may be a profound one, because the future being surrendered could dwarf any premium a rational buyer would pay. No acquirer pays full value for a future it must still execute and fund and risk; it pays a price that leaves room for its own return. The gap between what the platform will produce and what the acquirer will pay for the right to produce it is value that, in a sale, the original shareholders never see.

History bears this out, and the examples are exactly the companies Arrowhead is sometimes compared to. The most valuable platform companies in biotechnology, Regeneron, Vertex, Alnylam, the very names industry observers reach for when they describe what a successful platform looks like, share a defining trait: they did not sell early. Each reached a point where it could have been acquired, and each instead chose to build its own commercial organization and remain independent. The shareholders who held those companies through independence captured the compounding future that an acquirer would otherwise have taken, and the companies themselves grew into the ranks of the industry’s leaders, several now large enough to stand among the acquirers rather than the acquired. This is worth dwelling on, because it reveals what the independent path actually leads to. It is easy to picture going alone as simply staying small and unbought. It is the opposite. A company with commercial-scale manufacturing it owns, an approved product generating revenue, a delivery platform validated across tissue after tissue, a deep and expanding franchise, and a compounding data advantage is not the description of a larger biotech. It is the description of an emerging major biopharmaceutical company. The companies that sell early are, as a rule, the single-asset and limited-platform companies, the ones with less future to forgo. The pattern is not a coincidence. It is the Platform Gambit, played successfully, by the handful of companies that had a real platform to play it with. Arrowhead belongs in that category, which means the same choice, the same prize, and the same trajectory are available to it.

This is the heart of the Platform Gambit. To play it is to forgo the certain premium of a sale in order to keep that compounding future for current shareholders. There is a refinement worth adding here, because the choice is not as binary as a sale makes it sound. Through selective licensing, Arrowhead can monetize the parts of that future it chooses not to develop itself while keeping the rest, which means playing the gambit does not require keeping every program; it requires keeping the ones that matter most and funding them, in part, by licensing the ones that matter least. A sale hands the entire future to the buyer in one transaction. The gambit, played with licensing, lets Arrowhead keep the largest and best part of that future for its own shareholders while still drawing cash from the remainder. It is a gambit because it trades certainty for a larger but less certain prize, and because going alone carries real execution and clinical risk that a sale would transfer to someone else. Honesty requires stating the other side plainly: an acquisition delivers value now, with certainty, and offloads the risk of the long road ahead, and for that reason a sufficiently large offer can be the right answer, and some shareholders will rationally prefer the sure thing. The Platform Gambit is not a claim that independence always wins. It is the claim that, for a company whose platform will compound for decades, the standalone path may be worth more than any premium a rational acquirer will offer, and that a company able to play the gambit therefore holds something the market is not pricing. The point is not that Arrowhead must refuse to sell. It is that Arrowhead, because it can credibly refuse, is worth far more than a pipeline-by-pipeline valuation can capture, and any buyer must pay extraordinarily to take the gambit off the table.

X. Conclusion

The thesis of this paper can be put simply. Most biotechs are price-takers because they have no platform to stand on, so they are forced to sell, and a forced move is rarely a good one. Arrowhead is the rare company that is not forced, because the platform supplies what independence requires: the manufacturing it already owns, the regulatory record it has already earned, the proven strategy of entering through a rare indication and expanding into a large one, the self-reinforcing cascade a good readout would unleash, and the depth of pipeline that turns the cost of going alone into an investment spread across a franchise. The capability to go alone is real, and it is the platform that makes it real.

That capability is worth more than it first appears, on three levels. It is an option, valuable in its own right because it lets Arrowhead wait and choose rather than accept what it is offered. It is leverage, because a company that can walk away forces any buyer to pay full value. Most profoundly, it is a claim on the future, because the alternative to selling is keeping the entire compounding output of the platform for current shareholders rather than handing it to an acquirer for a one-time premium. This is the Platform Gambit: the move, available only to a true platform company, of declining the certain premium to keep the larger prize the platform will compound over time.

Whether Arrowhead ultimately plays the gambit or accepts an extraordinary offer is not the point, and this paper makes no prediction about which it will choose. The point is that it can play it, and that almost no other biotech can. A company that must sell is a price-taker. A company that can walk away sets the price. Arrowhead does not need a buyer, and that is precisely why, in the end, it will command an extraordinary one.

This framework also answers a doubt that the valuations elsewhere in this series are bound to provoke. Those numbers are high, high enough that a reasonable observer may wonder whether any acquirer would actually pay them. That doubt deserves a direct answer, and the Platform Gambit is the answer. If the fair value of the platform is genuinely so high that no financially rational buyer will pay it, the consequence is not that the value was imaginary. The consequence is that Arrowhead goes alone and its shareholders keep that value rather than selling it for less. Value that can be captured independently does not require anyone else to agree to pay for it. There remains one force that could overcome even a price beyond ordinary financial logic, an acquirer compelled to buy for strategic rather than financial reasons, one that cannot afford to let a rival capture the platform, which is a dynamic this series takes up elsewhere. Absent that compulsion, a skeptic who insists no one will pay such a price is not refuting the valuation. That skeptic is merely identifying which path realizes it, and that path is independence. The real question was never whether a buyer will pay. It is whether the platform will perform, and if it does, the value is real whether it is realized through a sale or through a company that was, in the end, too valuable to buy.

The market is still counting Arrowhead’s pieces one by one, a drug here, a program there, as though the company were the sum of its disclosed assets. It is not. It is a platform that can generate those assets for as long as it chooses to remain the one holding them, and if it performs, the independent path does not lead to a larger biotech but toward the ranks of major biopharma, the same trajectory the great platform companies followed before it. The market frames Arrowhead as something to be bought. The platform points toward a company that ends up on the other side of the table.

On the board that matters, then, Arrowhead is not the player waiting to be forced into a move. It is the player who can afford to wait, and the player who can afford to wait is the player who decides how the game ends.

A Note on Supporting Independent Research

If this white paper has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this white paper; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This white paper is published by BioBoyScout and is intended for informational and analytical purposes only. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security, and it is not a recommendation as to any corporate course of action. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results. The reader is solely responsible for any investment decisions. The author and BioBoyScout are not registered investment advisors. All analysis is based on publicly available information, including company disclosures, conference presentations, as of the date of publication. Quotations attributed to company executives are drawn from public transcripts and should be verified against original sources before any use. Forward-looking analysis is inherently uncertain, and preclinical and clinical outcomes cannot be predicted. The author assumes no obligation to update this paper or its conclusions.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

Robert Toczycki, JD, MBA
bioboyscout.com
bioboyscout@gmail.com
847.227.7909
X: @BioBoyScout

Executive Summary

A popular thesis holds that the next great pharmaceutical company will be built on artificial intelligence, on a smarter decision layer that predicts which drug programs will succeed. This paper argues that the thesis is half right and locates the advantage in the wrong place. Success rate is indeed the variable that matters, but the source of durable advantage is not AI itself. It is the data that makes AI useful, because in a specialized domain like RNA interference, AI models are widely available while the proprietary experimental data needed to make them perform is not.

This is an application of a now-established principle in machine learning, often called data-centric AI, which holds that when models are commoditized, performance is bound by the quality and quantity of data rather than the sophistication of the model. RNA interference drug design is close to a perfect case for the principle: the relevant data does not exist on the public internet, cannot be scraped or purchased, and can only be generated through years of laboratory experiments. The data also compounds, because each molecule tested teaches transferable lessons about sequence, chemistry, and delivery that narrow the design space for every future program. Its most valuable part is the record of failures, which is never published and therefore cannot be observed or reconstructed from outside the company that generated it.

Arrowhead Pharmaceuticals, which became a focused RNAi developer with its 2011 acquisition of Roche’s RNAi assets, has likely generated the most diverse extrahepatic RNAi dataset in the field, a consequence of pursuing delivery across more tissues, more aggressively, than competitors concentrated on the liver. Its candidate-generation cadence is the observable signature of that compounding data. The asset is, by the company’s own recent hiring, not yet fully unified into a model-ready form, which means its value lies ahead of the company rather than behind it.

The strategic implications are significant. A newly formed, AI-first competitor cannot replicate this position, because the only way to obtain the data is to spend the years generating it, during which the incumbent extends its lead, making the gap structural rather than temporary. The same fast, data-rich design engine also functions as a competitive weapon, letting the company reach more targets first and fence off the best chemistry with intellectual property. For an acquirer, this reframes what a purchase of Arrowhead represents: not a set of disclosed programs to absorb cheaply, but a generative capability that permanently lowers the cost and time of every future program, paired with a dataset that cannot be bought or built at any price. The data advantage de-risks the engineering of drug design, not the underlying biology, so it raises the odds and the speed of producing good molecules without guaranteeing any single clinical outcome. It is, finally, the part of the company least visible to conventional valuation and most central to what a strategic acquirer is actually buying.

The Question Everyone Is Asking Backwards

There is a popular thesis circulating in biotech investing circles that the next trillion-dollar pharmaceutical company will be built on artificial intelligence. The argument runs that the industry’s central problem is its dismal clinical success rate, that the cure is a smarter decision layer, an AI system that predicts which programs will succeed before the money is spent, and that whoever builds that system first will reorder the industry. It is a compelling thesis, and it is half right. It correctly identifies that success rate, not speed or cost, is the variable that matters. It then locates the solution in exactly the wrong place.

The clearest articulation of why comes, of all places, from a fireside chat. At the Leerink Global Healthcare Conference in March 2026, Arrowhead Pharmaceuticals chief executive Christopher Anzalone was asked about competitive risk from fast followers. His answer wandered, characteristically, into something more fundamental:

“There’s something to be said about banging your head against the RNAi wall for almost 20 years now. We’ve learned a heck of a lot over that time, and we’ve made hundreds and hundreds of thousands of RNAi molecules ... I don’t care what sort of powerful AI engine some of these upstart companies have. If they don’t have the data to feed into that engine, there’s only so much they can do. We have an awful lot of data we can feed into our rules and our AI engines to help us make the most potent RNAi molecules around.”

That is the entire argument of this paper, stated by the person with the most reason to understand it. AI is not the moat. AI is increasingly available to everyone. The moat is the data that makes AI useful, and that data cannot be bought, scraped, or shortcut. It can only be generated, slowly, expensively, over many years of laboratory work that most companies never undertake and that no newcomer can compress. Arrowhead has been generating it as a focused RNAi company since 2011, when it acquired Roche’s RNAi assets, and on delivery science for years before that. The market sees a drug company that uses AI. What it is looking at is something closer to the inverse.

I. The Flip

Consider how Arrowhead is conventionally understood. It is a clinical-stage, now commercial-stage, biopharmaceutical company that develops RNA interference therapeutics. It has an approved drug, a deep pipeline, a delivery platform called TRiM, and a manufacturing facility in Wisconsin. In this framing, the drugs and the pipeline are the product, the platform is the engine that produces them, and whatever data the company has accumulated along the way is a useful byproduct, exhaust from the main activity of making medicines.

Now invert the framing. Suppose the most durable and least replicable thing Arrowhead has built over the past decade and a half is not any single drug, nor even the platform in the abstract, but the accumulated record of what happens when you make hundreds of thousands of RNA interference molecules and test them: which sequences silence their targets and which do not, which chemical modifications confer stability and which degrade, which delivery ligands reach which tissues and at what dose, which combinations are toxic and which are tolerated. Suppose that record, the proprietary map of cause and effect across the entire design space of the modality, is the real asset. In that framing, the drugs are not the product. The drugs are how Arrowhead funded the long experiment that produced the dataset. The asset that looks like the weakest piece on the board may be the one quietly advancing toward the most valuable square.

This is not wordplay. The two framings imply very different valuations, because they imply different answers to the question an acquirer actually asks: what here can I not build myself? A pipeline can be replicated by other competent scientists given time. A delivery platform can, in principle, be reverse-engineered or designed around. A fifteen-year record of empirical results across an entire modality, however, cannot be reconstructed by anyone, at any budget, in any timeframe shorter than the years it took to generate. It is the difference between buying a finished product and buying the factory, the blueprints, and the years of accumulated manufacturing know-how that make the next product cheaper and faster than the last. That is the asset this paper is about, and the argument for why it matters begins not with biology but with a now-established principle in artificial intelligence itself.

II. What Actually Makes AI Good Is the Data

For most of the field’s history, progress in machine learning was understood as progress in models. Better architectures, better algorithms, better hyperparameter tuning. Andrew Ng, one of the most credible figures in the discipline, a co-founder of Google Brain and Coursera and a longtime Stanford faculty member, has spent recent years arguing that this emphasis is misplaced for most real-world applications. He calls the alternative data-centric AI, and the core observation is simple: now that high-quality models are widely available and broadly comparable in capability, the binding constraint on performance is usually the data, not the model.

Ng has made the point vividly. By his informal count, of roughly one hundred research papers in the field, ninety-nine focus on the model and only one focuses on the data, despite the data being where the leverage increasingly lies. In a frequently cited demonstration involving a steel-defect detection task, a model-centric approach, holding the data fixed and tuning the model, failed to improve accuracy at all, while a data-centric approach, holding the model fixed and improving the data, raised accuracy by sixteen percentage points. His summary line captures it: all that progress in algorithms means it is now time to spend more time on the data. Data, in this view, should be treated as a fundamental asset that outlasts the applications and infrastructure built on top of it.

This principle is not unanimous across all of AI. The last several years of large language model development have shown that model scale and architecture still matter enormously when you can train on a meaningful fraction of the entire internet. That exception proves the rule for our purposes, however, because it depends on the existence of vast, general, publicly available data. Data-centric AI bites hardest precisely where that condition fails: in specialized technical domains where the relevant data is scarce, proprietary, expensive to generate, and impossible to scrape from public sources. In those domains, whoever owns the data owns the performance ceiling, and no amount of model sophistication closes the gap. The question, then, is whether RNA interference drug design is such a domain. It is almost a perfect example of one.

The clearest confirmation of this came in June 2026, when Alnylam, the other leading RNAi company, announced a collaboration with the AI firm Inceptive valued at up to two billion dollars. The structure of that deal is the entire argument of this paper, made by the industry’s pioneer. Alnylam’s contribution was described as its RNAi platform and, in the announcement’s own words, more than twenty years of proprietary data. Inceptive’s contribution was its foundation models, built by among others a co-inventor of the transformer architecture that underlies modern AI. In other words, the two ingredients were named explicitly and separately: the proprietary data on one side, the frontier AI on the other. The party that brought the data was the established drug developer; the party that brought the models was an AI specialist. That a company can now pair its proprietary dataset with best-in-class models through a partnership confirms exactly what this paper argues, that the models are an input one can acquire while the data is the scarce asset that determines what those models can do. The announcement even noted that AI achieved strong results from relatively small datasets, which is only remarkable, and only possible, when the data is proprietary and high in quality. The race in RNAi is not a race to build the best AI. It is a race to own the best data and then point capable models at it.

III. Why RNAi Data Compounds

Designing an RNA interference therapeutic is a modular engineering problem with a small number of interacting components: the nucleotide sequence that determines which gene is silenced, the chemical modifications applied to that sequence to confer stability and reduce immunogenicity, and the targeting ligand conjugated to it that determines which tissue the molecule reaches. Each of these components has an enormous combinatorial design space, and the components interact, so that a chemistry that works beautifully in one sequence context may fail in another, and a ligand that delivers efficiently to one tissue may not to the next.

The consequence is that every molecule a company designs, synthesizes, and tests produces information that transfers to the next molecule. A result about a particular chemical modification’s effect on potency is not a fact about one drug; it is a fact about the modification, applicable across the whole portfolio of future drugs that might use it. This is what makes the data compound rather than merely accumulate. Each experiment narrows the design space for every subsequent program. A company that has run hundreds of thousands of these experiments is not sitting on hundreds of thousands of isolated facts; it is sitting on a map of the design space, and the map gets more complete and more valuable with every molecule added to it.

This is precisely the specialized, limited-data domain in which data-centric AI dominates. The data that matters here does not exist on the public internet. There is no body of labeled RNA interference structure-activity results to scrape, because the companies that generate such results regard them as among their most sensitive competitive assets and do not publish them in any systematic way. The only way to obtain this data is to do the experiments, which means building the laboratories, hiring the chemists and biologists, synthesizing the molecules, running the assays, and waiting. A well-funded newcomer with the best available AI models and no proprietary data is, in this domain, a powerful engine with an empty fuel tank. This is exactly what Anzalone was describing.

IV. The Failures Are the Valuable Part

There is a subtlety here that is easy to miss and that turns out to be the heart of the matter. When we imagine a company’s accumulated knowledge, we tend to picture its successes: the molecules that worked, the programs that advanced, the drugs that were approved. The successes, however, are the smaller and less valuable part of the record. The larger and more valuable part is the catalog of failures, the hundreds of thousands of molecules that did not work, and the precise reasons why.

This is because designing a new molecule correctly is largely a matter of avoiding the ways molecules fail. Knowing that a particular chemical modification destabilizes a particular structural motif, that a given ligand fails to reach a given tissue above a certain molecular weight, that a certain sequence feature triggers an immune response, this negative knowledge is what allows a company to design the next molecule right the first time, skipping the dead ends that a less experienced competitor would have to discover for themselves. A dataset of successes tells you what worked once. A dataset of failures, comprehensive and decades deep, tells you the rules.

The failures are also the part that is most perfectly irreproducible. A competitor might, with effort, learn what worked for Arrowhead by reading its patents and its clinical disclosures, because successes get published and protected. Failures are never published. No company advertises the hundreds of molecules it abandoned or the modifications that backfired. That information exists in exactly one place, the internal records of the company that ran the experiments, and it is the information that matters most for designing the next generation of molecules. Fifteen years of failures, properly recorded, is not a liability or a sunk cost. It is the moat, and it is a moat made of precisely the material that cannot be observed from outside the company that owns it.

V. What Arrowhead Actually Has

Several features of Arrowhead’s history suggest it holds one of the richest such datasets in the industry, and the most distinctive feature is breadth. The dominant achievement in RNA interference delivery for most of the field’s history was the liver, where the asialoglycoprotein receptor offered a reliable route and where most of the approved RNAi drugs to date have acted. Arrowhead’s distinguishing strategic choice was to push delivery beyond the liver, into the lung, skeletal muscle, adipose tissue, and the central nervous system, with further frontiers in heart and the eye. Each new tissue required generating an entirely new body of empirical data about what delivers there and what does not. The result is that Arrowhead has likely generated the most diverse extrahepatic RNA interference delivery dataset in existence, because it has pursued more tissues, more aggressively, than competitors who remained concentrated on the liver.

The scale and the pace corroborate the picture. Arrowhead became a focused RNAi company in 2011, when it acquired Roche’s RNA interference assets and intellectual property, and built its proprietary TRiM platform after retiring an earlier delivery approach in 2016. Anzalone, reaching further back to include the predecessor delivery-science work, describes making hundreds of thousands of molecules over nearly twenty years. By either clock, the accumulated record is more than a decade deep and generated by a focused organization. The throughput is visible in the public record: from optimizing the TRiM platform for liver delivery in 2017, the company advanced eighteen drug candidates into clinical studies across multiple cell types by the end of 2023, a span of just six years. Management has described a cadence of reaching a new cell type every eighteen to twenty-four months. This pace is not merely a sign of productivity; it is the observable signature of the compounding effect described earlier. Each new program builds on the data generated by prior programs, which is what allows the cadence to be sustained rather than slowing as the easy targets are exhausted. Anzalone said as much years before the current AI conversation began, describing the platform’s ability to develop drugs in a way that is, in his words, predictable and reproducible, with each new program building upon prior programs in a way that could make them progressively lower risk.

That phrase, from a 2021 earnings call, is worth pausing on, because predictable and reproducible is the language of a manufacturing process, not a research gamble. It describes a company that has converted drug discovery, at least at the delivery and chemistry layer, from an artisanal endeavor into something closer to an engineering discipline, and the thing that makes that conversion possible is the accumulated data.

VI. Building the Asset

Honesty requires an important qualification. To say that Arrowhead possesses an extraordinary dataset is not to say that the company has already extracted its full value from it. The most likely picture, and the one the public evidence supports, is that Arrowhead already uses AI today but against data that is still substantially fragmented, which means that AI is doing specific, task-level work rather than drawing on the full sweep of the company’s accumulated experience at once. In 2026 Arrowhead posted a senior opening for an Executive Director of Artificial Intelligence and Enterprise Data Management, a role charged, in the posting’s own words, with transforming fragmented data into a strategic asset, building an enterprise data platform to integrate previously siloed systems, and scaling the company’s existing artificial intelligence efforts into a formal enterprise function. That posting tells us two things at once: AI is in use now, and the data it runs on is not yet unified.

Both halves matter, and they cut in opposite directions. The candid reading is that the data is currently scattered across siloed systems and is not yet consolidated into the clean, queryable, model-ready whole that the strongest version of this thesis imagines. The raw material exists, generated and retained over more than a decade, but the work of connecting it so that an AI engine can learn across all of it, rather than from one slice at a time, is underway, not finished. A skeptic is entitled to note that a company hiring someone to unify its data is a company that has not yet unified its data.

It is worth being precise about what that work involves, because the posting describes transforming fragmented data into a strategic asset, not merely consolidating it, and the distinction is the whole point. Unification is not just moving records into one place. It is curation: ensuring the data is clean and usable, and that anomalous results are identified and labeled as such rather than left to corrupt what a model learns. This is precisely the activity the data-centric principle identifies as the highest-leverage work in applied machine learning. A large dataset that is noisy, inconsistent, or unlabeled produces a poor model; the same dataset, curated and properly annotated, produces a far better one. The difference between a warehouse of raw material and a model-ready training asset is exactly this curation, which is why the unification effort, unglamorous as it sounds, is the step that converts Arrowhead’s accumulated record into something an AI engine can fully exploit.

The more important reading, though, is that the value here lies ahead of the company rather than behind it. The dataset, the irreproducible record of more than a decade of experiments, already exists and is already owned. What the new function will do is connect and curate the fragments so that AI can work across the whole, which is a different and far larger capability than running narrow queries against isolated pieces. For an investor or an acquirer, an asset in the middle of that transition is more interesting, not less, than a fully exploited one, because its value is not yet reflected in anything observable. The market cannot price the productivity gains from a data-unification effort that has barely begun. The seriousness of that effort, an executive-level hire, an enterprise mandate, generative and agentic AI deployed across functions, signals that management understands what it holds and intends to capitalize on it. The data is the proven part. What unification unlocks is the value still to come.

VII. Why Newcomers Cannot Replicate It

Return now to the popular thesis with which this paper began, that an AI decision layer will produce the next great pharmaceutical company. The difficulty with locating the moat in AI is that AI is the most replicable component in the entire stack. Foundation models are available by subscription. Machine learning talent is mobile. The architectures are published. Any well-capitalized entrant can assemble a sophisticated AI capability in months. If AI were the source of advantage, the advantage would be competed away almost immediately, because nothing about it is scarce.

The data is the opposite. It is the least replicable component in the stack. A newcomer cannot subscribe to a decade and a half of proprietary structure-activity results. It cannot hire them, because while talented people carry expertise, the dataset itself is institutional, embedded in records and systems rather than in any individual’s head. It cannot scrape them, because they were never public. It cannot buy them, because they are not for sale and the only entities that have them are precisely the competitors who would never sell. The data also enjoys a peculiar form of durability as intellectual property: unlike a patent, which is published and expires, a proprietary dataset can be held as a trade secret indefinitely, protected not by a legal monopoly with a clock on it but by the simple fact that no one else has it. That leaves the newcomer only one option, to generate the data itself, and the next section explains why that option fails.

This is why the framing matters so much. If you believe AI is the moat, Arrowhead looks like one of many companies adopting a widely available technology, and you would be right to wonder what protects it. If you understand that the data is the moat, Arrowhead looks like the owner of an asset that its competitors, including the best-funded AI-native entrants, structurally cannot acquire. The same set of facts supports opposite conclusions depending on which layer you believe is scarce. The argument of this paper is that the scarce layer is the data, and that this is not a matter of opinion but of which component can and cannot be replicated.

VIII. What the Acquirer Is Actually Buying

All of this becomes most concrete when viewed from the perspective of an acquirer, because the data asset changes what an acquisition of Arrowhead even is. Consider the two kinds of biopharmaceutical acquisition. In the first, an acquirer buys a company for a drug, or a small handful of drugs. The logic is straightforward: the buyer wants the revenue stream, integrates the asset, cuts what duplicates its own functions, and tries to capture the product as efficiently as possible. It is fundamentally a cost-minimization exercise applied to a static asset. The drug is worth what it is worth; the acquirer’s job is to pay a sensible price and absorb it cheaply. Whatever data came with that one drug is incidental, and as we will see, close to useless.

In the second kind of acquisition, the buyer acquires not a product but a productive capability: a platform engineered to generate many drugs, and, crucially, the accumulated data that makes the platform good at it. This is a different transaction in kind, not degree. The acquirer is not buying a static asset to absorb cheaply. It is buying a generative asset that will make drugs that are more potent, more durable, and better delivered, and that will make them faster, more efficiently, and at lower cost per program, for as long as the platform operates. The value is not the drugs in hand. The value is the permanently improved economics of every drug the acquirer will develop on the platform thereafter.

That triad is worth separating, because each part is a distinct source of value. Better drugs: the accumulated structure-activity data lets the designer reach for the chemistry and the ligand most likely to produce a potent, stable, durably-acting molecule, rather than rediscovering those choices program by program. Faster: the data eliminates the dead ends, compressing the time from target selection to a clinic-ready candidate, because the design space has already been mapped and the failures already catalogued. Cheaper: every dead end not pursued is money not spent, so a company designing from a deep empirical base burns less capital per candidate than one designing from scratch. The throughput documented earlier, the multi-tissue candidate cadence that competitors have not matched, is what these three forces look like when they operate together and are read off the public record.

Now the decisive contrast. The data that comes with a one-off drug acquisition is not merely smaller than Arrowhead’s; it is structurally the wrong kind of data to be useful in the way that matters. There are several reasons, and they compound. It is too small: a single program produces a handful of molecules and a narrow band of results, which is an anecdote, not a dataset an engine can learn from. It is success-skewed: a one-off that reached approval generated mostly the molecule that worked and abandoned the systematic exploration of failure long before, so it lacks precisely the negative examples that, as argued above, carry most of the design value. It is narrow: one target, usually one tissue, one chemical approach, so what it teaches does not transfer to the next target in a different tissue with different chemistry. It is also unstructured for learning: a one-off program optimizes toward a single answer rather than deliberately varying parameters and recording outcomes, so even the little data it generates is sparse and poorly shaped for training. An acquirer who buys a one-off drug to feed an AI engine has bought a few unrepresentative data points. An acquirer who buys Arrowhead has bought the dataset the engine was waiting for.

This reframes the premium. A skeptic looking at an acquisition of Arrowhead through the lens of the disclosed pipeline will see a high price for a set of programs and conclude the buyer overpaid. A buyer who understands the asset is paying for something the pipeline does not capture: a structural, permanent reduction in the cost and time of every future program, multiplied across decades of programs the platform will generate, plus a body of data that makes the buyer’s own AI investments actually work. That is not a premium for the drugs. It is the rational price of acquiring a generative capability that cannot be built, and it is invisible to anyone counting only the molecules currently on the chart.

IX. Why the Newcomer Cannot Catch Up

Generating the data itself is the newcomer’s only remaining path, and it is worth following that path to see where it leads, because doing so reveals that the data advantage is not merely a static barrier but a widening one. Grant the newcomer everything on the model axis: the best AI talent money can hire, the most capable models available, a large funding round. Grant that it matches or even exceeds Arrowhead on every dimension except the data. It still begins with an empty reservoir, because it has run almost no experiments, and the data-centric principle established earlier tells us what that means: a powerful model trained on little relevant data has a low performance ceiling, no matter how good the model is. The only way to raise that ceiling is to run the experiments.

Running them means building laboratories, synthesizing molecules, running assays, and waiting for results across the same long span that Arrowhead has already traversed. This is what makes the gap structural rather than temporary. While the newcomer spends years generating its first usable body of data, Arrowhead is not standing still. It is running its own experiments at its established cadence, adding to a lead that already measures more than a decade, and feeding the new results into an engine already trained on everything that came before. The newcomer is chasing a finish line that moves away at least as fast as the newcomer can run toward it.

Capital cannot collapse this gap, because the binding constraint is not money but accumulated empirical time, and experimental time cannot be parallelized beyond a point. You can hire more chemists, but biology runs on its own clock: assays take what they take, animal studies take what they take, and the iterative loop of design, test, learn, redesign cannot be compressed below the duration of the experiments themselves. A newcomer with unlimited funding still cannot run fifteen years of sequential, compounding experimentation in two. This is why the established position is not a head start that erodes as competitors catch up, the way a first product advantage often does. It is a lead that compounds, because the asset that produces the lead is itself the output of time, and the leader keeps accumulating time at the same rate as everyone else while remaining permanently ahead on total accumulation.

The conclusion is specific and defensible, and it is worth stating precisely so it is not mistaken for a broader claim. The point is not that Arrowhead’s eventual AI engine will be superior to every conceivable competitor, including other data-rich incumbents who have also spent years in the field. The point is narrower and more certain: against the AI-first newcomer, the entity the popular thesis imagines as the disruptor, the established RNAi developer with a deep proprietary dataset holds a structural advantage that the newcomer cannot close by any means available to it. The newcomer’s defining feature, that it is new, is precisely the feature that makes its position in this field hopeless, because in a domain where the data is the moat, being new means starting with an empty reservoir and no way to fill it faster than the incumbents fill theirs.

It is worth being honest about who this argument does not dispose of. The newcomer cannot catch up, but a data-rich peer is a different matter. Alnylam, with its own two decades of proprietary data and six approved drugs, is the one competitor whose dataset plausibly rivals Arrowhead’s, and its June 2026 partnership with Inceptive shows that such a peer can acquire frontier AI capability through a partnership rather than building it, and can do so quickly. The moat described in this paper is therefore a moat against new entrants, not against the handful of established RNAi developers who have also been accumulating data for twenty years. Among that small group the contest is real, and it is a contest on two fronts: the depth and breadth of the underlying data, where Arrowhead’s distinctive push across multiple tissues is its edge, and the speed of activating that data with capable models, where Alnylam has now moved first. This does not weaken the central thesis; it sharpens it. The scarce asset is the data, which is exactly why the meaningful competition has narrowed to the few who own a comparable amount of it, and why the relevant questions for Arrowhead are how its multi-tissue breadth compares and how quickly it completes the unification that turns its record into a fully usable asset.

X. Pressing the Advantage

So far the argument has been largely defensive: the data cannot be replicated, and the newcomer cannot catch up. That understates what the asset does, because a fast, data-rich design engine is not only a wall against competitors but a weapon for taking ground. The same capability that makes each molecule better and cheaper also lets Arrowhead win races that are decided by speed, and in this field many of the most valuable races are.

Consider what it means to reach a target first. In RNAi, as across drug development, the company that gets to a validated target ahead of the field captures advantages that compound: the first clinical data, the first regulatory dialogue, and often the controlling intellectual property on the most effective sequences and chemistries for that target. A design engine that compresses the time from target selection to a clinic-ready molecule means Arrowhead reaches more targets first, and converts each into a first-mover position, and the patents that defend it, before a slower competitor has nominated a candidate. The data advantage does not merely win the engineering contest. It wins the land grab that precedes it, fencing off the best targets and the best chemistry against them while the field is still deciding what to pursue.

Speed functions defensively as well as offensively. Because each new program costs less and moves faster, Arrowhead can profitably pursue targets that a slower, costlier competitor would deprioritize as marginal, which widens the set of opportunities it can credibly chase and narrows the white space left for everyone else. The same speed lets the company respond to a rival’s disclosed program by rapidly designing a differentiated or superior molecule against the same target, turning the tables on any would-be fast follower who assumed a head start would hold. In a field where being first confers durable advantage, the ability to move faster than anyone else is itself a form of protection, independent of the quality of any individual molecule.

These advantages feed one another. Every program Arrowhead runs first generates more data, which sharpens the engine, and more patents, which fence off more ground, which together let the company run the next program faster still. Speed produces data and intellectual property; data and intellectual property produce more speed. This is the same compounding loop described throughout this paper, viewed from the competitive rather than the technical angle, and it is why the advantage is best understood not as a fixed lead but as a flywheel that accelerates the further it turns.

XI. What It Is Worth

It is tempting, having argued that the dataset is irreproducible and that newcomers cannot catch up, to reach for a valuation, or to claim the data asset is worth more than any single drug program. Both temptations should be resisted, the first because any specific figure would be invented and the second because it misunderstands how the asset creates value. The data is not a standalone asset to be ranked against a drug. It is a multiplier on everything the company will ever do. Its value is not a number to be added to the pipeline; it is a factor that raises the expected value of every program in the pipeline, disclosed and undisclosed, present and future, by making each one faster, cheaper, and more likely to yield a viable molecule.

This is the right way to understand its relationship to the company’s lead clinical program. A successful readout for the lead central nervous system asset is a discrete, near-term, and largely quantifiable event: it validates the subcutaneous central nervous system thesis, de-risks a large portion of the pipeline, and is the most plausible trigger for an acquisition. The data asset is none of those things. It is diffuse, long-horizon, and resistant to quantification. The two are not competing claims on the title of most important thing about the company, because they operate on entirely different axes. The clinical catalyst is the event that most plausibly causes a sale. The data is one of the things that determines the price that sale clears at. The catalyst opens the door; the data is part of what is on the other side of it, and part of why an acquirer conducting genuine diligence pays a premium beyond what the visible pipeline alone would justify.

The most honest and the most powerful statement of the asset’s value is therefore not a dollar figure but a structural one: it cannot be bought at any price, because the only entities that possess comparable data will not sell it, and it cannot be built at any price, because building it requires a span of time that no amount of capital compresses. An asset that is simultaneously essential to the future of the modality and unavailable for purchase at any price is, in the most literal sense, priceless, not because its value is infinite, but because the market has no mechanism to put a price on a thing that cannot be transacted independently of the company that holds it. The only way to acquire it is to acquire Arrowhead.

XII. The Honest Limit

A thesis is only as credible as its acknowledged boundaries, and this one has a clear boundary that must be stated plainly. The data advantage described here de-risks the engineering problem, not the biology problem. It makes Arrowhead faster and more reliable at the task of designing a potent, stable, well-delivered molecule against a chosen target. It does not tell the company, or anyone, whether silencing that target will actually treat the disease in human beings. That is a question of biology and clinical reality, and no quantity of structure-activity data answers it.

This is why the data moat, however real, does not eliminate clinical risk. Arrowhead’s lead central nervous system program must still demonstrate in its clinical readout that silencing its target produces the intended biological effect, and that readout could disappoint regardless of how elegantly the molecule was designed. The dataset improves the odds and the speed of getting a good molecule to the clinic; it does not guarantee that the target was the right one. An honest version of this thesis holds both ideas at once: the engineering moat is large, durable, and underappreciated, and the biological risk on any given program remains, and remains irreducible by data alone. The data is an enormous advantage in the half of the problem it touches. It is silent on the other half.

XIII. Why the Market Cannot Price It

If the data asset is as significant as this paper argues, why is it largely absent from the analysis of Arrowhead’s value? The answer is structural, and it connects to a theme that runs through the broader analysis of this company. The standard tool for valuing a clinical-stage biopharmaceutical company is risk-adjusted net present value, which enumerates the disclosed programs, assigns each a probability of success and a projected peak revenue, and discounts the result. By construction, this method can only value what it can enumerate. It can value a named program with a definable market. It cannot value a dataset, because a dataset has no peak sales, no phase of development, no line on the pipeline chart. The compounding dataset is invisible to the very method most analysts use to value the company that owns it.

This is the same blind spot that causes conventional valuation to understate platform companies generally. A platform’s worth lies partly in the programs it has not yet disclosed and the efficiency with which it will generate them, and rigorous strategic valuation, the kind an acquirer actually performs, accounts for this where mechanical net present value cannot. The data asset is the most extreme case of the pattern, the part of the company most valuable to a strategic acquirer conducting genuine diligence and simultaneously the part least visible to the public market, because it appears on no financial statement and in no pipeline table. The acquirer values it because the diligence question is what the capability would cost to build; the public market overlooks it because there is no line on which to record a thing that has never been transacted.

XIV. Conclusion

The argument of this paper can be compressed into a single claim: in RNA interference, the scarce and durable asset is not the artificial intelligence but the proprietary experimental data that makes it work, and Arrowhead has spent more than a decade quietly accumulating one of the deepest such datasets in the field. Each strand of the argument reinforces the others. The data-centric principle establishes that data, not models, bounds performance in specialized domains. The modular nature of RNAi design makes that data compound rather than merely accumulate. The record of failures, the most valuable and most irreproducible part, can never be observed from outside. The asset’s breadth across tissues, finally, the consequence of Arrowhead’s choice to pursue delivery beyond the liver, makes it the most diverse dataset of its kind.

From those foundations the competitive and financial consequences follow with unusual force. A newcomer cannot catch up, because the only way to build the data is to spend the years, during which the incumbent pulls further ahead. The same engine that designs better molecules also wins the races decided by speed, reaching targets first and fencing them off. For an acquirer, the data is not a line item to be added to a pipeline valuation but a multiplier on every future program and a capability that cannot be bought or built at any price, which is precisely why it is invisible to conventional valuation and central to strategic value. None of this eliminates the biological risk that any individual program carries, a boundary this paper has been careful to mark. The data makes Arrowhead faster and more reliable at designing molecules; it does not choose the right targets for it. The edge, in the end, is not AI. The edge is the data behind it, and it has been compounding in plain sight, on no balance sheet, since the company became a focused RNAi developer in 2011.

There is a piece in chess that begins as the weakest on the board. The pawn moves one square at a time, slow and easy to ignore, and most of the attention in a game goes to the powerful pieces already in motion. A pawn that survives the long march to the far side of the board, however, does not stay a pawn. It becomes a queen, the most powerful piece in the game, and there is no way to rush it there: the pawn has to make every move, one rank at a time, and an opponent who starts that march late can never make up the distance.

Arrowhead’s data is that pawn. For fifteen years it has been advancing one molecule at a time, overlooked because it looked like the weakest thing on the board, the byproduct of the real work of making drugs. It is now deep in the far half, a step from the rank where it transforms into the most valuable asset the company owns. The market is still watching the powerful pieces, the pipeline, the platform, the approved drug. It has not yet noticed the pawn about to queen.

A Note on Supporting Independent Research

If this white paper has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this white paper; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This white paper is published by BioBoyScout and is intended for informational and analytical purposes only. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results. The reader is solely responsible for any investment decisions. The author and BioBoyScout are not registered investment advisors. All analysis is based on publicly available information, including company disclosures, conference presentations, and job postings, as of the date of publication. Quotations attributed to company executives are drawn from public conference and earnings call transcripts and should be verified against original sources before any use. The author assumes no obligation to update this paper or its conclusions.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

Robert Toczycki, JD, MBA
bioboyscout.com
bioboyscout@gmail.com
847.227.7909
X: @BioBoyScout

I. Executive Summary

The thesis. Every genetic medicine, on the market or in development, does one of two things to a patient’s biology. It makes a temporary change that can be stopped, or it makes a permanent change that cannot. That single distinction, reversible versus permanent, is the most important and most underpriced idea in the field today, and it is the subject of this paper.

The framework. Reversibility is a premium, not a consolation prize. When a reversible medicine can do the job for a given disease, the permanent option must clear a much higher bar, because permanence carries one risk the reversible option never will: if something goes wrong years later, it cannot be undone. The right mental model is a dial rather than an on/off switch. The dial turns toward permanence as a disease grows more severe and acceptable alternatives disappear, and it turns back toward reversibility as effective reversible options exist. This framework is anchored to the language of the FDA’s own gene editing guidance, which recommends reserving irreversible, first-in-human treatment for patients who have no available or acceptable alternative.

The case studies. Two diseases anchor the argument at opposite ends of the dial. PCSK9, the cholesterol target behind Eli Lilly’s permanent gene editing program acquired with Verve, sits at the wrong end: it is the most crowded target in cardiology, already served by statins, antibodies, and the twice-yearly reversible therapy inclisiran. The adherence problem that gene editing claims to solve has already been attacked reversibly, the residual gap is operational with further unused fixes such as a mailed home autoinjector, and the modest convenience of a single treatment cannot justify a permanent, irreversible change. Alpha-1 antitrypsin deficiency sits at the right end: its alternatives are poor, and a single mutation damages two organs in opposite ways, a problem only correction, not silencing, can address. Reversible RNA editing now does exactly that in humans, at protein levels associated with protection.

The investment view. If reversible correction is where a meaningful part of genetic medicine is heading, the investment question is who owns the rails. ProQR, a small Dutch company, holds the foundational, opposition-tested patents on the kind of RNA editing that performs this correction, which makes it a potential toll booth on the entire modality. Wave Life Sciences leads the clinic, having delivered the first human proof of RNA editing, and it may need to license rights from ProQR. The clearest confirmation that the framework is real comes from the demand side: Lilly owns both the permanent editing program and a reversible RNA editing collaboration with ProQR, treating the two not as rivals but as a portfolio matched to the disease.

The risks. The thesis carries real risks worth stating plainly. RNA editing is clinically young, with far less long-term human data than established gene silencing. ProQR’s broad patents could be narrowed or invalidated. Strong early gene editing data, combined with an FDA posture that increasingly favors acceleration, could overrun the alternatives argument in the marketplace regardless of its merits. The reader should weigh the framework against the possibility that momentum, not logic, decides the near term.

II. A Plain-Language Primer: Four Ways to Change a Gene

Start with a kitchen. To follow the argument, you only need one analogy, and it holds up surprisingly well.

Think of your DNA as a master cookbook locked in a vault. It contains every recipe your body knows how to make. When a cell wants to cook one dish, it does not drag the whole cookbook out. It makes a quick photocopy of the single recipe it needs. That photocopy is called RNA. The cell follows the photocopy to make the dish (a protein), then throws the photocopy away and makes a fresh one next time. The master cookbook in the vault never moves.

A genetic disease is usually a typo. Somewhere in the cookbook, one letter is wrong, so the photocopy is wrong, so the dish comes out wrong or even poisonous. There are four ways to deal with that typo, and they differ in one decisive way: whether you touch the disposable photocopy or the permanent cookbook.

Option one, RNA interference (RNAi), is silencing. This shreds the bad photocopy before the cell can cook from it. The dish simply does not get made. The master cookbook is untouched, and the moment you stop the medicine, the cell goes back to making photocopies as before. This is what Arrowhead Pharmaceuticals and Alnylam do. Inclisiran, the cholesterol drug also known as Leqvio, works this way, as does Arrowhead’s alpha-1 drug fazirsiran. It is fully reversible.

Option two, RNA editing, is correction. Instead of shredding the photocopy, this fixes the typo on the photocopy itself, so the dish comes out right. It does this by recruiting a tool the cell already owns, a natural spell-checker enzyme called ADAR, and pointing it at the exact letter that needs changing. Because you are only editing disposable photocopies, the change fades when you stop dosing. The master cookbook is still untouched. This is what Wave Life Sciences and ProQR do. It is also fully reversible.

Option three, base editing, is a permanent single-letter rewrite. Now you are no longer touching photocopies. You are walking into the vault and changing a single letter in the master cookbook itself. Modern base editing does this cleanly, changing one letter without cutting the book. Every photocopy from then on is correct, forever, after a single treatment. This is what Verve Therapeutics, now owned by Eli Lilly, does to the PCSK9 cholesterol gene. It is permanent. You cannot undo it.

Option four, nuclease (CRISPR) editing, is a permanent cut and patch. This is the original CRISPR approach. It cuts the cookbook at the target spot and lets the cell patch it. It is powerful, but cutting the book is a bigger disruption than changing one letter, and like base editing it is permanent. This is what the approved sickle cell therapy Casgevy uses.

Figure 1 lays the four side by side. The pattern to notice is simple and runs through the whole paper: as you move down the ladder, the change becomes more permanent, and the amount of unknown, long-tail risk goes up with it. Reversible options let you stop if something surprising shows up years later. Permanent options do not.

III. The Dial, Not the Switch: A Framework

How to choose. Two questions decide which rung of the ladder a given disease should use.

The first question is what job needs doing. If the problem is too much of a harmful protein, silencing it (RNAi) is enough. If the problem is a missing or broken protein that must be restored, you need correction (RNA editing) or a permanent rewrite (gene editing), because shredding photocopies cannot manufacture a working protein. Silencing and correcting are different jobs.

The second question is what alternatives already exist for that specific disease. This is where reversibility earns its premium. Reversibility is, in plain terms, the ability to change your mind. That ability is worth the most precisely when you know the least, and genetic medicine is young. We do not yet have decades of data on what a permanent edit does twenty or thirty years out. A reversible medicine lets a patient and doctor course-correct if a late problem appears. A permanent one does not offer that exit.

An analogy from chess. Chess players respect this instinct. The pawn is the only piece that can never move backward, so a careful player commits one only when the position leaves no better option, and keeps every other piece free to maneuver. A reversible medicine is a piece that can be repositioned. A permanent gene edit is a pawn that can never be called back.

What the FDA actually says. Regulators understand this. The U.S. Food and Drug Administration, in its January 2024 guidance on gene editing products, addresses exactly this point in its section on who should be enrolled in the first human trials. Because these products carry significant risks and uncertain benefits, the agency recommends that first-in-human gene editing trials generally enroll only patients for whom no other treatment option is available or acceptable. In plain terms: try the permanent, irreversible thing first on people who have nothing else that works.

Three details matter, and the paper will hold to them honestly. The recommendation is nonbinding guidance, not law. It applies specifically to first-in-human trials, not to the eventual marketed population. The phrase is available or acceptable, not merely available, which leaves room for argument about patients who have options on paper but are not well controlled by them. Even with those caveats, the principle is clear and it is the FDA’s own: irreversible risk should be reserved for situations where the alternatives have run out.

Put the two questions together and you get a dial, shown in Figure 2. It is not a ban on gene editing. It is a way to ask, for any given disease, how far toward permanence the situation actually justifies going.

IV. The Wrong End of the Dial: PCSK9 and One and Done

What is at stake. PCSK9 is a gene that raises LDL cholesterol, the bad kind tied to heart attacks and strokes. Turn PCSK9 down and LDL falls. People born with naturally low PCSK9 have low cholesterol for life and are strongly protected from heart disease. That genetic fact is the inspiration for trying to switch the gene off permanently.

What Verve and Lilly have. Eli Lilly acquired Verve Therapeutics in 2025 for roughly one billion dollars to obtain VERVE-102, a base editing medicine that permanently turns off PCSK9 in the liver with a single infusion. The early data are genuinely good, and this paper will not pretend otherwise. In the Heart-2 study reported in May 2026 and published in the New England Journal of Medicine, a single dose reduced PCSK9 by up to 88 percent and LDL cholesterol by up to 62 percent, with the effect lasting, no serious treatment-related adverse events, no dose-limiting toxicities, and no discontinuations to date. Lilly plans to begin a Phase 2 study by the end of 2026 and has built in 15 years of long-term safety follow-up.

In short, the science works. The question this paper raises is not whether it works. It is whether permanently editing a person’s DNA is the right tool for this particular disease, and the answer turns on the alternatives.

The crowded field. PCSK9 is the most crowded target in all of cardiology. A patient with high cholesterol already has a deep bench of effective, reversible options, shown in Figure 3. This is the opposite of a disease where the alternatives have run out.

Verve’s best argument: adherence. Verve’s strongest argument is not really about cholesterol numbers. It is about adherence. In the real world, patients stop taking chronic medicines. They miss doses, they quit within a year, and a drug that half of patients abandon prevents fewer heart attacks than its clinical trial suggests. A one-and-done treatment, the argument goes, cannot be abandoned, because there is nothing left to keep taking. This is a serious argument, and it deserves a serious answer rather than a dismissal.

The rebuttal. Here is the answer. The adherence problem in this drug class has already been attacked, reversibly, and the attack is on the market. Inclisiran is given as an injection twice a year, administered in a clinic by a provider. A patient cannot forget a medicine they do not self-administer and receive only every six months. Before reaching for a permanent edit to solve adherence, we should first ask how well the reversible twice-yearly option already solves it.

The honest answer, from real-world data, is that it helps a lot but does not fully solve the problem, and the exact numbers matter because they cut both ways. Figure 4 collects the main studies. A large U.S. claims analysis found that about 20 to 32 percent of inclisiran patients discontinued within a year, depending on how a missed dose is counted, compared with roughly 45 percent for the every-two-week antibodies. One head-to-head real-world study in Saudi Arabia found inclisiran persistence at nine months of about 58 percent, statistically no different from the antibody it was supposed to beat. The common drop-off point is the second dose at around day 90, which tells you the residual problem is patients not returning for an appointment, not patients forgetting a pill.

What this means. The claim that a reversible twice-yearly shot has fully solved adherence is therefore false, and this paper will not make it. Notice, though, what the residual problem actually is: people not showing up for an appointment. That is an operational problem, fixable with reminders and by folding the injection into routine visits, and it is fixable without permanently editing anyone’s DNA.

The unused lever: a home autoinjector. There is a further reversible fix that has not even been tried yet. Today, inclisiran is supplied as a prefilled syringe and is given in a clinic by a healthcare provider, and Novartis has promoted that twice-yearly, provider-administered model as itself an adherence feature, on the logic that the clinic, not the patient, controls the dose. The trouble is that this same design is exactly why the main drop-off happens when patients do not come back for the second visit. The obvious answer is not a permanent edit. It is a home autoinjector, a prefilled pen mailed to the patient, which is the very delivery model that GLP-1 medicines for obesity and diabetes have normalized for tens of millions of people. The technology is straightforward, because inclisiran is already a subcutaneous injection placed in the abdomen, upper arm, or thigh, the same route and sites those pens use. A patient who self-injects twice a year at home cannot miss a clinic appointment, because there is no appointment to miss. To be precise, no such home autoinjector for inclisiran is approved today, which is the point: it is an available, low-risk lever that has not yet been pulled.

The principle. The broader principle matters more than the single example. The reversible side of this contest still has several low-risk levers to close the adherence gap: the clinic model, a mailed autoinjector, appointment reminders, telehealth follow-up, or some combination of them, none of which requires changing a single letter of anyone’s DNA. When a problem can still be attacked with reversible tools that have not even been fully deployed, reaching first for the one tool that is permanent and cannot be undone is the weakest possible justification. The existence of unused reversible options is itself an argument against jumping to permanence.

The asymmetry. The decisive point is the trade itself. The extra benefit of a permanent edit over an already-good reversible option is real but modest: it closes a 20-to-30-percent adherence gap and spares a twice-yearly visit. The extra risk is categorical: you can never stop it. If a rare off-target effect or a slow problem appears years later, a reversible drug can be discontinued, and a permanent edit cannot. Modest extra benefit cannot buy categorical, permanent, irreversible risk. That asymmetry is the heart of the case.

The monitoring contradiction. There is a sharper version of the argument that uses Verve’s own premise against it. The FDA recommends up to 15 years of safety monitoring after a gene edit, to catch off-target and long-term effects. Now hold two claims together. Verve says these patients are too unreliable to keep taking a medicine. The 15-year monitoring plan assumes these same patients will reliably return for a decade and a half of follow-up. Both cannot be true. The patient too non-adherent for a twice-yearly injection is the worst possible candidate for 15 years of mandatory monitoring. Editing does not rescue the non-adherent patient. It gives them a single permanent change and then loses them to follow-up exactly as a prescription would lapse, except now there is an unmonitored permanent edit instead of a refill someone can simply restart.

The lifetime-exposure point. One more deflation. Verve’s grander pitch is that a permanent edit mimics being born with low PCSK9, and therefore delivers lifelong protection that a drug started in midlife cannot. The edit, however, is given to a middle-aged adult who has already accumulated decades of cholesterol exposure and, often, existing plaque. It does not reach back and undo those years. The real advantage over inclisiran, then, is not lifelong protection an injection cannot match. It is, once again, skipping the injections. The lofty framing collapses back into the convenience claim, and convenience cannot carry permanence.

Where Verve is right. Now the concession that makes the rest credible. There are real patients for whom one and done is not about convenience at all. People with the severe inherited form (homozygous familial hypercholesterolemia), patients dependent on blood-filtering apheresis, and patients in settings where returning every six months is genuinely not realistic, are cases where a durable single treatment can be a matter of survival, not comfort. For them the dial points toward permanence, and this paper concedes that cleanly. The argument has never been that gene editing should not exist. It is that the justification is strong at the severe end and grows weak as the target population widens toward ordinary, well-managed cholesterol.

The verdict. The concern, then, is not the drug. It is indication creep: the steady widening of an irreversible treatment from the severe patients who need it toward the large, well-served population who do not. The right posture is vigilance about that drift, not outrage at the medicine.

V. The Right End of the Dial: Alpha-1 and Why Fixing Beats Silencing

The textbook case. Alpha-1 antitrypsin deficiency, or AATD, is the cleanest illustration of why correction can beat silencing, and why the dial sometimes points decisively toward reversible RNA editing.

One typo, two opposite problems. AATD is caused by a single-letter typo in one gene, called the Z mutation. The remarkable thing is that this one typo causes two opposite problems in two different organs. In the liver, the misfolded protein piles up and becomes toxic; this is a problem of a harmful protein being present, a gain of bad function. In the lungs, the body lacks enough of the working protein that normally protects lung tissue; this is a problem of a good protein being absent, a loss of function. One typo, two opposite diseases.

Why silencing solves only half. This is exactly where the difference between shredding the photocopy and fixing it becomes decisive. Silencing (RNAi) shreds the photocopy of the bad gene. That clears the toxic protein out of the liver, which genuinely helps the liver. Shredding, however, cannot manufacture the good, working protein the lungs need. Silencing therefore solves the liver half of the disease and does nothing for the lung half. Figure 5 shows the split.

An honest note on Arrowhead. A point of intellectual honesty is required here, because the leading silencing drug for AATD is fazirsiran, which is Arrowhead’s own program, partnered with Takeda, and the author of this paper is long Arrowhead. Fazirsiran is a genuinely important and validated treatment. Before it, AATD liver disease had essentially no option but transplant, and fazirsiran addresses that real unmet need. The lung limitation described above is not a criticism of the drug or of Arrowhead’s execution. It is a property of the silencing approach applied to this particular two-sided disease. A fair framing presents fazirsiran as the validated liver treatment and notes the structural ceiling, rather than hiding either.

Why fixing wins here. Now the other side of the dial. RNA editing does not shred the photocopy; it fixes the typo, turning the bad Z protein back into the normal, working M protein. Conveniently, the Z mutation happens to be exactly the kind of single-letter change the ADAR spell-checker can reverse. Because you are restoring a working protein, you help both organs with one medicine, and because you are only editing disposable photocopies, the treatment stays reversible.

What Wave has shown. Wave Life Sciences has shown this in humans with WVE-006, partnered with GSK. In 2024 it became the first-ever RNA editing medicine to work in people, with the data deepening through 2025 and 2026. The numbers, in Figure 6, are not just a mechanism demonstration; they clear the level of protein associated with protection. Patients reached total AAT around 11.9 micromolar, above the roughly 11 micromolar protective threshold, with the newly produced working M protein making up about 64 percent of the total and the harmful Z protein cut by about 71 percent. The effect was sustained, dosing is roughly monthly and therefore reversible, and the body even raised its AAT output during infections, a dynamic, on-demand response that a fixed-dose protein infusion cannot match.

Why the dial points here. In AATD the alternatives are genuinely poor. The only approved treatment for the lung disease is weekly intravenous infusions of the protein (augmentation), a heavy burden, and the only option for advanced liver disease has been transplant. With alternatives that thin and a disease that needs a working protein restored in two organs at once, the dial points decisively toward reversible correction. This is the indication that proves the framework is not anti-editing. It is pro-fit: it sends each disease to the rung of the ladder that actually suits it.

VI. The Toll Booth: Who Owns RNA Editing

The investment angle. If reversible correction is where a meaningful slice of genetic medicine is heading, the investment question becomes: who owns the rails everyone has to run on? The answer points to ProQR.

ProQR’s position. ProQR invented the core idea of recruiting the cell’s own ADAR spell-checker with a guide molecule back in 2014, and filed its first patent that same year. Its broad U.S. patent covers, in effect, using any guide molecule that recruits the body’s own ADAR to make this kind of edit. Crucially, the breadth has been tested rather than merely granted: ProQR has beaten anonymous challenges (known as strawman oppositions) at both the European and Japanese patent offices, and its estate now spans more than a dozen patent families and dozens of individual patents. Patents that have survived determined attack are a far stronger moat than patents that have simply been issued. Figure 7 summarizes the estate.

The Wave question, stated carefully. Now the most important and most carefully stated claim in this section. Wave’s WVE-006, the alpha-1 success story, works by recruiting the body’s own ADAR, which is the very activity ProQR’s broad claims describe. On its face, that means Wave may need to license ADAR rights from ProQR. The emphasis belongs on may. There are three honest possible outcomes, and no one outside the parties knows which holds: Wave may have designed around ProQR’s specific claims, Wave or its partner may be able to invalidate them, or there may already be a licensing arrangement that has not been disclosed. The strongest counterweight is that GSK, Wave’s deep-pocketed partner, did its freedom-to-operate homework before committing 170 million dollars upfront and up to 525 million dollars in milestones for the alpha-1 program, which means it reached some conclusion on this question that it found acceptable.

The risk. The risk to ProQR’s side is the mirror image of its strength. The same breadth that makes the claims valuable also makes them a target. Broad claims invite invalidity challenges, academic work in the field predates some of the claims, and a serious challenge in the United States has not yet been resolved. A reader should treat the licensing question as open and as optionality, not as a settled infringement finding.

The reality check. A plain reality check keeps the thesis honest. Wave, not ProQR, leads the clinic in RNA editing today; ProQR’s own lead program, AX-0810, is only at the earliest stage of human testing, with initial target-engagement data due in the first half of 2026. In addition, RNA editing can only make certain letter changes, so it is not a universal fix. The ProQR case is therefore an intellectual-property and platform case, the toll booth on a road others are paving, not a claim that ProQR has the best drug in the clinic.

VII. The Tell: Lilly Owns Both Horses

Follow the money. The cleanest evidence that the reversible-versus-permanent framework is real comes not from any argument in this paper but from the behavior of the largest buyer in the field.

Eli Lilly owns Verve, the permanent PCSK9 editing program, and also has an RNA editing collaboration with ProQR, the reversible approach. The single most important company in the space is deliberately hedging across the exact line this paper draws. That is not a contradiction on Lilly’s part, it is portfolio logic. Lilly is betting that permanence and reversibility are not rivals to be chosen between, but different tools matched to different diseases, which is precisely the dial. When the biggest player treats your framework as its acquisition strategy, the framework is not a thesis anymore, it is the market structure.

VIII. The Drifting Standard

A tension worth naming. The framework has a complication on the regulatory side that an honest paper has to put on the table, because it cuts against the argument as much as for it.

What the guidance says. On one hand, the FDA’s written guidance encodes real caution. It reserves first-in-human gene editing for patients with no available or acceptable alternative, and it reserves its fastest approval lane, accelerated approval, for serious or life-threatening diseases that lack available alternatives. Read literally, that restriction does work against permanent editing in a crowded, well-served target like broad-population cholesterol, because such a population is hard to describe as lacking alternatives.

What the agency does. On the other hand, the agency’s posture in practice has leaned hard toward acceleration. Peter Marks, who ran the relevant FDA center until his resignation in March 2025 and was the field’s most prominent champion, publicly described base editing as a potential game changer, not only for rare diseases but for more common ones. He did note that as gene therapy moves toward common diseases, the FDA and payers may prefer traditional approval over the fast lane. Industry, for its part, pushed back on any hint that gene editing should face a higher hurdle, and the agency accommodated rather than doubled down. The leadership that followed has leaned further into speed.

On the word convenience. The honest read is that the caution in the FDA’s own guidance is in tension with the FDA’s own acceleration agenda. That makes the critique here one about a drifting standard, not about a villainous company. It also disciplines the argument in one specific way worth stating plainly. The FDA has not said that convenience can never justify approval, and it would be wrong to claim it did. Better adherence is a real, recognized clinical benefit, not a mere comfort. The defensible point is narrower and stronger: improving adherence is a benefit, but a modest one when a reversible twice-yearly option already exists, and the agency’s own pathway design reserves its fastest lane for serious, no-alternative diseases, which leaves broad-population editing to clear the longest, hardest path, full traditional approval on hard cardiovascular outcomes, the very evidence the reversible alternatives already carry.

IX. What to Watch, and What It Means for Investors

The catalysts. Several near-term events will test this framework in public, and they are worth tracking together rather than one at a time. Figure 8 lists the main ones.

Implications, stated as considerations. The following are factual considerations for a reader’s own analysis, not recommendations, and the author is not a financial advisor.

The reversible modalities, RNAi and RNA editing, are the category with the more forgiving risk profile and, in many diseases, the better fit, because they preserve the option to stop. ProQR is the intellectual-property toll booth on RNA editing if its claims hold, with the licensing question as the key swing factor. Wave is the clinical leader in ADAR editing today and the company that has put the first human proof on the board. Arrowhead remains the leader in RNAi, and its alpha-1 drug fazirsiran is a validated liver treatment; the lung limitation in AATD is a feature of the silencing approach for that disease, not a company-specific weakness.

Risks to the thesis. Several stand out, and each deserves honest weight. RNA editing is clinically young, with far less long-term human data than RNAi. ProQR’s broad claims could be narrowed or invalidated, which would deflate the toll-booth case. Strong VERVE-102 data combined with the FDA’s acceleration agenda and payer interest in one-time treatments could simply overrun the alternatives argument in the marketplace, regardless of its merits. A reader should weigh the framework against the possibility that momentum, not logic, decides the near term.

X. Conclusion

Reversibility is a premium, not a consolation prize. When a reversible medicine can do the job, a permanent edit must clear a much higher bar, because permanence carries one risk nothing reversible does: it cannot be undone, and in a field this young, the ability to change your mind is worth a great deal.

PCSK9 is the wrong end of the dial. It is the most crowded target in cardiology, its adherence problem has already been attacked reversibly and has obvious reversible fixes still unused, such as a mailed home autoinjector of the kind GLP-1 medicines made routine, the extra benefit of permanence is modest, and the patients least likely to stay adherent are the least suited to fifteen years of mandatory post-edit monitoring. Alpha-1 antitrypsin deficiency is the right end. Its alternatives are poor, it needs a working protein restored in two organs at once, and only correction, not silencing, can do that, which reversible RNA editing now does in humans at protective levels.

The companies that own reversible correction sit on the right side of that line: ProQR on the patents, if they hold, and Wave in the clinic. The clearest confirmation comes from the biggest buyer: Eli Lilly owns both the permanent horse and the reversible one, treating the dial not as a debate but as a portfolio. The question for the field, and for investors, is not whether gene editing should exist. It is how far down the severity gradient permanence should be pushed before the trade stops making sense, and on the evidence today the field is pushing it too far, too fast, for diseases that do not need it.

Chess offers the right picture to close on. The pawn is the only piece that can never move backward, which is why a careful player pushes one only when the position truly demands it. Gene editing is the pawn move of genetic medicine: sometimes necessary, always permanent, and never worth spending on mere convenience. Right now the field is pushing pawns to save a tempo it has not lost. The smartest move, in medicine and in markets alike, is the one you can still take back.

Appendix A. Glossary

ADAR. The body in your DNA’s master cookbook analogy. A natural spell-checker enzyme that the body already makes, which RNA editing recruits to fix a single letter on an RNA photocopy.

Base editing. Permanently changing a single DNA letter without cutting the DNA. Used by VERVE-102. Not reversible.

Nuclease (CRISPR) editing. Permanently cutting and patching DNA at a target site. The original CRISPR approach. Used by Casgevy. Not reversible.

LDL cholesterol. The bad cholesterol most tied to heart attacks and strokes.

PCSK9. A gene that raises LDL cholesterol. Turning it down lowers LDL.

RNA interference (RNAi). Shredding the RNA photocopy so a protein is not made. Silencing. Reversible. Used by inclisiran and fazirsiran.

RNA editing. Fixing the typo on the RNA photocopy so the right protein is made. Correction. Reversible. Used by Wave’s WVE-006 and ProQR’s Axiomer.

Alpha-1 antitrypsin deficiency (AATD). A genetic lung and liver disease caused by one typo (the Z mutation) that creates two opposite problems: toxic protein in the liver and too little working protein in the lung.

Adherence and persistence. Whether a patient keeps taking a medicine as prescribed over time. Persistence is the share still on treatment after a set period.

Appendix B. Sources

All figures and data points draw on the public sources below, each linked to its canonical page. Quotations have been avoided in favor of paraphrase; figures cite their sources in the captions above.

1. Eli Lilly and Company. VERVE-102 Heart-2 Phase 1b results, investor release, May 25, 2026. https://investor.lilly.com/news-releases/news-release-details/single-dose-lillys-pcsk9-base-editor-verve-102-reduced-pcsk9-88

2. In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia. New England Journal of Medicine, May 25, 2026. https://www.nejm.org/doi/full/10.1056/NEJMoa2601283

3. Eli Lilly and Company. Completion of the acquisition of Verve Therapeutics, investor release, July 25, 2025. https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-verve-therapeutics-advance-one-time

4. Verve Therapeutics. Lilly to acquire Verve Therapeutics; terms of about 1.0 billion dollars at closing and up to about 1.3 billion dollars with the contingent value right, June 17, 2025. https://vervetx.gcs-web.com/news-releases/news-release-details/lilly-acquire-verve-therapeutics-advance-one-time-treatments

5. Wave Life Sciences. First-ever therapeutic RNA editing in humans achieved in the RestorAATion-2 trial of WVE-006, October 16, 2024. https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announces-first-ever-therapeutic-rna-editing

6. Wave Life Sciences. RestorAATion-2 update, 200 mg and 400 mg cohorts of WVE-006, September 3, 2025. https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announces-positive-update-ongoing

7. Wave Life Sciences. RestorAATion-2 update, MZ-like phenotype across biweekly and monthly dosing of WVE-006, May 18, 2026. https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announces-positive-update-restoraation-2

8. ProQR Therapeutics. Successful defense of patent EP 3234134 B1 at the European Patent Office against two strawman oppositions, March 14, 2023. https://www.proqr.com/press-releases/proqr-announces-successful-defense-of-a-key-axiomerr-patent-protecting-adar-mediated-rna-editing

9. ProQR Therapeutics. Japanese Axiomer patent JP 7244922 upheld after opposition; estate then exceeding 13 patent families and 27 patents, February 15, 2024. https://www.proqr.com/press-releases/proqr-announces-japanese-axiomertm-patent-upheld-following-opposition-against-its-leading-ip-estate-for-adar-mediated-rna-editing

10. ProQR Therapeutics. Successful defense of patent EP 3507366 B1 at the European Patent Office, April 19, 2024. https://www.proqr.com/press-releases/proqr-achieves-successful-defense-of-new-challenge-to-its-axiomertm-ip-portfolio

11. ProQR Therapeutics. AX-0810 Phase 1 safety and pharmacokinetic data, 2026 outlook, and Eli Lilly collaboration milestones; target-engagement data expected in the first half of 2026, January 8, 2026. https://www.proqr.com/press-releases/proqr-announces-encouraging-ax-0810-phase-1-safety-and-pk-data-development-candidate-selections-and-2026-outlook

12. ProQR Therapeutics. Year-end 2025 operating and financial results; about 92.4 million euros cash and runway into mid-2027, March 12, 2026. https://www.proqr.com/press-releases/proqr-announces-year-end-2025-operating-and-financial-results

13. Eli Lilly and Company. Expansion of the RNA editing collaboration with ProQR using the Axiomer platform, December 22, 2022. https://investor.lilly.com/news-releases/news-release-details/lilly-and-proqr-expand-rna-editing-collaboration

14. Treatment patterns among early inclisiran versus anti-PCSK9 antibody users, a US Komodo Health claims analysis; 12-month discontinuation 31.6 percent and proportion of days covered 0.77. Heart, Lung and Circulation, 2024. https://www.heartlungcirc.org/article/S1443-9506(24)01567-1/fulltext

15. Adherence and persistence of twice-yearly inclisiran versus twice-monthly evolocumab in Saudi Arabia, the Twice study; 9-month persistence 58.4 versus 59.8 percent. Atherosclerosis, 2025. https://www.atherosclerosis-journal.com/article/S0021-9150(25)01008-1/fulltext

16. Inclisiran efficacy in the real world, systematic review and meta-analysis; about 43 percent LDL-C reduction versus about 52 percent in trials, 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12194546/

17. VICTORION-INITIATE, a randomized inclisiran-first versus usual-care implementation trial; LDL-C reduction about 60 percent versus 7 percent at day 330, goal attainment more than tripled, statin discontinuation noninferior. Journal of the American College of Cardiology, 2024. https://www.jacc.org/doi/10.1016/j.jacc.2024.03.382

18. Novartis. Leqvio (inclisiran) receives FDA approval for first-line monotherapy, describing twice-yearly, healthcare-provider-administered dosing, July 31, 2025. No home autoinjector or patient self-administration is approved to date. https://www.novartis.com/us-en/news/media-releases/novartis-twice-yearly-leqvio-inclisiran-receives-fda-approval-new-indication-enabling-first-line-use

19. U.S. Food and Drug Administration. Human Gene Therapy Products Incorporating Human Genome Editing, final guidance, January 30, 2024, Federal Register notice. https://www.federalregister.gov/documents/2024/01/30/2024-01788/human-gene-therapy-products-incorporating-human-genome-editing-guidance-for-industry-availability

20. U.S. Food and Drug Administration. Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products, June 2015. https://www.fda.gov/media/106369/download

21. U.S. Food and Drug Administration. Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing, draft guidance, April 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-assessment-genome-editing-human-gene-therapy-products-using-next-generation-sequencing

22. U.S. Food and Drug Administration. Press announcement on the genome-editing next-generation-sequencing draft guidance and the agency’s innovation posture, April 2026. https://www.fda.gov/news-events/press-announcements/fda-issues-draft-guidance-genome-editing-safety-standards-advance-gene-therapy-development

23. Hogan Lovells. Summary of the FDA webinar on the finalized 2024 genome-editing guidance, including study-population and accelerated-approval recommendations. https://www.hoganlovells.com/en/publications/how-to-navigate-gene-editing-regulatory-hurdles-fda-webinar-clarifies-newly-finalized-guidance

24. Peter Marks on base editing as a potential game changer for rare and more common disease. Fierce Biotech, 2023. https://www.fiercebiotech.com/biotech/peter-marks-says-base-editing-could-be-incredible-game-changer

25. Peter Marks on traditional approval as gene therapy turns toward more common diseases. Fierce Biotech, May 2024. https://www.fiercebiotech.com/biotech/preventing-3-billion-visits-fda-year-cbers-peter-marks

26. Cell and gene therapy loses a champion at the FDA: resignation of Peter Marks as Director of the Center for Biologics Evaluation and Research, March 2025. BioPharma Dive. https://www.biopharmadive.com/news/peter-marks-cell-gene-therapy-champion-fda-departure/744026/

A Note on Supporting Independent Research

If this white paper has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

· all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;

· he was not compensated in any form for producing this white paper; and

This white paper is published by BioBoyScout and is intended for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss. All financial projections, acquisition price estimates, and valuation analyses herein are hypothetical frameworks for analytical purposes and do not represent predictions of actual outcomes. Readers should conduct their own due diligence and consult a registered investment advisor before making investment decisions. All data cited herein were sourced from publicly available company disclosures, SEC filings, press releases, and peer-reviewed literature as of June 2026.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

A Deep-Dive Conviction Analysis of ARO-MAPT’s Phase 1/2a Readout Across Three Lines of Evidence, Twelve Primate Brain Regions, and a 50-70 Percent CSF Tau Reduction Range

Robert Toczycki, JD, MBA
bioboyscout@gmail.com
847.227.7909
X: @BioBoyScout

Arrowhead Pharmaceuticals will read out human Phase 1/2a data for ARO-MAPT, its subcutaneous tau-lowering drug for Alzheimer’s disease, in the second half of 2026. The case for a position before that readout rests on three converging lines of preclinical and clinical evidence: a tau target already clinically validated by BIIB080, a subcutaneous transferrin-receptor (TfR1) delivery route structurally better matched to the deep brain regions where Alzheimer’s pathology starts, and primate data predicting a 50 to 70 percent cerebrospinal fluid tau reduction in humans. This is corroborated by Arrowhead’s revealed-preference behavior across partnership structure, CNS portfolio expansion, and manufacturing capacity options. The argument is not that ARO-MAPT cannot fail, the argument is that the structure of evidence assembled to date justifies meaningful conviction in the readout, well above the generic Phase 1 base rate.

Companion to The Endgame, the fourth paper in the BioBoyScout white paper series

Executive Summary

Arrowhead Pharmaceuticals will read out human Phase 1/2a data for ARO-MAPT, its subcutaneous tau-lowering drug for Alzheimer’s disease, in the second half of 2026. The case for entering a position before that readout rests on three converging lines of preclinical and clinical evidence, assembled across two and a half years of progressively detailed scientific disclosure, corroborated by Arrowhead’s own revealed-preference behavior.

The tau target is de-risked. BIIB080, a competitor drug developed by Biogen and Ionis using intrathecal delivery, has demonstrated in a 46-patient Phase 1b trial that lowering tau in Alzheimer’s patients produces 63 to 67 percent reductions in cerebrospinal fluid tau, reductions in aggregated tau pathology across all six brain regions scanned, and directional cognitive trends matching the approved amyloid antibodies. The biology has been validated by a competitor. ARO-MAPT inherits that validation.

The delivery route is structurally superior to the established alternative. Subcutaneous injection through Arrowhead’s transferrin-receptor-mediated platform distributes drug uniformly across brain tissue. Intrathecal injection produces a surface-to-deep gradient with weakest concentrations in the deep medial temporal regions where Alzheimer’s pathology starts. Arrowhead’s primate data, presented at the December 2025 CNS Delivery Summit, shows 70 to 80 percent tau messenger RNA reduction across all twelve brain regions tested, including the deep regions intrathecal struggles to reach.

A successful Phase 1/2a is sufficient as a strategic catalyst. Subcutaneous delivery of RNA interference (RNAi) drugs to the brain has been the largest unsolved problem in the modality for two decades. Arrowhead is the company that built the platform that solves it. ARO-MAPT is the first drug on the platform to enter the clinic, with dosing under way as of December 2025. SRP-1005 (formerly ARO-HTT, licensed to Sarepta) is the second clinical program, with first-in-human dosing planned for the second quarter of 2026. ARO-SNCA (licensed to Novartis at the preclinical stage) is the third. As of April 2026, ARO-MAPT remains the only clinical-stage subcutaneous RNAi CNS program in development; the most recent independent preclinical disclosure of the same mechanistic configuration (Dyne Therapeutics, April 27, 2026) is years from human dosing and is being positioned for partnership rather than internal advancement. The 2026 ARO-MAPT readout would be the first human clinical validation of the platform. Once that validation arrives, every potential pharmaceutical acquirer faces both the offensive question (how much is the platform worth to acquire) and the defensive question (how much is it worth to keep it from a competitor). Novartis and Sarepta have already committed substantial diligence-stage capital against the platform; the price of clinical validation will sit on top of those commitments. Section IV develops the platform argument and partnership economics in detail.

The case is corroborated by Arrowhead’s revealed-preference behavior. The company retained ARO-MAPT and the broadest tauopathy indications while monetizing the periphery through Novartis and Sarepta partnerships, has staked seven CNS programs across the platform before any human validation, and holds a 6.24-acre land option adjacent to its Verona manufacturing facility that expires in 2028, the binding decision on which sits in management’s hands roughly eighteen months after the readout. Each is a forward commitment of capital or commercial intent that only makes sense if leadership believes the platform will be validated.

The case is not without risk. The primate-to-human translation could fail. The cognitive benefit suggested by BIIB080’s directional Phase 1b data may not replicate at scale. The Phase 1/2a sample size is small enough that a noisy result is possible. The history of failed anti-tau antibody programs creates a default skepticism that is reasonable. The Bottom Line section addresses each of these risks in detail. The honest framing is that the case justifies meaningful conviction, not certainty.

I. The Question

A. Why This Paper Exists Now

Arrowhead Pharmaceuticals has been disclosing scientific progress on its central nervous system program at increasing levels of detail for two and a half years. The company has presented at four separate venues, with each disclosure adding meaningful new evidence over the prior one. The first came at the June 2023 Analyst R&D Day, where Arrowhead introduced its blood-brain-barrier-crossing TRiM platform with preliminary mouse data showing 80 to 90 percent knockdown via subcutaneous administration and primate data showing 72 percent knockdown across all brain regions, including the deep brain. The second came at TIDES USA in May 2024, where Christine Esau, the company’s Vice President of Biology, presented the same platform to a scientific delivery-focused audience, confirming continued internal commitment to the subcutaneous CNS approach. The third came at the RNA Leaders USA Congress on September 10, 2025, where Esau presented the first ARO-MAPT-specific dataset: a head-to-head primate comparison showing subcutaneous administration produces uniform deep-brain knockdown while intrathecal does not, MAPT messenger RNA reductions across twelve primate brain regions, and a 65 percent cerebrospinal fluid tau reduction sustained after four months of repeat dosing in non-human primates (Source: Esau, RNA Leaders USA Congress, September 10, 2025, slide 20). On the same day, Arrowhead disclosed that it had filed the Clinical Trial Application in New Zealand for the human Phase 1/2a study. The fourth, and most detailed to date, came at the 7th Annual CNS Delivery Summit on December 10, 2025, where Agnieszka Glebocka, Ph.D., the company’s Vice President of Discovery Chemistry, presented the full scientific package: 70 to 80 percent MAPT messenger RNA reduction across all twelve brain regions tested, 50 to 60 percent cerebrospinal fluid tau reduction sustained for five months, and the dosing schedule for the human program.

Figure 1. Two and a half years of progressively detailed scientific disclosure on Arrowhead’s subcutaneous CNS platform, from the June 2023 Analyst R&D Day (mouse and preliminary primate data) through the December 2025 CNS Delivery Summit (full ARO-MAPT preclinical package). The 2H 2026 Phase 1/2a readout is the next disclosure milestone.

Across these four disclosures, the underlying data has been internally consistent and progressively more rigorous. The story Arrowhead is telling in December 2025 is the same story it began telling in June 2023, but with more detailed scientific evidence at each step and with ARO-MAPT-specific data emerging in September 2025. This pattern is meaningful. It suggests the company has been confident enough in its central nervous system platform to keep disclosing publicly, in increasing detail, for two and a half years. It also suggests that the December 2025 data should not be interpreted as a one-off slide deck. It is the latest milestone in a steady, publicly visible scientific program that began with mouse data in 2023 and has now produced primate data sufficient to support a human clinical trial.

The Endgame, the fourth paper in the BioBoyScout white paper series, asked what Arrowhead Pharmaceuticals would be worth if ARO-MAPT succeeds. The answer ran 84 pages: a 12-asset inventory, strategic value analysis methodology, competitive bidder landscape, fully diluted per-share acquisition price math. The valuation work was done. What was not done was the harder question that every reader of The Endgame eventually asked: how confident should we be that ARO-MAPT will succeed in the first place?

That is the question this paper answers. The Setup is not a valuation paper. The Endgame already did that work, and that work stands on its own. This paper takes the valuation case as given and assembles the evidence that supports the underlying clinical event: a strong cerebrospinal fluid tau readout in the second half of 2026. The reader’s job is to weigh the evidence and arrive at their own level of conviction. The paper’s job is to lay out the evidence as completely and as honestly as the available data allows.

B. What This Paper Is Not

Three things this paper is not. First, it is not a valuation paper. The Endgame did that work, and readers who want the per-share acquisition math should read that paper. This paper is about the underlying clinical event. Second, it is not a forecast of what ARWR stock will do in the second half of 2026. The realized stock price will depend on the actual readout, on the market’s reaction, and on broader conditions outside the scope of this paper. Third, this is not a paper that argues ARO-MAPT cannot fail. It can. The Bottom Line section acknowledges the residual risks, including primate-to-human translation, the small sample size of the Phase 1/2a, and the historical track record of anti-tau drugs in Alzheimer’s disease. Each risk is real. The argument is not that failure is impossible, the argument is that the structure of evidence assembled to date justifies a meaningful level of conviction in the readout, well above the generic Phase 1 base rate.

With those caveats made explicit, the paper assembles its case across the rest of the sections. The paper begins with the strongest argument, that the underlying tau biology has already been clinically validated by a competitor, and builds from there. By the time the reader reaches the synthesis sections, the argument should land naturally. The reader can then apply their own judgment to the strength of the evidence as a whole.

The 2026 readout will produce its own answer. This paper is about what the appropriate level of conviction should be when that answer arrives, and what the structure of the evidence already assembled tells us about how to weigh that answer.

The Endgame asked what ARWR would be worth if ARO-MAPT succeeds. The Setup asks how confident we should be that ARO-MAPT will succeed. The scientific answer is built on four publicly disclosed scientific presentations spanning two and a half years, on independent peer-reviewed primate work characterizing how each delivery route performs in the brain, on the clinically validated tau biology that a competitor has already demonstrated, and on the structural anatomy of how drugs distribute through the brain. That scientific case is corroborated by Arrowhead’s own revealed-preference behavior in partnership structure, CNS portfolio expansion, and manufacturing capacity options. The readout in the second half of 2026 will produce the verdict. This paper is about how to read it when it arrives.

II. The Tau Target Is De-Risked

A. The Bottom Line First

Someone else’s drug already proved that tau works as a target in Alzheimer’s disease. That drug is BIIB080, developed by Biogen and Ionis, and its Phase 1b trial in 46 mild Alzheimer’s patients produced the strongest body of clinical evidence any tau-targeting therapy has ever generated. By the end of the long-term extension, BIIB080 had reduced cerebrospinal fluid tau by 63 to 67 percent at the high doses, reduced aggregated tau pathology across all six tau positron emission tomography regions of interest scanned, and produced cognitive trends in the same range as the approved amyloid antibodies.

This matters for ARO-MAPT for one specific reason. The hardest question any new drug has to answer is whether the underlying biology actually works, whether changing the target produces the disease benefit the developer claims it will. BIIB080 has answered that question. The biology works. Tau lowering produces measurable, sustained biomarker effects in real patients with real Alzheimer’s disease.

ARO-MAPT does not have to discover that tau works. BIIB080 already did the discovery. ARO-MAPT only has to demonstrate that its specific molecule, delivered through subcutaneous injection rather than spinal injection, can match what BIIB080 achieved. That is a fundamentally easier question to answer than the one most Phase 1/2a candidates face. Most Phase 1/2a candidates are simultaneously asking whether the target works and whether their molecule works. ARO-MAPT is only asking the second question.

This section walks through what BIIB080 actually showed, what those results mean for ARO-MAPT, and why the question of clinical success in 2026 is structurally different from a generic Phase 1/2a coin flip.

B. What “Target De-Risked” Actually Means

Drug development asks two separate questions. First: does changing this molecular target actually help the patient? This is the target validation question, and it is a question about biology. Second: can this particular molecule, with its specific chemistry and delivery profile, change the target effectively and safely? This is the compound validation question, and it is a question about a specific drug.

These two questions fail in different ways. Drugs fail target validation when the underlying science turns out to be wrong, the disease isn’t actually caused by what we thought it was caused by. Drugs fail compound validation when the science is right but the specific molecule has problems: it can’t reach the target tissue, it has off-target effects, it can’t be dosed at therapeutically relevant levels, it triggers an immune response.

BIIB080 separated these two questions for ARO-MAPT. Because BIIB080 already demonstrated that lowering tau produces measurable disease-relevant effects, the target validation question for ARO-MAPT is largely answered before the trial begins. The Phase 1/2a in 2026 is testing the compound validation question for ARO-MAPT specifically. That is a meaningful and answerable question, but it is not the same question as testing whether the underlying biology works.

C. What BIIB080 Actually Showed

BIIB080 (also called MAPTRx) is a spinal-injection drug developed by Biogen and Ionis. Technically it is an antisense oligonucleotide (ASO), a synthetic strand designed to bind and silence the messenger RNA that codes for tau protein. Mechanistically, BIIB080 works through different molecular machinery than ARO-MAPT (Section III explains the difference), but both drugs target the same underlying biology: lower tau messenger RNA, lower tau protein, lower tau pathology in the brain.

The BIIB080 Phase 1b trial enrolled 46 patients with confirmed mild Alzheimer’s disease across 12 centers in Canada, Finland, Germany, the Netherlands, Sweden, and the United Kingdom. Patients received the drug by spinal injection, with the highest doses administered every three months. The trial ran for an initial 36-week placebo-controlled phase (13 weeks of dosing followed by a 23-week post-dosing follow-up), and patients could then enter a long-term extension where every patient eventually received the active drug. The headline results, published in Nature Medicine in 2023 and presented at a major Alzheimer’s conference later that year, are striking.

Three results matter for the ARO-MAPT thesis. First, BIIB080 produced large, sustained, dose-dependent reductions in cerebrospinal fluid tau, in the 63 to 67 percent range at the high doses, after roughly two years of follow-up. This is not a marginal effect. It is one of the largest pharmacodynamic effects any central nervous system drug has demonstrated in mild Alzheimer’s disease, comparable in pharmacological terms to what the approved ALS drug tofersen achieves. Second, BIIB080 reduced aggregated tau pathology measured by tau positron emission tomography. The reductions were present across all six prespecified regions of interest, including the deep medial temporal lobe where Alzheimer’s pathology starts. Tau positron emission tomography is a regional measurement, not whole-brain, so the precise framing is that all six imaged regions showed reductions, not that every neuron in the brain was reached.

Third, BIIB080 produced directional cognitive benefits suggestive of clinical activity. When the Phase 1b participants were compared against a matched control group drawn from the contemporaneous TANGO trial, the high-dose patients showed approximately 2.0 to 2.4 points of advantage on the Clinical Dementia Rating Sum of Boxes scale at week 100, against an estimated TANGO placebo decline of approximately 3.1 points. Two important caveats apply. The Phase 1b sample of 46 patients was too small for those differences to reach statistical significance. The TANGO comparator group was not randomized to BIIB080, so the comparison is hypothesis-generating rather than benefit-quantifying, the kind of analysis that motivates a properly powered Phase 2 trial rather than substituting for one. With those caveats acknowledged, the direction was consistent across every clinical scale measured, and the magnitude, if reproduced under randomized conditions, would substantially exceed what the approved amyloid antibodies achieved, lecanemab at 27 percent slowing on the same scale and donanemab at 36 percent. The properly powered test of whether tau lowering produces statistically significant cognitive benefit is the BIIB080 Phase 2 (CELIA) study, which reads out in mid-2026.

D. Why This Matters for ARO-MAPT

The BIIB080 dataset establishes three things that flow directly into the ARO-MAPT investment thesis.

First, tau lowering is achievable in real Alzheimer’s patients. This is no longer a hypothesis. There is a published clinical trial showing it in 46 humans. ARO-MAPT does not need to discover this. ARO-MAPT only needs to demonstrate that its molecule, delivered through its route, achieves comparable effects in its trial.

Second, tau lowering translates into measurable downstream effects. The cerebrospinal fluid tau reduction was not an isolated biomarker. It was accompanied by reductions in phosphorylated tau (the form most directly linked to Alzheimer’s pathology), by reductions in aggregated tau across the brain regions where the disease actually lives, and by directional cognitive benefits that pattern-match the approved amyloid antibodies. The chain from messenger RNA reduction to cognitive effect is no longer hypothetical. It has been observed.

Third, the bar for ARO-MAPT’s Phase 1/2a is now specific rather than abstract. The Phase 1/2a does not have to ask whether tau lowering produces effects. It only has to ask whether ARO-MAPT, delivered subcutaneously, produces cerebrospinal fluid tau reductions broadly comparable to BIIB080’s 63 to 67 percent. The ARO-MAPT primate data, characterized in Section III.E, predicts cerebrospinal fluid tau reductions in the 50 to 70 percent range in humans, which would either match BIIB080 or fall modestly below it while still representing a pharmacologically meaningful effect. That is a specific, measurable bar.

Two studies published in early 2026 reinforce the case for upstream protein-pathology intervention as the right therapeutic strategy in Alzheimer’s disease. A UC Irvine team (Nakagawa et al., Nature Neuroscience 2026) showed in an APP-knock-in mouse model that amyloid pathology drives downstream dopamine dysfunction in the entorhinal cortex, the same deep memory region where Alzheimer’s pathology starts. The dopamine deficit is a consequence of upstream protein pathology, not an independent disease mechanism. The therapeutic implication is that addressing the upstream protein buildup matters more than treating downstream neurochemical consequences in isolation. ARO-MAPT works at the upstream level by reducing the production of one of those toxic proteins. A UC San Diego team (Jati et al., Acta Neuropathologica Communications 2026) identified a natural protective mechanism in patients who carry full amyloid and tau pathology yet remain cognitively intact, the so-called asymptomatic Alzheimer’s disease state. Roughly twenty to thirty percent of older individuals fall into this category. Patients who progress to clinical dementia are the ones whose natural protection has failed, and for them the link between toxic protein buildup and cognitive decline holds. Those are the patients ARO-MAPT will treat. A companion paper from the same UC San Diego group (Jati et al., bioRxiv 2026) is itself characterizing a therapeutic intervention to lower tau pathology through an adrenergic-inhibition mechanism distinct from RNAi, which underscores that the field treats tau pathology as a real and consequential drug target. The 2026 literature continues to validate the underlying biology that BIIB080 first demonstrated clinically.

In drug development, there are two ways a drug can fail. The first is that the target is wrong, the disease isn’t actually caused by what scientists thought it was caused by. The second is that the target is right but the specific drug doesn’t work, it can’t reach the right tissue, has side effects that limit dosing, or can’t be administered safely.

BIIB080 took the first failure mode off the table for ARO-MAPT. Lowering tau, in real Alzheimer’s patients, produces measurable effects in the brain and directional cognitive benefits. ARO-MAPT inherits that proof.

What ARO-MAPT still has to prove is that its specific molecule, given as a subcutaneous injection rather than a spinal injection, can match what BIIB080 achieved. That is the question the 2026 readout will answer.

E. The Takeaway

The underlying biology of tau lowering in Alzheimer’s disease has been clinically validated by a competitor. ARO-MAPT inherits that validation. The readout in 2026 is therefore not asking whether tau works as a target. It is asking whether ARO-MAPT, the specific drug, can match what BIIB080 already showed is achievable through a different delivery route.

That is a different question from the one a generic Phase 1/2a candidate faces. It does not guarantee the readout will be positive. ARO-MAPT could still fail, not because tau is the wrong target, but because the specific molecule, the specific delivery, or the specific dose schedule produces a weaker biomarker effect than the trial design requires. Section III addresses why Arrowhead’s subcutaneous transferrin-receptor delivery is structurally well-suited to produce the biomarker effects the readout will measure, and the residual risks are addressed explicitly in the Bottom Line.

For the purpose of this section, the conclusion is narrower and cleaner. The tau target is de-risked. The disease-relevant biology has been demonstrated in patients. The biomarker pathway has been mapped. The cognitive readout has been pattern-matched to approved drugs. ARO-MAPT enters its readout with that foundation already laid.

BIIB080 already proved tau works as a target in Alzheimer’s disease. ARO-MAPT inherits that proof. The question for the 2026 readout is whether ARO-MAPT’s specific molecule, delivered subcutaneously rather than through spinal injection, can match what BIIB080 already showed is achievable. That is a different and easier question than the one most Phase 1 candidates face.

III. Subcutaneous Likely to Beat Intrathecal for Brain Penetration

A. The Bottom Line First

The standard analyst framing of the upcoming ARO-MAPT readout asks whether subcutaneous administration can match what BIIB080 achieved with intrathecal administration. This is the wrong question. It treats spinal injection as the gold-standard delivery route ARO-MAPT must catch up to. The available evidence, from peer-reviewed primate studies, from Arrowhead’s own non-human primate data, and from the basic anatomy of how drugs distribute through the brain, suggests the right question is the opposite. ARO-MAPT is likely to produce deeper, more uniform tau knockdown than BIIB080, particularly in the deep brain regions where Alzheimer’s pathology actually lives.

That is a strong claim. It rests on a structural argument about brain anatomy, on a published comparison of the two delivery approaches in primates, and on Arrowhead’s own primate data showing 70 to 80 percent tau messenger RNA reduction across all 12 brain regions tested, including the brain stem and deep brain structures where intrathecal delivery is weakest. If this argument holds, the implication is significant. It means the 2026 readout could produce a biomarker signal stronger than what BIIB080 produced, not because the underlying tau biology is different, but because the delivery route is fundamentally better suited to the disease’s geography.

This section explains why. It is built around three observations: how the two delivery routes actually distribute drug through the brain, where Alzheimer’s pathology actually lives, and what Arrowhead’s primate data shows about ARO-MAPT specifically.

B. How the Two Delivery Routes Actually Work

The dominant mental model among investors and even some clinicians is that an intrathecal injection (the spinal injection BIIB080 uses) delivers drug “into the brain” the way an IV infusion delivers drug “into the bloodstream.” This is incorrect, and the misconception matters because it obscures the structural asymmetry at the heart of the ARO-MAPT thesis.

When BIIB080 is injected into the spinal column, the drug enters the cerebrospinal fluid, the cushioning fluid that surrounds the brain and spinal cord. From there, it must travel up the spinal column, ascend through the base of the skull, perfuse around the surfaces of the brain, and gradually diffuse inward through the brain tissue to reach the neurons it is supposed to silence. This is a slow, gradient-driven process. Drug concentrations are highest at the brain’s surface and decline steeply as you move toward the deeper structures. The peer-reviewed literature on intrathecal ASO pharmacokinetics in primates, published in part by Ionis researchers themselves, confirms this pattern in detail (see Section III.D for the Mortberg single-cell map and the Frei follow-up characterizing the gradient at deep-brain anatomical resolution).

Subcutaneous delivery works differently. ARO-MAPT is injected under the skin, the way an insulin pen or a GLP-1 weight-loss drug is injected. The drug enters the bloodstream and circulates through the body. To reach the brain, it must cross the blood-brain barrier, the specialized layer of cells that protects the brain from most circulating molecules. Arrowhead’s technology accomplishes this by attaching the drug to a targeting ligand that binds the transferrin receptor protein, a protein that is expressed on the blood-brain barrier and that naturally shuttles molecules from the blood into the brain. The ligand binds the receptor, the receptor pulls the drug across the barrier, and the drug enters the brain tissue uniformly through the cerebrovasculature, the vast network of capillaries that supplies every region of the brain.

The structural difference is fundamental. Intrathecal delivery enters the brain at one place (the surface) and works inward. Subcutaneous transferrin-receptor delivery enters everywhere at once, through the capillaries that supply every tissue region. The two routes have inherently different distribution profiles. Neither is wrong. They are designed for different problems. However, for a target gene that is most consequentially expressed in deep brain structures, which is exactly what Alzheimer’s tau pathology is, the uniform-distribution route has a significant structural advantage.

C. Where Alzheimer’s Pathology Actually Lives

Alzheimer’s disease does not start at the surface of the brain. It starts in the deep medial temporal lobe, a structure called the entorhinal cortex, buried in the inner fold of the temporal lobe, and spreads outward from there in a stereotyped pattern. This pattern was first described by the German neuroanatomist Heiko Braak in the 1990s and is now the canonical staging system for Alzheimer’s pathology in postmortem brain tissue.

The disease progresses through six stages. The first two stages affect only the entorhinal cortex and immediately adjacent structures, some of the deepest, most buried regions of the brain. Stages III and IV expand into the hippocampus and the broader temporal lobe. Stages V and VI eventually reach the cortical surface, where Alzheimer’s pathology is most visible to a clinician but where it is also the latest to arrive. By the time the disease is clinically diagnosed, the deep regions have been accumulating tau pathology for years.

The implication for delivery is direct. The brain regions where Alzheimer’s pathology starts and where it is most pharmacologically consequential are exactly the regions that intrathecal delivery is structurally weakest at reaching. The brain regions where intrathecal delivery is structurally strongest, the cortical surfaces, are the regions where Alzheimer’s pathology arrives last. The two distributions are inverted. A drug that distributes uniformly through the brain via the cerebrovasculature, by contrast, reaches the deep medial temporal regions at the same time and in the same concentration as it reaches the cortical surface.

This is the structural argument at the heart of the ARO-MAPT thesis. BIIB080 has demonstrated that lowering tau works as a therapeutic strategy in Alzheimer’s patients, but BIIB080 is fighting its own delivery route. The drug is being delivered furthest from where the disease lives. ARO-MAPT, if its delivery route works as the primate data suggests, would not have that disadvantage.

D. Independent Corroboration from the Academic Literature

The argument that subcutaneous transferrin-receptor delivery is likely to outperform intrathecal ASO delivery in deep brain tissue is built on two distinct findings in the peer-reviewed literature, each from researchers with no commercial relationship to Arrowhead. The two findings, taken together, independently support both halves of the comparison: that intrathecal delivery is structurally limited in deep brain regions, and that transferrin-receptor-mediated delivery from the bloodstream can effectively reach those regions.

On the limitations of intrathecal delivery, Mortberg and colleagues at the Broad Institute and Ionis Pharmaceuticals (Nucleic Acids Research, 2023) published a single-cell map of ASO activity in mouse and macaque brain following intrathecal administration, characterizing ASO activity across cell types at unprecedented resolution and establishing that knockdown varies by cell type and tissue compartment. A follow-up paper from the same group (Frei and colleagues, 2025) extended this work to three deep brain regions specifically (thalamus, caudate, putamen) and demonstrated the surface-to-deep gradient pattern that constrains intrathecal ASOs in regions farthest from the cerebrospinal fluid. Together these papers represent the most rigorous published characterization of how intrathecal ASO delivery actually distributes in primate brain tissue.

On the feasibility of crossing the blood-brain barrier with transferrin-receptor-conjugated oligonucleotides delivered through the bloodstream, Barker and colleagues (Science Translational Medicine, 2024) published a peer-reviewed study demonstrating that an antibody-conjugated ASO targeting the transferrin receptor produces knockdown in deep brain regions following intravenous administration in non-human primates. The study used a different chemistry from Arrowhead’s ARO-MAPT (the conjugation was antibody-based rather than small-molecule-based) and a different administration route (intravenous rather than subcutaneous), but the underlying mechanism, transferrin-receptor-mediated transcytosis across the blood-brain barrier, is the same. The Barker paper established the modality, that transferrin-receptor-conjugated oligonucleotides can cross the blood-brain barrier from the bloodstream and engage targets in deep brain tissue at clinically relevant levels. Arrowhead’s primate data extends the modality to subcutaneous administration.

Arrowhead’s ARO-MAPT data therefore enters this literature in a particular position. The structural limitation of intrathecal delivery in deep brain regions has been demonstrated independently. The feasibility of subcutaneous transferrin-receptor delivery has been demonstrated independently. Arrowhead is bringing these two findings together with a specific molecule, ARO-MAPT, optimized for the MAPT target. The result is the most uniform deep-brain knockdown pattern published for any oligonucleotide-class drug, characterized in detail across twelve primate brain regions, with cerebrospinal fluid tau reductions sustained for five months. Whether that pattern translates to humans is the question the 2026 readout will answer.

E. What Arrowhead’s Own Primate Data Shows

Arrowhead has now characterized the ARO-MAPT preclinical program in two scientific disclosures at increasing levels of detail. The first, presented by Christine Esau, Ph.D., at the RNA Leaders USA Congress on September 10, 2025, was the first ARO-MAPT-specific dataset and included a direct head-to-head comparison of intrathecal versus subcutaneous siRNA delivery in non-human primates. The second, presented by Agnieszka Glebocka, Ph.D., at the 7th Annual CNS Delivery Summit on December 10, 2025, focused on the subcutaneous platform alone but characterized it in unprecedented detail across twelve brain regions and five months of dosing. Together, the two disclosures establish both the structural advantage of subcutaneous delivery (Figure 2) and the depth and durability of the resulting target engagement (Figures 3 and 4).

Figure 2. Head-to-head primate comparison of intrathecal (IT) versus subcutaneous (SC) siRNA delivery to four representative brain regions. Intrathecal delivery produces a steep surface-to-deep gradient: high concentrations in the Temporal Cortex (relative concentration 21.6) near the cerebrospinal fluid surface, moderate concentrations in the Thoracic Spinal Cord (11.0), and effectively no delivery to the deep-brain Caudate and Putamen (1.0 each), a 22-fold range. Subcutaneous transferrin-receptor delivery produces uniform distribution across brain regions: 3.6 in Temporal Cortex, 2.0 in Caudate, 3.3 in Putamen (less than a 2-fold range), with the Thoracic Spinal Cord (1.0) the only region where subcutaneous delivers less, consistent with the route’s design. Source: Esau, RNA Leaders USA Congress, September 10, 2025, slide 12.

The most direct way to understand the structural difference between intrathecal and subcutaneous delivery is to look at how each route distributes drug across the same primate brain regions. Figure 2 shows that comparison from the Esau RNA Leaders disclosure. The intrathecal panel shows a steep surface-to-deep gradient: drug concentrations are very high in the Temporal Cortex (21.6) close to the cerebrospinal fluid surface, moderate in the Thoracic Spinal Cord (11.0) which the cerebrospinal fluid bathes directly, and effectively absent in the deep-brain Caudate and Putamen (1.0 each). The subcutaneous panel shows uniform distribution across the brain regions: 3.6 in Temporal Cortex, 2.0 in Caudate, 3.3 in Putamen, less than a 2-fold range, with the Thoracic Spinal Cord (1.0) the only region where subcutaneous delivers less, consistent with the route’s design; subcutaneous transferrin-receptor delivery enters the brain through the bloodstream and bypasses the spinal cord.

A reader might note that intrathecal delivery achieves higher absolute concentrations in the Temporal Cortex (21.6) and Thoracic Spinal Cord (11.0) than subcutaneous achieves anywhere. This is true. The argument the figure makes is not that subcutaneous achieves higher peak concentrations than intrathecal; it is that subcutaneous achieves uniform concentrations across brain regions where intrathecal does not. A delivery platform that hits the surface cortex with twenty-two times the dose of the adjacent deep-brain Caudate and Putamen is not a deep-brain delivery platform; it produces high concentrations near the cerebrospinal fluid surface and effectively none in the structures where Alzheimer’s disease lives. The subsequent slide in the same Esau presentation shows the pharmacological consequence: intrathecal delivery produces minimal MAPT messenger RNA reduction in the deep-brain Caudate and Putamen despite the high cortex concentrations, while subcutaneous delivery produces even MAPT messenger RNA reduction across all four regions. The structural argument from Section III.B has now been documented in primates.

The Glebocka CNS Delivery Summit disclosure, presented three months later, then characterized the subcutaneous platform alone in greater depth. Two figures from that disclosure are particularly consequential.

Figure 3. ARO-MAPT MAPT messenger RNA reduction across 12 brain regions in non-human primates, after three weekly subcutaneous doses of 3 mg/kg, measured at Day 29. Reductions of 70 to 80 percent were achieved across all brain regions, including the brain stem and the deep medial temporal structures where Alzheimer’s pathology lives. Up to 85 percent knockdown was achieved in some cortical regions. Source: A. Glebocka, CNS Delivery Summit, December 10, 2025, slide 19.

Three things about this figure matter for the thesis. First, the deep brain regions are not the worst performers. The structures where intrathecal delivery is structurally weakest, the caudate, putamen, thalamus, and hippocampus, all show tau messenger RNA reductions in the 70 to 80 percent range. Second, the brain stem and spinal cord regions, which intrathecal delivery does reach reasonably well, show somewhat lower knockdown than the cortical regions. This is exactly the pattern the structural argument predicts: subcutaneous delivery is engineered for crossing the blood-brain barrier, not for delivering to the spinal cord. Third, the data was measured at Day 29, two weeks after the last of three weekly doses, demonstrating both potency (achieving the knockdown in the first place) and durability (sustaining it for weeks after dosing stopped).

This is consistent with the company’s November 2025 fiscal year-end earnings call, on which CEO Christopher Anzalone described “better than 75% knockdown of tissue-level MAPT mRNA in the CNS” from clinically translatable doses in monkeys. The 70 to 80 percent range disclosed in detail in December 2025 is the more granular scientific version of the same finding.

The third figure is more directly predictive of the human Phase 1/2a readout.

Figure 4. Cerebrospinal fluid total tau reduction in non-human primates dosed with ARO-MAPT at 3 mg/kg subcutaneously: three weekly loading doses (Days 1, 8, 15) followed by approximately monthly maintenance dosing (Days 26, 71, 99, 127). CSF tau reductions of 50 to 60 percent were sustained throughout the five-month dosing window. The CSF tau biomarker is the same biomarker the human Phase 1/2a will measure as its primary pharmacodynamic endpoint. Source: A. Glebocka, CNS Delivery Summit, December 10, 2025, slide 23.

This figure is the most consequential disclosure in the entire ARO-MAPT preclinical package, and it deserves careful attention. The biomarker being measured is cerebrospinal fluid total tau, the same biomarker BIIB080 produced 63 to 67 percent reductions in (Section II), and the same biomarker the human Phase 1/2a in 2026 will measure as its primary pharmacodynamic endpoint. The reductions shown are 50 to 60 percent, sustained for five months in primates, after monthly subcutaneous dosing.

Two implications flow directly. First, the biomarker that the human readout will measure has now been characterized in non-human primates, and the magnitude is in the same range BIIB080 achieved in humans. The 50 to 60 percent range in primates is consistent with a 50 to 70 percent range in humans (primates and humans typically translate at this rate for cerebrospinal fluid biomarkers, sometimes with humans showing somewhat stronger effects due to differences in baseline tau turnover). Second, the durability of the effect, with 50 to 60 percent CSF tau reduction sustained for five months under approximately monthly maintenance dosing in primates, supports the dosing schedule Arrowhead has indicated for the human program: monthly to quarterly subcutaneous injection. This is the same dosing cadence as plozasiran (REDEMPLO), which is approved for quarterly subcutaneous injection.

BIIB080 has shown that lowering tau works as a treatment strategy in Alzheimer’s patients. However, BIIB080 is delivered by spinal injection, which produces drug concentrations that are highest at the brain’s surface and decline as you move toward the deep brain regions where Alzheimer’s pathology actually lives. The drug is fighting its own delivery route.

ARO-MAPT is delivered under the skin, the way an insulin pen is. The drug enters the bloodstream, crosses the blood-brain barrier through a specialized targeting molecule, and reaches every region of the brain through the capillary network. This produces uniform distribution, deep regions and surface regions get the drug in the same concentration.

Arrowhead’s primate data confirms this is happening. Tau messenger RNA reductions of 70 to 80 percent were measured across all 12 brain regions tested, including the deep regions where Alzheimer’s pathology starts. Cerebrospinal fluid tau reductions of 50 to 60 percent were sustained for five months. These are the same kinds of measurements the human Phase 1/2a in 2026 will produce.

F. The Takeaway

The conventional framing of the 2026 readout asks whether ARO-MAPT can match what BIIB080 achieved through spinal injection. The available evidence suggests this is the wrong framing. Subcutaneous transferrin-receptor delivery produces a fundamentally different distribution pattern than spinal injection, and that distribution pattern is better matched to the geography of Alzheimer’s pathology. ARO-MAPT is likely to do more than match BIIB080. It is likely to produce deeper, more uniform tau knockdown in the regions where the disease actually lives.

The structural argument is supported by independent peer-reviewed primate work, on the intrathecal limitation side by Mortberg and colleagues at the Broad Institute (2023), and on the subcutaneous transferrin-receptor feasibility side by Barker and colleagues (2024). It is also supported by Arrowhead’s own primate data, presented in detail at the December 2025 CNS Delivery Summit, showing 70 to 80 percent tau messenger RNA reductions across all brain regions and 50 to 60 percent cerebrospinal fluid tau reductions sustained for five months. The 2026 human readout will test whether this pattern translates from primates to humans.

The right question is not whether ARO-MAPT can catch up to BIIB080. The right question is whether ARO-MAPT can do something BIIB080 structurally cannot, deliver tau lowering uniformly across the deep brain regions where Alzheimer’s pathology actually lives. The available evidence suggests the answer is yes. The 2026 readout will tell us.

IV. Why Phase 1 Is the Catalyst

A. The Bottom Line First

A reasonable reader will accept the case so far and still ask why the 2026 readout matters as an investment catalyst when commercial approval is years away. Why not wait for Phase 2 or Phase 3?

The answer is that the readout will not just validate one drug. It will validate a uniquely valuable platform. Subcutaneous delivery of RNAi therapeutics to the brain has been the most strategically important unsolved problem in the modality for two decades. Arrowhead has now built it. A successful Phase 1/2a readout for ARO-MAPT would be the first human clinical validation of that platform, and the platform itself is what large pharmaceutical acquirers value. The strategic scarcity is the reason Phase 1 is sufficient as a catalyst rather than just a milestone toward a later one.

B. Why Subcutaneous CNS Delivery Is the Holy Grail of RNAi

RNAi produces drugs that work by silencing specific genes. Eight such drugs have been approved by the FDA since 2018, and all eight target genes expressed in the liver, the easiest tissue to deliver to. The brain has been the hardest. The blood-brain barrier exists specifically to keep large molecules out of brain tissue, and RNAi drugs are exactly the kind of large molecule it excludes. For two decades, the entire field has worked on the problem of getting these drugs into the brain at scale. Subcutaneous delivery, the same way an insulin pen is administered, has been the goal but has remained out of reach.

This matters strategically because the brain is where the largest unmet medical needs live. Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, frontotemporal dementia, ALS, the spinocerebellar ataxias, a category of diseases that affect tens of millions of patients globally and for which the drug industry has produced almost nothing that meaningfully changes disease progression. RNAi is in principle ideally suited to most of these diseases, because they are caused by the toxic accumulation of specific proteins, and silencing the gene that produces the protein is exactly what RNAi does. The technology has been ready for years. The delivery has been the wall. A company that solves the delivery problem at scale has access to the largest unmet need in modern medicine.

C. Arrowhead Has Built the Platform, and the Platform Is Now Being Extended

Arrowhead’s central nervous system pipeline has two architectural layers, and the distinction between them is essential to understanding what the 2026 readout actually validates. The first layer is the older intrathecal CNS approach, which delivers drug directly into the cerebrospinal fluid via spinal injection. The most advanced program on this older route is ARO-ATXN2 for spinocerebellar ataxia type 2, partnered with Sarepta Therapeutics under the November 2024 licensing agreement and currently dosing patients in a Phase 1/2 trial in Australia, New Zealand, Canada, Taiwan, and other jurisdictions. The Sarepta partnership covers a broader portfolio that also includes muscle and lung programs, with deal economics of approximately $825 million in initial value plus up to $10 billion in development and commercial milestones across all licensed programs. The CNS programs are not the entire deal, but their inclusion alongside muscle and lung programs is itself a data point: a major pharmaceutical partner saw enough value in Arrowhead’s tissue-targeting capabilities, including but not limited to CNS, to commit at this scale.

The second layer is the newer subcutaneous transferrin-receptor-mediated platform, the platform this paper has been describing throughout. Three programs occupy this layer as of April 2026, with additional programs in earlier development. ARO-MAPT for tau in Alzheimer’s disease and other tauopathies is the first to enter the clinic. The company’s December 2025 press release announcing first dosing explicitly described it as “Arrowhead’s first investigational RNAi-based therapy to utilize a new proprietary delivery system which, in preclinical studies, has achieved blood-brain-barrier penetration and deep knockdown of target genes across the central nervous system, including deep brain regions, after subcutaneous injection.” ARO-SNCA for alpha-synuclein in Parkinson’s disease is the second program on the platform, currently preclinical, with Novartis having taken an exclusive worldwide license in September 2025. SRP-1005, the program formerly designated ARO-HTT and licensed to Sarepta in November 2024, is the third. In January 2026 Sarepta announced submission of a Clinical Trial Application in New Zealand for the INSIGHTT Phase 1 study; Medsafe granted approval in February 2026, and Sarepta has guided to first-in-human dosing in the second quarter of 2026. Sarepta’s public description of SRP-1005 confirms the delivery architecture: “subcutaneous dosing” via “an advanced TfR1 (transferrin receptor protein 1) approach,” “intended to target the deep brain.” Beyond these three, two additional Sarepta-licensed programs are advancing through the platform: ARO-ATXN3 for spinocerebellar ataxia type 3 (preclinical) and ARO-ATXN1 for spinocerebellar ataxia type 1 (discovery), per Arrowhead’s September 2025 disclosure of its CNS portfolio. An additional preclinical program targets an undisclosed cardiometabolic CNS gene referenced as “Gene X” in Arrowhead’s December 2025 CNS Delivery Summit presentation, where ~90 percent target mRNA reduction was demonstrated across all NHP brain regions including deep brain after subcutaneous administration. Counting both architectural layers, the disclosed CNS portfolio comprises seven programs as of early 2026: six on the new subcutaneous transferrin-receptor platform (ARO-MAPT, ARO-SNCA, SRP-1005, ARO-ATXN1, ARO-ATXN3, Gene X) and one on the older intrathecal platform (ARO-ATXN2). Section V develops the implications of the seven-program portfolio in detail.

The strategic implication of this two-layer structure is sharper than the single-layer version of the argument would be. ARO-MAPT is not the most advanced of five interchangeable programs on a proven platform. It is the lead clinical asset on an entirely new platform whose first human validation is its own readout. The 2026 result is not incremental confirmation. It is the first time anyone, anywhere, will have human data showing whether subcutaneous transferrin-receptor delivery of an RNAi therapeutic produces target engagement in the central nervous system. SRP-1005 will follow with its own Phase 1 readout on a related but independent target, providing a second platform read at a similar moment in time. The two readouts together will, in combination, either validate the platform across multiple targets or call its translation into question. ARO-MAPT goes first.

Two facts make this binary less binary than it may first appear. First, the underlying mechanism, transferrin-receptor-mediated transcytosis across the blood-brain barrier, has been independently validated in non-human primates by Denali Therapeutics (Barker et al., 2024, Section III.D), so the modality itself is not in question. The 2026 readout is asking whether Arrowhead’s specific molecule on its specific delivery chemistry produces the cerebrospinal fluid tau reductions the primate data predicts. Second, multiple Big Pharma diligence processes have already concluded the platform is worth substantial money at the preclinical stage. Novartis’s September 2025 license of ARO-SNCA for $200 million upfront and up to $2 billion in milestones, and Sarepta’s broader $825 million-plus collaboration covering ARO-HTT (now SRP-1005) and related programs, are independent diligence-stage validations of what the platform could be worth once human data exists. Diligence judgments are not clinical data, but they are also not nothing.

D. The Clinical Lead Is the Moat, and Big Pharma Knows It

Other companies in the RNAi and oligonucleotide space have approached central nervous system delivery, but none has reached comparable clinical advancement. Alnylam Pharmaceuticals, the largest RNAi company by revenue and approved drugs, has all six of its approved drugs targeting genes expressed in the liver; its central nervous system efforts use C16 lipid conjugates that are administered intrathecally, not subcutaneously. Atalanta Therapeutics is developing branched divalent siRNA scaffolds (di-siRNA) for Huntington’s disease and other central nervous system targets, but its delivery route is also intrathecal/cerebrospinal fluid administration rather than subcutaneous. Ionis Pharmaceuticals is the closest competitor in central nervous system oligonucleotide delivery overall, but Ionis uses ASO chemistry rather than RNAi, and its approved central nervous system drugs (nusinersen for spinal muscular atrophy and tofersen for SOD1 ALS) all use intrathecal delivery. Denali Therapeutics has demonstrated transferrin-receptor-mediated ASO BBB crossing in primates (Barker et al., 2024) but has not advanced an oligonucleotide-conjugate CNS program into the clinic; Denali’s clinical CNS work to date has used antibody-conjugated enzymes (DNL310 for MPS II, DNL126 for MPS IIIA, DNL952 for Pompe) rather than RNA-class therapeutics. Wave Life Sciences uses a different oligonucleotide chemistry, and Wave’s subcutaneous siRNA work has been demonstrated for hepatic targets, not for central nervous system targets. Switch Therapeutics, City Therapeutics, and other newer entrants in the broader RNAi space remain at preclinical stages and have not announced subcutaneous CNS clinical programs.

The most relevant competitive disclosure is the most recent. On April 27, 2026, Dyne Therapeutics announced preclinical data from its FORCE platform showing approximately 75% MAPT mRNA knockdown in non-human primates using a transferrin-receptor-binding antibody fragment conjugated to MAPT siRNA, with widespread and consistent delivery across brain regions including the deep brain. Dyne also confirmed equivalent MAPT mRNA reduction with subcutaneous and intravenous administration in mice. This is the first competitive disclosure from a non-Arrowhead-licensee that addresses the same mechanistic configuration (transferrin-receptor-mediated subcutaneous siRNA-to-CNS) that Arrowhead’s platform addresses. Several aspects of the Dyne disclosure warrant precision. The 75% knockdown is reported for an optimized FORCE Fab variant (Conjugate 2); the original clinically validated FORCE Fab (Conjugate 1) was shown active in NHP but its knockdown magnitude was not quantified in the announcement. The press release confirmed subcutaneous-equivalent activity in mice but did not specify whether the NHP study itself used subcutaneous or intravenous administration. Dyne disclosed mRNA knockdown only; no protein-level effects, durability data, or tolerability data were reported. Most importantly, the program is preclinical and Dyne explicitly stated it is “evaluating potential next steps for the preclinical development of these conjugates with the goal of maintaining capital efficiency and maximizing shareholder value,” which in industry context indicates the program is being positioned for partnership rather than internal clinical advancement. Dyne’s primary commercial focus remains Duchenne muscular dystrophy and myotonic dystrophy type 1, where its lead clinical assets are advancing.

The Dyne disclosure has two implications, and they cut in opposite directions. The first is that the underlying transferrin-receptor-mediated subcutaneous siRNA-to-CNS modality has now been independently demonstrated in non-human primates by a second platform, which strengthens confidence in the modality at the mechanism level. The biology works. The route of administration is feasible. Tau as a target is reachable. These are confirmations of what Arrowhead’s preclinical package had already suggested. The second implication is that the field is no longer literally empty outside the Arrowhead-licensee ecosystem. The accurate framing is that as of April 2026, Arrowhead has the only clinical-stage subcutaneous RNAi CNS program in development, with ARO-MAPT dosing patients since December 2025 and the Phase 1/2a readout expected in the second half of 2026. Dyne’s preclinical-stage program would, even on an aggressive development timeline, require approximately two to three years to reach human dosing if Dyne or a future partner chose to advance it. The clinical lead is years, and clinical leads in regulated drug development compound rather than decay. Each additional month of human data Arrowhead generates while competing platforms remain in preclinical evaluation is an additional month of widening moat.

This scarcity creates two layers of acquisition pressure on potential pharmaceutical bidders. The first is the obvious one: any pharmaceutical company that wants near-term subcutaneous central nervous system RNAi capability has, today, a single credible target to acquire to get it. Any longer-term competitor, including a future-licensed Dyne program, would arrive at clinical validation years later, behind a platform with established intellectual property, accumulated human data, and entrenched commercial relationships. That alone supports premium valuations.

The second layer is more important and is rarely discussed explicitly in research notes. Pharmaceutical companies are intensely strategic about platform technologies, and they do not just want platforms for themselves, they specifically do not want their competitors to control them. A pharmaceutical company that lets a rival acquire Arrowhead would not just lose the chance to acquire the platform; it would watch a competitor secure a multi-decade durable advantage in central nervous system drug development, in the disease category with the largest unmet need in modern medicine. The defensive logic compounds the offensive logic. Once Arrowhead’s platform is clinically validated by the 2026 readout, the question for each potential acquirer becomes not just whether to bid, but how much it would cost to let someone else win. Competitive auctions driven by both offensive and defensive logic produce the highest acquisition prices in pharmaceutical mergers and acquisitions, and the dynamic is exactly what The Endgame paper develops.

E. What This Means for the 2026 Readout

The 2026 Phase 1/2a readout is the catalyst because it converts Arrowhead’s subcutaneous central nervous system platform from preclinically promising to clinically validated. Two external data points already speak to what that conversion is worth. First, in September 2025 Novartis announced a global licensing agreement for ARO-SNCA, the preclinical Parkinson’s program on the SC transferrin-receptor platform. The deal terms: $200 million upfront, plus up to $2 billion in development, regulatory, and sales milestones, plus tiered royalties on commercial sales. The deal closed in October 2025. Critically, Novartis committed at this scale before any human data existed for the platform. Second, Sarepta’s January–2026 CTA submission and February–2026 CTA approval for SRP-1005 (formerly ARO-HTT) means a second major pharmaceutical sponsor has now committed to running its own Phase 1 study on the same subcutaneous transferrin-receptor delivery architecture, with first-in-human dosing planned for the second quarter of 2026. The implied valuation per program from each of these transactions reflects diligence-stage assessment of platform risk, not validated platform risk. The price of clinical validation, when it arrives, will sit on top of the price of preclinical validation, not next to it.

The investor implication is that the readout is sufficient to trigger material reassessment of Arrowhead’s value, through whichever mechanism eventually delivers it, stock price re-rating, partnership announcements, milestone payments, or outright acquisition. The reader is not being asked to predict which mechanism. The reader is being asked to weigh whether a position at current prices, before the catalyst, is justified by the structure of the evidence.

F. The Takeaway

Subcutaneous delivery of RNAi drugs to the brain has been the largest unsolved problem in the modality for two decades. Arrowhead is the company that built the platform that solves it. ARO-MAPT is the first drug on that platform to enter the clinic, with first-in-human dosing in December 2025 and the Phase 1/2a readout expected in the second half of 2026. SRP-1005, licensed to Sarepta, is the second drug on the platform to enter the clinic, with dosing planned for the second quarter of 2026. ARO-SNCA, licensed to Novartis, is the third program on the platform, preclinical, with a $200 million upfront and up to $2 billion in milestones already paid against the diligence-stage assessment of platform risk. As of April 2026, Arrowhead has the only clinical-stage subcutaneous RNAi CNS program in development; the most recent independent preclinical disclosure (Dyne Therapeutics, April 27, 2026, Section IV.D) is several years from clinical entry and is being positioned by Dyne for partnership rather than internal advancement. The 2026 ARO-MAPT readout is the first human clinical validation event for the platform. The platform itself is what large pharmaceutical acquirers value, both for what it gives the acquirer and for what it denies the competition.

The 2026 ARO-MAPT readout will not just validate one drug. It will be the first human test of an entirely new modality, the first subcutaneous transferrin-receptor delivery of an RNAi therapeutic to be tested in patients, in the disease area with the largest unmet need in modern medicine. SRP-1005, on the same platform, will follow with its own Phase 1 readout shortly after. Once human data exists, every potential pharmaceutical acquirer faces both the offensive question (how much is the platform worth to us) and the defensive question (how much is it worth to keep it from a competitor). Novartis’s September 2025 decision to pay $200 million upfront plus up to $2 billion in milestones for a single preclinical asset on the platform, and Sarepta’s broader collaboration covering SRP-1005 and related programs, already tell us what the diligence-stage assessment looks like. The price of clinical validation, when it arrives, will sit on top of that. The Endgame develops the resulting valuation scenarios in detail.

V. Signs that Arrowhead Knows What It Has

A. The Bottom Line First

Companies tell you what they believe by what they retain, where they stake their next bets, and where they pre-position their physical capacity. By every observable signal, Arrowhead is acting like a company that has already concluded what the 2026 readout will show. Leadership has positioned the company to execute when the readout arrives.

The argument in this section is not that the readout is more likely to succeed because management is acting confidently. Confidence does not produce data. The argument is narrower and cleaner. An investor who concludes the platform is uniquely valuable is reaching the same conclusion management has already reached, and is doing so before the public market repricing that the 2026 readout will trigger.

B. The Verona Facility and the 6.24-Acre Land Option

Arrowhead’s Verona, Wisconsin facility is a validated, FDA-inspected GMP manufacturing operation with three parallel production lines capable of supporting nine clinical programs simultaneously. As The Endgame establishes in detail in its Section XIII, Arrowhead also holds an option to acquire 6.24 acres of land directly adjacent to the Verona campus, with the option expiring in 2028.

A clarification on what this option does and does not signal is in order. The option itself predates ARO-MAPT and predates the broader subcutaneous CNS delivery platform. It was secured as general manufacturing optionality supporting Arrowhead’s broader platform strategy rather than as a response to any specific clinical asset. Its existence is therefore not by itself evidence of MAPT-specific confidence. What matters is what Arrowhead does with the option in 2026 and 2027.

The timing alignment is the key fact going forward. The 2H 2026 ARO-MAPT readout sits roughly eighteen months ahead of the option expiration. If the readout produces the cerebrospinal fluid tau reductions the primate data predicts, Arrowhead will need to make a binding decision on commercial-scale manufacturing capacity well before the option lapses. The expected behavior, if the readout succeeds, is exercise. If the readout disappoints, one may expect the option to lapse with the existing facility to continue supporting the pipeline at current scale.

This makes the option a forward-looking signal rather than a backward-looking one. The reader should watch for the exercise decision in 2026 or 2027 as a specific revealed-preference signal of management’s response to the data. Exercise would constitute the most explicit form of capital commitment Arrowhead can make in response to the readout: bigger than a hire, more durable than a partnership term, less reversible than a capital raise. The full acquisition-currency analysis, including the $1 to $3 billion in combined facility-and-option value to a strategic acquirer, is developed in The Endgame.

C. The Partnership Retention Pattern

Section IV develops the offensive valuation signal embedded in Arrowhead’s two large partnership transactions: $200 million upfront and up to $2 billion in milestones from Novartis for ARO-SNCA in September 2025; over $825 million in initial value plus up to $10 billion in milestones from Sarepta for SRP-1005 (formerly ARO-HTT) and related programs in November 2024. Those numbers tell the reader what Big Pharma is willing to pay for diligence-stage access to programs on the platform.

The same transactions tell a different and complementary story when read in reverse. What Arrowhead retained matters as much as what Arrowhead sold. ARO-MAPT, the lead asset in the largest indication (Alzheimer’s disease), is wholly owned by Arrowhead. The broadest tauopathy indications are wholly owned by Arrowhead. The therapeutic areas the platform may unlock as new tissue-targeting capabilities mature, including additional CNS targets beyond the partnered set, the obesity programs, the ocular and cardiomyocyte programs, are wholly owned by Arrowhead.

The retention pattern is the behavior of a company that has internalized the platform’s strategic value and is selling at the periphery while holding the core. A company that believed the lead asset was worth what the partnered programs imply would not retain it. It would license it on similar terms and capture the upfront economics, the way a typical pipeline company monetizes its best-in-class asset. Arrowhead did not.

D. Pre-Validation Target Staking

The strategic logic for a platform company that believes its platform works is to stake as many high-value targets as possible during the period before public validation. The reason is structural. Arrowhead’s manufacturing lead is durable: new commercial-scale oligonucleotide facilities take five to seven years to build, which is roughly the lead time the company has banked. Target staking is a separate and faster race. The moment human data confirms the subcutaneous CNS delivery platform works, every Big Pharma neurology team and every well-funded RNAi specialist will redirect resources toward CNS targets that Arrowhead has not already claimed. The cheap window for staking is now.

Arrowhead has been executing this strategy. The publicly disclosed CNS portfolio includes seven programs as of early 2026: ARO-MAPT (Alzheimer’s and tauopathies, wholly owned, lead clinical asset); ARO-HTT, now SRP-1005 (Huntington’s disease, partnered with Sarepta, dosing planned for 2Q 2026); ARO-SNCA (Parkinson’s and synucleinopathies, partnered with Novartis, preclinical); ARO-ATXN1 (spinocerebellar ataxia type 1, partnered with Sarepta, discovery); ARO-ATXN2 (spinocerebellar ataxia type 2, partnered with Sarepta, Phase 1 intrathecal); ARO-ATXN3 (spinocerebellar ataxia type 3, partnered with Sarepta, preclinical); and an undisclosed cardiometabolic CNS target referenced as “Gene X” in Arrowhead’s December 2025 CNS Delivery Summit presentation, where ~90 percent target mRNA reduction was demonstrated across all NHP brain regions including deep brain after subcutaneous administration. The fact that Arrowhead disclosed primate efficacy data on Gene X without disclosing the target itself indicates that the program is being held proprietary, likely because the target is novel and competitively sensitive. Five of the seven disclosed programs are partnered. The structure of those partnerships is itself revealing.

The Sarepta deal in November 2024 explicitly covered four CNS targets in a single transaction (HTT, ATXN1, ATXN2, ATXN3), plus muscle and lung programs. The Novartis deal in September 2025 included not only ARO-SNCA but also options on a limited number of additional collaboration targets outside Arrowhead’s pipeline, to be developed using the TRiM platform. Arrowhead is not just selling individual assets. The company is selling target-staking access to its platform, on terms structured to protect the lead asset and keep the discovery engine in-house. This is what a platform company does when it has more high-value targets in front of it than it can advance alone, and wants to lock them up before competitors can.

The broader CNS opportunity space is real and being pursued. Other companies have demonstrated that CNS protein-lowering through oligonucleotide therapeutics is therapeutically valuable: tofersen for SOD1-ALS, the first such drug approved; BIIB080 for tau (Section II); Wave Life Sciences’ prior C9orf72 program; Ionis’s ongoing PRNP program for prion disease; and multiple academic and industry programs targeting GBA1, KCNT1, SCN1A, SCN8A, APP, TDP-43, and additional aggregation-prone CNS proteins. Each is currently being pursued through intrathecal delivery, the structurally inferior route established in Section III. Once Arrowhead’s subcutaneous platform is clinically validated, every one of these targets becomes addressable through a delivery route that is patient-acceptable rather than burdensome, with broader brain distribution than intrathecal can achieve. Arrowhead is structurally advantaged to compete for any of them. The cheap staking window is the period before that advantage becomes broadly priced into the competitive landscape.

The forward question is whether the pace continues. If management’s behavior reflects their internal probability assessment of the readout, expect additional CNS targets to be disclosed before the data arrives. Likely vehicles: new preclinical programs unveiled at industry conferences, expanded partnership terms that pull additional targets under existing deals, or a new partnership entirely. Additional CNS programs disclosed in 2026 ahead of the readout would be another concrete revealed-preference signal of the same kind. The window for cheap staking closes the day the readout is announced.

Companies tell you what they believe by what they do, not by what they say. By that standard, Arrowhead has been telling the story of an enormously valuable platform since well before the 2026 readout could confirm it.

The partnership deals that look generous to Novartis and Sarepta are conspicuously absent the lead asset, ARO-MAPT, which Arrowhead kept. Seven CNS programs have already been staked (six named plus an undisclosed cardiometabolic CNS target), with partnership structures that pull additional targets under platform terms. And a 6.24-acre land option adjacent to Verona expires in 2028, meaning the most concrete capital decision of all sits in management’s hands roughly eighteen months after the readout.

Investors who conclude the platform is uniquely valuable are arriving at the same conclusion management has already reached. The behavior is the evidence.

E. The Takeaway

The behavioral evidence assembled in this section does not change the probability of a successful 2026 readout. What it does is establish that Arrowhead’s leadership has been positioning the company for the readout’s success across the dimensions where its conviction is most observable: a partnership structure that retains the lead asset while monetizing the periphery, a CNS portfolio that has staked seven programs before any human validation exists, and a Verona land option whose exercise decision sits in management’s hands roughly eighteen months after the readout. Each is consistent with the same internal conclusion. The platform is uniquely valuable, and the 2026 readout will validate that.

The Verona land option occupies a particular epistemic role. The option itself predates the subcutaneous CNS platform and does not speak directly to MAPT-specific confidence. The exercise decision in 2026 or 2027, however, will. Watch for it. Exercise would be the most concrete demonstration of management’s response to the data that Arrowhead can produce, and it would arrive in a form that no analyst report and no earnings call language can match: dirt, equipment, and a permanent expansion of the company’s commercial-scale manufacturing footprint.

The investor’s job between now and the readout remains the same as it was at the end of Section IV: weigh the evidence and decide whether the structure of the case justifies a position before the readout resolves the question. This section adds one more piece to that weighing. The company is acting as if it has already drawn its conclusion.

VI. The Bottom Line

ARO-MAPT is not a generic Phase 1 candidate. The tau target has already been clinically validated by BIIB080, which produced 63 to 67 percent cerebrospinal fluid tau reductions in 46 mild Alzheimer’s patients and directional cognitive trends matching the approved amyloid antibodies. The delivery route, subcutaneous injection through a transferrin-receptor-mediated platform, distributes drug uniformly across the brain rather than producing the surface-to-deep gradient that intrathecal injection produces. This matters because Alzheimer’s pathology starts in the deep medial temporal lobe, where intrathecal delivery is structurally weakest. Arrowhead’s primate data shows 70 to 80 percent MAPT messenger RNA reductions across all twelve brain regions tested, with deep brain regions performing as well as cortical regions, and 50 to 60 percent cerebrospinal fluid tau reductions sustained for five months.

The Phase 1/2a trial measures cerebrospinal fluid tau as its primary pharmacodynamic biomarker, the same biomarker BIIB080 lowered, the same biomarker Arrowhead’s primate program characterized, and the same biomarker the human readout will produce. The 2026 readout will either show ARO-MAPT produced the cerebrospinal fluid tau reductions the primate data predicts, or it will not.

The argument is not that ARO-MAPT cannot fail. It can. The primate-to-human translation could disappoint. The Phase 1/2a is a small study, and inter-subject variability in cerebrospinal fluid biomarkers is substantial. The track record of anti-tau drugs in Alzheimer’s disease is poor, although the failed programs targeted extracellular tau or worked through unrelated mechanisms, and ARO-MAPT operates upstream of those failures. Each of these risks is real. None of them changes the underlying structure of the evidence. The argument is that the evidence assembled across the prior sections justifies a meaningful conviction in the readout, well above the generic Phase 1 base rate, while leaving the residual risk to be sized by each reader’s own conviction.

The 2026 readout will deliver the verdict. The investor’s job between now and then is to weigh whether the preclinical and clinical evidence already assembled: four progressively detailed scientific disclosures over two and a half years, the BIIB080 clinical validation of the underlying biology, the academic literature characterizing intrathecal’s gradient limitation and transferrin-receptor delivery’s feasibility for crossing the blood-brain barrier, the structural anatomy argument about where Alzheimer’s lives in the brain, and the partnership pricing that establishes diligence-stage Big Pharma valuation, corroborated by the revealed-preference behavior of Arrowhead’s leadership, justifies a position before the readout resolves the question. This paper has assembled that evidence as completely as the available data allows. The conclusion is the reader’s to draw.

A Note on Supporting Independent Research

These white papers took hundreds of hours to produce. The asset inventory, valuation methodology, bidder analysis, comparable transaction work, acquisition thesis, competitor analysis, supporting charts, and science analytics are the result of deep primary research and is not available in sell-side coverage. Most of the analysis presented represents independent research not published elsewhere. It is being shared freely because the thesis deserves the widest possible audience. If ARO-MAPT delivers in 2H 2026, every Arrowhead shareholder benefits from a well-informed market that understands what the data means and what the asset is worth. That is why this paper exists.

If this research has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 or more reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed; and

• he was not compensated in any form for producing this white paper.

This white paper is published by BioBoyScout and is intended for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss. All financial projections, acquisition price estimates, and valuation analyses herein are hypothetical frameworks for analytical purposes and do not represent predictions of actual outcomes. Readers should conduct their own due diligence and consult a registered investment advisor before making investment decisions. All data cited herein were sourced from publicly available company disclosures, SEC filings, press releases, and peer-reviewed literature as of May 2026.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

A Deep-Dive Valuation Analysis of ARO-MAPT's Path to Acquisition Across Four Methodologies, Three Phase 1 Scenarios, and a $55 to $150 Billion Range of Outcomes

Robert Toczycki, JD, MBA
bioboyscout@gmail.com
847.227.7909
X: @BioBoyScout

On November 18, 2025, the FDA approved Arrowhead Pharmaceuticals’ first commercial product, Redemplo (plozasiran). In the second half of 2026, Phase 1 data will read out from ARO-MAPT, Arrowhead’s subcutaneous tau-silencing program for Alzheimer’s disease. This readout is the single most consequential re-rating event for Arrowhead’s valuation: positive data validates subcutaneous CNS delivery and converts the company from pipeline biotech to strategic acquisition target. The stock trades at approximately $9.8 billion. This paper argues that number is materially mispriced. A Stage 1 acquisition range of $55 to $90 billion, roughly six to nine times today’s market cap, reflects what a disciplined competitive process produces, with Stage 2 forward optionality of $110 to $150 billion if positive Phase 2 cognitive data follows in 2029 to 2030.

Executive Summary

Arrowhead Pharmaceuticals (ARWR) trades at approximately $9.8 billion. In the second half of 2026, ARO-MAPT, Arrowhead’s subcutaneous tau-silencing program for Alzheimer’s disease, will produce Phase 1 human data.

The quality of that data will force one of three outcomes: probable acquisition in the $55 to $90 billion range (5.6× to 9.2× today’s market cap), meaningful re-rating with licensing as a realistic alternative path, or invalidation of the acquisition thesis bounded by a non-CNS floor at approximately today’s market cap. The asymmetric entry point is today, before the readout.

Key parameters

The three scenarios

Scenario probabilities are the paper’s assessment based on the prior evidence developed in Section I; reasonable alternative weightings produce qualitatively similar conclusions. If positive Phase 1 data does not result in a transaction within 12–18 months, positive Phase 2 cognitive endpoint data in 2029–2030 would open a subsequent valuation window at approximately $110–$150B. Stage 2 is treated as conditional forward optionality rather than a primary scenario.

Why now

The prior evidence base for positive Phase 1 data is substantial: BIIB080 has validated MAPT-silencing as a biomarker-active mechanism in humans; trontinemab has validated TfR1-mediated blood-brain-barrier transcytosis as a delivery route; Arrowhead’s non-human-primate CSF tau reduction data supports translational feasibility. Taken together, this prior evidence makes the weak Phase 1 scenario less probable than the current $9.8 billion valuation implies. Section VI develops the full probabilistic case.

Series context

This paper is the fourth in the BioBoyScout Arrowhead research series. The first, The Needle Wins (March 2026), established that the rapid adoption of GLP-1 auto-injectors has normalized subcutaneous injection as a chronic-disease delivery format, benefiting every commercial-scale RNAi therapeutics company. The second, Redemplo vs. Tryngolza (March 2026), analyzed the competitive dynamics between plozasiran and Ionis’s Tryngolza in the severe hypertriglyceridemia market following Ionis’s 2025 pricing action. The third, The Year of Tau (April 2026), examined the ARO-MAPT program in detail, the non-human-primate CSF tau reduction data, the TfR1-mediated blood-brain-barrier delivery mechanism, and the clinical development plan leading to the Phase 1 readout in 2H2026. Read together, the four papers trace the investment thesis from platform viability to commercial competitive dynamics to clinical catalyst to acquisition outcome.

What this paper establishes

The analysis that follows documents the asset inventory, the four valuation methodologies pharma M&A teams use to triangulate acquisition pricing, the Monte Carlo enterprise value distribution that anchors the Stage 1 range, and the specific acquirer and licensee rationales for Eli Lilly, Roche, Novartis. It commits to specific ranges for each scenario rather than deferring to qualitative conclusions.

Risk note: If ARO-MAPT Phase 1 data does not meet the moderate threshold, the acquisition thesis is invalidated. The downside is bounded by a non-CNS commercial business whose probability-adjusted value sits near today’s market cap. This is a meaningful but not catastrophic downside.

I. The Thesis

Arrowhead Pharmaceuticals trades at approximately $9.8 billion. The central argument of this paper is that this market capitalization underprices a specific and near-term opportunity: in the second half of 2026, Arrowhead’s lead CNS program, ARO-MAPT, will produce Phase 1 data that, depending on its quality, will force one of three distinct outcomes. One of those outcomes is probable acquisition at a valuation multiple of today’s market cap. Another is meaningful re-rating with extended optionality through licensing or delayed acquisition. The third is invalidation of the acquisition thesis, bounded by a non-CNS floor that limits downside. The purpose of this paper is to make the probabilistic case for each outcome.

The Phase 1 readout is the single most consequential event for Arrowhead’s valuation in the next three years.

ARO-MAPT is designed to silence MAPT, the gene that encodes tau protein, by delivering a subcutaneous RNAi therapeutic across the blood-brain barrier using Arrowhead’s TRiM delivery platform. Success means two things simultaneously: validation of tau-silencing as a disease-modifying approach to Alzheimer’s disease, and validation that Arrowhead has built the only subcutaneous CNS-delivery platform in the industry. The first makes ARO-MAPT commercially valuable, and the second makes Arrowhead strategically irreplaceable. No other siRNA company has demonstrated subcutaneous blood-brain-barrier crossing with therapeutic-scale gene silencing in humans. A positive Phase 1 readout converts Arrowhead from a pipeline company with an interesting platform into an acquisition target that strategic acquirers will find difficult to leave untouched.

The data will not be binary.

Phase 1 readouts produce continuous measurements on multiple dimensions: CSF tau reduction depth, durability of effect, blood-brain-barrier penetration efficiency, dose-response relationships, and tolerability signals. The market’s response, and the strategic response from potential acquirers, will be calibrated to the specific quality of the data, not to a simple yes/no outcome. This paper therefore organizes its analysis around three scenarios that capture the realistic distribution of Phase 1 outcomes, each with its own re-rate magnitude, acquisition probability profile, and alternative licensing path. The thresholds for each scenario are anchored to the published BIIB080 Phase 1b benchmark, the most directly comparable tau-silencing dataset in the clinical literature. The BIIB080 high-dose cohorts (60 mg monthly, 115 mg quarterly) achieved 51–56% CSF total tau reduction during the 3-month multiple ascending dose treatment period, with sustained approximately 60% reduction across all dose groups through the long-term extension. BIIB080 is delivered intrathecally; ARO-MAPT is delivered subcutaneously. A direct biomarker comparison therefore tests whether Arrowhead’s subcutaneous delivery platform achieves tau-silencing pharmacology comparable to or superior to the intrathecal benchmark.

Figure 1: The Three Phase 1 Scenarios and Their Consequences

Figure 1: Three Phase 1 readout scenarios with corresponding re-rate ranges, acquisition outcomes, and alternative paths. Market cap multiples are anchored to Arrowhead’s approximately $9.8 billion current valuation. Per-share implications and detailed bidder dynamics are developed in later sections.

Two investment consequences follow.

First, the asymmetric entry point is today, before the Phase 1 data arrives. Under the strong data scenario, the re-rate alone produces a 2.6× to 4.6× return, and a subsequent acquisition at the Stage 1 range of $55 to $90 billion extends that to 5.6× to 9.2×. Under the moderate scenario, the re-rate produces a 1.5× to 2.6× return with extended upside optionality. Under the weak scenario, the downside is bounded by the non-CNS business at approximately 70–100% of today’s market cap. The expected value calculation across the distribution is favorable to entering a position today rather than waiting for the readout.

Second, the investor’s task today is not to predict which scenario will materialize, because Phase 1 data quality cannot be forecast with precision. The task is to assess the prior probability of each scenario given what is currently known: BIIB080’s validation of MAPT-silencing as a biomarker-active mechanism in humans, trontinemab’s validation of TfR1-mediated blood-brain-barrier transcytosis as a therapeutic-scale delivery route, Arrowhead’s non-human-primate CSF tau reduction data, and the ARO-MAPT Phase 1 dose escalation design. The weight of this prior evidence reduces the probability of the weak scenario below what the current market cap implies. Section VI quantifies this gap using Monte Carlo simulation across nine input variables; the probabilistic case is built there.

A note on terminology and the longer horizon.

Throughout this paper, “Stage 1” refers to the acquisition outcome that follows from the strong Phase 1 scenario: the $55 to $90 billion range developed in Section II and the sections that follow. “Stage 2” refers to the valuation window that opens if positive Phase 1 data does not produce a transaction within 12 to 18 months and Phase 2 cognitive endpoint data subsequently reads out positive in 2029–2030, which the paper estimates at approximately $110 to $150 billion. Stage 2 is treated as conditional forward optionality rather than a primary scenario; the analysis focuses on the Phase 1 readout and its immediate consequences because that is where the asymmetric investment opportunity lives.

If ARO-MAPT delivers, Arrowhead will either be acquired or will license ARO-MAPT at economics that produce a multi-fold return from today's market cap. If ARO-MAPT does not deliver, the downside is bounded by a real commercial business that exists independent of the platform thesis. The analysis in this paper commits to specific ranges for each path.

II. Price vs. Value

Arrowhead is worth somewhere between $55 billion and $90 billion in a competitive acquisition process if ARO-MAPT’s Phase 1 data meets the strong-case threshold developed in Section I. That range is roughly six to nine times today’s market cap. Both the market cap and the acquisition range are correct numbers. They answer different questions.

Today’s market cap is a price. A price is what the marginal public investor is willing to pay for the marginal share of common stock on any given trading day. It is the aggregate output of rNPV analysis applied by thirteen sell-side analysts, institutional positioning decisions made by portfolio managers who model disclosed programs against stage-dependent probability assumptions, and retail and algorithmic trading that moves on headlines and momentum without reference to the underlying asset’s strategic value. The price fluctuates with market sentiment, sector rotation, and news flow. It is real, and it is the liquidity-weighted consensus of what a diversified portfolio holder should pay for the right to own the share today.

The $55 to $90 billion range is a valuation. A valuation is what a strategic acquirer, evaluating the asset against their own infrastructure, their competitive landscape, and their long-term strategic plan, concludes the asset is worth plugged into their operations. It is the product of detailed synergy analysis, competitive positioning analysis, regulatory and commercial infrastructure analysis, and, critically, the cost-of-not-owning-it calculation that incorporates what happens if a competitor secures the platform first.

These two numbers diverge for Arrowhead specifically because the platform sits at a delivery inflection point and the public market cannot price platform inflections. Understanding why this is structurally true, not a temporary inefficiency that will correct through ordinary trading, is the foundation of the rest of this paper’s argument.

Why Big Pharma Does Not Use rNPV to Value Acquisitions

rNPV is the standard methodology taught in every pharmaceutical finance MBA program and applied by every sell-side analyst covering biotech. Estimate peak revenue for a drug program. Apply stage-dependent success probability. Discount back to present value. Sum across programs.

The methodology is internally consistent, defensible against audit, and appropriate for diversified pipeline companies where programs are largely independent. It is also structurally inadequate for platform companies at delivery inflection points, which is why no pharmaceutical M&A team applies rNPV as the primary valuation framework for acquisition decisions. M&A teams build their own rNPV as a standalone baseline, the number that anchors the floor of what a rational board would accept, and then apply strategic value adjustments, synergy quantification, competitive positioning analysis, and scenario modeling to arrive at the authorized bid range. The rNPV number is not the prediction of acquisition price, it is the floor beneath the acquisition price. The ceiling is set elsewhere.

The Eight Reasons Strategic Value Analysis Produces a Different Number

For Arrowhead specifically, eight structural factors drive the divergence between public market rNPV-derived pricing and strategic acquirer valuation. These are not rhetorical flourishes. Each one represents a specific valuation input that appears in an acquirer’s model and does not appear in a sell-side rNPV.

One: Platform optionality and correlated probability updates.

TRiM has validated delivery across six tissue types, five clinically (liver, lung, muscle, adipose, and CNS neurons via subcutaneous BBB crossing) and one preclinically (ocular). When ARO-MAPT validates subcutaneous TfR1-mediated BBB delivery, the probability of success for ARO-SNCA, ARO-HTT, ARO-ATXN3, and every future CNS program sharing that delivery mechanism rises simultaneously. rNPV treats each program as an independent probability tree. An acquirer treats these probability updates as correlated, which produces materially higher expected portfolio value.

Two: The engine generates candidates faster than rNPV can model them.

Arrowhead’s undisclosed pipeline includes a cardiometabolic program labeled Gene X, presented at the 7th Annual CNS Delivery Summit in December 2025 with approximately 90% mRNA knockdown in non-human-primate brains. That program is not in any sell-side model. An acquirer is not buying the disclosed pipeline; they are buying the engine that generates future pipelines. The engine has economic value independent of any specific current program.

Three: Acquirer-specific synergy.

Lilly’s commercial infrastructure reduces the cost of commercializing ARO-MAPT by approximately 20–25 points of margin. Roche’s trontinemab overlap reduces manufacturing and regulatory costs by 10–15 points. Novartis’s existing ARO-SNCA collaboration reduces technical integration costs by 5–10 points. These synergies are acquirer-specific, meaning they appear in an acquirer’s internal model and are entirely absent from any rNPV. The synergy premium is what allows different bidders to arrive at meaningfully different internal valuations for the same asset, the basis of competitive auction dynamics.

Four: Defensive value.

If Lilly does not acquire Arrowhead and Roche does, the competitive damage to Lilly’s Kisunla franchise has a present value of $15 to $30 billion over a decade. This is not a hypothetical cost. It is a real strategic liability that a rational acquirer factors into willingness to pay. rNPV cannot model competitive scenarios because rNPV is a single-entity cash-flow model. Defensive value is one of the largest single reasons acquirers bid above standalone rNPV.

Five: Combination therapy economics.

A two-mechanism AD franchise, IV amyloid clearance paired with subcutaneous quarterly tau silencing, has pricing power that neither asset achieves standalone. Combination regimens in oncology and immunology command 25–40% premiums over component pricing. For Lilly, the combination of Kisunla and ARO-MAPT is commercially additive in ways that neither drug can replicate individually. For Roche, trontinemab and ARO-MAPT combined produce the only two-mechanism AD franchise in existence where both drugs use TfR1-mediated BBB transcytosis as their delivery route. This scientific and commercial coherence is priced in the acquirer’s model and absent from sell-side rNPV.

Six: Diagnostic-therapeutic franchise coherence (Roche-advantaged).

Roche owns the Elecsys laboratory diagnostic platform, the dominant global infrastructure for Alzheimer’s blood-based biomarker testing. A Roche acquisition of Arrowhead creates a vertically integrated franchise: patient identification with Elecsys pTau-181 and pTau-217 assays, amyloid clearance with trontinemab, tau silencing with ARO-MAPT, and progression monitoring with the same biomarker platform. Note that Roche co-developed the Elecsys pTau blood tests with Lilly under a 2023 partnership, and Elecsys pTau-181 received FDA approval for primary care use in October 2025, so diagnostic access itself is not exclusive to a Roche bid. What remains uniquely Roche’s is ownership of the diagnostic infrastructure, per-test revenue capture across all AD testing volumes, and the ability to vertically integrate diagnostic-therapeutic economics without a partnership revenue-share. That vertical integration is strategic value that appears in Roche’s model and nowhere else.

Seven: Manufacturing and delivery moat.

TRiM requires proprietary chemistry, conjugation, and purification at scale. Arrowhead’s Verona facility provides three operational GMP lines with a 2028 option to acquire 6.24 adjacent acres for commercial-scale expansion. Replacement cost of building this infrastructure from scratch is approximately $2 to $4 billion and five to seven years of construction and qualification. An acquirer values this infrastructure as strategic currency, immediately usable capacity that contract manufacturers cannot replicate. The 6.24-acre adjacent parcel under option through 2028 is an additional layer of strategic value that deserves specific attention. Exercising the option and building expansion capacity on the adjacent parcel would cost an acquirer an estimated 40–60% less than constructing a comparable greenfield GMP facility at a new location, with a timeline compression of roughly 18–24 months. The cost advantage reflects reuse of existing site infrastructure (utilities, permits, environmental qualification, shared services) and partially reusable design work; the time advantage reflects the elimination of site selection, permitting, and initial regulatory qualification phases. For an acquirer planning to scale TRiM manufacturing across multiple commercial products over the next decade, this expansion pathway is not a theoretical asset, it is a pre-positioned capability with quantifiable economic value that a standalone Arrowhead would realize more slowly. rNPV does not assign value to manufacturing beyond the implicit assumption that production capacity exists.

Eight: Accelerated development through acquirer clinical infrastructure.

Lilly and Roche each operate thousands of active clinical trial sites globally, with dedicated CNS trial infrastructure and established protocols for AD-specific enrollment. Plugging ARO-MAPT into that network compresses Phase 2 and Phase 3 enrollment timelines by an estimated 12 to 24 months compared to Arrowhead running these trials standalone. For a Phase 3 AD trial running four to six years, that time compression has material present value; earlier approval, earlier revenue, earlier patent-life capture. This value appears in an acquirer’s model as a line item and is entirely absent from a sell-side rNPV that assumes standalone development timelines.

Why Competitive Bidding Makes Strategic Value Analysis the Only Relevant Framework

In a negotiated M&A transaction with two or more motivated bidders, the final price is controlled by the second-highest bidder’s maximum willingness to pay plus a minimum increment to win. This is not a theoretical proposition; it is the mechanical consequence of auction dynamics applied to corporate M&A. The auction mechanism produces price discovery by forcing each bidder to reveal, through the act of raising their bid, progressively more of their internal valuation.

For Arrowhead post-Phase 1, under the strong data scenario developed in Section I, three strategic bidders, Lilly, Roche, and Novartis, evaluate ARO-MAPT against their own strategic value frameworks. Their internal valuations differ, in absolute terms probably by $20 to $40 billion at Stage 1, because each bidder’s synergy stack, defensive liability, and platform integration value is different. But every one of those internal valuations reflects strategic value analysis with acquirer-specific synergy, defensive value, and positioning economics. None of them reflect sell-side rNPV.

The final price is therefore set by the interaction of these strategic valuations, not by the rNPV framework that generates the public-market stock price. The $9.8 billion market cap is an interesting datapoint, it tells an acquirer what they cannot bid below, because Arrowhead’s board would have fiduciary grounds to reject any bid at a trivial premium over market cap. The market cap does not set the ceiling. The ceiling is set by the most motivated bidder’s strategic value number, constrained downward only by the need to exceed the second-highest bidder’s maximum.

The gap between price ($9.8 billion) and strategic value ($55 to $90 billion at Stage 1) is not a market inefficiency that will close through ordinary trading. It is a framework inefficiency that will close only when a framework-appropriate event, positive Phase 1 data, forces the market to shift from rNPV pricing to strategic value pricing. That shift is the re-rate modeled in Section I’s three scenarios.

What an Acquirer Pays For

A strategic acquirer of Arrowhead at Stage 1 is paying for five distinct categories of value. Understanding these categories helps calibrate why the total exceeds any individual asset’s rNPV.

Assets in the current disclosed pipeline.

Plozasiran franchise across FCS (approved), sHTG (near approval), and the CAPITAN CVOT optionality; ARO-MAPT across AD and the orphan tauopathies (PSP, CBD, FTD-MAPT); obesity pipeline; pulmonary programs including ARO-RAGE; complement programs (ARO-C3, ARO-CFB); Sarepta and Novartis partnership streams. These are the programs a sell-side analyst would find in a model, probability-weighted against published trial timelines.

Platform capacity to generate future programs.

Gene X. Ocular TRiM. Cardiomyocyte TRiM. Programs that exist in Arrowhead’s internal roadmap but are not in sell-side models because they have not been disclosed in sufficient detail to model. An acquirer pays for the engine, not just the current output. The engine has produced ARO-MAPT, ARO-RAGE, ARO-SNCA, Gene X, and numerous other candidates; there is no analytical reason to assume it will stop producing.

Strategic positioning.

The cost of not owning the platform if a competitor owns it instead. For Lilly, this is the Kisunla defensive premium, the value of preventing a subcutaneous tau silencer from pressuring the IV amyloid franchise for a decade. For Roche, this is the trontinemab scientific coherence, the value of being the only company to operate both approved TfR1-delivered drugs. For Novartis, this is the ARO-SNCA collaboration integration, the value of controlling the full platform after already paying for partial access.

Infrastructure.

Verona GMP manufacturing with expansion option; clinical operations including the ARO-MAPT Phase 1 protocol execution; TRiM chemistry expertise accumulated over fifteen years of platform development; regulatory team experience across nine IND filings in multiple therapeutic areas. Replacement cost of building this from scratch is $2 to $4 billion and five to seven years of construction, hiring, and qualification. An acquirer integrates this infrastructure on day one.

Optionality on competitive landscape.

The platform becomes more valuable as competitive alternatives emerge (defensive value rises as competitors threaten Kisunla or other approved AD therapies) and as the platform generates additional validated tissue types (offensive value rises as more therapeutic indications become accessible). A Stage 1 acquirer is buying optionality on both directions of this evolution, a call option on defensive value and a call option on offensive platform expansion.

Comparable Pharmaceutical Acquisitions

History anchors the math. The question is not whether strategic pharmaceutical acquisitions at multi-billion-dollar premiums over market cap occur, they occur regularly, but at what multiples, for what types of assets, and with what structural characteristics. Figure 2 summarizes four recent comparable transactions, each one a catalyst-driven acquisition involving a clinical-stage or early-commercial biotech with a validated mechanism.

Figure 2: Comparable Pharmaceutical Acquisitions

Figure 2: Four historical pharmaceutical acquisitions with both pre-data and immediate pre-deal multiples. Arrowhead’s projected Stage 1 multiples sit within the historical range on both dimensions: the 5.6–9.2× pre-data multiple is consistent with Prometheus (10.8×), MyoKardia (6.5×), Karuna (9.3×), and ImmunoGen (12.6×); the approximately 2.0–2.4× immediate pre-deal multiple is consistent with the typical acquisition-premium-over-re-rated-market-cap range across all four comparables.

The Prometheus transaction is the most instructive single comparable. Prometheus traded at roughly $1 billion market cap at $36 per share before reporting positive Phase 2 TL1A data in ulcerative colitis (ARTEMIS-UC) and Crohn’s disease (APOLLO-CD) in December 2022. The clinical results triggered a market re-rate to approximately $5.4 billion by April 2023. Merck then paid $10.8 billion (a 75% premium over the re-rated market cap) to acquire the company. The compound multiple from pre-data entry to acquisition close is 10.8×.

The structural parallel to Arrowhead-today is direct. An investor positioned in Prometheus before the Phase 2 data captured the full compound return (10.8×) through the combination of the re-rate and the subsequent acquisition premium. An investor who waited until the data was reported, re-rated the stock, and then bought at the re-rated level captured only the acquisition premium (2.0× from the re-rated market cap). The asymmetric entry point was before the data, not after. Arrowhead today sits in the analogous position: $9.8 billion market cap before Phase 1 data, with a three-scenario outcome distribution that makes today’s entry the asymmetric position.

MyoKardia, Karuna, and ImmunoGen each follow the same structural pattern at somewhat different magnitudes. MyoKardia traded at approximately $2 billion market cap before positive Phase 3 EXPLORER-HCM data; BMS subsequently paid $13.1 billion for a 6.5× pre-data multiple. Karuna traded at approximately $1.5 billion market cap before positive Phase 3 EMERGENT-2 schizophrenia data; BMS subsequently paid $14 billion for a 9.3× pre-data multiple. ImmunoGen traded at approximately $0.8 billion market cap before the November 2022 FDA accelerated approval of Elahere; AbbVie subsequently paid $10.1 billion for a 12.6× pre-data multiple. In each case, the catalyst was a single data or regulatory event that shifted the market’s framework from speculative clinical valuation to acquisition-premium valuation. Arrowhead’s Phase 1 CSF tau readout in 2H2026 is the same category of event.

Note on Alnylam.

Alnylam Pharmaceuticals, Arrowhead’s nearest RNAi competitor, trades at approximately $42 billion as of this writing. Alnylam is not a transaction comparable, it has not been acquired and no public acquisition process is underway, but it establishes what a diversified commercial-stage RNAi platform is worth in the public market today. Alnylam has approved products across multiple indications and validated delivery to liver, muscle, and CNS (via intrathecal administration). Arrowhead, with a more differentiated delivery platform that includes subcutaneous CNS crossing (which Alnylam has not replicated) and a broader clinical pipeline (nineteen programs across ten owned and nine partnered vs. Alnylam’s narrower focus), should not trade at a permanent discount to Alnylam. The current $9.8 billion Arrowhead market cap versus $42 billion Alnylam market cap reflects the delivery-platform validation gap that the Phase 1 readout will resolve. Resolving it in favor of Arrowhead’s subcutaneous CNS validation produces a public market re-rate that begins to close the Alnylam gap, independent of any acquisition process.

Why Large Platform Acquisitions Prove Value-Accretive

The most important historical precedent for understanding why a rational strategic acquirer might pay $55 to $90 billion for Arrowhead is not in the recent comparable-deal data set. It is in Roche’s 2009 acquisition of the remaining public stake in Genentech for approximately $46.8 billion.

At the time of the transaction, the Genentech deal was characterized as expensive, even aggressive. Analysts questioned whether Roche could justify the premium. Within a decade, the acquisition was recognized as one of the most value-accretive transactions in pharmaceutical industry history. The Genentech antibody platform became the foundation of Roche’s oncology franchise and produced multi-hundred-billion-dollar cumulative revenue across Herceptin, Rituxan, Avastin, Perjeta, Kadcyla, and subsequent programs. The apparent premium at acquisition was trivial compared to the value the platform generated under Roche ownership.

The structural argument for an Arrowhead acquisition is the same argument, applied to a different platform technology at a different inflection point. A strategic acquirer who pays $55 to $90 billion for Arrowhead at Stage 1 is not primarily paying for ARO-MAPT in Alzheimer’s disease, though that asset is the immediate value driver. They are paying for a delivery platform that has validated mechanisms across six tissue types and has demonstrated the capacity to generate clinical-stage candidates at a rate that exceeds the industry’s delivery-platform benchmarks. If that platform produces two or three additional approved drugs over the next decade, a reasonable base case given the current pipeline, the acquisition economics justify themselves independent of any single asset’s commercial outcome. The Genentech precedent is the correct analytical frame for understanding what acquirers actually pay for when they acquire platforms, and why the apparent premium at transaction is not the right lens for evaluating the transaction ex post.

Arrowhead’s $9.8 billion market cap reflects public-market rNPV pricing. A strategic acquirer evaluating ARO-MAPT after positive Phase 1 data applies strategic-value analysis, which incorporates synergy, defensive value, and platform optionality that rNPV structurally cannot capture. The gap between those two frameworks is the investment opportunity.

III. Analyst Coverage

Approximately a dozen sell-side analysts cover Arrowhead Pharmaceuticals with active 12-month price targets. The consensus target sits in the range of $76 to $82 per share, implying a target market cap of roughly $10.5 to $11.5 billion. The high-end target on the street is approximately $110 per share, implying a market cap of roughly $15 billion. The low-end target, from a small number of bearish firms, is approximately $35 per share, implying a market cap of roughly $5 billion.

Every one of these numbers is dramatically below the $55 to $90 billion Stage 1 acquisition range developed in this paper. Even the most bullish analyst on the street today is producing a price target that implies a market cap roughly 15% of the Stage 1 acquisition floor. This is not because the analysts believe Arrowhead is worth less than the market assigns; the consensus target represents a modest premium over the current price. It is because the institutional sell-side price target framework cannot accommodate the kind of conditional acquisition thesis this paper describes.

Sell-side price targets are built on three structural constraints that prevent strategic acquisition value from being incorporated.

Twelve-month time horizon.

A sell-side price target is a prediction of what the stock will trade at in approximately twelve months under normal-course-of-business operating assumptions. It is not a target price under an acquisition scenario. An analyst whose 12-month price target reflected an 8× return from current prices would be immediately accused of speculation; their compliance department would flag the note; their sales force would not distribute it. The framework is designed to produce small-magnitude price movements against current prices, which structurally excludes acquisition value by construction.

Probability-weighted scenarios around a base case.

Most sell-side models produce a base case (rNPV-derived), a bull case (somewhat higher peak revenue or earlier timelines), and a bear case (pipeline setbacks). The bull case rarely incorporates acquisition scenarios because acquisitions are idiosyncratic events that cannot be probability-weighted in a defensible way for a 12-month horizon. The analyst who writes “my bull case assumes a $70 billion acquisition from Lilly” is producing an unmodelable claim. The analyst who writes “my bull case assumes 15% higher peak sales and a 12-month earlier launch” is producing a standard, defensible sell-side bull case. The framework selects against the former and selects for the latter.

rNPV as the central valuation discipline.

Every covering analyst uses some variant of rNPV. As established in Section II, this methodology is appropriate for diversified pipeline companies but systematically inadequate for platform companies at delivery inflection points. rNPV applied to Arrowhead today produces the current spread of target prices across the $35 to $110 per share range. The analysts are not wrong within their framework, they are correctly applying an inappropriate framework.

The Implication

When Phase 1 data arrives in the second half of 2026 and the stock re-rates, sell-side coverage will update. Analysts will raise their price targets, probably substantially, given the magnitude of the prior evidence base this paper has laid out, but their updated price targets will still reflect rNPV-based frameworks, now with higher probability inputs for the ARO-MAPT program. The analyst consensus after a strong Phase 1 readout will converge toward a target range consistent with the strong-case market cap developed in Section I’s scenario framework. The sell-side consensus, in other words, will eventually arrive at the re-rated market cap this paper projects, but it will do so by tracking the market’s own pricing, not by anticipating it. Even after this re-rate, the analyst consensus will remain well below the acquisition range. The gap between rNPV-derived targets and strategic acquisition value is not a gap that closes; it is a framework boundary.

An individual investor who waits for sell-side price targets to capture the full acquisition thesis will be waiting indefinitely. The analysts’ framework converges on an rNPV-compliant representation of the re-rated market cap. It does not converge on the acquirer’s willingness to pay, because the analysts’ framework cannot produce that number without violating the institutional constraints that define sell-side coverage.

The One Path Toward a Conditional Analyst Note

There is, however, one path by which a sell-side analyst could begin to close this gap without violating any of the structural constraints described above. A conditional scenario note, framed as follows:

If ARO-MAPT delivers positive Phase 1 human data in 2H2026, we believe strategic acquisition interest from Lilly, Roche, or Novartis could realistically value ARWR in the range of $55 to $90 billion, representing a per-share price of approximately $355 to $581 on a fully diluted basis.

That sentence is compliance-defensible because it is conditional and range-bound. It is analytically honest because the math supports it. It is commercially significant because the first analyst who publishes it will produce the most-read piece of research on this stock in years. The remaining analysts will have to respond, either by engaging with the conditional framework or by explicitly rejecting it. In either case, the market begins pricing the acquisition optionality that it has, to this point, been ignoring.

When that repricing occurs, whether because an analyst publishes the conditional note or because Phase 1 data arrives and forces the reframing, the analytical work that preceded the institutional consensus will have served its purpose. Until then, the reader cannot outsource the acquisition-thesis analytical work to the sell side. The framework constraints that produce the current $76 to $82 average price target are the same framework constraints that will prevent the sell-side from naming the acquisition range until after it is no longer an asymmetric entry point.

The dozen analysts covering Arrowhead produce price targets clustered at $35 to $110 per share, 5 to 15 percent of the Stage 1 acquisition range developed in this paper. The analysts are not wrong within their framework; they are applying an rNPV framework that cannot incorporate acquisition value by construction.

IV. The Non-ARO-MAPT Portfolio

The three-scenario framework developed in Section I depends on understanding what Arrowhead is worth besides ARO-MAPT. In the strong scenario, the non-ARO-MAPT portfolio is what an acquirer gets beyond the Alzheimer’s program; it drives a significant portion of the $55 to $90 billion valuation range. In the weak scenario, the non-ARO-MAPT portfolio is what bounds the downside; it establishes the approximately 70 to 100 percent of today’s market cap floor that the Phase 1 failure case assumes.

This section catalogs those assets. It does not attempt to build comprehensive revenue forecasts or probability-weighted valuations for each program; Sections V and VI take up that work using formal valuation methodology. The purpose here is to establish what is in the portfolio, what stage each program has reached, and what makes each relevant to the acquisition thesis.

The Commercial Cardiometabolic Franchise

Arrowhead transitioned into a commercial-stage company on November 18, 2025, when the FDA approved REDEMPLO (plozasiran) for familial chylomicronemia syndrome (FCS). REDEMPLO is Arrowhead’s first approved medicine and the anchor of the cardiometabolic franchise. Arrowhead is launching the drug independently in the United States using the One-REDEMPLO pricing model, which establishes a consistent price across current and potential future indications, a deliberate strategic choice that simplifies payor negotiations as the drug expands into additional triglyceride-lowering indications. China’s NMPA approved REDEMPLO for FCS in April 2026, with Sanofi handling commercialization in Greater China under the agreement that Sanofi purchased from Visirna in 2025.

The FCS indication itself is a modest commercial opportunity. Roughly 6,500 people in the United States live with genetic or clinical FCS, characterized by triglyceride levels 10 to 100 times higher than normal and substantial risk of acute pancreatitis. The FCS market, at commercial orphan-disease pricing, represents peak revenue in the range of a few hundred million dollars annually. The commercial importance of REDEMPLO’s FCS approval is not the FCS market itself, it is that the approval establishes plozasiran’s regulatory foundation and commercial infrastructure for the much larger indications that follow.

The severe hypertriglyceridemia (sHTG) opportunity is where plozasiran becomes a major commercial asset. The SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 trials complete in mid-2026, with supplemental NDA filing expected by year-end 2026. The FDA granted Breakthrough Therapy designation for plozasiran in sHTG in December 2025. sHTG is an addressable market measured in millions of patients globally, with peak revenue estimates in the multi-billion-dollar range at commercial pricing. Plozasiran’s head-to-head positioning against Ionis’s Tryngolza in sHTG, where Ionis cut pricing substantially in 2025, is developed in detail in the prior BioBoyScout analysis Redemplo vs. Tryngolza (March 2026). The summary conclusion is that plozasiran’s once-quarterly subcutaneous dosing profile and clinical efficacy support a two-winner market outcome at minimum.

Beyond plozasiran, the cardiometabolic franchise includes zodasiran (Phase 3 for homozygous familial hypercholesterolemia, an orphan indication with commercial optionality) and ARO-DIMER-PA, the first clinical-stage dual-functional RNAi therapeutic. ARO-DIMER-PA silences both PCSK9 and APOC3 genes in a single molecule, with Phase 1/2a dosing of the first subjects initiated January 2026 in mixed hyperlipidemia. Mixed hyperlipidemia is a high-prevalence disorder affecting millions, and the dual-gene approach represents a meaningful platform expansion, not just a new drug candidate but the first demonstration that TRiM can deliver dual-functional RNAi molecules. The commercial opportunity, if Phase 1/2a data supports advancement, is comparable to or larger than plozasiran’s mixed-hyperlipidemia opportunity in CAPITAN.

Figure 3: Non-ARO-MAPT Clinical-Stage Asset Inventory

Figure 3: Clinical-stage assets in Arrowhead’s non-ARO-MAPT portfolio. Commercial infrastructure anchored by REDEMPLO (plozasiran) FCS approval; near-term expansion into sHTG and mixed hyperlipidemia through existing plozasiran trials; standalone obesity program with first human adipocyte-gene knockdown data. Partnered programs (Sarepta, Novartis, Takeda) are discussed separately below. Peak revenue estimates are industry-consensus ranges; probability-weighted rNPV treatment is developed in Section V.

The Obesity Program

Arrowhead disclosed interim Phase 1/2a data from ARO-INHBE and ARO-ALK7 in January 2026. Both programs target the Activin E / ALK7 pathway, a mechanism that is mechanistically distinct from GLP-1 receptor agonism and addresses specific limitations of current obesity standard-of-care: loss of lean mass, GI tolerability, reduced response in patients with diabetes, and disproportional fat mass regain after therapy cessation.

The interim data is clinically meaningful. ARO-INHBE monotherapy produced 9.9 percent visceral fat reduction at week 16 (single dose) and 15.6 percent placebo-adjusted visceral fat reduction at week 24 (two doses), with a 3.6 percent increase in lean muscle tissue. In combination with tirzepatide, ARO-INHBE approximately doubled weight loss and tripled reductions in visceral fat, total fat, and liver fat compared to tirzepatide alone in obese patients with type 2 diabetes. ARO-ALK7 became the first RNAi therapeutic to demonstrate knockdown of an adipocyte-expressed gene in humans, achieving 88 percent mean ALK7 mRNA reduction (94 percent maximum) and 14.1 percent placebo-adjusted visceral fat reduction from a single dose at week 8.

The strategic significance of the obesity program to an acquirer is material. Lilly and Novo Nordisk have built multi-billion-dollar franchises around GLP-1 mechanisms; both face pressure from next-generation approaches that address GLP-1’s limitations. An obesity asset that preserves lean mass, improves GLP-1 combination economics, and addresses the T2D subpopulation where GLP-1s underperform is commercially valuable as standalone or as a combination therapy with existing GLP-1 backbones. Arrowhead has stated its intention to keep both ARO-INHBE and ARO-ALK7 in-house through development, which means an acquirer of Arrowhead inherits both programs intact.

Additional Clinical Programs

Arrowhead’s pulmonary franchise, centered on ARO-RAGE for severe uncontrolled asthma and related indications, continues to advance through Phase 2. The complement franchise (ARO-C3, ARO-CFB) is in earlier stages but covers indications including IgA nephropathy, geographic atrophy in AMD, and paroxysmal nocturnal hemoglobinuria, each with multi-billion-dollar commercial potential in its primary indication. These programs do not carry the same magnitude of near-term catalyst value as plozasiran or the obesity candidates, but they contribute to the platform breadth that acquirers value.

Partnered Programs: Sarepta, Novartis, and Takeda

Arrowhead’s three largest active partnerships represent substantial inherited deal value for any acquirer.

The Sarepta Therapeutics agreement, closed February 2025, covers four clinical-stage programs (ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-DM1 for myotonic dystrophy type 1, ARO-MMP7 for idiopathic pulmonary fibrosis, ARO-ATXN2 for spinocerebellar ataxia 2) plus three preclinical programs, with Sarepta able to nominate up to six additional targets during a five-year term. The transaction economics at closing included $500 million upfront, $325 million equity investment at $27.25 per share (a 35 percent premium at the time), $250 million in equal annual installments over five years, and up to $300 million in near-term milestones tied to ARO-DM1 Phase 1/2 enrollment progress. Total deal value, including all future milestones and royalties, is up to approximately $11 billion. Arrowhead also manufactures clinical drug supply for all programs and commercial drug product for the four clinical programs, which represents ongoing revenue-sharing economics that persist through commercial launches.

The Novartis agreement, closed October 2025, grants Novartis exclusive worldwide rights to ARO-SNCA, the alpha-synuclein siRNA for Parkinson’s disease and other synucleinopathies, plus additional collaboration targets. The transaction economics at closing included $200 million up front with up to $2 billion in potential milestone payments plus commercial royalties. The strategic significance of the Novartis deal is compounded by its use of the same subcutaneous CNS-delivery mechanism that underlies ARO-MAPT. Novartis’s commitment to ARO-SNCA at a preclinical stage, based on the delivery platform’s demonstrated non-human-primate data, is external validation of the same delivery mechanism whose translation to humans the Phase 1 ARO-MAPT readout will resolve.

The Takeda agreement on fazirsiran (ARO-AAT) for alpha-1 antitrypsin deficiency-associated liver disease is earlier-established but represents structurally different deal economics from Sarepta and Novartis. The program is actively enrolling in the 160-patient Phase 3 REDWOOD trial, with primary endpoint (≥1 stage reduction in liver fibrosis by biopsy) at week 102. Phase 2 SEQUOIA data showed 94 percent median reduction in hepatic Z-AAT accumulation, 68 percent mean reduction in histologic globule burden, and fibrosis regression in 50 percent of treated patients, results published in The New England Journal of Medicine. Fazirsiran carries FDA Breakthrough Therapy designation for AATD-LD. Deal economics provide Arrowhead with a 50/50 US profit share and tiered 20 to 25 percent royalties on ex-US net sales, a structurally more lucrative economic profile than the pure-royalty partnerships, and one that an acquirer inherits in full.

Beyond Sarepta, Novartis, and Takeda, Arrowhead maintains smaller partnerships and revenue streams from GSK, and Visirna/Sanofi (the latter for Greater China rights to plozasiran). Each contributes milestone and royalty streams; none individually moves the acquisition thesis, but collectively they demonstrate a pattern of institutional pharma validation of the TRiM platform across multiple therapeutic areas.

The Undisclosed Pipeline

Arrowhead presented preclinical data at the 7th Annual CNS Delivery Summit in December 2025 showing approximately 90 percent mRNA knockdown in non-human-primate brains for a deliberately undisclosed cardiometabolic target labeled Gene X. Other undisclosed programs exist across ocular TRiM delivery and cardiomyocyte TRiM delivery, tissue-specific delivery mechanisms that extend the platform’s validated range but have not been assigned to specific clinical candidates publicly.

These undisclosed programs do not appear in any sell-side model. They are the forward output of the platform engine. For an acquirer, they represent pre-disclosed optionality: a pipeline that is already producing at a rate the sell-side cannot model, priced into acquisition valuations because acquirers buy the engine, not just its current disclosed output.

What This Portfolio Establishes

Taken together, the non-ARO-MAPT portfolio establishes two things that the thesis depends on.

First, a non-CNS floor in the weak scenario.

If ARO-MAPT Phase 1 data fails the minimum thresholds developed in Section I, Arrowhead remains a commercial-stage company with an approved first-in-class RNAi therapeutic in plozasiran, near-approval sHTG expansion, a meaningful obesity program with human data, multiple clinical-stage programs in cardiometabolic and pulmonary indications, and ongoing milestone and royalty streams from Sarepta, Novartis, Takeda, and other partnerships. The probability-adjusted value of this business sits near today’s market cap, not dramatically above or below, which is what Section I’s weak scenario asserts.

Second, an acquisition-scenario addition beyond ARO-MAPT.

In the strong Phase 1 scenario, an acquirer is not paying $55 to $90 billion for ARO-MAPT alone. They are paying for ARO-MAPT plus plozasiran’s commercial trajectory, plus the obesity program with best-in-class potential in a mechanism GLP-1 incumbents do not own, plus the inherited Sarepta, Novartis, and Takeda deal economics, plus the platform engine’s undisclosed pipeline output. Each of these is modest individually compared to ARO-MAPT; together they account for a meaningful share of the acquisition range.

Before a single ARO-MAPT scenario is modeled, Arrowhead’s non-CNS portfolio supports a standalone acquisition value of $22 to $34 billion. This is the floor that bounds the weak-scenario downside and the foundation on which the ARO-MAPT acquisition premium is built.

V. Valuation Methodology

Large pharmaceutical acquisitions are valued using four methodologies in parallel, each producing a number that is then triangulated against the others. Understanding how M&A teams actually do this work helps calibrate the $55 to $90 billion Stage 1 acquisition range against defensible methodology rather than asserting it.

Each methodology answers a different question. rNPV asks what the asset is worth on its own cash flows. Peak revenue multiple asks what the market is paying for comparable assets on a revenue basis. Comparable transactions asks what acquirers have paid in similar situations. Monte Carlo asks what the probability distribution of outcomes looks like under realistic input ranges. An acquirer’s M&A team runs all four and looks for convergence. When the four methods converge on a similar range, the thesis is robust. When they diverge, something is off, either the inputs are mis-specified, or the strategic framework is wrong, or both.

Method 1: Risk-Adjusted Net Present Value (rNPV)

rNPV serves as the standalone baseline, the value of the target company operating independently, without acquirer synergies. The M&A team produces their own rNPV using their internal assumptions rather than relying on sell-side consensus, but the framework is similar to sell-side work: estimate peak revenue for each program, apply stage-dependent success probability, discount cash flows at a discount rate appropriate to the asset class, sum across the portfolio.

For Arrowhead, the bottom-up gross sum-of-parts is approximately $83 to $165 billion. Plozasiran franchise across all three indications (FCS approved, sHTG near approval, CAPITAN mixed hyperlipidemia CVOT) contributes approximately $22 to $34 billion on probability-weighted peak revenue. ARO-MAPT in Alzheimer’s disease, at conservative pre-catalyst probability assumptions of 20 to 25 percent at Stage 1, contributes approximately $32 to $54 billion. Orphan tauopathies (PSP, CBD, FTD-MAPT) contribute $8 to $18 billion. Partnered streams (Sarepta, Novartis, Takeda, and smaller agreements) contribute $8 to $18 billion in milestone and royalty-adjusted present value. Extended platform programs, including the obesity franchise, complement, pulmonary, and undisclosed programs, contribute $13 to $41 billion depending on which ones are assigned non-trivial probabilities. The distribution is wide because pipeline probabilities vary materially across assets and discount assumptions compound over long commercial horizons.

After applying a conservative 40 to 50 percent portfolio-level probability haircut, which reflects execution risk across the full asset inventory rather than treating every program’s success as independent, the standalone rNPV range is approximately $45 to $65 billion. An M&A team’s rNPV produces a substantially higher figure than sell-side consensus for three specific reasons. First, M&A teams apply asset-specific probability adjustments after data maturity events rather than industry base rates; sell-side CNS programs are typically assigned 10 to 15 percent probability of approval, while an M&A team looking at ARO-MAPT post-Phase-1 applies 20 to 25 percent because BIIB080 has validated MAPT-silencing mechanism in humans and trontinemab has validated TfR1-mediated BBB delivery. Second, M&A teams include platform optionality, undisclosed pipeline programs, manufacturing capacity, and partnered milestone streams that public-market models typically exclude or heavily discount. Third, M&A teams use discount rates that reflect the acquirer’s weighted cost of capital (8 to 10 percent) rather than the small-cap biotech risk premium sell-side analysts bake into their DCF models (12 to 15 percent). The cumulative effect produces an M&A-internal rNPV two to three times the sell-side consensus for the same underlying asset.

The $9.8 billion current market cap reflects a much deeper delivery-risk discount than even the probability-haircut rNPV supports. The gap between the current market cap and the $45 to $65 billion standalone rNPV range is the first piece of evidence for systematic mispricing. The gap between the $45 to $65 billion standalone rNPV and the $55 to $90 billion Stage 1 acquisition range is the synergy premium, addressed in a later subsection.

Method 2: Peak Revenue Multiple

M&A teams cross-check rNPV using peak revenue multiples drawn from comparable pharmaceutical transactions. Historical pharmaceutical acquisitions have transacted at 4 to 7 times peak revenue for validated-mechanism single-asset deals and 2 to 4 times peak revenue for diversified pipeline companies. The mechanism of this methodology is different from rNPV: it captures what acquirers have paid for the right to commercialize assets at scale, which implicitly includes both standalone cash flow value and some of the strategic premium that pure cash-flow discounting misses.

Arrowhead’s risk-adjusted peak revenue at Stage 1 is approximately $18 to $25 billion. Plozasiran franchise contributes $8 to $12 billion (FCS at a few hundred million, sHTG at $4 to $5 billion global peak, CAPITAN mixed hyperlipidemia at $3 to $7 billion risk-adjusted). ARO-MAPT across AD and orphan tauopathies contributes $10 to $13 billion at the 20 to 25 percent probability used in rNPV (which produces $8 to $10 billion from AD alone at peak) plus tauopathies at smaller but non-trivial contribution. Minor contributions from obesity, partnered streams, and other programs round out the estimate.

Applied to a 4 to 6 times multiple, the validated-mechanism range, appropriate for a company where the core assets are either approved, near-approved, or about to resolve a binary catalyst, this produces an enterprise value range of approximately $72 to $120 billion. The peak revenue multiple range runs higher than rNPV because it implicitly captures a portion of the strategic premium that rNPV excludes by construction. This is not a methodology error; it is a different question being answered. rNPV asks “what are the risk-adjusted cash flows?” Peak revenue multiple asks “what has the market paid for comparable revenue streams?” The two numbers should differ, and they do.

Method 3: Comparable Transaction Multiples

The comparable transaction framework anchors against market-cap multiples from closed pharmaceutical acquisitions. As developed in detail in Section II (Figure 2), validated-mechanism platform acquisitions have transacted at pre-data multiples of 6.5 to 12.6 times pre-data market cap in the four closest comparables: Prometheus 10.8×, MyoKardia 6.5×, Karuna 9.3×, ImmunoGen 12.6×. Each of these deals involved a catalyst-driven acquisition where a pharmaceutical acquirer paid a compound multiple that captured both the post-catalyst market re-rate and the acquisition premium.

Applied to Arrowhead’s current $9.8 billion market cap at a Stage 1 multiple range of 5.6 to 9.2 times, the comparable transactions methodology produces $55 to $90 billion in enterprise value. This range sits below the average historical multiple (which would produce approximately $95 billion at the midpoint) for two reasons. First, the restructured paper takes a conservative position on Stage 1 relative to the comparable set; the comparables average 9.8× pre-data multiple, while the paper uses 5.6 to 9.2× to reflect execution uncertainty and to leave room for Stage 2 and beyond. Second, Arrowhead’s pipeline breadth is greater than any single comparable, which moderates the per-asset multiple that would otherwise apply to a single-asset comparable.

The comparable transactions methodology is the most directly anchored of the four methods because it references actual deal consideration rather than modeled cash flows. An M&A team defending a $55 to $90 billion bid to a board uses the comparable transactions work first because it is the least theoretically contestable: the deals happened, the multiples are what they are, and the analytical question becomes whether Arrowhead’s structural characteristics justify placing the deal within, above, or below the comparable range. The paper’s position is that Arrowhead’s characteristics justify a placement within the range, anchored to the Stage 1 pre-data multiple.

Method 4: Monte Carlo Simulation

The fourth methodology is probabilistic rather than deterministic. Rather than produce a single enterprise value, Monte Carlo simulation runs 10,000 iterations varying key input assumptions across their stage-appropriate distributions: ARO-MAPT AD approval probability, peak revenue, discount rate, regulatory timing, pricing dynamics, competitive entry, platform success across non-disclosed programs. The output is a probability distribution of enterprise value outcomes, from which the M&A team identifies the range that defines a value-accretive bid.

Section VI develops the Monte Carlo in detail, including the input distributions and the resulting enterprise value percentiles. The summary at this level: the Monte Carlo median enterprise value at Stage 1 sits in the range of $75 to $105 billion, with the 25th to 75th percentile band spanning approximately $55 to $140 billion. The median range sits above the rNPV band and below the upper end of the peak revenue multiple band, which is the expected pattern when rNPV is conservative on probability inputs and peak revenue multiples capture partial strategic premium.

The Synergy Adjustment

The four standalone methodologies produce a distribution of standalone enterprise values, what the target is worth without reference to the specific acquirer. In any real M&A transaction, however, the final price reflects acquirer-specific synergies: the additional value that an asset generates when plugged into a particular acquirer’s infrastructure rather than operating standalone. This synergy premium is the difference between the standalone valuation and the acquisition price.

Stage 1 synergy values are acquirer-specific and substantial. For Lilly, the total synergy has two components. The first, AD-focused synergy, comprising Kisunla defensive value, the Kisunla + ARO-MAPT two-mechanism AD franchise pricing power, and commercial infrastructure integration, produces an estimated $30 to $50 billion. The second, obesity-focused synergy, comprising defensive value against competitor acquisition of Arrowhead’s obesity program, the tirzepatide + ARO-INHBE combination product economics (where January 2026 Phase 1/2a data showed doubled weight loss and tripled visceral/total/liver fat reductions versus tirzepatide alone), and commercial synergy across Lilly’s obesity auto-injector platform, produces an estimated $15 to $35 billion. Combined, Lilly’s Stage 1 synergy value is approximately $45 to $85 billion. For Roche, the trontinemab scientific coherence, the Elecsys diagnostic-therapeutic integration, and the Genentech antibody platform integration produce approximately $25 to $40 billion. For Novartis, the ARO-SNCA collaboration scaling and broader CNS expertise integration produces approximately $10 to $20 billion. Section X develops these synergy values in detail and defends the specific numbers against counter-arguments, including why Lilly’s two-franchise strategic fit produces a total synergy materially larger than the other bidders’.

In any negotiated acquisition, buyers capture 50 to 70 percent of synergy value for their own shareholders and pay 30 to 50 percent to sellers as the acquisition premium above standalone. Applied to the standalone valuation range and the synergy value range, the math produces the $55 to $90 billion Stage 1 acquisition range: a standalone valuation anchored around the $45 to $65 billion rNPV baseline, plus the seller’s captured share of acquirer-specific synergies, plus the competitive dynamic that drives bidders toward their maximum willingness to pay in an auction process.

Methodology Convergence

The four standalone methodologies and the synergy adjustment converge on the $55 to $90 billion Stage 1 range. Figure 4 consolidates the output of each methodology at Stage 1.

Figure 4: Methodology Convergence at Stage 1

Figure 4: Four independent valuation methodologies applied at Stage 1, with the paper’s acquisition range for comparison. Each methodology uses independent inputs and assumptions. All four methodology ranges overlap the $55 to $90 billion Stage 1 conclusion: comparable transactions produces the range directly, peak revenue multiple fully contains it, Monte Carlo median sits in the upper band, and rNPV sits just below (reflecting the synergy premium excluded from standalone valuation).

The ranges produced by the four methodologies are not identical, nor should they be. Each methodology answers a different question and captures a different aspect of strategic value. What matters analytically is that all four methodology ranges overlap the $55 to $90 billion acquisition range, meaning every methodology individually produces outputs consistent with the paper’s conclusion. Two of the four (peak revenue and comparable transactions) fully contain the range. Monte Carlo’s median sits inside the upper band. rNPV sits just below, and the gap between rNPV and the acquisition range is the synergy premium that standalone valuation methodologies cannot capture by construction.

When four independent methodologies with different inputs and different theoretical bases produce ranges that converge on the same conclusion, the conclusion is robust. That convergence is the analytical signal that the $55 to $90 billion Stage 1 range is not the output of a single methodology’s assumptions but the consensus of the valuation framework pharmaceutical M&A teams actually use. It is the number an acquirer’s board would see if their team performed this work independently, which is a different claim than saying the market will arrive at this number through ordinary trading.

Four independent methodologies, rNPV plus synergy, peak revenue multiple, Monte Carlo, and comparable transactions, converge at a Stage 1 acquisition range of $55 to $90 billion under the strong Phase 1 scenario. Convergence from methodologies with no shared inputs is the strongest possible analytical signal that the range is structurally correct, not the output of any single model’s assumptions.

VI. Monte Carlo Distribution

The Monte Carlo simulation is the probabilistic counterpart to the deterministic methodologies in Section V. Rather than produce a single point-estimate enterprise value, it runs 10,000 iterations varying nine key input variables across stage-appropriate probability distributions, and reports the resulting enterprise value distribution by percentile. The exercise does two things that deterministic methods cannot. First, it quantifies the uncertainty around each of the four standalone methodology outputs, making clear which assumptions drive the largest swings in enterprise value. Second, it produces a probability-weighted answer to the question any acquirer’s M&A team has to answer for their board: what is the likelihood that a bid at a given price is value-accretive for the acquirer?

The Monte Carlo at pre-Phase-1 produces enterprise value ranges that are dramatically wider than the stage-conditioned ranges that follow each data resolution event. This is the central observation: at today’s information state, the uncertainty around Arrowhead’s fair value is enormous, because the single most consequential variable, ARO-MAPT’s probability of ultimate AD approval, has a pre-Phase-1 distribution that spans an order of magnitude of possible values. Phase 1 data collapses this distribution significantly, which is why the Phase 1 readout is the single largest re-rating event in the Arrowhead timeline.

The Driving Variable: ARO-MAPT AD Approval Probability

The single most consequential input in the Monte Carlo is ARO-MAPT’s probability of ultimate AD approval. This variable is scenario-conditioned: its distribution depends on the information state, which in the restructured framework depends on which of the three Phase 1 scenarios materializes.

At pre-Phase-1 (today’s information state), historical base rates for Phase 1 CNS programs produce a 10 to 15 percent probability of ultimate approval. For ARO-MAPT specifically, the argument for a higher probability rests on BIIB080 having validated MAPT-silencing mechanism in humans and trontinemab having validated TfR1-mediated blood-brain-barrier crossing in humans. These are real but partial validations. An appropriate pre-Phase-1 probability is 15 to 20 percent.

Under the strong Phase 1 scenario, delivery risk is retired by positive human CSF tau reduction data meeting or exceeding the BIIB080 benchmark, the probability that ARO-MAPT will silence MAPT in the human brain is no longer speculative. What remains uncertain is whether tau silencing translates to clinical benefit in a cognitive endpoint trial. The strong-scenario probability of ultimate approval is 20 to 25 percent. This reflects the real residual risk that tau knockdown, even at high magnitude, may not produce the cognitive benefit required for approval, a risk that BIIB080’s CELIA Phase 2 cognitive data will partially but not fully retire.

Under the moderate Phase 1 scenario, CSF tau reduction in the 40 to 55 percent range, mechanism validated without clear superiority to the BIIB080 benchmark, delivery is partially validated but the strength of efficacy signal is weaker. The moderate-scenario probability of ultimate approval is 12 to 18 percent, reflecting retained mechanism viability but compressed superiority assumptions.

Under the weak Phase 1 scenario, CSF tau reduction below 40 percent, tolerability issues, or insufficient BBB crossing evidence, the CNS platform thesis compresses materially. The weak-scenario probability of ultimate approval is 5 to 10 percent. At this level, AD expected value becomes a small contributor to total enterprise value, and the Monte Carlo distribution collapses toward the non-CNS floor.

Figure 5: Monte Carlo Input Variables and Distributions

Figure 5: Nine input variables modeled in the Monte Carlo simulation. Central estimates and ranges correspond to the strong Phase 1 scenario. The probability of AD approval and peak AD revenue are the two highest-variance inputs and together drive approximately 60 percent of the distribution width. Moderate- and weak-scenario simulations use the same variable set with scenario-appropriate probability distributions (e.g., AD probability central estimate shifts to 15 percent for moderate, 7 percent for weak).

AD Probability Sensitivity: The Dominant Driver

Before examining the full nine-variable Monte Carlo output, it is useful to see the impact of the single most important variable in isolation. Figure 6 shows the AD indication expected value at different probability assumptions, holding peak revenue and multiple at their central estimates.

Figure 6: Sensitivity of AD Expected Value to Probability Assumption

Figure 6: AD indication expected value as a function of probability assumption. The AD indication valuation is dominated by the probability assumption. Each row is internally coherent and represents a different information state. The 22 percent probability at Stage 1 reflects delivery risk retirement without cognitive endpoint confirmation. Individual investors who disagree with this assumption can substitute their own number and recalculate the acquisition range using this sensitivity table. The dominance of this single variable in the distribution motivates running a full Monte Carlo rather than relying on point estimates.

Scenario-Conditioned Enterprise Value Distribution

Figure 7 presents the full Monte Carlo output: enterprise value distribution percentiles under four information states, today (pre-Phase-1), and the three Phase 1 scenario outcomes. Each distribution is based on 10,000 simulations varying all nine input variables within their scenario-appropriate probability distributions.

Figure 7: Scenario-Conditioned Monte Carlo Enterprise Value Distribution

Figure 7: Monte Carlo enterprise value distribution by percentile, under four information states. Each distribution reflects 10,000 simulations with scenario-appropriate probability inputs. The median row, bolded, is the central output for each scenario. The distribution is right-skewed pre-Phase-1 because AD probability uncertainty is right-skewed; post-Phase-1 distributions are progressively less skewed as delivery and efficacy risk are retired. The acquisition price in any scenario falls below the enterprise value median, reflecting the competitive discount an acquirer captures by pricing below their maximum willingness to pay.

Figure 8: Enterprise Value Distribution by Scenario — Visual Comparison

Figure 8: Monte Carlo enterprise value distribution visualized across four information states. The visual makes two observations immediately legible: first, Arrowhead trades today at approximately the 7th percentile of its own pre-Phase-1 distribution, far below the $47 billion pre-Phase-1 median; second, the jump from today’s median to the Strong scenario median is approximately 1.9×, the single largest repricing event in the Arrowhead timeline. The Weak scenario distribution is bounded near today’s market cap (the non-CNS floor), while the Moderate scenario median sits modestly below the pre-Phase-1 median and the Strong scenario median extends substantially above it.

Key Observations from the Distributions

Today’s market cap prices Arrowhead at roughly the 7th percentile of the pre-Phase-1 distribution.

The pre-Phase-1 Monte Carlo median is $40 to $55 billion, while Arrowhead trades at a $9.8 billion market cap. That valuation corresponds to approximately the outcome in which ARO-MAPT fails entirely and platform optionality evaporates, the scenario the prior evidence base developed in Section I argues against.

The Strong scenario median contains the $55 to $90 billion Stage 1 acquisition range.

The Strong scenario 50th percentile is $75 to $105 billion; the 25th percentile is $60 to $80 billion. The $55 to $90 billion Stage 1 acquisition range sits approximately at the 25th to 40th percentile of the Strong scenario distribution. This placement is the signature of a value-accretive acquisition: the buyer pays below the enterprise value median, which means the acquisition is value-accretive for the buyer in the majority of simulated outcomes. An acquisition priced at the median would require the seller to capture 100 percent of synergy, which does not happen in competitive auctions. The $55 to $90 billion range is where a rational acquirer’s board approves the bid because the probability of overpayment is bounded below 40 percent of the simulated distribution.

The Phase 1 readout is the single largest repricing event.

The jump from today’s $40 to $55 billion pre-Phase-1 median to the Strong scenario’s $75 to $105 billion median is approximately 1.8× to 1.9×. This is the single largest percentile-level re-rating in the Arrowhead timeline, larger than any subsequent data event would produce. The reason: Phase 1 retires the delivery risk that dominates the pre-Phase-1 uncertainty. After Phase 1, the remaining distribution is dominated by cognitive-endpoint uncertainty, pricing, and timing; all important, but none as consequential as the binary question of whether TfR1-mediated subcutaneous delivery produces meaningful tau silencing in humans.

The Moderate scenario still produces a meaningful re-rate.

The Moderate scenario median of $30 to $45 billion represents roughly a 3× to 4.5× lift from today’s $9.8 billion market cap. Even in the scenario where ARO-MAPT produces partial efficacy without superiority to the BIIB080 benchmark, the expected value math supports a meaningful positive return from today’s entry point. The Moderate scenario is not a failure, it is a reduced but still economically positive outcome.

The Weak scenario is bounded.

The Weak scenario median of $9 to $13 billion sits at or slightly above today’s $9.8 billion market cap. The 25th percentile is $8 to $10 billion; the 10th percentile is $6 to $8 billion. Even in the failure case, the distribution is bounded above today’s level at its median and does not collapse into single-digit-billion territory at the 25th percentile. This is the non-CNS floor that Section IV established, expressed in probabilistic terms: the commercial business anchored by plozasiran’s cardiometabolic franchise, the obesity program, and the partnered streams supports a floor valuation that approximately brackets today’s market cap.

Monte Carlo as Confirmation

The Monte Carlo output confirms the three other methodologies from Section V. rNPV ($45 to $65 billion standalone) sits below the Strong scenario Monte Carlo median ($75 to $105 billion), with the gap representing the synergy premium that standalone valuation excludes by construction. Peak revenue multiple ($72 to $120 billion) overlaps the Strong scenario 50th to 75th percentile band. Comparable transactions ($55 to $90 billion) aligns with the Strong scenario 25th to 40th percentile band, which is precisely the band where value-accretive acquisition pricing occurs. The four methodologies converge because the underlying analytical framework they share, probability-weighted asset valuation, strategic premium, competitive bidder dynamics, produces consistent outputs regardless of which methodology is used to generate the point estimate.

What the Monte Carlo adds beyond the deterministic methods is the probability context. An acquirer’s M&A team uses the Monte Carlo to answer the question the board asks: what is the probability that our bid is value-accretive? For a bid at $55 billion, the probability of overpayment against the Strong scenario distribution is approximately 10 to 15 percent, the bid sits near the 15th percentile. For a bid at $90 billion, the probability of overpayment is approximately 35 to 45 percent, the bid sits near the 40th percentile. The range between these two bounds is the $55 to $90 billion Stage 1 acquisition range, and the probability of overpayment across the range is bounded below 50 percent under every simulated input combination. That is the analytical condition that makes the bid approvable at an acquirer’s board. It is also the analytical condition that does not hold at Arrowhead’s current $9.8 billion market cap, a point where the probability of overpayment is essentially zero but the probability of underpayment exceeds 90 percent.

The pre-Phase-1 Monte Carlo median is $40 to $55 billion. Arrowhead trades at $9.8 billion, approximately the 7th percentile of the simulation output. The market is pricing Arrowhead today as if the weak scenario, the outcome in which ARO-MAPT fails entirely, were the probability-weighted base case.

VII. The Three Scenarios

Section I introduced the three Phase 1 readout scenarios as a framework for pricing the investment today. Sections IV through VI built the valuation machinery that each scenario implies. This section narrates what each scenario actually looks like in practice: how the data reads out, how the market reacts, what strategic response each scenario produces from potential bidders and from Arrowhead management, and where the investor ends up across each path through 2030.

The three scenarios are defined by the Phase 1 CSF tau reduction threshold relative to the BIIB080 high-dose MAD benchmark of 51 to 56 percent. A strong readout meets or exceeds that benchmark. A moderate readout produces tau reduction in the 40 to 55 percent range with durability or tolerability questions that prevent clear superiority. A weak readout falls below 40 percent, reveals tolerability issues, or shows insufficient blood-brain-barrier crossing evidence. The sections that follow describe each scenario’s chronology from the readout day forward. Figure 9 summarizes the three trajectories at key milestones for reference.

A note on the scenarios that follow.

The narratives in this section and in the bidder, licensing, and auction sections that follow describe analytical hypotheticals constructed for illustrative and valuation purposes only. Specific outcomes, stock price movements, acquisition timing, bidder behavior, licensing structures, are conditional forecasts derived from publicly available information about the named companies’ strategic positioning, financial capacity, and pipeline logic, and from historical patterns in comparable pharmaceutical acquisitions. Nothing in this section reflects non-public communications, insider knowledge, or actual acquisition or licensing discussions involving Arrowhead Pharmaceuticals or the companies named. Investment banks mentioned as potentially engaged in an M&A process are identified by industry practice and historical precedent, not by any information about Arrowhead’s advisor relationships. Individual investors should evaluate these scenarios against their own probability assumptions and risk tolerance.

Figure 9: Scenario Trajectories Through 2030

Figure 9: Key milestones and outcomes under each Phase 1 readout scenario. The columns map the temporal progression from the Phase 1 readout forward through the 2029–2030 Phase 2 cognitive endpoint window. The narrative subsections that follow describe each scenario in detail.

The Strong Scenario: Positive Phase 1 Data and the Acquisition Path

The data.

ARO-MAPT Phase 1 reports CSF tau reduction of 55 percent or higher, sustained through at least 12 weeks post-dose, with clean tolerability and dose-dependent biomarker engagement across multiple cohorts. The data demonstrates ARO-MAPT is at least on par with, and probably superior to, Biogen/Ionis’s BIIB080 high-dose MAD benchmark of 51 to 56 percent. Critically, the tolerability profile shows no hepatotoxicity signals from off-target TfR1 binding in liver, no neurotoxicity from non-neuronal brain cell uptake, and no dose-limiting safety findings. The subcutaneous delivery route is validated. The mechanism works in humans.

The market reaction.

The stock opens halted before market open on the readout day. The press release goes out pre-market. When trading resumes, the stock opens 100 to 200 percent higher on the first print. Over the following three to five trading sessions, as sell-side analysts scramble to update models and institutional investors re-allocate, the market cap settles in the $25 to $45 billion range, a 2.6 to 4.6 times re-rate from today’s $9.8 billion. The initial re-rate is driven by probability revision: ARO-MAPT’s probability of ultimate approval moves from the pre-Phase-1 base of 15 to 20 percent to the post-strong-Phase-1 range of 20 to 25 percent, and the full platform valuation compounds because delivery risk retirement validates every CNS program in the pipeline, not just ARO-MAPT.

The sell-side response.

Sell-side analysts update their price targets over the two to four weeks following the readout. The first analyst to publish a conditional acquisition-value note, the one-paragraph scenario described in Section III, becomes the most-read research piece on the stock that year. The other analysts are forced to respond: either engage with the conditional acquisition framework or explicitly reject it. The market begins to price the acquisition optionality that it has, to this point, been ignoring. Re-rated consensus targets cluster in the $160 to $290 per share range by the end of the first post-readout quarter, consistent with the strong-case market cap developed in Section I.

The strategic response from bidders.

Within the first 72 hours of the readout, informal outreach from potential acquirers begins. The initial contacts are by bankers, not company executives, standard pre-transactional practice that preserves optionality without creating disclosure obligations. By the end of the first post-readout month, the potential bidders identified in Section VIII (Lilly, Roche, and Novartis) have each engaged their M&A teams to perform independent valuation work. By months two to four, at least two of the three bidders have signed confidentiality agreements with Arrowhead and gained access to a data room. The company’s bankers, the major pharmaceutical M&A specialists at firms like Centerview, Goldman Sachs, and Morgan Stanley, are engaged to run a formal process. The CEO and board weigh the strategic options: remain independent, license ARO-MAPT, or sell the company. With multiple bidders engaged and public market pressure building for liquidity realization, the path of least resistance is a sale process.

The auction window.

Over months four through twelve, the auction develops. Each bidder performs detailed due diligence on the clinical, regulatory, manufacturing, and commercial dimensions of the company. The process is competitive because the synergy math differs materially across the three bidders, as Section V outlined: Lilly’s total synergy value of $45 to $85 billion (AD plus obesity) gives Lilly the highest maximum bid ceiling. Roche’s $25 to $40 billion synergy and Novartis’s $10 to $20 billion put them in the bidding but at lower ceilings. The auction mechanics detailed in Section XI describe how this competitive dynamic converges on the $55 to $90 billion clearing price, anchored to comparable transaction multiples, consistent with the Monte Carlo 25th to 40th percentile of the Strong scenario distribution, and inside Lilly’s maximum willingness to pay with room for competing bids to push toward the upper end of the range.

The terminal outcome.

The acquisition is announced 6 to 18 months after the Phase 1 readout. The announcement includes a cash bid, or cash-and-stock in some structures, at a per-share price of $355 to $581 on a fully diluted basis, corresponding to the $55 to $90 billion total enterprise value. Hart-Scott-Rodino antitrust clearance proceeds in parallel with shareholder approval proxies. The transaction closes within three to nine months of announcement. The investor who entered at today’s $9.8 billion market cap realizes a return of 5.6 to 9.2 times their initial capital, delivered over a window of roughly 18 to 30 months from today. The company’s commercial operations continue under the acquirer’s ownership. The platform engine, including the undisclosed pipeline programs, is now deployed inside the acquirer’s infrastructure. Stage 2, the forward optionality that would have opened at Phase 2 cognitive data in 2029–2030, accrues to the acquirer, not to public shareholders. The public market chapter of Arrowhead’s story ends.

The Moderate Scenario: Partial Efficacy and the Licensing Path

The data.

ARO-MAPT Phase 1 reports CSF tau reduction in the 40 to 55 percent range, mechanism validated in humans, but without clear superiority to the BIIB080 high-dose MAD benchmark. Either the higher-end numbers are achieved but with durability questions (post-dose tau rebound before the 12-week readout), or the more sustained numbers are achieved only at the lower end of the tau reduction range. Tolerability may be acceptable or may show minor signals that raise questions at higher doses. The data is consistent with a working mechanism but does not decisively establish best-in-class potential. The investment thesis survives; the magnitude of the upside compresses.

The market reaction.

The stock opens meaningfully higher but not at the strong-case level. Over the following trading sessions, the market cap settles in the $15 to $25 billion range, a 1.5 to 2.6 times re-rate from today’s $9.8 billion. The initial re-rate is driven primarily by delivery validation (the mechanism demonstrates human efficacy, which matters for the entire CNS platform) and secondarily by modest probability improvement on ARO-MAPT AD approval, with the probability moving from the pre-Phase-1 base of 15 to 20 percent to the moderate-scenario range of 12 to 18 percent. The apparent inconsistency, a re-rate despite lower probability than pre-Phase-1, resolves when decomposed: the mechanism validation produces platform-wide value even as cognitive-endpoint risk keeps AD probability compressed.

The strategic response.

Moderate data does not produce a formal M&A auction. Bidders watch closely but do not engage bankers. The reasoning is straightforward: a bidder paying a strong-case acquisition premium for moderate-case data is overpaying against both standalone rNPV and against the probability-adjusted expected value. Bidders instead wait for Phase 2 cognitive data to resolve the efficacy question. Arrowhead management, recognizing that acquisition dynamics are unavailable in the moderate scenario, pivots to licensing. The ARO-SNCA deal structure with Novartis from October 2025, $200 million upfront, $2 billion in milestones, royalties on commercial sales, becomes the template for an ARO-MAPT licensing transaction. Section IX develops the licensing path economics; the summary is that a moderate-data ARO-MAPT licensing deal can extract $8 to $24 billion in probability-adjusted deal value for the ARO-MAPT program alone, preserving the non-ARO-MAPT portfolio entirely under Arrowhead’s independent control.

The terminal outcome before Phase 2.

Within 12 to 18 months of the Phase 1 readout, a licensing transaction is announced. The deal structure includes an upfront payment (approximately $500 million to $1.5 billion), milestone payments tied to Phase 2 and Phase 3 success ($2 to $4 billion total), and tiered royalties on commercial sales (mid-to-high teens). The licensing partner is typically one of the three strategic buyers identified in Section VIII, most plausibly Roche or Lilly, but could be a fourth player like Biogen, which already has BIIB080 and would view ARO-MAPT as a complementary subcutaneous alternative. The public market continues to hold Arrowhead at the re-rated $15 to $25 billion level through the licensing announcement, then trades in a range as investors price the licensing economics against Phase 2 optionality. The investor who entered at today’s $9.8 billion market cap realizes a 1.5 to 2.6 times return on the market cap re-rate plus some portion of the licensing upfront and near-term milestone economics as they accrue to Arrowhead’s balance sheet.

The Phase 2 resolution window.

Phase 2 cognitive endpoint data reads out in 2029 or 2030. At that point, the moderate scenario bifurcates. If Phase 2 is positive, ARO-MAPT demonstrates that its moderate-magnitude tau silencing produces clinical cognitive benefit, the licensing economics trigger additional milestones, the partnered asset advances toward approval, and Arrowhead’s valuation expands toward the $110 to $150 billion Stage 2 range. The licensing partner may also initiate acquisition discussions at that point; the Stage 2 acquisition dynamics, while not modeled in detail in this paper, represent additional forward optionality. If Phase 2 is negative, tau silencing does not translate to cognitive benefit, the thesis collapses, Arrowhead’s ARO-MAPT royalty stream becomes substantially less valuable, and the stock re-rates downward toward the non-CNS floor of approximately $7 to $10 billion market cap. The moderate scenario is therefore not a single terminal outcome but a branching path with Phase 2 as the definitive resolution event.

The Weak Scenario: Failed Data and the Non-CNS Floor

The data.

ARO-MAPT Phase 1 reports CSF tau reduction below 40 percent, or tolerability issues that call the mechanism into question, or insufficient blood-brain-barrier crossing evidence. This threshold sits clearly below BIIB080’s 51 to 56 percent high-dose MAD benchmark and above BIIB080’s low-dose failure zone of approximately 30 percent, but only by a margin that would not support commercially competitive subcutaneous quarterly tau silencing. Alternatively, the data may show acceptable tau reduction but reveal safety signals that cap the dose at levels insufficient for commercial therapeutic effect. In any of these variants, the CNS platform thesis compresses materially.

The market reaction.

The stock opens sharply lower. Over the following trading sessions, as the market digests the data and re-prices the CNS platform thesis, the market cap de-rates to the $7 to $10 billion range, a 0.7 to 1.0 times multiple of today’s $9.8 billion valuation. The de-rate is bounded at that level because the non-CNS commercial business remains intact: plozasiran is already commercial for FCS, the sHTG Phase 3 program is complete and awaiting regulatory approval, the obesity program has meaningful Phase 1/2a human data, and the partnered streams from Sarepta, Novartis, and Takeda continue to produce milestone and royalty economics. The weak scenario de-rate reflects a collapse in the CNS platform valuation, not a collapse in the company’s overall commercial viability. Section IV established the non-CNS floor in asset-inventory terms; the weak scenario de-rate is the market’s probabilistic expression of that floor.

The strategic response.

No acquisition process develops in the weak scenario. The core thesis that motivated the $55 to $90 billion Stage 1 range, validated subcutaneous CNS delivery supporting a platform that includes ARO-MAPT, ARO-SNCA, and undisclosed CNS programs, does not hold under weak Phase 1 data. Bidders who had performed preliminary valuation work on the strong scenario deactivate those files. Arrowhead management pivots the strategic narrative from CNS platform validation to cardiometabolic commercial execution: plozasiran launch, sHTG approval, CAPITAN CVOT read-out, obesity program advancement, ARO-DIMER-PA Phase 1/2a progression. The Sarepta partnership remains intact but loses its subcutaneous-CNS-validation halo; the Novartis ARO-SNCA deal enters a challenging period because the underlying delivery mechanism thesis has been partially invalidated. The company’s earnings calls reset expectations around cardiometabolic revenue trajectory rather than CNS platform optionality.

The terminal outcome.

Over the 6 to 18 months following a weak readout, the market settles Arrowhead at a valuation consistent with a cardiometabolic-focused commercial-stage biotech with a first-in-class FCS approval, a Phase 3-complete sHTG program, an obesity program with encouraging early data, and an active CVOT. This business is real and commercially viable; the weak scenario does not produce a failing company, it produces a company without the CNS platform optionality that made the thesis transformative. Probability-adjusted valuation sits in the $9 to $13 billion range per the Section VI Monte Carlo median for the weak scenario. The investor who entered at today’s $9.8 billion market cap realizes a modestly positive to modestly negative outcome depending on where within the weak distribution the market settles. The downside is bounded, not zero, but bounded. This is the asymmetry that makes entry today attractive: the weak scenario loses roughly what the moderate scenario gains on a percentage basis, while the strong scenario produces multiples that are not available anywhere else in the distribution of outcomes.

The Asymmetric Entry Point

The three scenarios are not equally probable. Section I argued that the prior evidence base, BIIB080’s human MAPT-silencing validation, trontinemab’s human TfR1-mediated BBB delivery validation, Arrowhead’s non-human-primate CSF tau reduction data, and the Phase 1 dose escalation design, reduces the probability of the weak scenario below what today’s $9.8 billion market cap implies. Section VI’s Monte Carlo simulation quantified this gap by placing today’s valuation at roughly the 7th percentile of the pre-Phase-1 distribution, well below the $40 to $55 billion pre-Phase-1 median.

The asymmetry of the trade can be stated compactly. Entering at today’s market cap, the investor’s payoff profile across the three scenarios is approximately: strong scenario produces 5.6 to 9.2 times return with an acquisition in 6 to 18 months; moderate scenario produces 1.5 to 2.6 times re-rate with additional licensing economics and a Phase 2 branching path that could reach Stage 2 valuations; weak scenario produces approximately 0.7 to 1.0 times outcome bounded by the non-CNS floor. The geometric mean across the three scenarios under any reasonable probability weighting exceeds 2 times from today’s entry point, and the upside distribution has a tail that extends well beyond any typical late-stage biotech investment.

The Phase 1 readout is the single event that resolves the distribution. Before the readout, the investor is buying a probability-weighted claim on all three scenarios. After the readout, the scenario is revealed and the asymmetric entry point is no longer available. The scenarios that follow from this section, which specific bidders execute the strong-scenario acquisition, what the licensing path looks like under the moderate scenario, what the auction dynamics produce at the $55 to $90 billion clearing price, develop the analytical detail behind each outcome path, but the investment decision is made today, against the probability distribution of outcomes, before the data arrives.

Strong data produces a probable $55 to $90 billion acquisition within 6 to 18 months. Moderate data produces a $15 to $25 billion re-rate with licensing as a realistic alternative. Weak data produces a non-CNS floor at roughly today’s market cap. The probability-weighted expected value from today’s entry point is decidedly positive.

VIII. The Strategic Buyers

The bidder profiles in this section describe the three strategic buyers most likely to compete for Arrowhead in the strong Phase 1 scenario: Eli Lilly, Roche, and Novartis. The analysis below is subject to the disclaimer in Section VII; the profiles are analytical hypotheticals constructed from publicly available information about each company’s strategic positioning, financial capacity, and pipeline logic, and do not reflect any non-public communications, insider knowledge, or actual acquisition discussions.

The final acquisition price in a competitive auction is determined not by what the asset is worth in the abstract, but by what the most motivated bidder is willing to pay to win and what the second-most motivated bidder is willing to pay. Arrowhead in the strong Phase 1 scenario has three bidders with acquisition-scale financial capacity and distinct strategic rationales, which is structurally rare in pharmaceutical M&A. Figure 10 maps the three bidders on two dimensions: strategic motivation (how much each needs the asset) and financial capacity (whether each can execute at Stage 1 scale). All three occupy the high-capacity quadrant; they differ in the strength and specificity of their strategic motivation, which determines probability of winning and maximum willingness to pay.

Figure 10: Bidder Landscape

Figure 10: Three strategic bidders positioned on motivation, probability, and synergy value. All three have acquisition-scale financial capacity. Stage 1 synergy values are the Section V estimates of acquirer-specific value creation above the standalone rNPV of Arrowhead. Probability of winning sums to 85–115%, with the residual reflecting low-probability outcomes not modeled here (consortium bids, unexpected fourth parties, or a non-acquisition outcome under strong-scenario data). Probabilities are conditional on the strong Phase 1 scenario; in moderate or weak scenarios, the competitive auction dynamic does not develop. The probability allocations reflect the author’s synthesis of strategic fit, financial capacity, and competitive urgency across the three bidders. Reasonable alternative assessments could shift the allocation materially, particularly between Lilly and Roche, without changing the core claim that a competitive auction develops and clears in the $55 to $90 billion range.

Eli Lilly: The Two-Franchise Strategic Fit

Strategic position.

Lilly is the dominant pharmaceutical company in two of the three therapeutic areas most relevant to Arrowhead’s strategic value: Alzheimer’s disease, where Kisunla (donanemab) is the established first-line anti-amyloid therapy with its distinctive “finite therapy” stop-dosing protocol; and obesity, where Zepbound and Mounjaro together capture approximately 60 percent of new US GLP-1 prescriptions. Lilly’s market capitalization crossed $1 trillion in late 2025, the first pharmaceutical company to reach that threshold, before pulling back approximately 15 percent, and currently sits at approximately $860 billion. The balance sheet, cash generation, and equity currency available to Lilly for acquisitions remain the largest in the industry.

The AD motivation.

Kisunla is commercially established but faces mechanism-specific limitations that an AD franchise should address. Amyloid clearance produces meaningful slowing of cognitive decline, but tau pathology continues to progress, and patients who stop Kisunla after plaque clearance still decline if their tau burden is high. A subcutaneous anti-tau therapy administered quarterly, which is what ARO-MAPT would be if the strong Phase 1 scenario materializes, combines mechanistically with Kisunla to produce a two-mechanism AD franchise addressing both hallmark pathologies. This combination is uniquely available to Lilly because Lilly owns the anti-amyloid side. No competitor can fully replicate the combination without either licensing Kisunla from Lilly (unlikely) or developing a competitive anti-amyloid therapy from scratch (time-prohibitive). The defensive value is equally important: if a competitor acquires Arrowhead, the competitor owns the anti-tau side of a two-mechanism franchise that positions against Kisunla. Lilly’s estimated AD-focused synergy value is $30 to $50 billion, comprising Kisunla defensive protection, two-mechanism franchise pricing power, and commercial infrastructure integration across the AD sales force, prescriber education programs, and payor contracts Lilly has already built.

The obesity motivation.

Lilly has won the first generation of the GLP-1 wars, but the second-generation competitive question is different. As patents mature, payor pressure mounts, and new mechanisms emerge, the durability of Zepbound’s franchise depends on Lilly’s ability to evolve beyond pure GLP-1 agonism. Arrowhead’s obesity program, ARO-INHBE targeting Activin E and ARO-ALK7 targeting ALK7, operates through a mechanistically distinct pathway (non-GLP-1) and addresses structural limitations of GLP-1 therapy including lean muscle mass loss, GI tolerability, and weight regain after cessation. In January 2026, interim Phase 1/2a data from ARO-INHBE combined with tirzepatide showed doubled weight loss and tripled visceral, total, and liver fat reductions compared to tirzepatide alone. If those data replicate in pivotal trials, a Lilly-owned tirzepatide + ARO-INHBE combination product extends the Zepbound franchise beyond its patent cliff and commands premium pricing for second-line positioning. The defensive value is substantial: if Novo Nordisk or another competitor acquires the Arrowhead obesity program, Lilly faces a direct combinatorial threat to its dominant obesity franchise. The obesity-focused synergy value is $15 to $35 billion, comprising the combination product economics, defensive protection, and auto-injector commercial platform synergy.

The two-franchise argument.

Combined, Lilly’s Stage 1 synergy value is approximately $45 to $85 billion, materially larger than Roche’s ($25 to $40 billion) or Novartis’s ($10 to $20 billion). The reason is structural rather than aggressive: Lilly has two strategic franchises where Arrowhead’s pipeline creates value, while Roche has one (AD via trontinemab) and Novartis has one (neuroscience via ARO-SNCA). This two-franchise strategic fit is why Lilly is the highest-probability winner and why Lilly’s maximum willingness to pay can reach the upper end of the Stage 1 range. Section X develops the synergy decomposition in detail and makes the case that Lilly’s standalone bid capacity alone can exceed $100 billion when the full synergy captured by the seller is added to the standalone rNPV, though the paper holds the $55 to $90 billion range as the competitive-auction clearing price anchored to comparable transactions rather than to Lilly’s maximum willingness to pay in isolation.

Track record and execution.

Lilly under CEO Dave Ricks has a consistent pattern of paying premium prices for validated platforms and executing decisively when diligence confirms the strategic thesis, including the Loxo Oncology, Prevail Therapeutics, and Verve Therapeutics acquisitions. A Stage 1 Arrowhead acquisition fits this pattern; validated human CNS delivery, two-franchise strategic fit, and platform breadth that justifies paying above pure financial valuation. The estimated probability of Lilly winning a competitive auction for Arrowhead in the strong Phase 1 scenario is 50 to 60 percent.

Roche: The Trontinemab Coherence

Strategic position.

Roche operates the most comprehensive AD development portfolio of any pharmaceutical company and has returned to Alzheimer’s with a novel therapeutic approach that differentiates structurally from first-generation anti-amyloid antibodies. Trontinemab, developed through Roche’s Brainshuttle antibody engineering platform, uses a transferrin receptor (TfR1) binding fragment attached to the gantenerumab antibody to cross the blood-brain barrier via receptor-mediated transcytosis. The Phase 3 TRONTIER 1 and TRONTIER 2 studies initiated in late 2025, enrolling approximately 1,600 patients with primary completion in June 2030; a separate PrevenTRON Phase 3 in preclinical AD is also planned. Roche’s market capitalization is approximately $319 billion on trailing twelve-month revenue of $76 billion.

The TfR1 mechanism overlap.

The most consequential synergy available to Roche but to no other bidder is the delivery mechanism overlap between trontinemab and ARO-MAPT. Trontinemab crosses the blood-brain barrier by binding TfR1 on BBB endothelial cells. ARO-MAPT crosses the blood-brain barrier by binding TfR1 on BBB endothelial cells. Same receptor, same crossing mechanism, complementary therapeutic payloads: trontinemab removes amyloid, ARO-MAPT silences tau. A Roche-owned combination of the two assets produces the only two-mechanism Alzheimer’s franchise where both drugs use TfR1-mediated BBB transcytosis as their delivery route. The scientific coherence is unique; no other bidder has TfR1-validated CNS delivery in their own pipeline. The combination could support sequential or co-administered dosing protocols, manufacturing economies of scale around TfR1 binding domain production, and shared clinical development infrastructure for BBB-crossing therapeutics across Roche’s broader CNS pipeline. The trontinemab-specific component of Roche’s synergy value is estimated at $5 to $15 billion.

The Elecsys diagnostic integration.

Roche Diagnostics is the world leader in laboratory diagnostics and has invested heavily in Alzheimer’s blood-based biomarker tests including the Elecsys pTau-217 assay now integrated into TRONTIER screening, the pTau-181 plasma test (FDA-approved October 2025 for primary care use), and complementary amyloid-beta ratio assays. A Roche-owned ARO-MAPT combined with Roche-owned Elecsys diagnostics produces an integrated patient-identification-to-therapy workflow where Roche captures economics at multiple points: diagnostic testing volumes, companion diagnostic-therapeutic pricing power, and vertical integration of the AD patient journey. Lilly has diagnostic partnerships but does not own equivalent infrastructure; the Elecsys co-development with Lilly under the 2023 partnership shares diagnostic access, not ownership. The Elecsys integration synergy is estimated at $10 to $20 billion.

The constraints.

Two considerations temper the Roche probability below Lilly’s. First, financial capacity. Roche’s $319 billion market cap is substantial but materially smaller than Lilly’s ~$860 billion, and a $55 to $90 billion Stage 1 acquisition would represent 17 to 28 percent of Roche’s market cap versus 6 to 10 percent of Lilly’s. Roche can execute the transaction but will require more debt financing and may face greater shareholder scrutiny on the near-term dilutive impact. Second, strategic priority. Roche’s trontinemab is already a Phase 3 anti-amyloid asset that management has substantial conviction in; a Roche-owned ARO-MAPT would complement trontinemab, but Roche can also pursue AD leadership with trontinemab alone if the cost-benefit of an Arrowhead acquisition exceeds internal thresholds. Lilly cannot similarly decline to compete because Lilly’s AD franchise is already commercial and the threat of a competitor owning the tau-silencing asset is more acute. Combined, Roche’s Stage 1 synergy value is $25 to $40 billion, and the estimated probability of Roche winning a competitive auction is 25 to 35 percent.

Novartis: The Platform Insider

Strategic position.

Novartis has pursued an explicit neuroscience-by-M&A strategy, publicly articulated at the January 2026 J.P. Morgan Healthcare Conference: the company intends to win in neuroscience through acquisitions and licensing rather than purely through internal development. Two recent transactions execute this strategy. In October 2025, Novartis announced the $12 billion cash acquisition of Avidity Biosciences, bringing a muscle-directed RNA delivery platform and three late-stage neuromuscular programs; the transaction closed February 27, 2026. Earlier in 2025, Novartis announced the $1.7 billion acquisition of Regulus Therapeutics. Beyond acquisitions, Novartis has executed the most substantial licensing deal with Arrowhead to date: the October 2025 ARO-SNCA agreement for $200 million upfront, up to $2 billion in milestones, and tiered royalties on global sales. Novartis’s market capitalization is approximately $290 billion on trailing twelve-month revenue of $57 billion.

The platform insider advantage.

The ARO-SNCA transaction gives Novartis the deepest external diligence of any potential acquirer. The BD and R&D teams that evaluated ARO-SNCA have spent meaningful time inside Arrowhead’s TRiM platform, understand the chemistry of the TfR1 ligand conjugate subcutaneous CNS delivery mechanism as well as any external party can, and have already approved the platform at a level that committed $200 million in upfront capital plus up to $2 billion in contingent consideration to a single program. From Novartis’s perspective, Arrowhead is not a blind diligence target. It is a known platform with a specific commercial and scientific track record. This lowers execution risk and shortens the diligence window that would otherwise be required for a Stage 1 acquisition. The insider advantage translates directly to probability of executing at speed in a competitive auction.

The mitigating factors.

Two factors temper the Novartis probability below Roche’s, despite the platform insider advantage. First, capital absorption. The Avidity acquisition closed in Q1 2026, committing $12 billion in cash to a neuromuscular RNA platform. A second neuroscience acquisition at Stage 1 scale ($55 to $90 billion) in the same calendar year would be structurally unusual, it would roughly double Novartis’s announced M&A commitment for the period and test both balance sheet capacity and internal integration bandwidth. Second, strategic fit specificity. Novartis lacks an established AD franchise equivalent to Kisunla or an AD Phase 3 program equivalent to trontinemab. Their neuroscience strategy is broader (neuromuscular, CNS, kidney-adjacent) and less anchored to the specific AD indication that drives most of ARO-MAPT’s value. Novartis would acquire Arrowhead for the platform, not for ARO-MAPT specifically, which is a valid strategic rationale but a smaller synergy magnitude than either Lilly’s two-franchise fit or Roche’s trontinemab coherence. The Novartis Stage 1 synergy value is $10 to $20 billion, reflecting ARO-SNCA collaboration scaling, broader CNS expertise integration, and RNA therapeutics platform consolidation across Avidity, Regulus, and Arrowhead assets.

Role in the auction.

Novartis is most likely to participate as a serious early-round bidder that forces Lilly and Roche to bid closer to their maximum willingness to pay rather than to settle the asset at a synergy-light price. The insider advantage and the existing ARO-SNCA relationship give Novartis credibility in early bidding rounds; the Avidity capital absorption and lower synergy magnitude make it less likely that Novartis submits the winning final bid. The estimated probability of Novartis winning a competitive auction for Arrowhead in the strong Phase 1 scenario is 10 to 20 percent, with the midpoint lower than the old analysis would have suggested because the Avidity transaction has materially reduced the 2026 neuroscience M&A capital envelope.

Three Motivated Bidders, Three Strategic Cases

The three bidders are motivated by non-overlapping strategic rationales: Lilly by two-franchise fit across AD and obesity, Roche by the unique TfR1 delivery mechanism coherence with trontinemab, Novartis by RNA platform consolidation and the ARO-SNCA platform insider advantage. Each has a path to winning that does not depend on the others’ strategic cases.

The competitive dynamic this produces is the condition that drives auction pricing into the $55 to $90 billion Stage 1 range rather than into a discount-to-standalone outcome. With one motivated bidder, the asset prices at rNPV plus a modest negotiated premium. With three motivated bidders, each of whom has a genuine strategic case and genuine fear of losing to the others, the asset prices at a competitive clearing level that meaningfully exceeds standalone rNPV and approaches the seller’s share of each bidder’s synergy value. Section XI develops the auction mechanics that convert this three-bidder landscape into the $55 to $90 billion final clearing price. Section X develops the synergy math that bounds the range from below (standalone rNPV plus seller’s share of minimum motivated synergy) and from above (the maximum willingness to pay of the highest-synergy bidder, tempered by auction dynamics that prevent the winner from paying their full walk-away price).

Three motivated, capacity-endowed strategic buyers with non-overlapping rationales is structurally rare in pharmaceutical M&A and is itself a driver of the Stage 1 valuation. It is the reason the comparable transactions band in Section V’s Figure 2 clusters above 8× pre-data multiples: those acquisitions also featured multiple motivated strategic bidders, and the final prices reflect competitive pricing dynamics rather than single-bidder negotiations.

Three strategic acquirers, Lilly, Roche, and Novartis, have non-overlapping rationales to compete for Arrowhead. Lilly’s two-franchise fit (Alzheimer’s disease plus obesity) produces total synergy of $45 to $85 billion, materially larger than Roche’s $25 to $40 billion or Novartis’s $10 to $20 billion. Lilly is the highest-probability winner at 50 to 60 percent.

IX. The Licensing Alternative

The scenarios in Section VII identified licensing as the primary outcome path under moderate Phase 1 data; the case where mechanism is validated in humans but efficacy magnitude does not decisively support an acquisition premium. This section develops the licensing path economics and explains why licensing is the equilibrium outcome in the moderate scenario rather than a failure mode. The analysis is subject to the disclaimer in Section VII.

Licensing is not the preferred outcome in the strong Phase 1 scenario. Strong data produces competitive auction dynamics that favor acquisition over licensing for reasons developed below, and strategic bidders will work to convert licensing discussions into acquisition offers when the data supports it. Licensing becomes the equilibrium outcome specifically when acquisition economics do not comfortably exceed the licensing alternative, the condition that materializes under moderate data but not under strong data. Under weak data, neither licensing nor acquisition produces meaningful transactions because the underlying delivery and efficacy thesis has not been validated.

The ARO-SNCA Precedent

On October 20, 2025, Arrowhead announced a licensing agreement with Novartis for ARO-SNCA, their preclinical subcutaneous SNCA-silencing program for Parkinson’s disease and other synucleinopathies. Deal terms: $200 million upfront, up to $2 billion in clinical and regulatory milestones, plus tiered royalties on global net sales. The structure is the appropriate scaling benchmark for an ARO-MAPT licensing transaction because it is recent, involves the same TRiM platform technology, was priced in the current pharmaceutical transaction market, and represents Novartis’s direct valuation of a TfR1-mediated subcutaneous CNS asset.

Two features of the ARO-SNCA deal are particularly relevant. First, the transaction allowed Arrowhead to retain the TRiM platform as its own property and preserved optionality on additional CNS targets. Novartis acquired a specific asset (ARO-SNCA), not the delivery platform. Second, the deal was priced for a preclinical asset with no human data. ARO-SNCA had completed preclinical development and IND-enabling studies, but no Phase 1 had begun at the time of the deal. The $200 million upfront and $2 billion potential milestone value reflect Novartis’s willingness to pay for platform technology validation and for the asset’s preclinical profile, before any human efficacy data existed. An ARO-MAPT licensing transaction following positive Phase 1 data would be priced on substantially stronger evidence.

ARO-MAPT Licensing Economics Post-Phase 1

Figure 11 scales the ARO-SNCA structure for an ARO-MAPT licensing transaction following moderate Phase 1 data. The scaling factors are the stage uplift (Phase 1 data versus preclinical), the AD market multiplier (AD is substantially larger than the synucleinopathy market), and the probability adjustment (moderate Phase 1 data retires delivery risk but leaves cognitive-endpoint risk materially unresolved).

Figure 11: ARO-MAPT Licensing Economics — Post-Phase 1 Moderate Scenario

Figure 11: Post-Phase 1 ARO-MAPT licensing economics under the moderate scenario. The $8 to $24 billion probability-weighted present value represents the total expected value to Arrowhead from the licensing transaction, including upfront, milestones, and royalty stream discounted over the asset’s patent life. The range width reflects uncertainty across royalty rate, Phase 2 and Phase 3 success probability, and peak revenue assumptions.

The $8 to $24 billion licensing value is a 3 to 5 times multiple of today’s $9.8 billion market cap from the ARO-MAPT licensing transaction alone, before any value contribution from plozasiran, the extended pipeline, the obesity program, Sarepta partnered streams, or the undisclosed CNS programs. Combined with the public market re-rate to $15 to $25 billion that Section VII describes for the moderate scenario, the total outcome path is a meaningful positive return from today’s entry point rather than a failure mode, even though it is compressed relative to the strong-scenario acquisition outcome.

Why Strategic Acquirers Generally Prefer to Buy Rather Than License

The licensing path is the equilibrium outcome under moderate data specifically because strategic acquirers evaluate licensing and acquisition against each other and, under most data conditions, prefer acquisition. Three structural factors drive this preference.

Control of development pace.

A licensing arrangement requires Arrowhead to execute the Phase 2 and Phase 3 development program. Acquiring Arrowhead gives the acquirer direct operational control of timelines, trial design, protocol amendments, site selection, and commercial launch preparation. For an Alzheimer’s disease program where every quarter of delay has billion-dollar commercial consequences, particularly when competitors including Roche’s trontinemab and Lilly’s own LY-3954068 tau program are advancing in parallel, this control is materially valuable to the acquirer.

Commercial synergy capture.

Under a licensing structure, the acquirer pays Arrowhead a royalty (say mid-teens percent) on global net sales and bears commercial launch cost through its own infrastructure. Under an acquisition structure, the acquirer captures 100 percent of revenue at the marginal cost of deploying their existing infrastructure. For a $40 to $50 billion peak-revenue AD asset, this difference is worth $15 to $25 billion in present value to a commercial-infrastructure-rich acquirer like Lilly. The licensing royalty structure systematically gives away economic value that acquisition preserves.

Platform ownership.

An exclusive license for ARO-MAPT is not a license for the TRiM platform. If the acquirer wants additional CNS programs to complement ARO-MAPT, they would need to negotiate separate deals for each, or face the risk that Arrowhead licenses the next program to a competitor. Acquiring Arrowhead captures the platform as a whole, including the undisclosed pipeline and the platform engine’s capacity to generate additional CNS programs over time. The platform ownership dimension is particularly important for bidders like Roche (which could use TfR1-delivered assets across its broader CNS pipeline) and Novartis (which has already begun platform consolidation through the Avidity and Regulus acquisitions).

Combined, these three factors produce a wedge between what a strategic acquirer would pay to license ARO-MAPT and what they would pay to acquire Arrowhead. For Lilly specifically, the difference is approximately $30 to $60 billion at Stage 1, the gap between the $8 to $24 billion licensing value and the $55 to $90 billion acquisition range, adjusted for the acquirer’s share of the synergy capture. This wedge is what drives strategic acquirers to convert licensing discussions into acquisition offers whenever the data supports an acquisition thesis.

Why Licensing Is the Equilibrium Under Moderate Data

Under strong Phase 1 data, the acquisition wedge dominates: the acquirer’s willingness to pay an acquisition premium comfortably exceeds what they would pay to license the asset, and Arrowhead’s board faces a clear tender offer that exceeds any reasonable calculation of standalone-plus-licensing value. Under weak Phase 1 data, neither transaction is viable. Under moderate data, the economics shift: the acquirer’s willingness to pay an acquisition premium is compressed because the efficacy signal does not support strong-scenario peak revenue assumptions, while the licensing value remains substantially intact because licensing economics survive lower probability assumptions better than acquisition economics do.

The reason is structural. Licensing economics scale primarily with royalty rate and peak revenue; both survive moderate efficacy data reasonably well, with royalty rates potentially compressed slightly and peak revenue compressed moderately. Acquisition economics scale with probability-adjusted expected value plus synergy premium, both of which are more sensitive to efficacy uncertainty because they depend on the buyer’s internal conviction that Phase 2 will succeed. A bidder willing to pay $75 billion for an asset with 22 percent AD probability under strong data is not willing to pay $75 billion for the same asset with 15 percent probability under moderate data; the probability compression compounds through the synergy math. The acquirer’s maximum bid falls faster than the asset’s licensing value does.

For Arrowhead’s board, the moderate-scenario calculation then becomes: accept an acquisition offer that comes in at or below the acquirer’s standalone rNPV plus a modest premium, or license the asset at terms that capture $8 to $24 billion in probability-adjusted deal value while preserving independence, the TRiM platform, and the optionality to transact ARO-MAPT or other platform assets under different terms in the future. The ARO-SNCA decision in October 2025, licensing rather than selling ARO-SNCA or the full platform, is the most recent signal from management that licensing is the preferred mechanism when acquisition economics do not comfortably exceed the licensing alternative. Under moderate data, that condition is the base case.

The Cross-Program Licensing Extension

The ARO-MAPT licensing transaction is not the only licensing opportunity the moderate scenario enables. Arrowhead’s platform supports multiple potential CNS and extrahepatic licensing deals beyond ARO-SNCA and ARO-MAPT. ARO-HTT for Huntington’s disease, ARO-ATXN2 and ARO-ATXN3 for spinocerebellar ataxias, and ARO-FUS for amyotrophic lateral sclerosis are all partnered under the Sarepta collaboration but remain candidates for further licensing or sublicensing structures if Sarepta elects to transact portions of the collaboration portfolio. Undisclosed CNS programs in earlier-stage development could support additional licensing deals over the 2027 to 2030 window. Applied cumulatively across multiple CNS programs, the licensing path could extract $15 to $35 billion in cumulative deal value over the 2027 to 2030 window while preserving Arrowhead’s ownership of the TRiM platform and its standalone operations.

This cross-program extension strengthens the moderate-scenario outcome. Even if ARO-MAPT’s licensing value alone is the $8 to $24 billion range developed above, the platform’s capacity to generate additional licensing deals across the 2027 to 2030 window adds optionality that standalone public-market valuation does not capture. A moderate-scenario Arrowhead that executes ARO-MAPT licensing plus two additional CNS program licenses over 18 to 30 months could approach the lower end of the strong-scenario acquisition range in cumulative deal value terms, without ceding platform ownership.

The Licensing Floor

Licensing provides a floor under shareholder outcomes that does not require an acquisition. If positive Phase 1 data arrives at the moderate level and management pursues licensing rather than acquisition, the stock re-rates based on announced deal values and implied platform economics, and public shareholders retain economic exposure to ARO-MAPT royalty streams plus the remaining platform. The moderate-scenario outcome described in Section VII, public market at $15 to $25 billion plus $8 to $24 billion in licensing deal value, produces a meaningful positive return from today’s $9.8 billion entry point even without the strong-scenario acquisition premium.

The investment thesis is not dependent on the acquisition scenario materializing. The thesis is dependent on positive Phase 1 data at any magnitude that validates the delivery mechanism. Under strong data, the outcome is acquisition at $55 to $90 billion. Under moderate data, the outcome is licensing at $8 to $24 billion plus public market re-rate to $15 to $25 billion. Under weak data, the outcome is bounded by the non-CNS floor. The licensing alternative does not substitute for the acquisition scenario, it supplements it, by providing a positive outcome path under conditions where acquisition economics do not fully develop.

If ARO-MAPT Phase 1 data is moderate rather than strong, a licensing transaction modeled on the ARO-SNCA template extracts $8 to $24 billion in probability-weighted deal value while preserving platform ownership. The moderate scenario is not an acquisition downside; it is a different value-extraction path with materially positive returns from today’s entry.

X. The $55 to $90 Billion Range

Section V introduced the four valuation methodologies pharmaceutical M&A teams use to triangulate acquisition pricing and summarized their convergence at the $55 to $90 billion Stage 1 range. Section VI developed the Monte Carlo enterprise value distribution and confirmed the range sits in the 25th-to-40th percentile of the strong-scenario distribution, which is the band where value-accretive acquisitions clear. Section VIII profiled the three strategic bidders and attributed their distinct synergy magnitudes. This section develops the synergy math in detail and defends the $55 to $90 billion range specifically, both against the alternative that the clearing price should be lower (closer to standalone rNPV) and against the alternative that it should be higher (approaching the maximum willingness to pay of the highest-synergy bidder). The analysis is subject to the disclaimer in Section VII.

The analytical bridge from standalone rNPV to the acquisition range runs through two concepts: the seller’s share of acquirer-specific synergy, and the competitive auction mechanics that bound the clearing price. Standalone rNPV establishes the floor, the value of Arrowhead operating independently, without acquirer infrastructure or strategic fit. Acquirer-specific synergy is the incremental value that an acquirer generates beyond standalone operations: commercial infrastructure integration, defensive protection against competitor acquisition, combination-product pricing power, diagnostic-therapeutic integration, platform consolidation. The seller captures a portion of this synergy in negotiation; the acquirer retains the remainder. The seller’s share is what drives the acquisition range above standalone rNPV. The upper bound, however, is set not by the highest-synergy bidder’s maximum willingness to pay, but by the second-highest bidder’s maximum, because competitive auctions clear at the price required to defeat the second-best bid, not at the winning bidder’s walk-away point.

The Standalone rNPV Floor

Section V established Arrowhead’s standalone rNPV at $45 to $65 billion after a 40 to 50 percent portfolio-level probability haircut. This is the floor beneath any acquisition bid because no bidder would rationally pay less than the value the target could realize independently; the target’s board would reject the bid on fiduciary grounds. For Arrowhead at Stage 1, $45 to $65 billion is the no-synergy baseline. Every dollar above that floor reflects acquirer-specific value that the bidder believes they can generate beyond what Arrowhead can generate standalone. The question Section X answers is: how much of that acquirer-specific value does the seller capture in competitive negotiation, and what does that imply for the clearing price?

The Seller’s Share of Synergy in Competitive Auctions

In corporate M&A, when an acquirer generates synergy value beyond what the target could generate standalone, that synergy is split between buyer and seller in negotiated proportions. The seller’s share varies with the competitive intensity of the auction, the strategic criticality of the asset, the acquirer’s alternatives, and the seller’s walk-away position. In a single-bidder negotiation with a constrained seller, the seller’s share can be as low as 10 to 20 percent. In a competitive auction with multiple motivated bidders and a seller with real alternatives (independent operations, licensing path, walk-away optionality), the seller’s share typically runs 30 to 50 percent.

For Arrowhead at Stage 1, the seller’s share is at the upper end of the typical range because three structural conditions are satisfied. First, three motivated strategic bidders with non-overlapping rationales compete for the asset (per Section VIII), which forces each bidder to price closer to their maximum willingness to pay rather than to the target’s standalone valuation. Second, Arrowhead has a credible walk-away alternative, the licensing path developed in Section IX, which extracts $8 to $24 billion in probability-adjusted deal value without ceding platform ownership. This licensing alternative is real; management executed the ARO-SNCA transaction in October 2025 precisely because it valued platform retention over immediate liquidity. Third, ARO-MAPT in the strong scenario is uniquely positioned as the only validated subcutaneous tau-silencing asset, which means no acquirer can simply walk away and develop a comparable asset internally within a competitive timeframe. The combined effect produces a seller’s share of synergy that sits at 40 to 50 percent, not the 10 to 20 percent a distressed-seller situation would produce.

Bidder Walk-Away Prices

Applying the seller’s share framework to the three bidders produces their walk-away prices, the maximum each bidder could rationally pay while remaining value-accretive. Each walk-away is bidder-specific rNPV plus 50 to 70 percent of bidder-specific synergy. Section VIII developed each bidder’s synergy magnitude and strategic rationale; Figure 12 consolidates the walk-away calculation. The key observation is that Lilly’s walk-away at $73 to $124 billion (midpoint approximately $100 billion) materially exceeds the Stage 1 clearing range, which is set by Roche’s walk-away at $58 to $85 billion. In any auction, the winning bidder pays only enough to defeat the second-highest bidder plus a minimum increment; Lilly retains the remainder of its captured synergy as value accruing to the acquirer. This retained synergy is the economic rationale for Lilly to bid at all, without it, the acquisition would not be value-accretive for Lilly’s shareholders and would not receive board approval.

Figure 12: Bid Capacity by Strategic Bidder

Figure 12: The clearing price of a competitive auction is set by the second-highest walk-away (Roche at $58 to $85 billion) plus a bid increment, not by the highest walk-away (Lilly at $73 to $124 billion). Bid capacity estimates by strategic bidder: Standalone rNPV is the bidder-specific internal rNPV, which differs modestly from the paper’s generic $45 to $65 billion baseline due to bidder-specific discount rate and probability assumptions. Bidder-Specific Synergy is the Section V and VIII estimate. Seller’s Share is 50 to 70 percent of synergy, reflecting competitive auction dynamics. Walk-Away Price is standalone rNPV plus seller’s share of synergy.

How the Competitive Auction Produces the $55 to $90 Billion Range

In auction dynamics, the clearing price is set by the bid required to defeat the second-highest bidder, plus a minimum increment. Lilly wins by bidding just above Roche’s walk-away, not by bidding Lilly’s own maximum. Roche’s walk-away range of $58 to $85 billion therefore establishes the bounds of the clearing price, with $55 to $90 billion brackets reflecting the structural uncertainty around each bound.

The lower bound ($55 billion) is anchored by multiple independent inputs converging at approximately the same level. Standalone rNPV is $45 to $65 billion; even the smallest motivated synergy (Novartis at $10 to $20 billion, seller’s share at 40 to 50 percent) contributes $4 to $10 billion to a minimum-seller-share clearing price, producing a floor near $50 billion from the fundamentals-based arithmetic. Comparable pre-data transaction multiples (Prometheus 10.8×, MyoKardia 6.5×, Karuna 9.3×, ImmunoGen 12.6×) anchor the minimum pre-data multiple at 5.6×, which applied to Arrowhead’s $9.8 billion market cap produces $55 billion. The confluence of these independent anchors at $55 billion is why the paper holds that number as the lower bound rather than defaulting to the rNPV floor alone.

The upper bound ($90 billion) is set by Roche’s maximum walk-away plus the strategic premium Lilly pays to secure the asset in a contested three-way auction. In a competitive environment where the highest-synergy bidder (Lilly) recognizes that losing to Roche has long-term strategic cost, the Kisunla defensive damage Section VIII quantified, Lilly’s rational bid extends above the second bidder’s exact walk-away to ensure the transaction closes. The upper bound therefore sits at $90 billion rather than at Roche’s $85 billion walk-away, reflecting the contested-auction premium a high-synergy bidder will pay for certainty of execution.

Methodology Convergence at $55 to $90 Billion

The $55 to $90 billion range is not the output of a single methodology. It is the convergence point across the four independent methodologies introduced in Section V, each of which produces ranges consistent with the paper’s conclusion through different analytical mechanisms.

The rNPV standalone baseline ($45 to $65 billion) sits just below the acquisition range, with the gap representing the seller’s share of synergy ($10 to $25 billion) captured through competitive auction dynamics. The peak revenue multiple methodology ($72 to $120 billion) fully contains the acquisition range, reflecting the historical pattern that validated-mechanism platform assets transact at 4 to 6 times risk-adjusted peak revenue. The Monte Carlo median ($75 to $105 billion) sits slightly above the acquisition range, with the $55 to $90 billion range corresponding to the 25th to 40th percentile of the Strong scenario distribution, the band where value-accretive acquisition pricing occurs because the probability of overpayment is bounded below 40 percent. The comparable transactions methodology ($55 to $90 billion), anchored to pre-data multiples from Prometheus (10.8×), MyoKardia (6.5×), Karuna (9.3×), and ImmunoGen (12.6×), is exactly the paper’s conclusion, reflecting that the comparable transactions framework is the most directly evidence-anchored of the four methods and the one M&A teams lean on most heavily when defending a bid to their boards.

The convergence is analytically meaningful because the four methodologies share no common inputs. rNPV starts from peak revenue forecasts and discount rates. Peak revenue multiples start from historical acquisition ratios. Monte Carlo starts from probability distributions across nine input variables. Comparable transactions start from closed-deal premia. When four independent analytical frameworks with different theoretical foundations produce overlapping ranges, the conclusion is not the artifact of any one methodology’s assumptions, it is the structural answer to the valuation question. The $55 to $90 billion range is where all four methodologies agree, which is the analytical condition for high-confidence valuation conclusions in pharmaceutical M&A.

The Analytical Consensus

The $55 to $90 billion Stage 1 acquisition range is the analytical consensus across independent valuation methodologies, constrained by competitive auction mechanics, and consistent with bidder-specific walk-away prices. It is not the maximum Lilly could pay, nor is it the minimum Arrowhead’s board would accept. It is the price at which the second-highest bidder (Roche) is forced out of the auction, which is the point where competitive auctions clear in practice.

The range has bounds rather than a point estimate because each input has plausible uncertainty: bidder-specific rNPVs, synergy magnitudes, seller’s share, and bid increments all vary within defensible assumptions. The $55 to $90 billion range is the window within which a competitive Stage 1 auction for Arrowhead would clear under the strong Phase 1 scenario, with the specific clearing price determined by the resolution of these input uncertainties at the time of transaction.

Figure 13: Valuation Range Chart

Figure 13: Valuation range chart summarizing the paper’s valuation framework. Each horizontal bar shows the range produced by one input to the Stage 1 valuation question. The shaded $55 to $90 billion gold zone marks the paper’s conclusion, the Stage 1 clearing range.

Sections XI, XII, and XIII develop the remaining analytical work: Section XI describes the auction mechanics in operational detail (who engages whom, on what timeline, through what process); Section XII develops additional supporting evidence beyond the core valuation framework; Section XIII addresses the strongest counter-arguments to the thesis. The $55 to $90 billion range developed in this section is the analytical anchor those sections reference.

The $55 to $90 billion Stage 1 range is set by Roche’s walk-away price (the second-highest bidder), not by Lilly’s maximum. The lower bound is anchored by three independent methodologies converging at $55 billion. The thesis does not depend on the upper end of the range to produce a transformative return.

XI. The Stage 1 Auction

Section X developed the valuation math that produces the $55 to $90 billion Stage 1 acquisition range. This section describes the operational mechanics of how that range is realized in practice: the formal process trigger, the bidding rounds, the specific role of each bidder at each round, and the structural progression that produces the final clearing price. The auction described here is subject to the disclaimer in Section VII: the round-by-round bid trajectories are analytical hypotheticals constructed from publicly available information about pharmaceutical M&A practice and from the bidder walk-away prices developed in Section X, not predictions of actual bidding behavior or any current strategic process.

Large pharmaceutical M&A auctions are managed processes, not public tenders. They are typically run by investment banking advisors engaged by the target’s board, with sequential rounds of informal outreach, management presentations, due diligence access, and final-round sealed bids. The process from announcement of a strategic review to signing of a definitive agreement typically takes three to six months; from signing to close adds another three to nine months for regulatory clearance and shareholder approval. The total timeline from Phase 1 readout to close under the strong scenario is approximately 6 to 18 months, consistent with the Section VII strong-scenario narrative.

The Formal Process Trigger

The Arrowhead auction process begins at one of three moments following positive Phase 1 data. First, Arrowhead’s board could proactively initiate a strategic review process immediately after the readout, engaging investment bankers to run a formal sale process. This is the most likely path when the data is sufficiently strong to attract multiple serious bidders and management recognizes that public market re-rating alone will not capture the full value accessible through strategic acquisition. Second, an unsolicited approach from a bidder, most plausibly Lilly given their two-franchise strategic urgency, could trigger a formal process under the board’s fiduciary duty to evaluate all alternatives. Third, a bidding contest could develop organically if multiple parties approach Arrowhead simultaneously after the data publication, forcing the board to conduct a formal process to discharge its fiduciary obligations to shareholders.

In any of these scenarios, once positive ARO-MAPT data is public and multiple strategic acquirers are known to be evaluating the company, the board has a legal obligation to conduct a fair process. The mechanics from that point forward are standard: bankers issue confidentiality agreements, manage the data room, schedule management presentations, structure the bidding rounds, and run the final-round sealed bid process. The competitive dynamic described in the next subsections emerges naturally from this managed process rather than requiring any specific bidder behavior to trigger it.

The Pre-Auction Phase

Within the first 72 hours of the Phase 1 readout, informal outreach from potential acquirers begins. The initial contacts are typically by bankers, not company executives, standard pre-transactional practice that preserves optionality without creating disclosure obligations. By the end of the first post-readout month, the three potential bidders profiled in Section VIII (Lilly, Roche, and Novartis) have each engaged their internal M&A teams to perform independent valuation work using the frameworks from Sections V and X. By months two to four, at least two of the three bidders have signed confidentiality agreements with Arrowhead and gained access to a data room containing the clinical, regulatory, manufacturing, financial, and partnership documentation needed for formal diligence.

During this pre-auction period, the Arrowhead board engages its own advisors, typically the major pharmaceutical M&A specialists at firms such as Centerview, Goldman Sachs, and Morgan Stanley. These advisors construct the process: who is invited to bid, what information is disclosed at each round, the timeline for each phase, and the structure of the final round. The CEO and board weigh the strategic options during this period: remain independent and pursue licensing (per Section IX), license ARO-MAPT specifically while retaining the platform, or sell the company. With multiple bidders engaged and public market pressure building for liquidity realization at strong-scenario valuations, the path of least resistance in the strong scenario is a formal sale process.

The Bidding Rounds

The bidding process typically runs three rounds over approximately three to five months. Round 1 is the opening round following initial diligence access, where bidders signal interest and establish starting positions below their internal walk-away prices. Round 2 is the serious round following management presentations and deeper technical diligence, where bidders reprice based on their updated internal models. Round 3 is the final auction, typically a sealed-bid process among the two or three most serious remaining bidders. Figure 14 summarizes the expected bid trajectory by bidder across the three rounds, calibrated to the Section X walk-away prices.

Figure 14: Expected Bid Progression by Round

Figure 14: Expected bid progression across three rounds. Round 1 openings are disciplined starting bids below each bidder’s walk-away, designed to signal serious intent without revealing the ceiling. Round 2 bids reflect full diligence and the bidder’s updated internal valuation. Round 3 is the final auction among remaining bidders, with Lilly winning at $80 to $90 billion, above Roche’s final bid but well below Lilly’s $124 billion theoretical maximum. Novartis drops out in Round 2 or Round 3 as the bidding approaches their $47 to $64 billion walk-away range. The final clearing price sits within the $55 to $90 billion Stage 1 range developed in Section X.

Round 1: Opening Bids

Round 1 bids are disciplined openings. Each bidder has completed initial diligence but not yet conducted the deep management presentations and technical sessions that follow. The opening bids are designed to signal serious intent and meet the participation threshold set by the Arrowhead advisors without revealing the bidder’s full internal valuation. Lilly opens at $50 to $60 billion, a strong opening bid that pre-empts lower bids from competitors and demonstrates two-franchise strategic conviction. Roche opens at $45 to $55 billion, a disciplined opening that reserves capacity for later rounds while signaling engagement. Novartis opens at $40 to $50 billion, possibly accompanied by a request for right-of-first-refusal treatment given the existing ARO-SNCA partnership relationship.

The Round 1 bids cluster below each bidder’s walk-away because opening at the walk-away leaves no room to respond to competitive pressure in subsequent rounds. A bidder who opens at their maximum signals they have no additional capacity, which weakens their position in the negotiation. Each bidder’s Round 1 bid is also shaped by information asymmetry: Lilly has the most to lose defensively if they underbid and a competitor wins, which motivates their higher opening; Roche has unique synergy that the other bidders do not know about in detail, which allows them to bid with discipline knowing Round 2 and Round 3 remain available; Novartis has the narrowest synergy and is most price-sensitive, which explains their lower opening.

Round 2: The Serious Round

By Round 2, the bidders have conducted management presentations and deeper technical diligence on the clinical, manufacturing, commercial, and partnership dimensions of the company. Each bidder’s internal valuation has updated with information that was unavailable at Round 1, and the bids reprice accordingly. Lilly moves to $65 to $80 billion as they now incorporate the full AD franchise defensive damage calculation and the obesity program Phase 1/2a data into their internal model. Roche bids $60 to $75 billion as they finalize the trontinemab delivery mechanism synergy and the Elecsys diagnostic integration. Novartis bids $55 to $65 billion, having confirmed platform technical fit but recognizing that their synergy magnitude does not support bidding at the levels Lilly and Roche are reaching.

Round 2 is the round where Novartis’s role in the auction becomes visible. Their $55 to $65 billion bid sits at or slightly above their $47 to $64 billion walk-away, which means they cannot meaningfully raise in Round 3 without paying above their maximum willingness to pay. Novartis’s strategic value in the auction at this point is as a price-forcer that has compelled Lilly and Roche to bid closer to their higher walk-aways, not as a likely final winner. The probability distribution from Section VIII, Novartis at 10 to 20 percent, reflects the small but non-zero chance that Lilly and Roche both bid conservatively and Novartis wins at a price within their walk-away range.

Round 3: The Final Auction

Round 3 is typically a sealed-bid process run by Arrowhead’s advisors, in which the remaining bidders submit final bids simultaneously with no opportunity for further iteration. The bidders remaining in Round 3 are most likely Lilly and Roche; Novartis has either dropped out after Round 2 or submitted a Round 3 bid below the competitive threshold. Roche’s final bid is in the $75 to $85 billion range, at or near the upper end of their $58 to $85 billion walk-away. Lilly’s final bid is $80 to $90 billion, above Roche’s bid but well below Lilly’s own $73 to $124 billion walk-away — just high enough to win while preserving meaningful synergy capture for Lilly’s shareholders.

Lilly wins Round 3 at $80 to $90 billion. The competitive premium Lilly pays above Roche’s bid reflects the contested-auction dynamic developed in Section X; Lilly pays above the second-highest bidder’s walk-away to secure the asset and prevent the strategically devastating outcome of Roche owning a tau-silencing asset positioned against Kisunla. The final price is not what ARO-MAPT is worth to Lilly in isolation, it is the price at which Lilly defeats Roche by a sufficient margin to close the transaction.

The Clearing Outcome

The $80 to $90 billion Round 3 clearing price sits at the upper end of the $55 to $90 billion Stage 1 range developed in Section X. The Section X range reflects structural uncertainty around multiple inputs; the seller’s share of synergy could be 40 to 50 percent instead of 50 to 70 percent, Roche’s walk-away could be at the low end of $58 billion rather than the high end of $85 billion, Novartis could exit earlier than expected and reduce competitive pressure on Lilly, each of which would shift the clearing price downward within the range. Under the base case where the three bidders behave as Figure 14 describes and Section X’s walk-away estimates hold, the clearing lands in the $80 to $90 billion band. Under less favorable auction dynamics, the clearing could land as low as $55 billion; under more favorable dynamics or if Lilly pushes toward the upper end of their capacity, the clearing could touch $90 billion. The $55 to $90 billion range therefore brackets the plausible outcomes.

The per-share implication at the $80 to $90 billion base case is approximately $517 to $581 per fully diluted share (using 155 million diluted shares for the acquisition scenario), which is 7.4 to 8.3 times today’s $70 per share. The per-share range across the full Stage 1 band of $55 to $90 billion is $355 to $581, or 5.1 to 8.3 times today’s entry. Public shareholders receive this premium as consideration in the acquisition, typically in cash or a cash-and-stock mix depending on the acquirer’s transaction structure preferences.

Board Dynamics and Closing

The Arrowhead board evaluates the Round 3 bids against the fairness opinions from their advisors, the comparable transactions analysis, the standalone plan with licensing optionality (per Section IX), and the relative risk of accepting versus rejecting the winning bid. A bid in the $80 to $90 billion range substantially exceeds the standalone-plus-licensing value developed in Section IX ($15 to $25 billion public market re-rate plus $8 to $24 billion licensing deal value, under moderate scenarios) and exceeds the strong-scenario public market re-rate from Section I ($25 to $45 billion). The fiduciary calculation is straightforward under these conditions: the winning bid delivers shareholder value that Arrowhead cannot credibly generate independently on any reasonable timeline, and the board accepts.

The definitive agreement is typically signed within two to four weeks of Round 3 bid submission, following final negotiation on non-price terms (break-up fees, representations and warranties, regulatory closing conditions, employee retention structures). Announcement occurs at signing. Hart-Scott-Rodino antitrust clearance and shareholder approval proceed in parallel over the following three to nine months. The transaction closes approximately 6 to 18 months after the original Phase 1 readout. The investor who entered at today’s $9.8 billion market cap realizes their return at close, typically in cash, which is immediately reinvestable.

Sections XII and XIII develop the remaining analytical work: Section XII adds supporting evidence beyond the core valuation and auction framework developed in Sections V through XI, and Section XIII addresses the strongest counter-arguments to the thesis.

The Stage 1 auction runs standard pharmaceutical M&A mechanics: three rounds over three to five months, with Lilly winning Round 3 at $80 to $90 billion above Roche’s final bid of $75 to $85 billion. The clearing price is not what ARO-MAPT is worth to Lilly in isolation, it is the price at which Lilly defeats Roche by a sufficient margin to close the transaction.

XII. Additional Evidence

Sections I through XI developed the core thesis: three Phase 1 scenarios, four valuation methodologies, three strategic bidders, auction mechanics producing a $55 to $90 billion clearing range. This section adds three pieces of supporting evidence that reinforce the core argument but do not fit neatly within any single prior section. Each is concrete, recent, and specific to Arrowhead. Taken together, these supporting pieces reinforce the conclusion that Arrowhead at today’s $9.8 billion market cap is systematically mispriced relative to what an acquirer’s internal valuation produces under the strong Phase 1 scenario.

Alnylam’s 2025 Annual Report: The Competitor Capability Gap

Alnylam Pharmaceuticals is the most resourced siRNA company in the world: $2.99 billion in 2025 revenue, $42 billion market cap, and a validated commercial platform across liver, muscle, and CNS. In the 2025 Annual Report published April 2026, Alnylam disclosed its Alnylam 2030 strategic plan for the next five years. The CNS pipeline in that plan consists of five intrathecal programs delivered via lumbar puncture. Zero subcutaneous blood-brain-barrier-crossing programs. If the most capable siRNA company in the world had a credible path to subcutaneous CNS delivery on a competitive timeline, it would be in the strategic plan. It is not. Arrowhead has built something its largest competitor has not.

This is the strongest publicly available third-party validation of Arrowhead’s delivery platform. It is not an analyst opinion; it is a five-year capital-allocation plan published by the competitor best positioned to replicate the capability. When ARO-MAPT produces positive Phase 1 human data, the implication is structural: Arrowhead owns a delivery mechanism that the best-funded alternative in the field has not matched. That scarcity is the foundation of the strategic premium an acquirer pays above standalone rNPV.

Gene X: The Platform Engine’s Hidden Output

On December 10, 2025, at the 7th Annual CNS Delivery Summit, Arrowhead presented non-human primate data showing approximately 90 percent mRNA knockdown across all brain regions for a target they refused to name. The slide title identified the target only as “Gene X” and described the indication only as “cardiometabolic.” This disclosure is concrete evidence for a claim that otherwise depends on inference, that the platform engine generates programs at a pace and with performance characteristics that sell-side models cannot capture because the sell-side cannot model programs the company has not disclosed.

Several details make this disclosure unusually informative. First, the 90 percent knockdown efficacy is higher than what Arrowhead has publicly disclosed for any named CNS program, including ARO-MAPT (70 to 80 percent in deep brain regions), ARO-HTT, ARO-SNCA, or ARO-ATXN3. Arrowhead’s best publicly disclosed CNS knockdown data is for a target they have not named. Second, the audience at the CNS Delivery Summit was the business development and research teams of every major pharmaceutical company with a neuroscience or metabolic program. The disclosure was deliberately positioned to the exact decision-makers who would price platform value in a strategic evaluation. Third, the target is described as cardiometabolic, which is distinct from any of Arrowhead’s named CNS programs. This is a CNS-delivered therapeutic for a non-CNS disease area, an entirely new category of RNAi application, and one that no competitor has demonstrated.

The strategic message embedded in the Gene X disclosure is that the platform is not a single-asset story. The delivery mechanism works for multiple gene targets at exceptional potency, programs exist in development that have not been named, and the pace of pipeline generation exceeds what disclosed programs alone imply. An acquirer pricing platform optionality after seeing the Gene X slide is not speculating about future programs. They are pricing a confirmed capability with a concealed pipeline behind it. This is the kind of evidence that moves the platform optionality input in the Monte Carlo (Section VI) from speculative to evidenced, and it is one of the reasons the M&A team’s rNPV (Section V) diverges materially from sell-side consensus.

Manufacturing Infrastructure as Strategic Currency

Arrowhead’s Verona, Wisconsin manufacturing facility provides three operational GMP production lines currently producing clinical and commercial supply across the TRiM platform. In the standalone valuation, Verona shows up as a cost center on the balance sheet. In an acquirer’s internal valuation, Verona shows up as pre-positioned manufacturing capacity that an acquirer can deploy on day one of ownership; strategic currency that is immediately usable rather than infrastructure the acquirer must build from scratch.

The strategic value of Verona has three components. First, replacement cost. A comparable three-line GMP facility capable of TRiM chemistry production at commercial scale costs approximately $2 to $4 billion to construct, and the construction and qualification timeline is five to seven years. An acquirer that does not own Verona faces this cost and delay; an acquirer that acquires Arrowhead inherits the facility fully operational. Second, the adjacent parcel option. Arrowhead holds an option through 2028 to acquire 6.24 adjacent acres, on which expansion facilities can be constructed. The cost advantage of expansion on the adjacent parcel versus greenfield construction at a new site is approximately 40 to 60 percent, driven by shared utilities, shared permits, shared environmental qualification, and partially reusable design work. The time advantage is 18 to 24 months, driven by the elimination of site selection, initial permitting, and base regulatory qualification phases. For an acquirer planning to scale TRiM manufacturing across multiple commercial products over the next decade, this expansion pathway represents a specific economic asset worth an incremental $1 to $2 billion in avoided cost and accelerated time-to-capacity. Third, TRiM chemistry expertise. The operational know-how embedded in Arrowhead’s manufacturing staff, developed over fifteen years of platform work, is not purchasable off the shelf. An acquirer that buys the asset also buys the people who know how to make it at scale.

Taken together, the Verona infrastructure represents $3 to $6 billion in strategic currency to an acquirer, larger than the nominal book value of the facility by a factor of five to ten. This is a specific line item in an acquirer’s internal model and is entirely absent from sell-side rNPV, which treats manufacturing capacity as an implicit assumption rather than a valued asset.

The Long-Horizon Platform Value

The Stage 1 acquisition range of $55 to $90 billion answers a specific analytical question: what is Arrowhead worth to a strategic acquirer if ARO-MAPT produces positive Phase 1 data in 2H2026? It does not answer the broader question an acquirer’s board also asks: what does this platform look like on our income statement ten years from now? The answer to that broader question is why a strategic acquirer pays the Stage 1 premium in the first place, and it is the reason Stage 1 transactions of this kind are value-accretive even at prices that look aggressive at the moment of signing.

By 2036, the plozasiran cardiovascular franchise is at or approaching commercial peak, generating $15 to $30 billion annually across FCS, sHTG, and CAPITAN mixed hyperlipidemia indications (if CAPITAN reads out positive). ARO-MAPT in Alzheimer’s disease is in commercial ramp following expected 2035 launch, with the subcutaneous quarterly profile removing structural barriers that have constrained first-generation anti-amyloid uptake; early commercial revenues of $5 to $15 billion growing steeply. The obesity program, if validated in pivotal trials, is generating meaningful revenue through a differentiated non-GLP-1 mechanism. The Sarepta and Novartis partnered programs are producing milestone and royalty streams as their own clinical programs advance. The broader platform, Gene X, ocular TRiM, cardiac TRiM, and programs not yet named, is beginning to produce additional clinical-stage candidates at the pace the platform engine has demonstrated over the prior five years.

The total Arrowhead-derived revenue to an acquirer in 2036 is estimated at $45 to $85 billion annually, representing a material fraction of a major pharma acquirer’s total revenue base at that horizon. At the upper end of that range, Arrowhead-derived revenue could approach 15 to 20 percent of Lilly’s projected 2036 revenue, which is the order-of-magnitude contribution that justifies a $55 to $90 billion Stage 1 acquisition price even on purely financial grounds. The Genentech precedent referenced in Section II is the closest historical parallel: Roche paid $46.8 billion in 2009 for a remaining Genentech stake that analysts at the time characterized as expensive, and the platform subsequently generated hundreds of billions of dollars of cumulative revenue under Roche ownership across Herceptin, Rituxan, Avastin, Perjeta, Kadcyla, and subsequent programs. The Stage 1 Arrowhead acquisition is the same structural argument applied to a different platform technology at a different inflection point.

How These Pieces Reinforce the Core Thesis

The Gene X disclosure demonstrates that the platform’s output exceeds sell-side visibility; programs exist that no public model captures. The Verona infrastructure demonstrates that the company owns strategic currency that standalone valuation does not value; an acquirer inherits an operational manufacturing asset worth several billion dollars more than its book value. The long-horizon platform analysis demonstrates that Stage 1 acquisition economics are not driven by the immediate ARO-MAPT contribution alone, they are driven by a decade of platform revenue generation that justifies paying above standalone rNPV at signing.

None of these three pieces is necessary for the core thesis; the core thesis stands on the four valuation methodologies and the auction mechanics developed in Sections V through XI. But each reinforces the conclusion by adding specific evidence where the core framework uses inference. An investor evaluating whether the core thesis is robust can look to Gene X for evidence that the platform engine is real, to Verona for evidence that the manufacturing infrastructure is real, and to the long-horizon analysis for evidence that the Stage 1 premium is not aggressive when viewed against the ten-year revenue base an acquirer captures through ownership.

Gene X demonstrates the platform engine produces programs the sell-side cannot model. Verona represents $3 to $6 billion of strategic currency absent from rNPV. The 2036 long-horizon projects $45 to $85 billion of annual Arrowhead-derived revenue to an acquirer, the Genentech precedent applied to a different platform at a different inflection point.

XIII. Critic’s Brief

The thesis developed across Sections I through XII depends on a chain of analytical assumptions that are defensible but not beyond reasonable objection. This section addresses five specific objections, the strongest a sophisticated institutional skeptic would raise, and explains what each correctly identifies and why the thesis still holds. The objections are presented in their strongest form, not as strawmen.

Objection 1: The Magnitude of the Acquisition Range

The most fundamental objection to the thesis is the most basic one: no acquirer would pay $55 to $90 billion for a company whose lead asset has not yet completed Phase 1 and whose total revenue base is a fraction of the acquisition price. Base rates in pharmaceutical M&A run against this magnitude of outcome. The modal biotech acquisition premium over unaffected market cap is 30 to 50 percent, not the 460 to 820 percent the thesis implies relative to today’s $9.8 billion market cap. Pharmaceutical acquisitions above $50 billion are extraordinarily rare, and the handful that have cleared that threshold over the past twenty-five years were all for companies with substantial commercial revenue, none for a primarily clinical-stage biotech with a single lead asset awaiting Phase 1 data. The four comparables anchoring the paper’s 5.6× to 9.2× pre-data multiple all transacted from pre-data market capitalizations five to ten times smaller than Arrowhead’s $9.8 billion. Larger targets typically transact at compressed multiples. A board approving $85 billion for Arrowhead at Stage 1 would face shareholder litigation, proxy challenges, and structural political-economy resistance. And Arrowhead’s management has spent fifteen years building the company as an independent platform operator, with licensing agreements rather than sales, and no sell-side bankers engaged.

The objection correctly identifies multiple real patterns. Base rates are against extreme-magnitude outcomes; they are extreme by definition. Pharmaceutical acquisitions above $50 billion are historically rare and involve substantial commercial revenue that Arrowhead does not yet have. Larger targets transact at compressed multiples. Board political-economy constraints make extraordinary transactions structurally harder to approve than ordinary ones. Management positioning matters; Arrowhead’s leadership has demonstrated a clear preference for independence and licensing over acquisition. These observations are accurate, and the thesis does not deny them. The analytical question is whether Arrowhead’s specific structural characteristics place it in the tail of the distribution these base rates describe, or whether it belongs in the modal band.

The argument that Arrowhead is in the tail rests on three specific structural conditions that the modal biotech acquisition does not share. First, subcutaneous TfR1-mediated CNS delivery is unique. No competitor has replicated it, and no competitor can develop a comparable asset on a competitive timeframe, so an acquirer that wants this platform does not have an alternative target. Second, three motivated strategic bidders with non-overlapping rationales compete for the asset, a structural condition that is rare in pharmaceutical M&A and that specifically drives clearing prices above single-bidder negotiation outcomes. Third, the Lilly two-franchise fit (AD plus obesity) is distinctive; no other bidder has equivalent strategic exposure across two therapeutic areas where Arrowhead’s pipeline creates value. The relevant size precedent for this combination of conditions is Genentech ($46.8 billion in 2009), a platform acquisition where the acquirer was paying for the engine, not just current output, and which subsequently generated hundreds of billions of dollars of cumulative revenue under Roche ownership. Platform acquisitions at this scale are rare because the structural conditions that justify them are rare, not because the economics are irrational when those conditions hold.

The board and management objections cut differently than the skeptic frames them. Boards face scrutiny for paying extraordinary premiums; they also face scrutiny for missing transformational acquisitions that competitors capture. Lilly’s board declining to acquire Arrowhead while Roche acquires Arrowhead, and then watching Roche-owned ARO-MAPT pressure Kisunla over a decade, faces more severe political-economy consequences than paying $85 billion to secure the asset. The defensive calculation fundamentally changes the board’s risk-reward structure. On management positioning, fifteen years of platform-independence strategy is context, not destiny. The relevant question is not whether management prefers independence under ordinary conditions, but whether the board’s fiduciary obligation compels a sale when a strategic acquirer offers valuation that shareholders cannot credibly match through independent operations plus licensing. Under the strong Phase 1 scenario, an $85 billion offer against standalone-plus-licensing value of $25 to $45 billion is very difficult to decline. Management preference does not override fiduciary duty.

Objection 2: Acquirers May Rationally Wait for Phase 2 Cognitive Data

The thesis assumes acquirers move at Stage 1 following positive Phase 1 data. But Phase 1 data in 2H2026 resolves delivery risk and biomarker pharmacology, it does not resolve the cognitive endpoint question that ultimately determines whether ARO-MAPT reaches approval. BIIB080’s CELIA Phase 2 cognitive data is pending. A rational acquirer could decide that the cost of waiting for Phase 2 data in 2029-2030 is lower than the cost of paying a Stage 1 premium without cognitive confirmation. If Lilly waits, the auction doesn’t develop at Stage 1. Arrowhead remains public, re-rates on Phase 1 data to $25 to $45 billion, and the strong-scenario acquisition range is not realized on the thesis timeline.

This objection points to a real strategic decision each bidder faces. It is rational for a bidder to wait if the expected cost of waiting is lower than the Stage 1 premium. But the expected cost of waiting is not simply the Stage 2 acquisition premium minus the Stage 1 acquisition premium. It includes two additional components: the probability that a competitor acquires Arrowhead at Stage 1 (permanent loss of the asset, plus defensive damage), and the re-rating of Arrowhead’s public market cap between Stage 1 and Stage 2 (which compounds the Stage 2 entry price). The Stage 1 entry captures a specific competitive advantage that Stage 2 entry does not: preventing a rival from owning the asset during the Phase 2 development window.

For Lilly specifically, the defensive component dominates. If Roche acquires Arrowhead at Stage 1 and Roche-owned ARO-MAPT reaches Phase 2 cognitive readout in 2029-2030 as part of a Roche-developed program, Lilly faces a Kisunla franchise competitive threat that Lilly cannot respond to with internal development on any reasonable timeline. The Stage 1 acquisition for Lilly is therefore not primarily a decision about ARO-MAPT’s probability-adjusted expected value, it is a decision about defensive optionality. This is the specific reason Section VIII attributes a 50 to 60 percent probability to Lilly winning a Stage 1 auction: the defensive calculation produces a bid capacity above what a waiting-for-Phase-2 strategy would allow.

Objection 3: The Three-Bidder Competitive Auction May Not Develop

The $55 to $90 billion clearing range depends on at least two motivated bidders competing. If only Lilly bids seriously, the clearing price lands much closer to Arrowhead’s standalone rNPV than to the $55 to $90 billion range. Lilly can negotiate a transaction at $30 to $50 billion because there is no competitive pressure forcing the price higher. The objection challenges the structural assumption that Roche and Novartis bid aggressively. Roche may decline to bid given trontinemab is their AD priority and ARO-MAPT is a complement rather than a substitute. Novartis may decline given the $12 billion Avidity acquisition absorbed their 2026 neuroscience M&A capital. If both decline to bid aggressively, the auction does not produce the clearing dynamics Section XI describes.

Each bidder does have plausible reasons to decline aggressive bidding, and the paper does not claim the competitive auction is guaranteed, but three observations bound the downside. First, even a single-bidder Lilly negotiation produces an acquisition price well above today’s $9.8 billion market cap. A Lilly-only bid at standalone rNPV plus a modest premium would still produce $50 to $70 billion, a 5× to 7× return from today. Second, Roche’s strategic calculus specifically supports bidding even if trontinemab is their AD priority: if Lilly acquires Arrowhead and combines Kisunla with ARO-MAPT, Roche faces a Lilly-owned two-mechanism AD franchise that competes directly against trontinemab. Defensive value for Roche is real; they cannot credibly decline to bid while trontinemab is in Phase 3. Third, even if Novartis declines, a two-bidder auction between Lilly and Roche still produces competitive clearing dynamics, just with a lower second-highest walk-away anchor that produces clearing in the lower half of the range ($55 to $70 billion) rather than the upper half. That is still a significant return from today’s entry.

Objection 4: The Synergy Estimates Are Aggressive

The Lilly synergy total of $45 to $85 billion is the single largest input into the Stage 1 clearing range. A substantial portion of that synergy ($30 to $50 billion) is attributed to the AD franchise, anchored on $15 to $25 billion in Kisunla defensive value. The objection is that Kisunla is already facing competitive pressure from Leqembi, trontinemab, and potentially future anti-amyloid entrants. The incremental defensive damage attributable specifically to competitor ownership of a subcutaneous tau-silencing asset, as opposed to the damage Kisunla faces from existing competitors regardless, may be smaller than $15 to $25 billion. The two-mechanism franchise pricing power ($10 to $15 billion) similarly assumes combination regimens command 25 to 40 percent pricing premiums, which is a range observed in oncology and immunology but not yet tested in AD where pricing dynamics remain in early stages of establishment.

Specific dollar values do carry uncertainty, but the synergy estimates are ranges, not point estimates, and the paper’s competitive clearing analysis in Section X already absorbs significant input uncertainty without breaking the conclusion. The Lilly walk-away calculation uses 50 to 70 percent seller’s share of synergy, which already discounts the raw synergy totals. A 30 percent reduction in Lilly’s AD synergy estimate (from $30-$50B to $21-$35B) produces a Lilly walk-away of approximately $60 to $95 billion rather than $73 to $124 billion, which still exceeds the Stage 1 clearing range. The second-highest bidder (Roche) sets the clearing price, not Lilly’s maximum, so compression in Lilly’s synergy does not directly compress the clearing range.

The more consequential test for the thesis is whether Roche’s synergy estimate ($25 to $40 billion) survives compression. Roche’s synergy is anchored on three components that are less speculative than Lilly’s defensive calculations: trontinemab TfR1 delivery mechanism coherence (a scientific observation, not a competitive estimate), Elecsys diagnostic-therapeutic integration (an existing commercial infrastructure, not a projection), and comprehensive AD portfolio integration (an assemblage of existing assets, not contingent on new development). A reasonable downside on Roche’s synergy might compress it to $18 to $30 billion, which produces a Roche walk-away of $54 to $75 billion, still within the Stage 1 clearing range. The thesis does not depend on the upper end of the synergy estimates; it depends on the minimum-motivated-bidder synergy being large enough to produce a competitive clearing price meaningfully above standalone rNPV. That condition holds even under aggressive compression of the synergy estimates.

Objection 5: Tau Silencing May Not Translate to Cognitive Benefit

The long-horizon platform value developed in Section XII and the synergy estimates in Section X ultimately depend on ARO-MAPT reaching commercial approval for Alzheimer’s disease. That requires tau silencing to translate to cognitive benefit in a Phase 2 or Phase 3 cognitive endpoint trial. BIIB080’s CELIA Phase 2 data is expected to read out in 2026, potentially before the ARO-MAPT Phase 1 readout, and will partially but not fully resolve the cognitive translation question. If tau silencing does not produce the cognitive benefit required for approval, if biomarker success does not translate to endpoint success, the long-term AD franchise value compresses substantially, and the acquisition rationale that depends on that franchise weakens.

The objection identifies the single largest residual uncertainty in the long-term thesis. Even a successful Phase 1 biomarker readout does not resolve the cognitive translation question; it resolves delivery and biomarker pharmacology only. But the thesis this paper develops does not require cognitive translation to be resolved at Stage 1. The Stage 1 acquisition occurs under uncertainty about cognitive endpoints, that is precisely why the probability of ultimate AD approval in Section VI’s Monte Carlo is 20 to 25 percent at Stage 1 rather than the 50 to 60 percent it would reach after positive Phase 2 cognitive data. The $55 to $90 billion Stage 1 range already incorporates cognitive translation risk through the probability-adjusted rNPV inputs. An acquirer paying in this range is not betting that cognitive translation succeeds; they are buying probability-weighted exposure across the full outcome distribution, with the strategic premium over standalone rNPV compensating for the defensive value and platform optionality that are real independent of the cognitive translation question.

Tau silencing as a mechanism has substantial independent support: MAPT mutations cause familial tauopathies directly, tau accumulation correlates tightly with cognitive decline across all Alzheimer’s stages, and BIIB080 has established that tau can be safely silenced in humans at meaningful magnitude. What remains unresolved is not whether tau is a legitimate therapeutic target, but whether the magnitude and durability of silencing ARO-MAPT achieves translates to clinical benefit within the trial design and patient population chosen. That is a real risk, but it is the same risk every tau-silencing asset faces, and it is appropriately priced into the probability inputs used in the paper’s valuation methodologies. The CELIA readout adds a sequence risk worth flagging: a positive CELIA result before the ARO-MAPT Phase 1 readout would partially de-risk the cognitive translation question and raise the probability inputs across the paper’s methodologies, while a negative result would compress them in the opposite direction.

What the Thesis Requires and What It Does Not

The five objections above are the strongest counter-arguments a sophisticated skeptic would raise. None of them is fatal to the thesis. Each one compresses a specific input, the base-rate magnitude of the acquisition range and its comparable-transaction anchors, the probability the auction develops, the magnitude of acquirer-specific synergy, the timeline for acquisition, and the long-term cognitive translation probability, but none of them eliminates the central analytical observation: that Arrowhead at today’s $9.8 billion market cap is priced as if the weak Phase 1 scenario were the probability-weighted base case, which is inconsistent with the prior evidence base developed in Sections I and II.

The conditions the thesis requires map directly to the objections above. First, against Objection 1, the structural conditions that place Arrowhead in the tail of the base-rate distribution, unique subcutaneous CNS delivery, three motivated bidders, two-franchise Lilly fit, must hold at Stage 1. Second, against Objection 2, at least one strategic acquirer must engage at Stage 1 rather than waiting for Phase 2 cognitive data. Third, against Objection 3, competitive pressure must develop, at minimum a two-bidder auction where Roche participates, setting a clearing price above single-bidder negotiation outcomes. Fourth, against Objection 4, bidder-specific synergy must survive reasonable compression, the minimum-motivated-bidder synergy (Roche’s) must remain large enough to produce a walk-away meaningfully above standalone rNPV. Fifth, against Objection 5, the cognitive translation probability priced into the Section VI Monte Carlo (20 to 25 percent at Stage 1) must remain defensible, with CELIA providing partial resolution. None of these conditions is certain, but all are more likely than not under the prior evidence base developed across Sections I through XII.

The thesis does not require every element of Sections V through XII to materialize at the upper end of its range. It requires the middle of the range to be realistic and the lower end of the range to be protective. Both conditions hold under the analytical framework developed across this paper. That is the sense in which the thesis is robust to reasonable objection: not that it is immune to compression, but that the compressed outcome still produces a meaningful positive return from today’s entry point, and the uncompressed outcome produces a transformative return.

Five sophisticated objections each compress a specific input. None is fatal. The thesis is robust to reasonable objection: the compressed outcome still produces a meaningful positive return from today’s entry, and the uncompressed outcome produces a transformative return.

XIV. Conclusion

This paper answers one question: is today a better entry point for Arrowhead than the moment after the Phase 1 data arrives? The answer is yes. Today’s entry is asymmetric, the potential upside is much larger than the downside, in a way that won’t be true once the data is public. The asymmetry is large enough to justify a position despite the risks Section XIII catalogs.

If ARO-MAPT Phase 1 produces strong data in 2H2026, the probable outcome is an acquisition in the $55 to $90 billion range. That is 5.1 to 8.3 times today’s $70 share price, or $355 to $581 per share for investors holding through the transaction. Four separate valuation methods, each one grounded in how pharmaceutical M&A teams actually price deals, converge on this range. It is not one model’s forecast; it is where multiple independent frameworks arrive at the same answer. If no deal closes in the 12 to 18 months after positive Phase 1 data, a second acquisition window opens in the $110 to $150 billion range if Phase 2 cognitive data is positive in 2029 or 2030. That is forward upside for investors who stay in the position past Stage 1.

Today is the better entry point because the Phase 1 outcome is still unknown. An investor buying today is buying a claim on all three possible outcomes, strong, moderate, and weak, at a single price. An investor waiting for the readout is buying only the outcome that actually happens, at a price that has already moved to reflect it. The existing evidence, BIIB080’s tau-silencing data in humans, trontinemab’s validation of crossing the blood-brain-barrier with a similar delivery mechanism, and Arrowhead’s strong non-human-primate data, makes the weak scenario meaningfully less likely than today’s $9.8 billion market cap implies. Put simply: the market is priced as if the worst case is the likely outcome. The evidence says the worst case is not the likely outcome. The gap will close either when the Phase 1 data arrives or when other institutional investors recognize the mismatch first.

Here is what the investment case looks like scenario by scenario. If Phase 1 data is strong (estimated probability 40 to 50 percent), an investor holding the position earns 5 to 9 times their investment, either through an acquisition within 6 to 18 months of the readout or through a sharp re-rating in the public market with the second acquisition window as additional upside. If the data is moderate (estimated probability 30 to 35 percent), the stock re-rates 1.5 to 2.6 times, and an ARO-MAPT licensing deal adds $8 to $24 billion in probability-weighted value to shareholders, with a positive Phase 2 cognitive readout as a further path to upside. If the data is weak (estimated probability 20 to 25 percent), the return is approximately flat to mildly negative; the non-CNS commercial business (plozasiran for severe hypertriglyceridemia, the pre-commercial obesity program, the partnered Sarepta and Novartis assets) provides a floor near today’s market cap. The weighted average of these outcomes is clearly positive, and the large upside scenarios are not available at any price once the data is public.

The Phase 1 data readout expected in the second half of 2026 will resolve the central question this paper has analyzed. If ARO-MAPT delivers human confirmation of subcutaneous CNS delivery and measurable CSF tau reduction, the acquisition scenario described here moves from conditional to probable. The question will no longer be whether the platform works, it will be which company sits across the table from Christopher Anzalone, and how much they are willing to pay to not let the other bidder win.

Glossary

The following terms, abbreviations, and named products appear in the paper. Definitions are written for readers who may not share the author’s familiarity with biotech investing, pharmaceutical development, or M&A analysis. Entries are alphabetical.

AD

Alzheimer’s Disease. The most common form of dementia, affecting over seven million Americans. The primary target indication for ARO-MAPT.

Alnylam

Alnylam Pharmaceuticals. A competitor developing RNAi therapeutics, with a CNS program delivered intrathecally (via lumbar puncture). Contrasts with Arrowhead’s subcutaneous TRiM-BBB delivery.

ARIA

Amyloid-Related Imaging Abnormalities. Brain swelling or bleeding observed as a side effect of anti-amyloid therapies like Leqembi and Kisunla, requiring MRI monitoring. ARO-MAPT targets tau rather than amyloid and does not carry ARIA risk.

ARO-ALK7

Arrowhead’s preclinical RNAi therapeutic targeting ALK7 for obesity. Addresses adipocyte-level signaling, complementary to ARO-INHBE.

ARO-ATXN1, ARO-ATXN2, ARO-ATXN3

Arrowhead’s investigational RNAi therapeutics targeting ataxin genes for rare neurological diseases (SCA1, SCA2, SCA3). Licensed to Sarepta Therapeutics.

ARO-C3

Arrowhead’s investigational RNAi therapeutic targeting complement component 3 for IgA nephropathy and other complement-mediated diseases. Phase 1/2.

ARO-DIMER-PA

Arrowhead’s preclinical dual RNAi therapeutic silencing both PCSK9 and APOC3 in a single molecule. Delivers combined LDL-cholesterol and triglyceride reduction.

ARO-DM1

Arrowhead’s investigational RNAi therapeutic targeting the DMPK gene for myotonic dystrophy type 1. Licensed to Sarepta Therapeutics.

ARO-HTT

Arrowhead’s investigational RNAi therapeutic targeting huntingtin for Huntington’s disease. Licensed to Sarepta Therapeutics.

ARO-INHBE

Arrowhead’s investigational RNAi therapeutic targeting Activin E for obesity. January 2026 Phase 1/2a data showed doubled weight loss and tripled fat reduction when combined with tirzepatide.

ARO-MAPT

Arrowhead’s investigational RNAi therapeutic targeting the MAPT gene. Designed to silence tau production via subcutaneous injection crossing the blood-brain barrier. The central asset of this paper’s thesis. Phase 1 readout expected 2H 2026.

ARO-MMP7 (SRP-1002)

Arrowhead’s investigational RNAi therapeutic targeting matrix metalloproteinase 7 for idiopathic pulmonary fibrosis. Licensed to Sarepta Therapeutics.

ARO-RAGE

Arrowhead’s investigational RNAi therapeutic targeting the RAGE receptor for pulmonary inflammatory disease. Phase 1/2 achieved 90 to 95 percent gene knockdown via inhalation.

ARO-SNCA

Arrowhead’s preclinical RNAi therapeutic targeting alpha-synuclein for Parkinson’s disease. Licensed to Novartis in October 2025 for $200M upfront, $2B in milestones, plus royalties. The deal is the template for a potential ARO-MAPT licensing transaction.

Avidity Biosciences

Biotech company acquired by Novartis in October 2025 for approximately $12 billion, which absorbed a portion of Novartis’s 2026 neuroscience M&A capital.

BBB

Blood-Brain Barrier. The highly selective cellular barrier separating blood from brain tissue and the defining challenge of CNS drug delivery. ARO-MAPT crosses the BBB via TfR1-mediated transcytosis after subcutaneous injection.

Biomarker

A measurable biological indicator of disease activity or drug effect. CSF tau reduction is the primary biomarker for ARO-MAPT Phase 1.

Biogen

Major biotechnology company. Developer of BIIB080 (tau ASO) and partner of Ionis Pharmaceuticals on multiple CNS programs.

BIIB080

Ionis/Biogen’s intrathecal antisense oligonucleotide targeting MAPT. The first tau-silencing therapy in human trials. Phase 1b demonstrated 51 to 56 percent CSF tau reduction. Establishes the human proof-of-mechanism that ARO-MAPT builds on with a superior delivery route.

CAPITAN

Phase 3 cardiovascular outcomes trial of plozasiran in patients with mixed hyperlipidemia and residual cardiovascular risk. Potential readout approximately 2029.

CBD

Corticobasal Degeneration. A rare, fatal tauopathy with no approved disease-modifying therapy. An orphan indication in the ARO-MAPT indication ladder.

CELIA

Biogen’s Phase 2 clinical trial of BIIB080 in early Alzheimer’s disease. Expected to read out in 2026, potentially before the ARO-MAPT Phase 1 readout. A positive CELIA result would provide additional human validation that tau reduction slows cognitive decline.

CNS

Central Nervous System. The brain and spinal cord. The most challenging target for drug delivery because of the blood-brain barrier.

Comparable transactions

A valuation methodology that anchors on pre-data acquisition multiples paid in structurally similar prior deals. The paper anchors on Prometheus, MyoKardia, Karuna, and ImmunoGen as the closest comparables to an Arrowhead Stage 1 acquisition.

CSF

Cerebrospinal Fluid. The fluid surrounding the brain and spinal cord. CSF tau reduction is the primary pharmacodynamic endpoint for ARO-MAPT Phase 1.

CVOT

Cardiovascular Outcomes Trial. A large randomized trial designed to demonstrate that a drug reduces major cardiovascular events. Required for broad cardiovascular labeling. CAPITAN is Arrowhead’s CVOT for plozasiran.

Elecsys

Roche’s branded in vitro diagnostic platform. Includes AD diagnostic assays. A component of Roche’s strategic synergy in the Stage 1 acquisition thesis.

FCS

Familial Chylomicronemia Syndrome. An ultra-rare genetic disorder causing severely elevated triglycerides and risk of life-threatening pancreatitis. Plozasiran (Redemplo) received FDA approval for FCS in November 2025.

FDA

US Food and Drug Administration. The US federal agency responsible for approving drugs and biological products.

Fully diluted shares

The total number of shares outstanding after all stock options, warrants, convertible securities, and similar instruments are counted as if exercised. The acquisition per-share calculations in this paper use approximately 155 million fully diluted shares.

Gene X

Arrowhead’s undisclosed target referenced in a December 10, 2025 CNS Delivery Summit presentation showing approximately 90 percent non-human-primate brain knockdown for a cardiometabolic indication. Section XII uses Gene X as evidence that Arrowhead’s platform engine produces programs the sell-side cannot model.

Genentech

Biotechnology company acquired by Roche in 2009 for $46.8 billion. At the time analysts characterized the price as expensive. The platform subsequently generated hundreds of billions of dollars of cumulative revenue under Roche ownership. Referenced in the paper as the closest historical precedent for a platform acquisition at the scale the Stage 1 thesis contemplates.

GLP-1

Glucagon-Like Peptide-1 agonists. A class of injectable therapies for obesity and diabetes including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). GLP-1 adoption via auto-injector pens has normalized subcutaneous injection as a drug delivery format.

GMP

Good Manufacturing Practice. FDA-regulated standards for pharmaceutical manufacturing. Arrowhead’s Verona facility is GMP-compliant.

HCM

Hypertrophic Cardiomyopathy. A genetic heart muscle disease. The primary indication for mavacamten, the asset that drove BMS’s 2020 acquisition of MyoKardia (a paper comparable).

ImmunoGen

Comparable pre-data transaction: AbbVie’s 2023 acquisition at approximately 12.6× pre-data market cap. One of the four comparables anchoring the paper’s pre-data multiple range.

Intrathecal

A drug delivery route directly into the cerebrospinal fluid via lumbar puncture. Used by BIIB080 and by Alnylam’s CNS pipeline. Clinically significant barrier to patient uptake. Contrasts with ARO-MAPT’s subcutaneous delivery.

Ionis

Ionis Pharmaceuticals. Developer of antisense oligonucleotide therapeutics. Partner with Biogen on BIIB080 and other CNS programs.

Karuna

Comparable pre-data transaction: BMS’s 2023 acquisition at approximately 9.3× pre-data market cap. One of the four comparables anchoring the paper’s pre-data multiple range.

Kisunla

Eli Lilly’s approved anti-amyloid antibody (donanemab) for early Alzheimer’s disease. Positioned around finite therapy (patients stop dosing after amyloid clearance). A competitor-owned ARO-MAPT would threaten Kisunla’s positioning through mechanism adjacency, which produces much of the defensive synergy value in Lilly’s Stage 1 bid capacity.

Knockdown

The reduction in target gene expression (mRNA or protein) produced by an RNAi or antisense therapeutic. ARO-MAPT Phase 1 will report CSF tau knockdown as its primary pharmacodynamic readout.

Leqembi

Eisai/Biogen’s approved anti-amyloid antibody (lecanemab) for early Alzheimer’s disease. Competes directly with Kisunla. Carries ARIA risk and requires MRI monitoring.

LY-3954068

Eli Lilly’s own intrathecal tau siRNA program in Phase 1 for Alzheimer’s disease. Its existence confirms Lilly’s internal conviction that tau silencing is a valid mechanism, which raises Lilly’s internal probability estimate for ARO-MAPT and contributes to Lilly’s defensive rationale for acquiring the subcutaneous alternative.

M&A

Mergers and Acquisitions. The field encompassing the buying, selling, and combining of companies.

MAPT

Microtubule-Associated Protein Tau. The gene encoding the tau protein. Pathological tau accumulation is a hallmark of Alzheimer’s disease and other tauopathies. ARO-MAPT silences this gene.

Monte Carlo simulation

A probabilistic valuation methodology that runs thousands of iterations across probability-weighted input distributions (efficacy, probability of success, commercial adoption, pricing) to produce an output distribution of enterprise values rather than a single point estimate. Section VI develops Arrowhead’s Monte Carlo output.

MyoKardia

Comparable pre-data transaction: BMS’s 2020 acquisition for mavacamten at approximately 6.5× pre-data market cap. One of the four comparables anchoring the paper’s pre-data multiple range.

Non-human primate

Cynomolgus macaques used in ARO-MAPT preclinical studies. TRiM-BBB delivery produced 70 to 80 percent mRNA knockdown and 50 to 60 percent CSF tau reduction. TfR1 binding is confirmed identical between non-human primate and human.

Peak revenue multiple

A valuation methodology that applies historical pharmaceutical M&A multiples (typically 4 to 6 times) to risk-adjusted peak revenue forecasts for a target asset. One of the four valuation methodologies developed in Section V.

Phase 1 / Phase 2 / Phase 3

The three stages of clinical development prior to regulatory submission. Phase 1 tests safety and pharmacology in small numbers of subjects (typically 20 to 80). Phase 2 tests efficacy in patients (100 to 500). Phase 3 confirms efficacy in large randomized trials (often 500 to 5,000+). ARO-MAPT is in Phase 1; readout expected 2H 2026.

Plozasiran

Arrowhead’s approved RNAi therapeutic targeting APOC3 for severe hypertriglyceridemia. Brand name Redemplo. FDA approved for FCS in November 2025. Supplemental NDA for broader sHTG anticipated 2026.

Prometheus

Comparable pre-data transaction: Merck’s 2023 acquisition at approximately 10.8× pre-data market cap. One of the four comparables anchoring the paper’s pre-data multiple range.

PSP

Progressive Supranuclear Palsy. A fatal tauopathy affecting 20,000 to 30,000 US patients with no approved disease-modifying therapy. An orphan indication in the ARO-MAPT indication ladder.

Redemplo

Brand name of Arrowhead’s plozasiran, the first commercially approved RNAi therapeutic in Arrowhead’s cardiometabolic franchise.

Re-rate / re-rating

A repricing of a stock by the market following a catalyst (such as clinical data or regulatory decision). The Phase 1 readout is expected to produce a material re-rate of Arrowhead across all three scenarios.

RNAi

RNA Interference. A natural cellular mechanism that silences gene expression by degrading messenger RNA before protein is produced. The foundational mechanism used by all Arrowhead therapeutics.

rNPV

Risk-Adjusted Net Present Value. A standard pharmaceutical valuation methodology that projects probability-weighted future cash flows and discounts them to present value. Used by sell-side analysts. The paper argues this framework systematically undervalues platform companies at delivery inflection points, including Arrowhead today.

Sarepta

Sarepta Therapeutics. Licensing agreement announced November 2024 and closed February 2025 ($325M equity at 35 percent premium plus milestones and royalties), covering a portfolio of Arrowhead programs including ARO-HTT, ARO-ATXN1, ARO-ATXN2, ARO-ATXN3, ARO-MMP7 (SRP-1002), ARO-DM1, and ARO-DUX4.

sHTG

Severe Hypertriglyceridemia. Triglyceride levels at or above 500 mg/dL, affecting three to four million US patients. Plozasiran’s Phase 3 supplemental indication following FCS approval.

siRNA

Small Interfering RNA. The active RNA molecule in RNAi therapeutics that guides the cellular silencing machinery to its target mRNA. The effector component of ARO-MAPT and other Arrowhead programs.

Stage 1 / Stage 2

Paper-specific terminology for two distinct acquisition windows. Stage 1 is the window that follows strong Phase 1 data in 2H 2026, estimated at $55 to $90 billion. Stage 2 is the subsequent window that opens if no transaction clears within 12 to 18 months and positive Phase 2 cognitive endpoint data reads out in 2029 to 2030, estimated at $110 to $150 billion.

Subcutaneous

A drug delivery route via injection into the tissue layer beneath the skin, typically with a short needle similar to insulin or GLP-1 auto-injector devices. Distinguishes ARO-MAPT from intrathecal CNS therapeutics like BIIB080 that require lumbar puncture.

SVA

Strategic Value Analysis. The acquirer-specific valuation framework described in Section II, incorporating synergies, defensive value, competitive positioning, and platform optionality. Contrasts with rNPV, which does not incorporate these components.

Synergy

The incremental value an acquirer captures from combining a target with its existing operations. Includes revenue synergies (combination-product pricing, shared sales force), cost synergies (infrastructure integration), and defensive synergies (preventing a competitor from owning the asset). Section V develops bidder-specific synergy ranges for Lilly, Roche, and Novartis.

Tau / tauopathy

Tau is a microtubule-stabilizing protein in neurons. Abnormal tau accumulation is a hallmark of Alzheimer’s disease and other neurodegenerative diseases collectively called tauopathies, which include PSP, CBD, and FTD-MAPT.

TfR1

Transferrin Receptor 1. The protein that transports iron across the blood-brain barrier. ARO-MAPT is engineered to bind TfR1, enabling subcutaneous-to-CNS delivery via transcytosis. TfR1 binding architecture is confirmed identical between non-human primate and human.

Tirzepatide

Eli Lilly’s GLP-1/GIP dual agonist for obesity and diabetes. Brand names Mounjaro and Zepbound. Combination with ARO-INHBE showed doubled weight loss and tripled fat reduction versus tirzepatide alone in January 2026 Phase 1/2a data.

Transcytosis

The biological process of transporting a substance across a cell from one surface to the other. TfR1-mediated transcytosis is how ARO-MAPT crosses the blood-brain barrier after subcutaneous injection.

TRiM

Targeted RNAi Molecule. Arrowhead’s proprietary platform technology that conjugates a targeting ligand to a siRNA trigger, enabling delivery to specific cell types. Validated across liver, lung, adipose, muscle, tumor/kidney, and CNS (via BBB crossing) tissues in clinical or preclinical settings.

Trontinemab

Roche’s Phase 3 anti-amyloid antibody for early Alzheimer’s disease. Uses TfR1-mediated blood-brain-barrier transcytosis as its delivery mechanism, which is the same delivery mechanism class ARO-MAPT uses. Trontinemab’s clinical validation of TfR1-mediated BBB crossing in humans is one of the three pillars of prior evidence supporting ARO-MAPT.

Tryngolza

Ionis Pharmaceuticals’ olezarsen. An antisense oligonucleotide approved for FCS that competes with Redemplo (plozasiran). Examined in detail in the second BioBoyScout paper.

Verona

Arrowhead’s GMP manufacturing facility in Verona, Wisconsin. Three operational production lines for TRiM therapeutics, plus an option through 2028 on 6.24 adjacent acres for expansion. Section XII develops Verona as approximately $3 to $6 billion of strategic currency to an acquirer.

Walk-away price

In M&A, the maximum price a bidder is willing to pay while the acquisition remains value-accretive. Calculated as standalone rNPV plus the bidder’s share of acquirer-specific synergy. Section X develops walk-away prices for Lilly ($73 to $124 billion), Roche ($58 to $85 billion), and Novartis ($47 to $64 billion).

A Note on Supporting Independent Research

These white papers took hundreds of hours to produce. The asset inventory, valuation methodology, bidder analysis, comparable transaction work, acquisition thesis, competitor analysis, supporting charts, and science analytics are the result of deep primary research and is not available in sell-side coverage. Most of the analysis presented represents independent research not published elsewhere. It is being shared freely because the thesis deserves the widest possible audience. If ARO-MAPT delivers in 2H 2026, every Arrowhead shareholder benefits from a well-informed market that understands what the data means and what the asset is worth. That is why this paper exists.

If this research has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 or more reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

A Personal Note

When I started this paper, I expected to build a bull case, not to find one that kept getting stronger the deeper I went. My initial framing was a simple conditional: if ARO-MAPT works, what is Arrowhead worth to a strategic acquirer? I assumed the math would produce a large number that I would then need to stress-test and defend.

What I did not expect was for four independent valuation methodologies to converge on the same range without being forced to. I did not expect the comparable transaction analysis to anchor near the bottom-up rNPV result. I did not expect the Monte Carlo distribution to produce a median that sits above the acquisition target, with even the 10th percentile scenario still representing a multiple of today’s market cap.

Each time I revisited the probability assumptions, the thesis survived. Each time I rebuilt the valuation from a different direction, the numbers converged in the same place. That convergence, across methods and across probability scenarios, is what ultimately convinced me that the analysis is valid. Not that ARO-MAPT will succeed, I cannot know that, and the paper does not claim it. If it does, the numbers are real, the strategic logic is sound, and the gap between the current price and what this company is worth to the right acquirer is as large as the math says it is.

I hold a long position in ARWR. I held one before I started this paper. The research did not create the conviction, but it deepened it considerably.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed; and

• he was not compensated in any form for producing this white paper.

This white paper is published by BioBoyScout and is intended for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss. All financial projections, acquisition price estimates, and valuation analyses herein are hypothetical frameworks for analytical purposes and do not represent predictions of actual outcomes. Readers should conduct their own due diligence and consult a registered investment advisor before making investment decisions. All data cited herein were sourced from publicly available company disclosures, SEC filings, press releases, and peer-reviewed literature as of April 2026.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now